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IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS 
VAUGHN SCHMECHEL, individually and as ) 
surviving spouse and Personal Representative ) 
of the Estate of Rosie Schmechel, deceased ) 
and ROBERT P. LEWIS, KIM HOWARD ) 
and TAMARA HALL, natural children of ) 
ROSALIE SCHMECHEL, deceased, ) 
) 




CLINTON DILLE, M.D., SOUTHERN ) 
IDAHO PAIN INSTITUTE, an Idaho ) 
Corporation, THOMAS BYRNE, P. A., ) 
and JOHN DOE and JANE DOE, I through X, ) 
) 
Defendants/Respondents. ) 
CASE NO. CV 05-4345 
CLERK'S SUPPLEMENTAL RECORD ON APPEAL 
VOLUME6 
Appeal from the District Court of the Fifth Judicial District 
of the State of Idaho, in and for the County of Twin Falls 
HONORABLE G. RICHARD BEV AN 
David Comstock 
Byron Foster 
199 N Capitol Blvd., Ste 500 
P. 0. Box 2774 
Boise, ID 83701-2774 
District Judge 
Steven Hippler 
J. Will Varin 
601 W, Bannock Street 
P. O. Box 2720 
Boise, ID 83701-2720 
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Date: 9/11/2008 Fifth J~ al District Court • Twin Falls County User: COOPE 
Time: 09:38 AM ROA Report 
Page 1 of 17 Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, etal. vs. Clinton L Dille MD, etal. 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 
Date Code User Judge 
10/3/2005 NOAP QUAM Notice Of Appearance G. Richard Bevan 
QUAM Filing: A1 - Civil Complaint, More Than $1000 No G. Richard Bevan 
Prior Appearance Paid by: Mick Hodges 
Receipt number: 5024920 Dated: 10/3/2005 
Amount: $82.00 (Check) 
COMP QUAM Complaint Filed G. Richard Bevan 
SMIS QUAM Summons Issued x 3 G. Richard Bevan 
1117/2005 QUAM Filing: 11 A - Civil Answer Or Appear. More Than G. Richard Bevan 
$ 1000 No Prior Appearance Paid by: Givens 
Pursley, LLP Receipt number: 5027934 Dated: 
11/712005 Amount: $52.00 (Check) 
ANSW QUAM Answer To Complaint And Demand For Jury Trial G. Richard Bevan 
12/14/2005 HRSC COOPE Hearing Scheduled (Scheduling Conference G. Richard Bevan 
01/04/2006 01 :30 PM) 
OSCO COOPE Order for Scheduling Conference and Order RE: G. Richard Bevan 
Motion Practice 
12/19/2005 LETT COOPE Letter from David Comstock G. Richard Bevan 
12/2112005 HRVC COOPE Hearing result for Scheduling Conference held on G. Richard Bevan 
01/04/2006 01 :30 PM: Hearing Vacated 
12/30/2005 AFSV NIELSEN Affidavit Of Service G. Richard Bevan 
SMRT NIELSEN Summons Returned G. Richard Bevan 
1/5/2006 FERCH Filing: 17 A - Civil Answer Or Appear. All Other G. Richard Bevan 
Actions No Prior Appearance Paid by: Hall 
Farley Oberrecht Blanton Receipt number: 
6000440 Dated: 1/512006 Amount: $52.00 
(Check) 
NOAP FERCH Notice Of Appearance G. Richard Bevan 
ANSW FERCH Defendant Thomas J Byrne's Answer to plaintiffs G. Richard Bevan 
complaint and demand for jury trial 
1/20/2006 SMRT NIELSEN Summons Returned Clinton Dille, M.D. G. Richard Bevan 
SMRT NIELSEN Summons Returned Southern Idaho Pain Institute G. Richard Bevan 
2/6/2006 NOSV NIELSEN Notice Of Service G. Richard Bevan 
2/14/2006 HRSC COOPE Hearing Scheduled (Scheduling Conference G. Richard Bevan 
03/06/2006 01 :30 PM) 
2/15/2006 OSCO COOPE Order for Scheduling Conference and Order RE: G. Richard Bevan 
Motion Practice 
2/2412006 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
3/2/2006 STIP COOPE Stipulation for Scheduling and Planning G. Richard Bevan 
3/8/2006 HRVC COOPE Hearing result for Scheduling Conference held on G. Richard Bevan 
03/06/2006 01 :30 PM: Hearing Vacated 
HRSC COOPE Hearing Scheduled (Jury Trial 10/16/2007 09:00 G. Richard Bevan 
AM) Excluding Mondays 
HRSC COOPE Hearing Scheduled (Civil Pretrial Conference G. Richard Bevan 
09/24/2007 02:30 PM) 
".! n r.~ 1c 
.J.. Ii ._) L,E 
Date: 9/11/2008 Fifth JL. '<ti District Court· Twin Falls County User: COOPE 
Time: 09:38 AM ROA Report 
Page 2 of 17 Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, etal. vs. Clinton L Dille MD, etal. 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 
Date Code User Judge 
3/8/2006 HRSC COOPE Hearing Scheduled (Status/ADR 09/05/2007 G. Richard Bevan 
01 :32 PM) 
3/9/2006 NOJT COOPE Notice Of Jury Trial Setting, Pretrial Conf- Renee G. Richard Bevan 
And Order Governing Further Proceedings 
4/3/2006 NOTR NIELSEN Notice Of Preparation Of Transcript G. Richard Bevan 
4/6/2006 NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Defendant Clinton Dille, M.D. 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Thomas Byrne, PA 
4/18/2006 NOSV NIELSEN Notice Of Service G. Richard Bevan 
04-17-06 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Amber Zaccone 
5/1/2006 NOTC RKLINE Amended Notice Of Taking Video Deposition G. Richard Bevan 
Duces Tecum Of Thomas Byrne, PA 
NOTC RKLINE Amended Notice Of Taking Video Deposition G. Richard Bevan 
Duces Tecum Of Defendant Clinton Dille, M.D. 
5/10/2006 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
6/9/2006 NOTR NIELSEN Notice Of Preparation Of Transcript G. Richard Bevan 
NOTR NIELSEN Notice Of Preparation Of Transcript G. Richard Bevan 
NOTR NIELSEN Notice Of Preparation Of Transcript G. Richard Bevan 
6/19/2006 NODT NIELSEN Notice Of Taking Deposition Duces Tecum G. Richard Bevan 
(Timothy Floyd, M.D.) 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum G. Richard Bevan 
(Julian Nicholson, M.D.) 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum G. Richard Bevan 
(Records Custodian-Sun Valley Spine Institute) 
3/26/2006 NODT NIELSEN Amended Notice Of Deposition Duces Tecum G. Richard Bevan 
(Julian Nicholson, M.D.) 
NODT NIELSEN Amended Notice Of Deposition Duces Tecum G. Richard Bevan 
(Records Custodian - Sun Valley Spine Institute) 
3/30/2006 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
7/3/2006 SUBR NIELSEN Subpoena Returned G. Richard Bevan 
AFSV NIELSEN Affidavit Of Service G. Richard Bevan 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum G. Richard Bevan 
(Records Custodian - Spine Institute of Idaho) 
SUBR NIELSEN Subpoena Returned G. Richard Bevan 
AFFD NIELSEN Affidavit of Non-Service G. Richard Bevan 
7/13/2006 NOSV MCMULLEN Notice Of Service G. Richard Bevan 
7/14/2006 NOSV NIELSEN Notice Of Service G. Richard Bevan 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
7/17/2006 NTSD NIELSEN Notice Of Service Of Discovery Responses G. Richard Bevan 
NTSD NIELSEN Notice Of Service Of Discovery Responses G. Richard Bevan 1 r, r.w r:· .J.\i . J.J 
Date: 9/11/2008 Fifth J~ al District Court - Twin Falls County User: COOPE 
Time: 09:38 AM ROA Report 
Page3of17 Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, etal. vs. Clinton L Dille MD, etal. 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 
Date Code User Judge 
7/25/2006 SUBR NIELSEN Subpoena Returned G. Richard Bevan 
AFFD NIELSEN Affidavit of Non-Service G. Richard Bevan 
9/8/2006 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
9/29/2006 NOSV NIELSEN Notice Of Service G. Richard Bevan 
4/19/2007 MOTN NIELSEN Motion for Leave to Amend Complaint to Include G. Richard Bevan 
Claim for Punitive Damages 
fax 
4/20/2007 AFFD NIELSEN Supplemental Affidavit of Arthur G. Lipman, G. Richard Bevan 
Pharm.D. 
AFFD NIELSEN Affidavit of Arthur G. Lipman, Pharm.d. G. Richard Bevan 
MEMO NIELSEN Memorandum in Support of Plaintiffs' Motion for G. Richard Bevan 
Leave to Amend Complaint to Include Claim for 
Punitive Damages 
NIELSEN Plaintiffs' Expert Witness Disclosures G. Richard Bevan 
4/26/2007 HRSC COOPE Hearing Scheduled (Motion 06/18/2007 09:00 G. Richard Bevan 
AM) to amend complaint to add punitive 
damages 
NOHG NIELSEN Notice Of Hearing Re: Motion for Leave to G. Richard Bevan 
Amend Complaint to Include Claim for Punitive 
Damages 
5/11/2007 NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Kimberly Vorse, M.D. 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
David Verst, M.D. 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum $of G. Richard Bevan 
Juanita Peterson 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Carl Peterson 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Cindy Sheer 
5/18/2007 NIELSEN Defendant Thomas Byrne, PA's Disclosure of G. Richard Bevan 
Lay Witnesses 
5/23/2007 NIELSEN Plaintiffs' Lay Witness List G. Richard Bevan 
fax 
5/24/2007 NOSV NIELSEN Notice Of Service G. Richard Bevan 
NODT NIELSEN Amended Notice Of Taking Deposition Duces G. Richard Bevan 
Tecum of Carl Peterson 
NOTC NIELSEN Notice of Vacating Deposition Duces Tecum of G. Richard Bevan 
Juanita Peterson 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Kenneth Harris, M.D. 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Julian Nicholson, M.D. 
NODT NIELSEN amended G. Richard Bevan 
Notice Of Taking Deposition Duces Tecum of 1 n i:· r' 
Cindy Sheer l. \.Id ) 
Date: 9/11/2008 Fifth Jw II District Court. Twin Falls County User: COOPE 
Time: 09:38 AM ROA Report 
Page 4 of 17 Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, etal. vs. Clinton L Dille MD, etal. 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 
Date Code User Judge 
5/24/2007 NODT NIELSEN Notice Of Taking Deposition Ducas Tecurn G. Richard Bevan 
of Kent Jensen 
5/25/2007 NIELSEN DefendantThomasByrne,P.a.'sSupplemental G. Richard Bevan 
Disclosure of Lay Witnesses 
fax 
5/30/2007 NODT NIELSEN Amended Notice Of Taking Deposition Ducas G. Richard Bevan 
Tecum of Kimberly Vorse, M.D. 
Fax 
6/4/2007 AFFD NIELSEN Second Supplemental Affidavit of Arthur G. G. Richard Bevan 
Lipman, Pharm.D. 
NOHG NIELSEN Notice Of Hearing G. Richard Bevan 
AFFD NIELSEN Affidavit of Counsel in Support of Defendant G. Richard Bevan 
Thomas Byrne's Motion to Strike Portions of the 
Affidavits of Arthur G. Lipman, Pharm. D. 
MOTN NIELSEN Defendant Thomas Byrne's Motion to Strike G. Richard Bevan 
Portions of the Affidavits of Arthur G. Lipman, 
Pharm.D. 
AFFD NIELSEN Affidavit of Keri Fakata, Pharm.D G. Richard Bevan 
NIELSEN Defendant Thomas Byrne's Memorandum in G. Richard Bevan 
Support of Motion to Strike Portions of the 
Affidavits of Arthur G. Lipman, Pharm.D. 
6/6/2007 NIELSEN Defendant Clinton Dille, M.D.'s Joinder in Motion G. Richard Bevan 
to Strike Portions of the Affidavit of Arthur G. 
Lipman Pharm. D. 
fax 
6/11/2007 AFFD NIELSEN Affidavit of Byron V. Foster G. Richard Bevan 
AFFD NIELSEN Affidavit of Lorraine Shoafkadish BSN, RN G. Richard Bevan 
MEMO NIELSEN Plaintiff's Memorandum in Opposition to G. Richard Bevan 
Defendants' Motion to Strike Portions of the 
Affidavits of Arthur G. Lipman, Pharm.D. 
AFFD NIELSEN Affidavit of William Binegar, M.D. in Opposition to G. Richard Bevan 
Plaintiffs' Motion to Amend Complaint to Add a 
Claim for Punitive 
Damages 
fax 
NIELSEN Response to Plaintiffs' Motion for Leave to G. Richard Bevan 
Amend Complaint to Include Claim for Punitive 
Damages 
fax 
AFFD NIELSEN Affidavit of Counsel in Support of Defendant G. Richard Bevan 
Thomas Byrne, P.A.'s Memorandum in 
Opposition to Plaintiffs' Motion for Leave to 
Amend Complaint to Include Claim for Punitive 
Damages 





j_ \., ,_) I 
Date: 9/11/2008 
Time: 09:38 AM 
Page5of17 
Fifth Ju, \I District Court· Twin Falls County 
ROA Report 
User: COOPE 
Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, etal. vs. Clinton L Dille MD, etal. 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 
Date Code User Judge 
3/11/2007 NIELSEN Defendant Thomas Byrne, P.A.'s Memorandum in G. Richard Bevan 
Opposition to Plaintiffs' Motion for Leave to 
Amend Complaint to Include Claim for Punitive 
Damages 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Stephen P. Lordon, M.D. 
3/12/2007 AFFD NIELSEN Affidavit of Steven J. Hippler G. Richard Bevan 
AFFD NIELSEN Affidavit of Bradford Hare, M.D.PH.D in G. Richard Bevan 
Opposition to Plaintiffs' Motion to Amend 
Complaint to Add a Claim for Punitive Damages 
3/13/2007 NOWD NIELSEN Notice Of Withdrawal of Plaintiff's Motion for G. Richard Bevan 
Leave to Amend Complaint to Include Claim for 
Punitive Damages 
3/14/2007 HRVC COOPE Hearing result for Motion held on 06/18/2007 G. Richard Bevan 
09:00 AM: Hearing Vacated to amend complaint 
to add punitive damages 
motion to strike portions of affidavits of Arthur 
Lipman 
NOTC NIELSEN Notice of Vacating Deposition Duces Tecum of G. Richard Bevan 
Carl Peterson 
fax 
6/15/2007 NOTC NIELSEN Notice Vacating Hearing G. Richard Bevan 
fax 
NODT NIELSEN Amended Notice Of Taking Deposition Duces G. Richard Bevan 
Tecum of Cindy Scheer 
fax 
NOTC COOPE Notice Vacating Hearing G. Richard Bevan 
fax 
6/18/2007 NIELSEN Plaintiffs' First Supplemental Expert Witness G. Richard Bevan 
Disclosures 
NIELSEN Defendant Thomas J. Byrne's Disclosure of G. Richard Bevan 
Expert Witnesses 
NOTC NIELSEN Notice of Compliance G. Richard Bevan 
fax 
NOTC COOPE Notice of Vacating Hearing G. Richard Bevan 
6/19/2007 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
6/25/2007 SUBR NIELSEN Subpoena Returned G. Richard Bevan 
fax 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Dennis Chambers 
fax 
RETN NIELSEN Return Of Service G. Richard Bevan 
6-16-7 
fax 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum G. Richard Bevan 
fax 
1 f'i f.~ 0 
.t \• 0 U 
Date: 9/11/2008 Fifth Ju II District Court - Twin Falls County User: COOPE 
Time: 09:38 AM ROA Report 
Page 6 of 17 Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, etal. vs. Clinton L Dille MD, etal. 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 
Date Code User Judge 
6/27/2007 NODT NIELSEN Amended Notice Of Taking Deposition Ducas G. Richard Bevan 
Tecum of Arthur G. Lipman, Pharm. D. 
fax 
NODT NIELSEN Amended Notice Of Taking Deposition Duces G. Richard Bevan 
Tecum of Stephen P. Lorden, M.D. 
fax 
NODT NIELSEN Second Amended Notice Of Taking Deposition G. Richard Bevan 
Duces Tecum of Kimberly Vorse, M.D. 
fax 
7/3/2007 MOTN NIELSEN Motion for Protective Order G. Richard Bevan 
fax 
7/20/2007 SUBR NIELSEN Subpoena Returned G. Richard Bevan 
7/23/2007 NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
8/2/2007 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Rithard Bevan 
8/3/2007 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
8/6/2007 NODT NIELSEN Amended Notice Of Taking Deposition Duces G. Richard Bevan 
Tecum of Cornelius Hofman 
NOTC NIELSEN Notice of Vacating Deposition Ducas Tecum of G. Richard Bevan 
Dennis Chambers 
NOTC NIELSEN Notice of Vacating Deposition Duces Tecum of G. Richard Bevan 
Shaiyenne Shindle 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
8/13/2007 NODT NIELSEN Second Amended Notice Of Taking Deposition G. Richard Bevan 
Ducas Tecurn of Stephen P. Lorden, M.D. 
(Change of Location) 
NODT NIELSEN Amended Notice Of Taking Deposition Duces G. Richard Bevan 
Tecum of Jim Keller, M.P.H., PA-C 
NODT NIELSEN Second Amended Notice Of Taking Deposition G. Richard Bevan 
Duces Tecum of Arthur G. Lipman, Pharm. D. 
NODT NIELSEN Notice Of Taking Deposition Ducas Tecum G. Richard Bevan 
of Glen R. Graben 
NODT NIELSEN Amended Notice Of Taking Deposition Ducas G. Richard Bevan 
Tecum of Glen R. Groben 
NODT NIELSEN Second Amended Notice Of Taking Deposition G. Richard Bevan 
Duces Tecum of Glen R. Graben 
NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
8/22/2007 NODT NIELSEN Amended G. Richard Bevan 
Notice Of Taking Deposition Duces Tecumof 
Dennis Chambers l'r·r) 
fax 
d •.) . 
Date: 9/11/2008 
Time: 09:38 AM 
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8/22/2007 NODT NIELSEN Amended G. Richard Bevan 
Notice Of Taking Deposition Duces Tecum of 
Christopher Frey 
fax 
NODT NIELSEN Amended G. Richard Bevan 
Notice Of Taking Deposition Duces Tecum of 
Shaiyenne Shindle 
fax 
8/27/2007 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
8/29/2007 CONT COOPE Continued (Status/ADR 09/10/2007 11 :00 AM) G. Richard Bevan 
by phone with plaintiff's counsel to initiate 
COOPE Notice Of Hearing G. Richard Bevan 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
8/30/2007 NTSD NIELSEN Notice Of Service Of Discovery Responses G. Richard Bevan 
9/10/2007 NIELSEN Plaintiffs' Second Supplemental Expert Witness G. Richard Bevan 
Disclosures 
HRHD COOPE Hearing result for Status/ADR held on 09/10/2007 G. Richard Bevan 
11:00 AM: Hearing Held by phone with plaintiff's 
counsel to initiate 
LETT COOPE Letter from Byron Foster G. Richard Bevan 
CMIN COOPE Court Minutes Hearing type: Status/ADR Hearing G. Richard Bevan 
date: 9/10/2007 Time: 11 :03 am Court reporter: 
Virginia Bailey 
9/11/2007 NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
NIELSEN Plaintiffs' Third Supplemental Expert Witness G. Richard Bevan 
Disclosures 
fax 
9/12/2007 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
fax 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
fax 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
fax 
9/14/2007 NOSV NIELSEN Notice Of Service G. Richard Bevan 
9/17/2007 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
9/24/2007 NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Marty Bright 
fax 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Valerie Bothof/ 
fax 
1 t I r"' r·, .1 i, iJ _I 
Date: 9/11/2008 
Time: 09:38 AM 
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G. Richard Bevan 
Hearing result for Civil Pretrial Conference held G. Richard Bevan 
on 09/24/2007 02:30 PM: Hearing Held in 
Chambers 
Defendant Thomas Byrne, P .A.'s Exhibit List G. Richard Bevan 
fax 
Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain Institute Trial Exhibit List 
Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Trial Witness List 
Pretrial Conference Order Pursuant to I.R.C.P. 
16(d) 
Plaintiffs' Motion in Limine 
fax 
G. Richard Bevan 
G. Richard Bevan 
Memorandum in Support of Plaintiffs' Motion in G. Richard Bevan 
Limine 
fax 
Defendant Thomas Byrne, P.A.'s Witness List G. Richard Bevan 
fax 
Plaintiffs' Witness List G. Richard Bevan 
fax 
Plaintiffs' Exhibit List 
fax 
G. Richard Bevan 
Affidavit of Counsel in Support of Defendant G. Richard Bevan 
Thomas Byrne, P.A.'s Motion in Limine Re: 
Various Issues 
Defendant Clinton Dille, M.D. and Southern Idaho G. Richard Bevan 
Pain Institutes' Motions in Limine 
fax 
Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain Institutes' Memorandum in Support of 
Motions in Limine 
Memorandum in Support of Thomas J. Byrne's G. Richard Bevan 
Motion in Limine Re: Various Issues 
Affidavit of J. Will Varin in Support of Clinton Dille G. Richard Bevan 
and the Southern Idaho Pain lnstitute's Motions in 
Limine 
Notice Of Service G. Richard Bevan 
fax 
Hearing Scheduled (Motion 10/11/2007 10:00 G. Richard Bevan 
AM) Pretrial 
Affidavit of Counsel in Support of Defendant 
Thomas Byrne's Motion to Quash Subpoenas 
Duces Tecum 
fax 
G. Richard Bevan 
., ... (' ~ 
.l \) ·-:) .. 
Date: 9/11/2008 
Time: 09:38 AM 
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10/3/2007 MEMO NIELSEN Defendant's Memorandum in Support of Motion to G. Richard Bevan 
Quash Subpoenas Duces Tecum 
fax 
MOTN NIELSEN Defendant's Motion to Quash Subpoenas Duces G. Richard Bevan 
Tecum 
fax 
10/4/2007 MOTN NIELSEN Defendant's Motion to Shorten Time G. Richard Bevan 
fax 
NOHG NIELSEN Notice Of Hearing G. Richard Bevan 
fax 
NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Response to Plaintiffs' 
Motion in Limine 
fax 
AFFD NIELSEN Affidavit of Counsel in Support of Defendant G. Richard Bevan 
Thomas Byrne's Memorandum in Opposition to 
Plaintiffs' Motion in Limine 
fax 
MEMO NIELSEN Defendant Thomas J. Byrne's Memorandum in G. Richard Bevan 
Opposition to Plaintiffs' Motion in Limine 
fax 
MOTN NIELSEN Defendant Thomas Byrne, P.A.'s Joinder in G. Richard Bevan 
Clinton Dille, M.D. and Southern Idaho Pain 
lnstitute's Motion in Limine 
fax 
NIELSEN Amended Plaintiffs' Exhibit List G. Richard Bevan 
fax 
10/5/2007 MEMO NIELSEN Memorandum in Response to Defendant's G. Richard Bevan 
Motions in Limine 
MEMO NIELSEN Memorandum in Opposition to Defendant's G. Richard Bevan 
Motion to Quash Subpoenas Duces Tecum 
AFFD NIELSEN Affidavit of Byron V. Foster G. Richard Bevan 
AFFD NIELSEN Affidavit of J. Will Varin in Support of Clinton Dille' G. Richard Bevan 
and the Southern Idaho Pain lnstitute's Response 
to Plaintiffs' Motion in Limine 
NIELSEN Defendant Thomas J. Byrne's Supplemental G. Richard Bevan 
Disclosure of Expert Witnesses 
fax 
NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Joinder in Defendant 
Byrne's Motion to Quash and Response to 
Plaintiffs' Opposition to Motion to Quash 
fax 
NIELSEN Plaintiffs' Fourth Supplemental Expert Witness G. Richard Bevan 
Disclosure 
fax 
SUBR NIELSEN Subpoena Returned G. Richard Bevan 
AFSV NIELSEN Affidavit Of Service G. Richard Bevan •• ;t· f" (") l \] ,_i ~ 
Date: 9/11/2008 
Time: 09:38 AM 
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10/9/2007 HRSC COOPE Hearing Scheduled (Hearing Scheduled G. Richard Bevan 
10/11/2007 09:30 AM) 
MEMO NIELSEN Pretrial Memorandum G. Richard Bevan 
AFFD NIELSEN Affidavit of Byron V. Foster in Support of Plaintiffs' G. Richard Bevan 
Pretrial Memorandum 
MEMO NIELSEN Reply Memorandum in Support of Plaintiffs' G. Richard Bevan 
Motion in Lirnine 
NIELSEN Plaintiff's Proposed Jury Instructions G. Richard Bevan 
NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Reply to Plaintiffs' 
Response to Defendants' Motions in Limine 
NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Joinder in Defendant 
Byrne's Motion in Limine 
NIELSEN Defendant Thomas J. Byrne, P.A. 's Proposed G. Richard Bevan 
Spcial Verdict Form 
NIELSEN Defendant Thomas J. Byrne's Trial Brief G. Richard Bevan 
NIELSEN Defendant Thomas J. Byrne, P .A.'s Proposed G. Richard Bevan 
Jury Instructions 
10/10/2007 RSPN COOPE Defendant's Thomas Bryne, P.A.'s Joinder in G. Richard Bevan 
Clinton DIiie, M.D. and Southern Idaho Pain 
lnstitute's Reply to Plaintiff's Reponse to 
Defendants' Motions in Limine 
NIELSEN Defendants' Joint Exhibit List G. Richard Bevan 
fax 
NIELSEN Defendant Clinton Dille' M.D. and Southern Idaho G. Richard Bevan 
Pain lnstitute's Trial Brief 
NIELSEN Defendants Clinton DIiie, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Jury Instructions 
10/11/2007 CMIN COOPE Court Minutes Hearing type: Motion in Limines G. Richard Bevan 
Hearing date: 10/11/2007 Time: 10:07 am Court 
reporter: Virginia Bailey 
CMIN COOPE Court Minutes Hearing type: Jury Numbering G. Richard Bevan 
Hearing date: 10/11/2007 Time: 9:42 am Court 
reporter: Virginia Bailey 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
fax 
MISC COOPE Jury Seating Chart G. Richard Bevan 
MISC COOPE Jury Seating Chart (Hand written) G. Richard Bevan 
HRHD COOPE Hearing result for Hearing Scheduled held on G. Richard Bevan 
10/11/2007 09:30 AM: Hearing Held 
HRHD COOPE Hearing result for Motion held on 10/11/2007 G. Richard Bevan 
10:00 AM: Hearing Held Pretrial 
JTST COOPE Hearing result for Jury Trial held on 10/16/2007 G. Richard Bevan 
09:00 AM: Jury Trial Started Excluding 
Mondays " ,,. r~ '"1 11,l u ·,J 
Date: 9/11/2008 Fifth Jl. jal District Court - Twin Falls County User: COOPE 
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10/12/2007 NIELSEN Pocket Trial Brief Re: Hearsay Issue and Mrs. G. Richard Bevan 
Schmechel's Identification of Mr. Byrne 
fax 
NIELSEN Supplemental Trial Memorandum Re: Dr. Lipman G. Richard Bevan 
fax 
NIELSEN Second Supplemental Trial Memorandum Re: G. Richard Bevan 
Plaintiffs' Expert Jim Keller 
fax 
10/15/2007 AFFD NIELSEN Affidavit of Chris D. Comstock Regarding the G. Richard Bevan 
Parties' Motions in Limine 
NIELSEN Pocket Trial Brief Re: Hearsay Issue and Mrs. G. Richard Bevan 
Schmechel's Identification of Mr. Byrne 
MEMO NIELSEN Supplemental Trial Memorandum Re: Dr. Lipman G. Richard Bevan 
NIELSEN Second Supplemental Trial Memorandum Re: G. Richard Bevan 
Plaintiffs' Expert Jim Keller 
NIELSEN Defendant Thomas J. Byrne's Reply to Plaintiffs' G. Richard Bevan 
Pocket Trial Brief Re: Hearsay Issue and Mrs. 
Schemchel's Identification of Mr. Byrne 
fax 
JUIN COOPE Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's First Supplement Jury 
Instructions 
10/16/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 1 G. Richard Bevan 
Hearing date: 10/16/2007 Time: 9:18 am Court 
reporter: Virginia Bailey 
MISC COOPE Juror Questions Submitted by Defendants Dille G. Richard Bevan 
and Southern Idaho Pain Institute (in envelope 
with answers) 
MISC COOPE Jury Roll Call G. Richard Bevan 
MISC COOPE Peremptory Challenges G. Richard Bevan 
MISC COOPE Potential Jury Panel G. Richard Bevan 
ORDR COOPE Order Re: Motions in Limine G. Richard Bevan 
10/17/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 2 G. Richard Bevan 
Hearing date: 10/17/2007 Time: 8:45 am Court 
reporter: Virginia Bailey 
MISC COOPE Preliminary Jury Instructions G. Richard Bevan 
MISC COOPE Final Jury Panel G. Richard Bevan 
10/18/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 3 G. Richard Bevan 
Hearing date: 10/18/2007 Time: 9:09 am Court 
reporter: Virginia Bailey Audio tape number: ct rm 
1 
JUIN COOPE Plaintiff's First Supplemental Proposed Jury G. Richard Bevan 
Instructions Filed 
10/19/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 4 G. Richard Bevan 
Hearing date: 10/16/2007 Time: 9:00 am Court 
reporter: Virginia Bailey 
1 (' (' ,, 
.l I ] ·'..) I! 
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10/19/2007 BREF COOPE Plaintiffs' Bench Brief RE: Proposed "Reckless" G. Richard Bevan 
Instruction 
OBJC COOPE Plaintiffs' Objections to the Defendant's Proposed G. Richard Bevan 
Jury Instructions 
10/23/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 5 G. Richard Bevan 
Hearing date: 10/23/2007 Time: 9:00 am Court 
reporter: Virginia Bailey 
BREF COOPE Supplemental Bench Brief Regarding Jury G. Richard Bevan 
Instruction on Reckless Conduct 
10/24/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Hearing G. Richard Bevan 
date: 10/24/2007 Time: 9:00 am Court reporter: 
Virginia Bailey 
10/25/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 7 G. Richard Bevan 
Hearing date: 10/25/2007 Time: 9:10 am Court 
reporter: Virginia Bailey 
NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
10/26/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 8 G. Richard Bevan 
Hearing date: 10/26/2007 Time: 9:10 am Court 
reporter: Virginia Bailey 
JUIN COOPE Plaintiffs' Second Supplemental Proposed Jury G. Richard Bevan 
Instructions Filed 
OBJC COOPE Defendants' Joint Objections to Plaintiffs' G. Richard Bevan 
Proposed Jury Instructions 
10/30/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 9 G. Richard Bevan 
Hearing date: 10/30/2007 Time: 8:47 am Court 
reporter: Virginia Bailey 
MISC COOPE Final Jury Instructions G. Richard Bevan 
OBJC COOPE Defendants' Joint Objections to Court's Proposed G. Richard Bevan 
Final Jury Instructions 
OBJC COOPE Defendants' Objectionto Plaintiffs' Proposed G. Richard Bevan 
Rebuttal Testimony of Dr. Lipman 
MISC COOPE Declaration of Counsel in Support of Defendants' G. Richard Bevan 
Objection to Proposed Rebuttal Testimony of Dr. 
Lipman 
MISC COOPE Special Verdict Form G. Richard Bevan 
10/31/2007 LETT COOPE Letter from Comstock and Bush G. Richard Bevan 
11/5/2007 JDMT COOPE Judgment G. Richard Bevan 
11/9/2007 JDMT COOPE Judgment G. Richard Bevan 
CDIS COOPE Civil Disposition/Judgment entered: entered for: G. Richard Bevan 
Byrne, Thomas J PA, Defendant; Dille, Clinton L 
MD, Defendant; Doe, John, Defendant; Jane Doe 
I -x,, Defendant; Southern Idaho Pain Institute, 
Defendant; Hall, Tamara, Plaintiff; Howard, Kim 
Lee, Plaintiff; Lewis, Robert P, Plaintiff; 
Schmechel, Vaughn, Plaintiff. Filing date: 
11/9/2007 
·~ .r·i er· l. \' ,_; ,) 
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11/14/2007 AFFD NIELSEN Affidavit of Counsel in Support of Memorandum G. Richard Bevan 
of Costs 
MOTN NIELSEN Defendant Thomas Byrne, P.A.'s Motion for Costs G. Richard Bevan 
MEMO NIELSEN Defendant Thomas J. Byrne's Verified G. Richard Bevan 
Memorandum of Costs 
11/19/2007 MOTN NIELSEN Plaintiffs' Motion for New Trial G. Richard Bevan 
MEMO NIELSEN Memorandum in Support of Plaintiffs' Motion for G. Richard Bevan 
New Trial 
AFFD NIELSEN Affidavit of Byron V. Foster in Support of Plaintiffs' G. Richard Bevan 
Motion for New Trial 
11/20/2007 HRSC COOPE Hearing Scheduled (Motion for Attorney fees and G. Richard Bevan 
Costs 12/17/2007 09:00 AM) 
HRSC COOPE Hearing Scheduled (Motion 12/17/2007 09:00 G. Richard Bevan 
AM) for new trial -- Comstock 
11/21/2007 NOHG NIELSEN Notice Of Hearing re: Motion for New Trial G. Richard Bevan 
fax 
ORDR COOPE Order Returning Property to Investigating law G. Richard Bevan 
Enforcement Agency 
11/23/2007 MOTN NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Motion for Costs 
MEMO NIELSEN Verified Memorandum of Costs G. Richard Bevan 
11/26/2007 NIELSEN Defendant Thomas J. Byrne's Amended Verified G. Richard Bevan 
Memorandum of Costs 
NOHG NIELSEN Notice Of Hearing G. Richard Bevan 
fax 
11/28/2007 OBJC NIELSEN Plaintiffs' Objections to Defendant Thomas J. G. Richard Bevan 
Byrne's Verified Memorandum of Costs 
11/30/2007 NOHG NIELSEN Notice Of Hearing G. Richard Bevan 
12/3/2007 NIELSEN Defendant Thomas J. Byrne's Memorandum in G. Richard Bevan 
Opposition to Plaintiffs' Motion for New Trial 
AFFD NIELSEN Affidavit Keely E. Duke in Support of Thomas J. G. Richard Bevan 
Byrne's Memorandum in Opposition to Plaintiffs' 
Motion for New Trial 
NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Response to Plaintiffs' 
Motion for New Trial 
AFFD NIELSEN Affidavit of Steven J. Hippler in Support of Clinton G. Richard Bevan 
Dille and the Southern Idaho Pain lnstitute's 
Response to Plaintiffs' Motion for New Trial 
12/4/2007 OBJC NIELSEN Plaintiffs' Objections to Defendant Clinton Dille, G. Richard Bevan 
M.D. and Southern Idaho Pain lnstitute's Verified 
Memorandum of Costs 
fax 
12/13/2007 NIELSEN Defendant Thomas J. Byrne's Reply G. Richard Bevan 
Memorandum in Support of Motion for Costs 'lr1r-fl J. I_, J ) 
Date: 9/11/2008 
Time: 09:38 AM 
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Reply Memorandum in Support of Plaintiffs' G. Richard Bevan 
Motion for New Trial 
Affidavit of J. Will Varin in Support of Defendants G. Richard Bevan 
Clinton Dille, M.D. and Southern Idaho Pain 
lnstitute's Reply to Plaintiffs' Objections to 
Defendants Verified Memorandum of Costs 
Amended Verified Memorandum of Costs G. Richard Bevan 
Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Reply to Plaintiffs' 
Objections to Defendants Verified Memorandum 
of Costs 
Court Minutes Hearing type: Motion for New trial G. Richard Bevan 
and motion for atty fees Hearing date: 
12/17/2007 Time: 9:00 am Court reporter: Virginia 
Bailey 
Hearing result for Motion held on 12/17/2007 G. Richard Bevan 
09:00 AM: Hearing Held for new trial --
Comstock 
Hearing result for Motion for Attorney fees and 
Costs held on 12/17/2007 09:00 AM: Hearing 
Held Dille and Bryne 
G. Richard Bevan 
Memorandum Opinion and Order RE: Plaintiffs' G. Richard Bevan 
Motion for New Trial 
Memorandum Decision and Order RE: G. Richard Bevan 
Defendants' Motions for Costs 
Amended Judgment G. Richard Bevan 
Judgment Nunc Pro Tune 
Estimate Cost of Reporter's Transcript 2100 
pages 
Notice Of Appeal 
Clerk's Certificate Of Appeal 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
Filing: T - Civil Appeals To The Supreme Court G. Richard Bevan 
($86.00 Directly to Supreme Court Plus this 
amount to the District Court) Paid by: Comstock, 
David E. (attorney for Schmechel, Vaughn) 
Receipt number: 8006054 Dated: 3/5/2008 
Amount: $15.00 (Check) For: Schmechel, 
Vaughn (plaintiff) 
Miscellaneous Payment: For Making Copies Of G. Richard Bevan 
Transcripts For Appeal Per Page Paid by: 
Comstock and Bush Receipt number: 8006055 
Dated: 3/5/2008 Amount: $70.00 (Check) 
Miscellaneous Payment: Record Covers For G. Richard Bevan 
Appeals Paid by: Comstock and Bush Receipt 
number: 8006055 Dated: 3/5/2008 Amount: 
$30.00 (Check) 
Supreme Court Document Filed- Copy of Filing G. Richard Bevan 
Fee Receipt 11 r, r· ... , l \i '...' i 
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3/14/2008 SCDF COOPE Supreme Court Document Filed- Filing of Clerk's G. Richard Bevan 
Certificate 
SCDF COOPE Supreme Court Document Filed- Notice of Appeal G. Richard Bevan 
(T) 
3/17/2008 REQU COOPE Defendant Thomas J. Bryne, PA's Request for G. Richard Bevan 
Additional Transcript and Record 
REQU COOPE Defendants Clinton Dille M.D. and Southern Idaho G. Richard Bevan 
Pain lnstitute's Request for Additional Transcripts 
and Records 
3/18/2008 CCOA COOPE Amended Clerk's Certificate Of Appeal G. Richard Bevan 
3/24/2008 SCDF COOPE Supreme Court Document Filed- Order Granting G. Richard Bevan 
Court Reporter's Motion for Extension of Time 
SCDF COOPE Supreme Court Document Filed- Clerk's Record G. Richard Bevan 
& Transcript Due Date Reset 
3/28/2008 SCDF COOPE Supreme Court Document Filed- Document{s) G. Richard Bevan 
4/2/2008 AFFD NIELSEN Affidavit of Byron W. Foster G. Richard Bevan 
fax 
MOTN NIELSEN Plaintiff's Motion to Extend _Automatic Stay G. Richard Bevan 
fax 
AFFD NIELSEN Affidavit of Taylor L. Mossman G. Richard Bevan 
fax 
418/2008 NIELSEN Defendants Clinton Dille', M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Objection to Plaintiffs' 
Motion to Extend Automatic Stay 
fax 
AFFD NIELSEN Affidavit of Steven J. Hippler in Support of G. Richard Bevan 
Defendants' Objection to Plaintiffs' Motion to 
Extend Automatic Stay 
fax 
4/912008 COOPE Miscellaneous Payment: For Making Copies Of G. Richard Bevan 
Transcripts For Appeal Per Page Paid by: Givens 
Pursley Receipt number: 8009231 Dated: 
419/2008 Amount: $100.00 (Check) 
5/812008 HRSC COOPE Hearing Scheduled (Motion 05/28/2008 02:00 G. Richard Bevan 
PM) to stay execution and bond in interesting 
bearing acct., by phone 
NOTC COOPE Plaintifrs Notice of Posting of Cash Bond G. Richard Bevan 
MOTN COOPE Plaintiff's Motion to Stay Execution of Judgment G. Richard Bevan 
Pending the Appeal 
BNDC COOPE Bond Posted - Cash (Receipt 8011835 Dated G. Richard Bevan 
518/2008 for 35603.64) 
5/12/2008 OBJC NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Objection to Plaintiffs' 
Motion to Stay Execution of Judgment Pending 
the Appeal 
NOHG COOPE Notice Of Telephonic Hearing RE: Plaintiffs' G. Richard Bevan 
Motion to Stay Execution of Judgment Pending 1 ... 1 r~ o l \, J ,) 
the Appeal and Notice of Posting Cash Bond 
Date: 9/11/2008 
Time: 09:38 AM 
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Thomas Byrne, P.A.'s Joinder in Defendants G. Richard Bevan 
Clinton Dille, M.D. and Souther Idaho Pain 
lnstitute's Objection to Plaintiffs' Motion to Stay 
Execution of Judgment Pending the Appeal 
fax 
Court Minutes Hearing type: Motion Hearing date: G. Richard Bevan 
5/28/2008 Time: 10:00 am Court reporter: Virginia 
Bailey Audio tape number: ct rm 1 
Hearing result for Motion held on 05/28/2008 G. Richard Bevan 
02:00 PM: District Court Hearing Held 
Court Reporter: 
Number of Transcript Pages for this hearing 
estimated: to stay execution and bond in interest 
bearing acct., by phone 
Order Granting Plaintiffs' Motion to Stay 
Execution of Judgment Pending the Appeal 
Supreme Court Document Filed- Document 
G. Richard Bevan 
G. Richard Bevan 
Supreme Court Document Filed- Clerk's Record .G. Richard Bevan 
and Transcript Due Date Reset 
Supreme Court Document Filed- Order Granting G. Richard Bevan 
Court Reporter's Motion for Extension of Time 
Supreme Court Document Filed- Clerk's Record G. Richard Bevan 
& Transcript Due Date Reset 
Notice of Balance Due on Clerk's Record 
Notice of Balance Due on Clerk's Record 
Notice of Balance Due on Clerk's Record 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
Miscellaneous Payment: Personal Copy Fee Paid G. Richard Bevan 
by: Comstaock and Bush Receipt number: 
8016131 Dated: 6/24/2008 Amount: $61.70 
(Check) 
Miscellaneous Payment: For Making Copies Of G. Richard Bevan 
Transcripts For Appeal Per Page Paid by: 
Comstaock and Bush Receipt number: 8016131 
Dated: 6/24/2008 Amount: $291.25 (Check) 
Miscellaneous Payment: Record Covers For G. Richard Bevan 
Appeals Paid by: Comstaock and Bush Receipt 
number: 8016131 Dated: 6/2412008 Amount: 
$30.00 (Check) 
Miscellaneous Payment: For Making Copies Of G. Richard Bevan 
Transcripts For Appeal Per Page Paid by: Hall, 
Farley, Oberrecht & Blanton P.A. Receipt number: 
8016139 Dated: 6/24/2008 Amount: $269.00 
(Check) 
Miscellaneous Payment: Personal Copy Fee Paid G. Richard Bevan 
by: Hall, Farley, Oberrecht & Blanton P.A. Receipt 
number: 8016140 Dated: 6/24/2008 Amount: 
$6.90 (Check) 
Date: 9/1112008 
Time: 09:38 AM 
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User: COOPE 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 












































Miscellaneous Payment: For Making Copies Of 
Transcripts For Appeal Per Page Paid by: Hall, 
Farley, Oberrecht & Blanton P.A. Receipt number: 
8016140 Dated: 6/24/2008 Amount: $47.50 
(Check) 
Judge 
G. Richard Bevan 
Miscellaneous Payment: Personal Copy Fee Paid G. Richard Bevan 
by: Givens Pursley Receipt number: 8016141 
Dated: 6/24/2008 Amount: $62.00 (Check) 
Miscellaneous Payment: For Making Copies Of G. Richard Bevan 
Transcripts For Appeal Per Page Paid by: Givens 
Pursley Receipt number: 8016141 Dated: 
6/24/2008 Amount: $211.25 (Check) 
lodged Transcript Volume 1 G. Richard Bevan 
Lodged Transcript Volume 2 G. Richard Bevan 
Supreme Court Document Filed- Notice of G. Richard Bevan 
Transcript Lodged 
Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Objection to Clerk's Record 
and Request for Additional Items 
Defendant Thomas J. Byrne's Joinder in G. Richard Bevan 
Defendants Clinton Dille M.D. and Southern Idaho 
Pain lnstitute's Objection to Clerk's Record and 
Request for Additional Items 
fas 
Hearing Scheduled (Motion 09/03/2008 09:00 G. Richard Bevan 
AM) Objection to clerk's record 
Notice Of Hearing G. Richard Bevan 
Supreme Court Document Filed- Document (s) G. Richard Bevan 
Supreme Court Document Filed- Clerk's 
Record/Reporter's Trans. -Suspended-
G. Richard Bevan 
Stipulation re: to Clerk's Record and Request for G. Richard Bevan 
Additional Items 
Order RE: Objection to Clerk's Record and G. Richard Bevan 
Request for Additional Items and Stipulation RE: 
Objection to Clerk's Record and Request for 
Additional Items 
Hearing result for Motion held on 09/03/2008 G. Richard Bevan 
09:00 AM: Hearing Vacated Objection to clerk's 
record 
Notice of Balance due on Clerk's Record 
(Supplemental) 
Supreme Court Document Filed- Document( s) 
G. Richard Bevan 
G. Richard Bevan 
Supreme Court Document Filed- Clerk's Record G. Richard Bevan 
and Transcript Due Date Reset 
Keely E. Duke 
!SB #6044; ked@hallfarley.com 
Chris D. Comstock 
!SB #6581; cdc@hallfarley.com 
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HALL, FARLEY, OBER.RECHT & BLANTON, P.A. 
702 West Idaho, Suite 700 
Post Office Box 1271 
Boise, Idaho 83701 
Telephone: (208) 395-8500 
Facsimile: (208) 395-8585 
W:\2\2-404.53\Ncw Trlal Opp.doc 
Attorneys for Defendant Thomas J. Byrne 
IN THE DISTRICT COURT OF THE FIFTH WDICIAL DISTRICT 
OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS 
VAUGHN SCHMECHEL, individually, 
and as Surviving Spouse and Personal 
Representative of the Estate of ROSALIE 
SCHMECHEL, deceased, and ROBERT P. 
LEWIS, KIM HOWARD and TAMARA 




CLINTON DILLE, M.D., SOUTHERN 
IDAHO PAIN INSTITUTE, an Idaho 
corporation, THOMAS BYRNE, P.A. and 
JOHN DOE, I through X, 
Defendants. 
Case No. CV-05-4345 
DEFENDANT THOMAS J. BYRNE'S 
MEMORANDUM IN OPPOSITION 
TO PLAINTIFFS' MOTION FOR 
NEWTRIAL 
COMES NOW defendant, Thomas J. Byme (hereinafter "Mr. Byme"), by and through his 
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counsel of record Hall, Farley, Oberrecht & Blanton, P.A., and submits this Memorandum in 
Opposition to Plaintiffs' Motion for New Trial. 
I. INTRODUCTION 
This was an action for medical malpractice wherein plaintiffs alleged Mr. Byrne and Clinton 
Dille, M.D. (hereinafter "Dr. Dille") breached the applicable standard of care in their care and 
treatment of Mrs. Schmechel. This case was tried before the Honorable G. Richard Bevan, 
commencing on October 16, 2007. On October 31, 2007, the jury returned a w1animous verdict, 
finding that defendants did not breach the standard of care in their care and treatment of Rosalie 
Schmechel. Judgment for Mr. Bymewas entered on November 5, 2007 and judgment for Dr. Dille 
was entered on November 9, 2007. 
Plaintiffs' Motion for New Trial pursuant to Idaho Rule of Civil Procedure 59(a)(l)(3) and 
(7) alleges four issues which they assert warrant a new trial in this matter. First, plaintiffs argue the 
Court erred in precluding plaintiffs' experts from offering expert testimony regarding the Delegation 
of Services Agreement and how such Agreement pertains to the standard of care. Second, plaintiffs 
argue the Court erred in allowing defendants' expert, Dr. Smith, to testify at trial regarding his 
opinion as to the cause of Mrs. Schmechel' s death based upon an alleged late disclos,ire of such 
opinion. Third, plaintiffs allege the Court erred in not admitting the IDAP A regulations regarding 
physician assistants into evidence or instructing the jury as to negligence per se based upon such 
instruction. As a note, the Court did provide the jury with an instruction indicating the Court took 
judicial notice of the IDAPA regulations, but did not admit the Regulations themselves. Finally, 
plaintiffs allege the Court erred in biforcating the issue ofreoklessness. Plaintiffs' Motion for New 
Trial should be denied on all grounds, as they are unable to establish any errors oflaw, irregularities 
in the proceedings which prevented them from having a fair trial, or any surprises that could not have 
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been prevented with ordinary prudence. The Court appropriately recognized the discretionary nature 
of each of the above issues, and did not abuse such discretion with regard to any of its rulings. 
II. STANDARDS 
Plaintiffs' Motion for New Trial is based on Idaho Rule of Civil Procedure 59(a) whicl1 states 
in pertinent part:, 
A new trial may be granted to all or any of the parties and on all or 
part of the issues in an action for any of the following reasons: 
1. Irregularity in the proceedings of the court, jury or adverse party or 
any order of the court or abuse of discretion by which either party was 
prevented from having a fair trial. 
*** 
3. Accident or surprise, which ordinary prudence could not have 
guarded against. 
*** 
i En-or in law, occun-ing at the trial. 
The Court has wide discretion in determining whether to grant a motion for new trial and a 
trial cou1t' s decision will not be overturned unless the trial court abuses such discretion. Craig 
Johnson Const., LLC v. Floyd Town Architects, P.A., 142 Idaho 797, 800, 134 P .3d 648,651 (2006). 
Idaho appellate courts review the decision to grant or deny a motion for a new trial under an abuse of 
discretion standard. Warren v. Sharp, 139 ldaho 599,603, 83 PJd 773, 777 (2003). On appeal, the 
trial court's decision to grant or deny a new trial will not be disturbed absent a showing of manifest 
abuse. Dyet v. McKinley, 139 Idaho 526,529, 81 P.3d 1236, 1239 (2003). 
When considering whether to grant a new trial pursuant to I.R. C.P. 59( a)( 1 ), plaintiffs must 
establish that an irregularity in the proceedings of the Court, j my or adverse party prevented 
plaintiffs from receiving a fair trial. A comt' s determination of whether such an irregularity 
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prevented plaintiff from having a fair trial is a matter of discretion. Myers v. A. 0. Smith Harvestore 
Products, Inc., l 14 Idaho 432,440, 757 P.2d 695, 703 (Ct. App.,1988) 
A motion pursuant to I.R.C.P. 59(a)(3) requires a showing 1hat the alleged accident or 
surprise is one that "ordinary prudence could not have guarded against." LR.C.P. 59(a)(3). Hughes v. 
State, Idalw Dept. of Law Er/forcement, 129 Idaho 558,562,929 P.2d 120, 124 (1996). Fur1her, the 
moving party must establish that such accident or surprise caused prejudice. See Westfall v. 
Caterpillar, Inc., 120 Idaho 918,821 P.2d 973 (1991). 
Pursuant to Rule 59( a)(7), the trial court may grant a new trial for errors in law that occurred 
during trial, but only if such error affects a substantial right of the moving party. Highland 
Enterprises, Inc._ v. Barker, 133 ldaho 330,345,986 P.2d 996, 1011 (1999). The decision to grant or 
deny a motion for new trial on this ground is wi1hin the sound discretion of the trial court, and the 
trial court's decision will not be disturbed on appeal "unless it clearly appears to have been applied 
unwisely and to have been manifestly abused." Davis v. Sun Valley Ski Education Foundation, Inc., 
130 Idaho 400, 404-05, 941 P.2d 1301, 1305-06 (1997) (quotingSherwpodv. Carter, 119 Idaho 246, 
261, 805 P .2d 452, 467 (1991 )). The trial court is vested with "wide discretion" to grant or deny a 
motion for new trial pursuant to Rule 59(a)(7) when the substantial rights of the movant are not 
affected and that party is not entitled to a new trial as a matter ofright. Craig Johnson Const., LLC, 
142 Idaho at 801, 134 P.3d at 652. 
III. ARGUMENT 
A. The Court Properly Precluded Plaintiffs' Experts From Offering Expert Testimony 
Regarding the Delegations of Senriccs Agreement, as Plaintiffs Failed to Disclose 
Such Opinions. 
Plaintiffs argue they are entitled to a new trial based on the Court's ruling precluding their 
experts from offering expert testimony regarding whether defendants had breached the Delegation of 
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Services Agreement. Specifically, plaintiffs argue the 2003 Delegation of Services Agreement was 
untimely produced, and that such late disclosure prohibited them from addressing this issue with 
their experts prior to trial and supplementing their expert disclosures. As such, plaintiffs argue that 
the late disclosure constitutes an irregularity in the proceedings and unfair surprise, and that the 
Court's ruling to exclude their experts' testimony regarding the Agreement was an error in law. 
However, as discussed below, plaintiffs' arguments fail for the following reasons: (1) the 2003 DOS 
Agreement was produced as soon as it was discovered; (2) plaintiffs could have avoided any unfair 
surprise by providing their experts with the earlier produced 2004 DOS Agreement, 2001 Job 
Description and IDAP A regulations and disclosed whatever expert opinions they may have had; and 
(3) plaintiffs had an opportunity to present rebuttal evidence regarding the 2003 DOS Agreement but 
failed to do so and thereby waived their ability to argue such issue. 
1. The 2003 Delegation of Services Agreement Was Produced As Soon As it 
Was Discovered, 
The disclosure of the 2003 DOS Agreement on October 10, 2007, does not constitute an 
irregularity in the proceedings that would give rise to a new trial, as the disclosure did not prevent 
plaintiffs from having a fair trial. For purposes of background, a copy of the 2004 DOS Agreement 
as well as a copy·of a 2001 employment contract with Southern Idaho Pain Institute was produced at 
Mr. Byrne's deposition on May 18, 2006. 
On October 4, 2007, defendants received a letter from plaintiffs' counsel indicating a DOS 
Agreement was required in 2003, and to "kindly supplement your response." (See Affidavit of Byron 
Foster in Support of Plaintiffs' Motion for New Trial, Ex. D). After receiving this letter, counsel for 
Mr. Byrne realized that at Mr. Byrne's May 18, 2006 deposition, a copy of the 2004 DOS 
Agreement (not the 2003 Agreement) was produced. As such, counsel for Mr. Byrne asked Mr. 
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Byrne ifhe could search his records for a copy of a 2003 DOS Agreement. (See Duke Aff., 12). Mr, 
Byrne conducted a search of his records that were kept in storage and discovered the 2003 DOS 
Agreement and provided it to counsel, who the~1 irnrnediately_produce_1 th~ do~um~nt to plaintiffs' 
counsel on October 10, 2007. (See Defendant Thomas J. Byrne, P.A.'s Fourth Supplemental 
Responses to Plaintiffs' First Set of Requests for Production of Documents, Foster Aff., Ex. E). An 
assistant from plaintiffs' counsels' office emailed Mr. Byrne's counsel to examine the original 
document, and Ms. Duke emailed back indicating "you can come over any time." (See Duke Aff., 
Ex. 2 (October I 0, 2007 email from Margie Rosenberg to Ms. Duke and return email from Ms. Duke 
to Ms. Rosenberg). Plaintiffs' paralegal, Margie Rosenberg, inspected the original 2003 DOS 
Agreement on October 11, 2007. 
2: The 2003 and 2004 Delegation of Service Agreements are Nearly Identical. 
Plaintiffs argue in their motion for new trial 1hey incurred unfair prejudice in that the 2003 
DOS Agreement was not produced until October 10, 2007, and they did not have an opportunity to 
address issues relating to the Agreement in regard to standard of care as a result. However, plaintiffs 
had a copy of the 2004 DOS Agreement as of May 18, 2006, as well as a copy of the 2001 Job 
Description. Plaintiffs crumot establish any unfair prejudice or surprise, however, as the 2004 
Agreement is nearly identical to the 2003 DOS Agreement, and plaintiffs could have provided the 
2004 DOS Agreement, the 2001 Job Description and the IDAPA regulations regarding physician 
assistants in order to develop and disclose expert opinions prior to trial. 
The 2003 DOS Agreement (Ex. 40) ru1d the 2004 DOS Agreement (Attached as Ex. 4 to the 
Duke Aff.) vary in only very minor ru1d insignificant ways which are described below witb the 
changes underscored: 
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The first sentence of the paragraph under heading Re-Evaluation: 
o 2003 Agreement states: "The PA will be utilized in the re-evaluation of existing 
patients for medication management, prescription renewal and recommendations 
for further t·eatment within our facility." 
o 2004 Agreement states: "The PA will be utilized in the re-evaluation of existing 
patients for medication management & renewal and recommendations for further 
treatment within our facility." 
The second sentence of the paragraph under the heading of Minor Procedures: 
o 2003 Agreement States: "These include but are not limited to: trigger point 
injections, small joint injections, occipital injections, and laceration repair. 
o 2004 Agreement states: "These include but are not limited to: trigger point 
injections, small joint injections, occipital injections, and manipulations." 
The second paragraph under the heading of"Direction and Control," second line: 
o 2004 Agreement contains a typographical error that is not present in the 2003 
Agreement ("they" instead of "the"). 
The 7th line under heading "Emergency Procedures": 
o 2003 Agreement states a "primary or secondary physician will be available 24 
hours per day ... 
o 2004 Agreement states a "primary or secondary physician will be available 23 
hours per day ... " 
The third paragraph under the heading "Prescription Authority": 
o 2003 Agreement states: "Current prescribing privileges, now include Schedule 2, 
2N, 3, 3N, 4 and 5, after application and approval through the Idaho Board of 
Medicine and Federal Drug Enforcement Administration Guidelines." 
o 2004 Agreement states: "Current prescribing privileges, now include Schedule 2, 
2N, 3, 3N, 4 and 5. This change came after application and approval through the 
Idaho Board of Medicine and Federal Drug Enforcement Administration 
guidelines." 
The 6°1 line under heading "Care Review": 
o 2003 Agreement states: "In addition, a secondary supervising physician or I will 
be available 24 hours a day to provide the physician assistant with medical 
guidance and supervision." 
o 2004 Agreement states: "In addition l or a secondary supervising physician wilJ 
be available 23 hours a day to provide the physician assistant with medical 
guidance and supervision." 
As evidenced in the line by line comparison of the 2003 and 2004 DOS agreements, the 
substance of the two DOS agreements was not different-specifically, the portion that defendants 
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were primarily questioned on had to do with the paragraph entitled "Initial Evaluation of Patients." 
This paragraph is identical in both the 2004 and 2003 DOS Agreements: 
The physician assistant employed with Southern Idaho Pain & Rehabilitation will be 
utilized in the initial evaluation for patients seen in this facility. These patients stem -
from a physician referral base and also patient self-referrals. Patients will require a 
full history and physical on initial visit. Pertinent findings will be documented and 
recommendations made. The recommendations will be reviewed by the supervising 
physician to confirm findings and determine a treatment plan. 
3. Plaintiffs' Experts Testified at Deposition and Trial that Defendants 
Complied with Idaho Law. 
Interestingly, although the 2003 DOS Agreement was not produced to plaintiffs' experts until 
at least October 10, 2007, plaintiffs' experts did not opine that defendants were in violation ofidaho 
law for failing to have a 2003 DOS Agreement. Further, plaintiffs' experts testified at deposition 
and trial that Mr. Byrne had the authority to perform a history, initial evaluation., determine a 
treatment plan and prescribe Mrs. Schmechel medication, and that such authority complied with . . 
Idaho law. 
Specifically, Dr. Lordon testified at trial as follows: 
Q: Let's talk about physicians assistants a little bit. You would agree that a 
physician assistant is a physician extender? 
A: I would use that term. 
Q: Physician assistants evaluate and treat patients, and they do minor medical 
procedures; correct? 
A: That is correct? 
Q: And that's all appropriate for them to do those things? 
A: Yes, it is. 
Q: It was certainly okay, in your opinion, for Mr. Byrne to prescribe 
medications? 
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Q: That's something that Idaho law permits him to do? 
A: Yes. 
Q: And Idaho law also allows physician assistants to evaluate, plan, and 
implement plans of care, and you have 110 problem with that; correct? 
A: I have no problem with that. 
Q: So you are in no way critical of the fact that Mr. Byme treated Mrs. 
Schmechel; con-ect? 
A: No, none whatsoever. 
Duke Aff., Ex, 5 (relevant portions of Dr. Lordon's trial testimony), pp. 66-67, IL S-6. 
Plaintiffs' expert Mr. Keller testified in his deposition as follows: 
Q: But let me ask you this, it was okay, as I understand it, for Mr. Byrne to make 
the decisions as a physician assistant to alter the medication, correct? 
A: Sure. That's by any state regulation and supervisory dlctorum that you have 
and the relationship that you have with your supervising physician, a PA has 
the authority to do that. Sure. 
Q: You are not critical of him doing that aspect of it? 
A: No, absolutely not. 
(See Duke Aff., Ex. 6 (relevant portions of Mr. Keller's deposition transcript), pp. 55-65, II. I 9-3). 
Further, Mr. Keller testified at trial as follows: 
Q: Btit with respect to what I have up there, a physician assistant, taking medical 
histories., conducting physical examinations, prescribing medications, 
counseling and educating patients, monitoring patients, ordering diagnostic 
tests, performing minor surgery that's all within the scope of a physician 
assistant's practice; correct? 
A: Their practice and their education, yes. 
(See Duke Aff., Ex. 7 (October 18, 2007 testimony of Mr. Keller, p. 51, 11. 15-22)). 







Dr. Lipman testified in his deposition regarding Idaho physician assistant regulations as 
follows: 
Q: Do you understand that physician's assistants in Idaho have, or did in 2003, 
- have the authotity to see patients on initial evaluation and to prescribe a 
course of treatment, including Schedule II narcotics? 
A: Yes. 
Q: Without a physician first approving that course of conduct. 
A: Yes. (Deposition ofDr. Lipman, p. 191, IL 8-16). 
Dr. Lipman further testified in his deposition: 
Q: Is it your contention that Mr. Byrne or Dr. Dille violated any applicable 
statute or rule of law in the state of Idaho? 
A: No. 
(See Duke Aff., fx. 8 (Deposition of Dr. Lipman, p. 237, 11. 3-6)). The above testimony from trial 
and depositicms,indicates that plaintiffs' experts had the opportunity to opine regarding the scope 
and authority of a physician assistant as governed by Idaho law despite the production of the 2003 
DOS Agreement in October 2007. Further, the above testimony reveals these experts felt Mr. Byrne 
was within the scope of his allowable practice as outlined by Idaho law in his treatment and care of 
Mrs. Schmechel. 
4. The Timing of the Disclosure of the 2003 DOS Agreement Did Not Preclude 
Plaintiffs From Disclosing Expert Testimony Regarding the Scope of Mr. 
Byrne's Authority or Whether Defendants Had Complied With Idaho Law. 
Plaintiffs argue that as a result of the late disclosure of the 2003 DOS Agreement, they were 
precluded from disclosing their expert opinion regarding such Agreement. However, this argument 
fails, as plaintiffs had access to the IDAP A regulation indicating a DOS Agreement was requited, a 
copy of the 2004 DOS Agreement and the 2001 Job Description as ofMay 18, 2006. Plaintiffs could 
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have had their experts address the ID AP A regulations and their requirement that a DOS agreement 
be in place in 2003 and that if no such DOS agreement existed, defendants were violating such 
regulations.: or ~he ~g_11ag<:_ oft~e 2004 Agreement and 2001 Job Description. Plaintiffs faile~ to do 
so. In fact, it appears plaintiffs did not provide these documents to their experts until after they were 
deposed in this matter and just prior to trial. (See Plaintiffs' Fourth Supplemental Expert Witness 
Disclosures, dated October 5, 2007). 
Further, plaintiffs could have and should have supplemented their expert disclosures based 
upon the 2003 Agreement prior to trial. The parties both engaged in supplementation of expert 
witness opinions up to the time of trial. In fact, plaintiffs submitted their Fourth Supplemental 
Expert Witness Disclosures on October 5, 2007. As the Court stated in sustaining the objection to 
Dr. Lordon' s testimony regarding the 2003 Agreement: 
I am going to sustain the objection. I dete1mine that, even though it wasn't disclosed 
until last.week, that the nature of the inquiry and the circumstances surrounding this 
testimony were known in advance sufficiently to allow this disclosure to have been 
made. So I will sustain the defendant's objection. 
(See Duke Aff., Ex. 5, p. 39, IL 14-20). 
5, The Court Properly Excluded Plaintiffs' Experts Fram Offering 
Undisclosed Expert Testimony Regarding the DOS Agreement. 
Trial courts have "broad discretion in the admission.of evidence at trial, and [their] decision 
to admit such evidence will be reversed only when there has been a clear abuse of that discreti-011. 
The same standard applies to the admission of expe1i testimony." Karlson v. Harris, 140 Idaho 561, 
564, 97 P.3d 428, 43 l (2004 ). It is appropriate to exclude from trial the opinion testimony of any 
expert whose opinion was not disclosed pursuant to written requests for discovery. I,R.C,P. 26(e)(4); 
C/arkv. Ratay, 1)7 Idal10 343,347, 48 P.3d 672,676 (Ct. App. 2002). 
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Based on the foregoing, it is clear that the Court properly exercised its discretion in excluding 
plaintiffs' experts from offering undisclosed expert testimony regarding the 2003 DOS Agreement, 
as plaintiffs could have exercised ordinary prudence in avoiding any unfair surprise and disclosed 
such any such opinions prior to trial. Further, it is important to note the Court similarly precluded 
defendants' retained experts from testifying regarding their expert opinions as to whether Mr. Byrne 
and Dr. Dille complied with the 2003 Agreement for failing to disclose such opinions prior to trial. 
6. Plaintiffs Waived Their Right to Assert an Error by Failing to Address The 
2003 DOS Agreement in Rebuttal Testimony. 
At trial, the Court indicated it would consider allowing plaintiffs to address issues regarding 
the 2003 DOS Agreement on rebuttal. However, plaintiffs did not attempt to address this matter on 
rebuttal, and therefore failed to preserve this issue for appeal. By failing to attempt to offer rebuttal 
testimony from their experts regarding the 2003 DOS Agreement, the parties cannot know whether 
the Court would have allowed such rebuttal testimony. As such, plaintiffs failed to properly raise his 
issue at trial, and are precluded from doing so now. See Lankfordv. Nicholson lvffg, Co., 126 Idaho 
187,189,879 P.2d 1120, 1122 (1994). 
ln conclusion, plaintiffs are unable to show an irregularities in the proceedings, unfair 
surprise, or errors in law with regard to the Court's ruling to preclude plaintiffs' experts from 
offering their undisclosed expert opinions regarding the 2003 DOS Agreement. As noted by the 
Court, plaintiffs. had an opportunity to disclose such opinions prior to trial and failed to do so. 
Further, plaintiffs waived any such argument by failing to attempt to address this issue on rebuttal. 
B. Plaintiffs Were Not Unfairly Surprised by the Testimony of Dr. Smith. 
Plaintiffs argue the Court erred in allowing Dr. Smith to testify on the grounds that his 
opinions regarding causation were not seasonably supplemented, and that plaintiffs were prejudiced 
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in that based 011 the timing of the disclosures, they were not afforded an opporlunity to depose Dr. 
Smith or seek out a cardiology expett of their own. 
First, any alleged error in the admission of Dr. Smifi1' s testimony was harmless. Specifically, 
Dr. Smith did n6t testify regarding standard of care. Rather, the objected to testimony of Dr. Smith 
dealt exclusively with the issue of proximate cause. The jury unanimously decided that Mr. Byrne 
and Dr. Dille met the applicable standard of care and, were not required to decide.the issue of the 
cause of Mrs. Schmechel's death. InPeschke v. Carroll College, 929 P.2d 874,881 (Mont.,1996), 
the court found the trial court erred in allowing defendant's videotape reenactment into evidence. 
However, on appeal, the court held that such error was harmless, "[ s Juch timing evidence goes to the 
issue of causation, which the jury did not reach, having determined that Carroll had not breached its 
duty to warn and was therefore not negligent. Thus, we conclude that the court's error in this regard 
was harmless." Id. 
Regardless, plaintiffs are unable to show entitlement to a new trial, as discussed below, 
because Dr. Smith's original opinions were timely disclosed and once Dr. Smith had an opportunity 
to review the depositions of the pathologist, Dr. Groben, and the coroner, his supplemental opinions 
were seasonably supplemented. Further, as noted by the Court in denying plaintiffs' objection to Dr. 
Smith's testimony, plaintiffs had sufficient time to address Dr. Smith's testimony regarding 
causation. Therefore, plaintiffs' argument that they were "stonewalled" is without merit and the 
Court's discretionary ruling permitting Dr. Smith to testify a proper exercise of discretion. 
Trial courts have "broad discretion in the admission of evidence at trial, and [their] decision 
to admit such evidence will be reversed only when there has been a clear abuse of that discretion. 
The same standard applies to the admission ofexpert testimony." Karlson v. Harris, 140 Idaho 561, 
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564, 97 P.3d 428,431 (2004). Further, in the event of an inconect ruling regarding evidence, "anew 
trial is merited only if the eITor affects a substantial right of one of the parties." Id. 
In ruling on the admissibility of Dr. Smith's testimony at trial, the Court appropriately 
recognized its determination was a matter of discretion. Further, the Court noted in its ruling that 
plaintiffs had sufficient time to address Dr. Smith's supplemented opinion regarding cause of death. 
Therefore, plaintiffs cannot claim unfair surprise as they could have addressed Dr. Smith's opinions 
through ordinary prudence. 
Defendants disclosed Dr. Smith pursuant to the Court's Scheduling Order 011 June 18, 2007 
in Defendant Thomas J. Byrne's Disclosure of Expert Witnesses. The disclosure stated in relevant 
part that Dr. Smith would testify regarding the following subject matters "[a)pplicable medical 
principals, causation and damages." (emphasis added). The disclosure went 011 to state, "It is 
anticipated Dr. Smith will testify that the cause of Mrs. Schmechel's death is uncertain and that 
another condition she had was just as, if not more, likely to have caused her death than methadone 
and/or Hydrocodone." On June 20, 2007, counsel for the parties discussed scheduling depositions of 
experts and counsel for Mr. Byrne sent a letter to plaintiffs' counsel indicating in part, that Dr. Smith 
could be deposed after the deposition of Dr. Graben. (See Duke Aff., Ex. 9 (June 20, 2007 letter 
. from Keely E. Duke to Byron Foster). Scheduling of depositions continued to be difficult, and on 
Jnly 3, 2007, counsel for Mr. Byrne again wrote to plaintiffs' counsel attempting to schedule 
depositions of experts and Dr. Groben, and again indicated that Dr. Smith would not be made 
available to testify until "the pathologist in this case, Dr. Groben is deposed." (See Duke Aff., Ex. l 0 
(July 3, 2007 letter from Keely E. Duke to Byron Foster)). The July 3, 2007 letter went on to state 
efforts were being made to schedule Dr. Groben's deposition, and if Dr. Graben could be deposed 
during the week ofJuly 30, 2007, that Dr. Smith would be made available for deposition on August 
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16, 2007. Id. On July 6, 2007, counsel for Mr. Byrne sent a letter to plaintiffs' counsel indicating 
Dr. Groben was available for deposition on July 30, 2007, and Dr. Smith could be deposed 011 
August 16, 2007. (See Duke Aff., Ex. 11 (July 6, 2007 letter from Keely Duke to Byron Foster)). 
Dr. Graben was ·deposed on July 31, 2007. 
On July 27, 2007, four days before Dr. Graben was deposed, plaintiffs' counsel sent a letter 
to defense counsel stating "On further consideration, we will not be taking the depositions or (sic) 
your respective experts. Therefore, please cancel the deposition dates for those individuals." (See 
Duke Aff., Ex. i2 (July 27, 2007, letter from Byron Foster to Keely Duke and Steven Hippler)). 
Therefore, despite the knowledge that Dr. Smith would be testifying regarding causation and relying 
upon the deposition testimony of Dr. Graben, plaintiffs' counsel determined they would not depose 
Dr. Smith, or any of defendants' respective experts in this case, prior to the time that Dr. Graben was 
deposed. 
Further, as testified to by Dr. Smith during trial, the deposition testimony ofMs. Shindle was 
critical in forming his opinions as to causation, based upon the fact that she, and not Dr. Groben 
determined the manner of death. As testified to be Dr. Groben: 
Q: And it's true, is it not, that actually you don't determine the manner of death? 
A: No, I do-not, well, on this case, I don't. Depends on where it comes from. 
Q: That would be in the coroner's office, in this case Ms. Now Anton, then 
Shindle? 
A: Right. That's correct. 
(See Duke Aff., Ex. 13 (trial testimony of Dr. Graben), p. 25, ll. 10-16)). 
Defendants also faced difficulties in scheduling Ms. Shindle's deposition. Ms. Shindle was 
originally scheduled for deposition on July IO, 2007. (See Duke Aff., Ex. 14 {Notice ofTaldng 
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Deposition Duces Tecum ofShaiyenne Shindfo, dated June 6, 2007)), On June 7, 2007, an assistant 
from plaintiffs' counsel's office called indicating plaintiffs' counsel was not available for the July 
I 0, 2007 deposition of Ms. Shindle which had previously been scheduled. (See Duke Aff., Ex. 15, 
July 6, 2007, email from Ms. Pontakto Ms. Duke). Counsel for Mr. Byrne attempted to obtain dates 
from plaintiffs' counsel to reschedule Ms. Shindle's deposition in late June 2007. (See Duke Aff., 
Ex. 16 (July 2, 2007 letter from Byron Foster to Keely Duke)). Due to unavailability of Ms. Shindle 
and Dennis Chambers ( another Twin Falls County Coroner who was to be deposed), Mr. Byrne was 
unable to get another available date for Ms. Shindle until September 5, 2007. Ms. Shindle was 
deposed on September 5, 2007. Although Mr. Byrne had obtained records from Ms. Shindle, it was 
not until her deposition, that her opinion that Mrs. Schmechel was awake when she died came to 
light. Specifically, Ms. Shindle testified in her deposition that in her opinion Mrs, Schmechel was 
awake just prior to her death based on numerous factors, (See Duke Aff., Ex. 17 (Deposition 
transcript of Ms. Shindle), p. 44, 11. 1-4). Counsel received Ms. Shindle's deposition transcript on 
September 24, 2007, (See Duke Aff., Ex. 1 (September 24, 2007 email from M&M to Keely E, 
Duke). On September 26, 2007, Ms. Shindle' s deposition transcript was hand delivered to Dr. Smith 
for his review and consideration. (See Duke Aff., Ex, 3, September 26, 2007, letter from Kathy 
Savell to Dr. Smith). 
Once Dr. Smith was able to review both of these depositions, Dr. Smith's supplemental 
opinions were seasonably disclosed on October 4, 2007 and stated in relevant part, "It is anticipated 
that Dr. Smith will testify that on a more probable than not basis, the likely cause of Mrs. 
Schmechel' s death was a cardiac death, likely a fatal dysrhythmia. He will testify that the 
dysrhythrnia was caused by her 1mderlying cardiac and other co-morbid conditions." (See 
Defendants Clinton Dille and Southern Idaho Pain Institute's Supplemental Disclosure of Expert 
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Witnesses, p. 2). This disclosure went on to indicate Dr. Smith's opinions regarding Mrs. 
Schrnechel's cause of death were based in part upon the deposition of Dr. Groben, Dr. Groben's 
autopsy rep01t and toxicology report and the deposition testimony of Shaiyem1e Shindle. Id. 
Therefore, as of October 4, 2007, plaintiffs were fully aware of Dr. Smith's anticipated 
testimony regarding the cause of Mrs. Schmechel's death. Further, prior to such time, and prior to 
plaintiffs' determination to not depose defendants' experts, plaintiffs were aware that Dr. Smith 
would be relying upon the depositions of Dr. Groben and Ms. Shindle in fom1ulating his opinions as 
to causation. Plaintiffs could have opted to depose Dr. Smith and chose not do so. Therefore, 
whatever surprise plaintiffs' allege resulted from Dr. Smith's testimony could have been guarded 
against through ordinary prudence. 
C. The Court Properly Excluded the IDAPA's from Evidence and Did Not Abuse its 
Discretion in Not Giving a Negligence Per Se Instruction Regarding the IDAPA 
Regulations. 
Plaintiffs argue the Court erred in failing to give their proposed jury instruction regarding 
negligence per se based upon an alleged violation of the IDAPA regulations and erred in not 
admitting such regulations as exhibits. However, due to the fact that the JDAP A regulations failed to 
define a clear standard of conduct, such regulations do not give rise to a negligence per se 
instruction, and the Cornt properly exercised its discretion in not giving the requested instruction. 
Further, the Court's ruling to the regulations from evidence was not an abuse of discretion, and the 
Court allowed plaintiffs' counsel to question defendants regarding the regulations, read portions of 
the regulations and to show pottions of the regulations to the jury during such examinations. As 
such, plaintiffs cannot show that exclusion of the IDAPA regulations affected a substantial right. 
1. The Regulations Do Not Give Rise to Negligence Per Se. 
The decision to include or exclude jury instructions is left to the discretion of the trial court. 
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Highland Enterprises, Inc. v. Barker, 133 Idaho. 330, 986 P.2d 996 (I 999). The standard ofreview 
for issues concerning jury instructions is limited to a determination of whether the instructions, as a 
whole, fairly and adequately present the issues and state the law. Silver Creek Computers, Inc. v. 
Petra, Inc., 136 ldaho 879, 882, 42 P .3d 672, 675 (2002). If the jury instructions adequately present 
the issues and state the applicable law, no error is committed. Leazer v. Ki~fer, 120 Idaho 902, 904, 
821 P.2d 957,959 (1991), 
In the instant matter, the Comt's jury instructions fairly and adequately presented the issues 
and stated the law. A negligence per se instruction regarding the regulations was not warranted, 
because plaintiffs did not prove the necessary elements to establish that a violation of the IDAP A's 
in question established a claim for negligence per se. 
Negligence per se occurs where a person violates an ordinance or state law. Ahles v, Tabor, 
136 Idaho 393,395, 34 P.3d 1076, 1078 (2001). A claim of negligence per se requires plaintiffs to 
prove: ( 1) the statute or regulation clearly defines the standard of conduct; (2) the statute or 
regulation was intended to prevent the harm caused by defendant's act or omission; (3) plaintiff is a 
person of the class the statute or regulation was designed to protect; and (4)the violation must be a 
proximate cause of plaintiffs alleged injury. O'Guin v. Bingham County, 142 Idaho 49, 52, 122 
P.3d 308, 311 (2005). Negligence per seis a question oflaw for the court. Ahles, 136 Idaho at 395, 
34 P.3d at 1078. 
In Ahles v. Tabor, 136 Idaho 393, 34 P.3d 1076 (2001), the district court held that the 
defendant was negligent per se for violation of LC. § 49-63 3 for passing the plaintiff's vehicle on the 
right side and a subsequent collision. On appeal, the Idaho Supreme Court addressed each of the 
four requirements of negligence per se and determined that the statute did not allow for negligence 
per se. The Ahles court found that elements 2 and 3 were met as the statute was intended to protect 
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motorists and plaintiff fell within the protected category. However, the court held that "the standard 
of conduct described in LC. § 49-633, ... is far from clear and requires statutory interpretation 
including consideration of problematic definitions of terms used in the statute." Id. 136 ldaho at 396, 
34 P.3d at 1079. The Ahles court held there were numerous questions as to certain terms in the 
statute that were subject to interpretation, and that "[a]ll of these questions add to the complexity of 
the statute and show that the standard of conduct derived from interpreting the statute is less than 
clear and not easily asce1tained or applied." Id. As such, the Ahles court held that I.C. § 49-633 did 
not satisfy the test with regard to the "description of a clear standard of conduct. Accordingly, the 
alleged violation of the statute in this case cannot be deemed negligence per se." Id. 
In the instant matter, the Rules for the Li censure of Physician Assistants and the Delegation 
of Services Agreement are subject to interpretation and do not clearly define a required standard of 
conduct. Specifically, Idaho Administrative Code 22.01.03.28 SCOPE OF PRACTICE, indicates 
various items which a physician assistant may perform if included in the Delegation of Services 
Agreement including, "Diagnose and manage minor illnesses or conditions" and "manage the health 
care of the stable chronically ill patient in accordance with the medical regimen initiated by the 
supervising physician." IDAPA 22.01.03.28.03 and 22.01.03.28.04. 
The Regulations do not define minor illnesses or conditions or major illnesses or conditions 
or what constitutes chronically ill, nor do the regulations define the term "manage." As such, what 
constitutes a minor or major illness or condition is an1biguous and left to interpretation. In addition 
what constitutes mruiaged care of a stable chronically ill patient is left to interpretation. If Mrs. 
Schmechel's chronic pain was a minor condition (as testified to by Mr. Byrne) the Regulations 
would allow Mr. Byrne to diagnose and manage such condition. Therefore, the IDAP A regulations 
carmot give rise to a negligence per se instrnction as they fail to clearly define a standard of conduct. 
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As stated above, the fourth element required to find that violation of a statute or regulation 
equates to negligence per se is that "the violation must have been the proximate cause of the injury." 
Ahles, 136 Idaho at 395, 34 P.3d at 1078. Plaintiffs cannot meet this requirement as Dr. Dille 
testified in both his deposition and at trial, that witl1 regard to Mr. Byrne's treatment of Mrs, 
Schmechef, he "could not see where [he] would have made any changes or done anything different 
than what Mr, Byrne had." (See Duke Aff., Ex. 18 (Deposition of Dr. Dille), p. 29, 11. 17-21). Dr, 
Dille testified at-trial that if anything, he would not have been as conservative as Mr. Byrne in his 
Methadone dosing of Mrs. Schmechel. (See Duke Aff., Ex. 19 (trial testimony of Dr. Dille), p. 38, !!. 
l 1-17). Because Dr. Dille would not have changed the treatment provided by Mr. Byrne to Mrs. 
Schmechel, plaintiffs are unable to establish that any alleged breach of the Regulations was the 
proximate cause of Mrs. Schmechel's death. 
Further, as testified to by Dr. Lordon at trial after he had had an opportunity to review the 
2003 DOS Agreement: 
Q: And Idaho law also allows a physician assistants to evaluate, plan, and 
implement plans of care, and you have no problem with that; correct? 
A: I .have no problem wiili mat. 
Q: So you are in no way critical of the fact that Mr. Byrne treated Mrs. 
Schmechel; correct? 
A: No, none whatsoever. 
(See Duke Aff., Ex. 5, pp. 66-67, !1. 25-6). 
In conclusion, the IDAPA regulations did not set forth a necessary and required clear 
standard of conduct and therefore do not meet the requirements for a finding of negligence per se if 
such regulations are breached. As such, the .court did not commit error in not giving plaintiffs' 
requested jury instruction regarding negligence per se. 
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2. The Court Did Not Err In Excluding the IDAPA Regulations From 
Evidence. 
Trial courts have "broad discretion in the admission of evidence at trial, and [their] decision 
to admit such evidence will be reversed only when there has been a clear abuse of that discretion." 
Karlson v. Harris, 140 Idaho 561, 564, 97 P.3d 428,431 (Idaho 2004). In the case of an incorrect 
ruling regarding evidence, a new trial is merited only if the error affects a substantial right of one of 
the parties. Id; I.R.C.P, 61. In ruling on the admissibility of the Regulations, the Court noted that 
they were not clear enough to give rise to a per se jury instruction. Further, as made clear tln·oughout 
the trial, the Regulations themselves were confusing and ambiguous and would likely have misled 
the jury had they been admitted into evidence. As such, the Court properly exercised its discretion in 
excluding the Regulations from evidence. 
Even if such ruling was in error, plaintiffs are not entitled to a new trial as they are unable to 
establish such ruling affected a substantial right or that they incurred any unfair prejudice. 
Specifically, the Comt took judicial notice of the ID APA Regulations, allowed plaintiffs' counsel to 
question defendants regarding the Regulations, read portions of the regulations, and show portions of 
the Regulations to the Jury during examination. Further, the Court indicated it would allow plaintiffs 
to use the Regulations during closing argument. As the Fifth Circuit noted in Alexander v. 
Conveyors & Dumpers, Inc, when a party is allowed to read a safety code to the jury and question 
witnesses with the document the complaining party does not suffer any prejudice because it was not 
provided to the jury. Alexander v. Conveyors & Dumpers, Inc., 731 F.2d 1221, 1229 (5th Cir. Miss. 
1984) ("Secondly, no substantial right of Alexander's was affected by the failure to admit the Code as 
an exhibit because the relevant sections had already been read and shown to the jury.") 



















D. The Court's Bifurcation of Recklessness was Not an Abuse of Discretion. 
Defendants' objected to Dr. Lipman offering any testimony as to whether Mr. Byrne or Dr. 
Dille were reckless. Defendants' objections were ovenuled and Dr. Lipman was allowed to testify 
regarding the issue ofrec!<lessness. Defendants expressly reserve and do not waive those objections 
in addressing this issue for purposes of the instant motion. 
The decision to include or exclude jury instructions is left to the discretion of the trial court. 
Highland Enterprises, Inc. v. Barker, 133 Idaho. 330, 986 P.2d 996 (1999). The standard ofreview 
for issues concerning jury instructions is limited to a dete1mination of whether the instructions, as a 
whole, fairly and adequately present the issues and state the law. Silver Creek Computers, Inc. v. 
Petra, Inc., 136 Idaho 879, 882, 42 P.3d 672, 675 (2002). If the jury instmctions adequately present 
the issues and state the applicable law, no error is committed. Leazer v. Kiefer, 120 Idaho 902, 904, 
821 P.2d 957, 959 (1991). Reversible error occurs when an instruction misleads the jury or 
prejudices a party. Howell v. Eastern Idaho R.R., Inc., 135 Idaho 733,740, 24 P.3d 50, 57 (2001). 
Plaintiffs argue a new trial is warranted pursuant to Idaho Rule of Civil Procedure 59(a)(I) 
and (7) as a result of the Court bifurcating the issue of recklessness. Specifically, plaintiffs argue 
they were prejudiced by not including a reckless instruction in two ways. First, plaintiffs argue they 
elicited significant testimony from Dr. Lipman regarding the recklessness of Mr. Byrne's care, and 
that by not submitting a reckless instruction to the jury, such testimony was rendered "meaningless" 
or that is served to mislead or confuse the jury. 
Second, plaintiffs appear to argue the jury could have found Mr. Byrne recl<less "without ever 
reaching the question of whether the Defendant was negligent." (Memorandum in Supportatp. 13). 
Although identified as separate issues, the question for purposes of the motion is whether the CoUit 
ened in not providing the reckless instruction. 
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Plaintiffs' argument that the jury could have found recklessness without finding negligence 
defies common s_ense as well as the state of the law. The face of plaintiffs' proposed jury instruction 
even makes it clear "reckless" conduct is conduct bearing a higher degree of culpability than 
negligent conduct. Plaintiffs' proposed instruction on recklessness stated: 
The words "reckless conduct" when used in these instructions and when applied to 
the allegations in this case, mean more than ordinary negligence. The words mean 
acts or omissions under circumstances where the actor knew or should have known 
that the acts or omissions not only created an umeasonable risk ofhann to another, 
but involved a high degree of probability that such harm would actually result. 
(Emphasis added). 
Under Plaintiffs' own definition ofrecklessness, if Mr. Byrne was not negligent, he could not 
be reckless. Mariy Idaho cases recognize the distinction between "negligence" and "recklessness." 
See e.g. Athay v: Stacey, 142 Idaho 360,365, 128 P.3d 897,902 (2005); Galloway v. Walker 140 
Idaho 672,676, 99 P.3d 625,629 (Ct. App. 2004). Even Black's Law Dictionary recognizes the fact 
recklessness embraces a higher standard than negligence and states in its definition of recklessness 
that, "Recklessness involves a greater degree of fault than negligence but a lesser degree of fault than 
intentional wrongdoing." Black's Law Dictionary, 7th ed. (West 1999). 
Plaintiffs' argnrnent makes even less sense when considered in light ofidaho Code Sections 
6-1012 and 6-1013, which govern medical malpractice claims. These sections require plaintiffs "[i]n 
any case, claim or action for damages due to injury to or death of any person ... on account of the 
provision of or failnre to provide health care or on account of any matter incidental or related 
thereto" to prove through direct expert testimony that the defendant "negligently failed to meet the 
applicable standard of health care practice of the community in which such care allegedly was or 
should have been provided ... " (Emphasis added). Under these sections therefore, plaintiffs had to 
prove negligence to recover for medical malpractice, and their argument that a finding of 
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recklessness without negligence could have been sufficient must be rejected. 
Plaintiffs sought to instruct the jury on recklessness so they had a basis to pierce the statutory 
non-economic damages cap of [dal10 Code § 6-1603 if the jmy found the defendants negligent and 
returned a damage award above the cap. The issue of the statutory non-economic damage cap was 
only relevant if the jury found that defendants breached the standard of care, that such breaches were 
a proximate cause of Mrs. Schmechel's death, and awarded non-economic damages in excess of the 
cap. In fact, the.statute specifically provides the jury should not be info11ned of the cap during its 
deliberations. See LC. § 6-1603(3) "(If a case is tried to a jury, the jury shall not be informed of the 
limitation contained in subsection (1) of this section."). 
Finally, instructing the jury on recklessness and allowing plaintiffs' connsel to argue Mr. 
Byme was reckless would have greatly prejudiced the defendants, particularly when the issue of 
recklessness only applied to Mr. Byrne. There was no allegation or expert opinion offered that Dr. 
Dille or the Southern Idaho Pain Institute were reckless. Inserting inflammatory language, such as is 
contained in the reckless jury instruction, would have been particularly prejudicial to Dr. Dille and 
the Southern fdaho Pain Institute. The jury could easily have confused the parties to whom the 
recklessness standard applied and improperly applied the instructions. 
The Court considered the arguments of counsel with regard to the giving of the reckless 
instruction, including arguments of defendants that giving such instruction prior to a finding of 
damages in excess of the cap was mmecessary and m1duly prejudicial. The Court then appropriately 
exercised its discretion and bifurcated the recklessness issue. Plaintiffs caimot establish that such 
decision was an error, or that it caused them undue prejudice. Therefore, plaintiffs' motion should 
be denied. 
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IV. CONCLUSION 
Based on the foregoing, plaintiffs have failed to establish a right to a new trial pursuant to 
idaho Rule of Civil Procedure 59(a)( I )(3) or (7), and Mr. Byrne respectfully requests the Court deny 
plaintiffs' Motion for New Trial, and allow the well-reasoned verdict of the jury to stand. 
. -trd 
DATED this_.;---_ day of December, 2007. 
HALL, FARLEY, OBERRECI-IT 
& BLANTON, P.A. 
By~ML'!:-";f::~~~~<.4-~-----
Keely E uke - Of the Firn1 
Attorneys for Defendant Thomas J. Byrne 
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OPPOSITION TO PLAINTIFFS' MOTION FOR NEW TRIAL, by the method indicated below, 
and addressed to each of the following: 
David Comstock 
Law Offices of Comstock & Bush 
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P.O. Box 2774 
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Fax No.: (208) 344-772 l 
Steven J, Hippler 
GIVENS PURSLEY 
601 W. Bannock ST. 
POBox2720 
Boise ID 83701-2720 
Attorneys for Clinton Dille, MD. and· 
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Fax No.: (208) 388-1300 
Lu.s. Mail, Postage Prepaid 
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Hand Delivered 
__ Overnight Mail 
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Chris D. Comstock 
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HALL, FARLEY, OBERRBCHT & BLANTON, P.A. 
702 West Idaho, Suite 700 
Post Office Box 1271 
Boise, Idal10 83701 
Telephone: (208) 395-8500 
Facsimile: (208) 395-8585 
W:\2\2-404.53\New Trlal Opp.Byrne.KED.doc 
Attorneys for Defendant Thomas J. Byrne 
IN THE DISTRJCT COURT OF THE FIFTH JUDICIAL DISTRICT 
OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS 
V AUGE-IN SCHMECHEL, individually, 
and as Surviving Spouse and Personal 
Representative of the Estate of ROSALIE 
SCHMECHEL, deceased, and ROBERT P. 
LEWIS, KIM HOW ARD and TAMARA 




CLINTON DILLE, M.D., SOUTHERN 
IDAHO PAIN INSTITUTE, an Idaho 
corporation, THOMAS BYRNE, P.A. and 
JOHN DOE, I through X, 
Defendants. 
ST A TE OF IDAHO ) 
: ss. 
County of ADA ) 
' ' ,.,_, i ; \ 
Case No. CV-05-4345 
AFFIDAVIT KEELY E. DUKE IN 
SUPPORT OF THOMAS J. 
BYRNE'S MEMORANDUM IN 
OPPOSITION TO PLAINTIFFS' 
MOTION FOR NEW TRIAL 
Aff!DA V!T KEELY E. DUKE IN SUPPORT OF THOMAS J. BYRNE'S MEMORANDUM IN OPPOSITJON 
TO PLAINTJFFS' MOTJON FOR NEW TRIAL - l 
KEELY E. DUKE, being first duly sworn on oath, deposes and states as follows: 
J. I am an attorney with the fom Hall, Farley, Oberrecht & Blanton, P.A., the attorneys 
for defendant Thomas J. Bryne and, in that capacity, I make the following affidavit based upon my 
own personal knowledge and belief. 
2. I was not present at Mr. Byrne's May 18, 2006 deposition in this case. I was under 
the misimpression that Mr. Byrne's relevant Delegation of Services Agreement had been produced at 
his deposition. I did not look into the matter until I received a letter from plaintiffs' counsel on 
October 4, 2007, indicating they had not received a copy of the 2003 Delegation of Services 
Agreement. I had not looked into this matter because an issue regarding the Delegation of Services 
Agreement or lack of one had not been raised. After receiving the October 4, 2007, letter, I 
contacted Mr. Byrne and asked him to search through his records for a copy of the Agreement. Mr. 
Byrne was able to locate a copy of the Agreement within records he had in storage. I then 
immediately produced a copy of the Agreement to opposing counsel 
3. Attached hereto as Exhibit 1 is a true and correct copy of a September 24, 2007 email 
from M&M to Keely E. Duke attachlng an electronic copy of Ms. Shlndle's deposition transcript 
4. Attached hereto as Exhibit 2 is a true and correct copy of an October 10, 2007 email 
from Margie Rosenberg to Keely E. Duke and a return email from Keely Duke to Ms. Rosenberg. 
5. Attached hereto as Exhibit3 is a true and correct copy of a September 26, 2007, letter 
from Kathy Savell to Dr. Smith, enclosing a copy of Ms. Shi11dle's deposition transcript. 
6. Attached hereto as Exhibit 4 is a true and correct copy of the 2004 Delegation of 
Services Agreement. 
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7. Attached hereto as Exhibit 5 is a true and correct copy ofrelevantportions of Stephen 
Lordon, M.D. 's trial testimony transcript. 
8. Attached hereto as Exhibit 6 is a true and con-ect copy ofrelevant portions of James 
Keller's deposition transcript. 
9. Attached hereto as Exhibit 7 is a true and correct copy of portions of James Keller's 
trial testimony transcript. 
10. Attached hereto as Exhibit 8 is a true and cotTect copy of relevant portions of Arthur 
Lipman, PHARM.D.'s deposition transcript. 
11. Attached hereto as Exhibit 9 is a true and correct copy of a June 20, 2007, letter from 
Ms. Duke to Byron Foster . 
. 12. Attached hereto as Exhibit 10 is a tmeand correct copy of a July 3, 2007, letter from 
Ms. Duke to Mr. Foster. 
13. Attached hereto as Exhibit 11 is a true and correct copy of a July 6, 2007, letter from 
Ms. Duke to Mr. Foster. 
14. Attached hereto as Exhibit 12 is a true and correct copy ofaJuly27, 2007 letterfrom 
Mr. Foster to Ms. Duke and Mr. Hippler. 
15. Attached hereto as Exhibit 13 is a true and correct copy of portions of Glen Graben, 
M.D. 's trial testimony transcript. 
16. Attached hereto as Exhibit 14 is a true and correct copy of the June 6, 2007 Notice of 
Taking Deposition Duces Tecum of Shaiyenne Shindle. 
17. Attached hereto as Exhibit 15 is a trne and correct copy of a June 7, 2007, email from 
Ms. Pontak to Ms. Duke. 
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18, Attached hereto as Exhibit 16 is a true and correct copy of a July 2, 2007, letter from 
Mr. Foster to Ms. Duke. 
19. Attached hereto as Exhibit 17 is a bue and correct copy ofrelevant portions of the 
deposition transcript of Shaiyenne Shindle. 
20. Attached hereto as Exhibit 18 is a true and correct copy of relevant portions of 
Clinton Dille, M.D.'s deposition transcript. 
21. Attached hereto as Exhlbit 19 is a true and correct copy of relevant portions of 
Clinton Dille, M.D.'s trial testimony transcript. 
FURTHER YOUR AFFIANT SA YETH NOT. 
SUBSCRIBED AND SWORN TO before me this 3 4ay of December, 2007. 
a. 
FOR a, o 
Residing at: ()£.a£ 
Commission Expires: 0 0 - ;). 0 ·:;) 0 I 0, 
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CERTIFICATE OF SERVICE 
-:,r-4 
I HEREBY CERTIFY that on the _2-:::_ day of December, 2007, I caused to be served a true 
copy of the foregoing AFFIDAVIT KEELY E. DUKE IN SUPPORT OF THOMAS J. 
BYRNE'S MEMORANDUM IN OPPOSITION TO PLAINTIFFS' MOTION FOR 
NEW TRIAL, by the method indicated below, and addressed to each of the following: 
David Comstock 
Law Offices of Comstock & Bush 
. I 99 N. Capitol Blvd., Ste. 500 
P.O. Box2774 
Boise, Idaho 83701 
Attorney for Plaintiffs 
Fax No.: (208) 344-7721 
Steven J. Hippler 
GIVENS PURSLEY 
.601 W. Bannock ST. 
PO Box 2720 
Boise ID 83701-2720 
AttorneysforC!inton Dille, MD. and 
Southern Idaho Pain Institute 
/U.S. Mail, Postage Prepaid 
Hand Deli vercd 
__ Overnight Mail · 
~Telecopy 
,,........- U.S. Mail, Postage Prepaid 
Hand Delivered 
__ .Overnight Mail 
__ Telecopy 
AFFIDA VlT KEELY E. DUKE fN SUPPORT OF THOMAS J. BYRNE'S MEMORANDUM fN OPPOSITION 
TO PLAfNTIFFS' MOTION FOR NEW TRIAL - 5 
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EXHIBIT "1 11 
Page 1 of2 
Cathy A. Pontak ------------------------------
From: Cathy A. Pontak 
Sent: 
To: 
Monday, September 24, 20071:38 PM 
Kathy A. Savell 
Subject: FW: Dennis Chambers, Shaiyenne Anton depos 
Attachments: current.zip 
'~~-~ . . ,-..,-< 
From: M & M {Asuka Tada) [mailto:asuka@qwest.net] 
Sent: Monday, September 24, 2007 1:27 PM 
To: Keely E. Duke; Cathy A. Pontak 
Subject: Dennis Chambers, Shaiyenne Anton depos 
M & M COURT REPORTING SERVICE, INC 208-345-9611 800-234-9611 
The following transcripts can be downloaded online at the end of this business day: 
DATEfTIME: 9/5/2007 11:00:00 AM 
WITNESS: Dennis Chambers, Shaiyenne Anton 
CAPTION: Schmechel v. Dille 
CASE#: CV 05-4345 . 
VENUE: Twin Falls County, Idaho 
LOCATION: Tolman & Brizee, 132 Third Avenue East P.O. Box 1276, Twin Falls, ID 83303-1276 
M & M JOB No: 15129B4, 1513084 
*'NOTE: WE ARE FORWARDING THIS NOTIFICATION TO ALL PARTIES FOR USER NAME AND PASSWORD 
INFORMATION. IF YOU DID NOT ORDER, PLEASE DISREGARD, HOWEVER YOU MAY USE THIS LINK TO ORDER 
AT A LATER DATE. 
_Your user name is: Duke 
Double-click on the following address. If you are not able to reach the website by double-clicking, copy and paste the http 
info into the browser address: https:!icp1 .courtpages.net/loqon.asp?TB=&companyid=-1829437679 
Once you have accessed the site, you can change the password. All work will be posted at the end of the business day. 
If immediately needed, please reply and it will be promptly posted, 
You may view your proceeding calendar, download your transcripts, view invoices, schedule proceedings, or order 
products. Our online repository is always up to date with all the latest information for all your proceedings and/or invoices 
you have with our company. You may visit our website for additional seNices and information at: https://www.m-
mservice.com (Boise) or https:l/www.mmcourt.com (Coeur d'Alene). For scanning information, programs and software, 
please access M & M's Accuscan site: https:/lwww.accuscan.org. 
SERVICES AVAILABLE - M & M COURT REPORTING 
REAL TIME COURT REPORTING; SCANNING; VIDEOTAPErfRANSGRIPT SYNCHRONIZATION; SOFTWARE 
12/3/2007 
Page 2 of'2 
VENDORS; COURTROOM TRIAL PRESENTATION; IDAHO JURY INSTRUCTION PROGRAM; IDAHO INDUSTRIAL 
COMMISSION PROGRAM 
No virus found in this outgoing message. 
Cheeked by A VG Free Edition. 
Version: 7.5.488 /Virus Database: 269.13.30/1027 - Release Date: 9/24/2007 1 !:27 AM 
12/3/2007 1 ., {\ ..... j_ .\. _, I~ 
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Keely E. Duke 
Wednesday, October 10, 2007 5: 16 PM 
'mgr@comstockbush.com' 
'decomstock@comstockbush.com'; 'byron@bvfoster.com'; Cathy A Pontak; 
Kathy A. Savell 
Re: Schmechel 




From: Margie Rosenberg <mgr@comstockbush.com> 
To: Keely E. Duke 
Cc: David Comstock <decomstock@comstockbush.com>; Byron Foster 
<byron@bvfoster.com> 
Sent: Wed Oct,10 15:28:47 2007 
Subject: Schmechel 
Hi Keely, 
Thank you for the 2003 Delegation of Services Agreementr produced today in 
response to Plaintiffs' First Request for Production of Documents, Request No, 
9 1 propounded June 29 1 2006. We would like to have an opportunity to examine 
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EXHIBIT "3" 
ATTORNEYS 
HALL, FARLEY, OBERRECHT & BLANTON, P.A. 
702 WESTIDAHO $TREST, surrn 700 
KEY FTNANC[AL CENTER. 
BOfSE, IDAHO 83702 
POST OFFICE BOX 127 l 
BOISE, lDAHO 83701 
TELE-PHONE {208) 395,8500 
FACSIMILE (2011) 395-8585 
W:\2\2.-.404.53\Ex:perts\SmiUi 07 .doc 
6-MAIL: conta<::!@h-al!far!ey.com 
RICHARD E. HALL 
DONALDS. FAtu.SY 
PIULLW S. OUE.R.REC!-IT 
J. Cl{A.IU.8$ BLANTON 
RA ThfOND D. !'OWE~ 
CANDYW AGANOJ:i: DALE 
J.KEl/tNWBST 
OAltr W. BAR WOOD 
JOfil! l. BURkE 
KEVIN 1. SCANLAN 
TAMSEN L. LEACHMAN 
KeaYE.DUKE 
JAMES S, TiiOMSON, lI 
rm.'/ AN A. N1CKBLS 
CHIUS t'I. COMSTOCK 
l'ORTIAL. JEHKlNS 
KAREi~ 0. SHEEHAN 
KYLE M. YEARSLEY 
DANA M, HERBER.HOLZ 
MARK J. Ol~t.EI'. 
IEffREY !l. TOWNSEND 
WEB PAGE; www.baUforley.com Wilh ,!ltcrnt}'S Admitletf IQ Proctic,, J;.m,.• in 
(dalw, Oregon, Washl11gmn and Uu,h 
September 26, 2007 
CONFIDENTIAL COMMUNICATION 
VIA HAND DELIVERY 
· James Smitb, M.D. 
Boise Heart Clinic 
287 W. Jefferson 
Boise, ID 83 702 
Re: Claimant 
HFO&B File No. 
Dear Dr. Smith: 
Vaughn Schmechel, et al. 
2.404.53 
Enclosed for your review are the following depositions: 
l. De1mis Chambers 
2. Shaiyenne Anton 
3. Stephen Lordon, M. D ., part 2 
KAS/cp 
Enclosures 
Kathy Savell, Paralegal 
1 ' (· $; 
.l ·'· ·' J 
EXHIBIT "411 
1 1 <', 0. 
.1 ~\. ,_! J 
ATTORNEYS 
HALL, FARLEY, OBERRECHT & BLANTON, P.A. 
702 WEST lDAHO STREET, SUITE 700 
KEY FINANCIAL CENTER 
BOISE, IDAHO 83702 
POSTOFFICEllOX l27l 
BOISE, IDAHO 8370t 
TELEPHONE(208) 395-8500 
f A.CSJM!LE (208) 395-8585 
W:\2\2-404.53\Foslcr 19.doc 
E-MAIL: conuict@haUfarley ,com 
WEB PAGE: www.ha1lfur1ey.corn 




Law Offices of Comstock & Bush 
199 N. Capitol Blvd., Ste. 500 
P.O. Box 2774 
Boise, Idaho 8370 I 
Re: Schmechel v. Byrne, et al,, 
HFOB File No.: 2-404.53 
Dear Dave and Byron: 
Enclosed is Defendants' Exhibit 276. 
IUCHARD lo. [{ALL 
OONALDJ. FARI.EY 
PHILLll' S. 08EllRf:C!ff 
J. CHAR.LES "BLANrON 
RAYMOND D. POWERS 
CANDY WAGAH0f1" DA.LL\ 
I. KBVTNWEST 
OART W. HARWOOD 
JOHN J, DURKE. 
KEVIN J. SCANLAN 
TAMSENL. LEACHMAN 
KEELY £. DUKE 
Jf,MES S. THOMSON, U 
OR.YAN A. NlCKEt.S 
CHRIS D. COMSTOCK 
1'0RTIA L. .ffiNKlNS 
KAREt-f 0. SHEEHAN 
DANA M. HE!<.BERflOt..Z 
MARK J, ORLER 
1Eff'REY k.. TOWNS&ffi 
ROBERT A. DErutY 
MEOAN E. MOONEY 
With At1on1t)'S.Ad111/1r;;d 10 Proclict Law in 
/dahn, Or~g,:.m, Warhi11g1m,and Ulah 
Kathy Savell, Paralegal 
KAS/cp 
Enclosure 
cc: Steve Hippler (via fax w/encl.) 
' ' .··_ 0· l. .~. 
DELEGATION OF SERVICES AGREEMENT 
DELEGATION OF SERVICES AGREEMENT 
A OelegaUon or Services Agreement Is !o be malnlalned at each practice site \11\d avaltable to the Board upo~ request. The 
Dalegatlon ol Services (DOS) Agreement ts a written docu!mlntnwtually a~reed Ull0) and slgried and dated bylhe physlcian 
essl$tant and suparvlslng physician that defines 1he working relati0!18hlp and delegation or duties b<!lween the supervising 
physician and Uie physlclrul asslslant as specified by Board rule, The Board of Medlolne may review the written Delegation of 
Servloes Agreement, Job dascrlpllons, policy statements, or other documents 1hat define tha responslbllltl<:>s of the ph)'slclan 
assistant In l!ie practlca oottlng, and may requl/e such changes es noodod to achieve compliance with these rules, nod to 
safeguard Ille publlc, 
Tllo roll owing lnlo,m~Uon muol t,o leglbt&, u •• addlllonal oho els ,r no ... ,ary. DO Nar SUBMIT YOUR DEL!;GATION OF SER· 
VICES AGREEMENTS TO Tl-II; SOARD WITH YOUR APPLICATION FOO LIOENSUAc, 
l'hyalclan Asslolanl Name: 'J h tJ ...--j .- .:; -4, ,,.,,- ,..,_ -E:... , 
Supeivilllng Physl<:lan Name: "c /, ,,.., ro a tJ,' ffe · 
Alternate Suparllolng Phyok:lan(i} Nama{s): ______________________ _ 
PRACTICE SO'E(S): 
1, Natll-OofFaclllly: )Ovfl,r-~,~ . J <f~,-. /4,._ ,.,,.,/ d'r,;,/,j,.,/r, 
Mdroso; 2::, b ,,.., q,,.- + r --. · S"b-
T "'-', :,._ Alu / 
( 






Delegation of Seni= Agreement, 
Each licensed physician ..,,;smnt shall maintain acunoot oopy of1he Dclegalion of Services (j)OS). 
Agreelnoot between the physlclanassis1antaru! each of bis or her supervising physicians. This as=ent 
$ball nut be sent to a., Board, but roust be roaintainoo on file at each 1"""1ion in which the physician 
nssfatant is practicing. This ag,=nent ,hall be made immediatoly avrulable to the Board upon ooqu,:at aru! 
shall ioolude: 
• 
Activity 11nd Location 
A listi,,g of1ho specific aotMties, which wUJ be perfunncd by the phy,;ician assislant>md !Ile llj!OCific 
lccalloru; mid lncllitres in which the physician assisuuit will function. 
Location of Practice 
Souiliem [daho Pain aru! Rehabilitation 
236 Martin St 
Twin Falls, Idaho 833-01 
Specific Dulle,; -Activities 
loltw B~aluation of Patients 
8outhem Idaho Poin and Rehabilitation 
496 ll. Shoup Ave. Wes! 
Twin Falls, ID 8330! 
The physician assi- ernployed with Soothom Idaho Pain & Rcllahilibllion will be utilized in the initllll 
.-valuation fur p:ui- seen in thls facility, These pati- stem from a physi<i>n referral base and also 
patlcnl sclf-referrals. Pati"11s wm roquire • full lll,tozy and physical on initial visit Pertinont fiadin(!S will 
bedocumeatcd and rocommendaliom made. The =nunerulatioos will berevwwed by the supo,vising 
pbysician to eonfnm find!ll/!S and dotennlne a trorrunent plan. 
RB-Ewluatlon 
The PA will be utilized in the i,;,,,va[uat!on of e:dsfu,g patients fur medication management;, pre=ip!ion 
renewal and rocommendatiom for further treatment within our fu<,Uit:y. The l'A will perform appropriate 
aystem eKruDS based on the p,,liant'• ohlef ecmyloint. [/pon thisoxam, will =nnnond the type oftlwrapy 
ond/or procedure that is needed. Tue snporvislng physicion will m'iew and porll,rm prooedurcs as 
indicaiod. 
SuJ:mcal Assistant 
The pbyslcuw assislant will assist U1e supervising physician wilh oases preacnred in our surgery =re,. 
Thooe = will include but ore tw! limited to, opldun,l prooedlll'ell undor fiuorosoopy, epiduroll"'=, 
disoo$[M1s, stellate g,u,gllon blocks, lumber sympathetic blocks and Mcd!l:nnlc intrathecat trials. The 
supeNislng physician will train. the PA to assist him on all of the above procod...,,, 
Minor Prgco<!wes 
Tho PA will pcifunn several small office based procedures based on thcmcdi""1 ftndings on clinical exam 
within this iacilit:y. These include, but are not limited to: friggcrpolot injections, small joint i,,je<lloos, 
occipital injections, and laceration «pair. 
:rb.l'.Dllll: 
The FA will assist in llUllll\glng and cval.tu!ling patient, forvhysical therapy withln our fucilit:y. 
General QuldeHnes 
Tho Physician ,¾s!stonts tral.aing, backe,ound and experience make him qualified to funcrion in thls 
· capacity. Hlspraoticowill l>e®gmented by:24,oou,baokup "1ld support from lili, desigmwd prim,uy and 
secondary supervising Physician. 
2 
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Direction and Control 
The methods lo be used tD insure responsible direction and COO!rol of !he ru:tivifies of the physician 
assistant which $hall prov!db fur an on-slre m!t ot I~ moothly, regularlyocliedulcd confuronces betwocn 
the aupe,vislog phy,kiflll and the physicinnassi,tan~ and availability of the oopmislng physiclaa to the 
pbysfoian as.sistant in per,on or bytclephooo. 
PlO!lS<l describe how 1hfa will be a<o0mplished ot this pra,(lil:e site: 
As the physician assistant'• sup.&Vislug pbysicina twll!Jl'o aVililabl,, for ooosµlbltion, guidance, and 
supovmim> on most Im<= days, in lllY infrequent ab= a -,ndory mipervlslng physlclJm will be 
avoilab!e. 
l will perfurm ot !ea>t monthly poriodfo ohart and C>lOOrovicw.s, and will work witl1 wy phy,;lcian llSS!stant 
to cstabl!sh and maintain mutually agreed npon practlre prowool, & guidolJne,_ · 
Emergency l'ro~nres 
Avait.bilcy of the supervising pby,ician to the physician assistnntio poraon or by Mcphone an.cl 
proc«lures furprov:ldlng baclrup for the physician assistant in omergency situations- · 
Please descn'be how this will oooooomplished ot this practio• site. 
Wru,n a seriously ill or iajm<:d paffont -t to Sou them I<laho !'sin and Relmbilitation the ph)"'lcian 
assistant will initiato stabilizing care and maintain !l4icl adheroru» to ACLS, ATLS, and P ALll guideline&. 
Tho physician assistant wm move c,qx,ditiously to ttansfer the we of the patlent to an oppropriate 
pbysiehm or p!iysician ,peoiall,~ A prima,y or ,eoondary pilyslcinn wlll be availab!o 24 houm por day to 
provide consultation, guidance and supervision to the pl1ysiclan assismnt. 
Addressing Situations Outside the Scope or Praetlee 
Proccdutes for ru!dresaing situations outside the ,oope of practice of the ph)'llician assmtant. 
Pkruiedoocribe bow this will bo a<C(}tnpll,hed at this practice silo. 
Should a sltualion ocour truit is outside the scope ofp..,,,ti<x, fur the pby,;foian assistant ho will lmmcdiotely 
<>ontact. a primazy or =•dary l!llj>OrVi:;ing physician forronsultation, guidai= and insftucuon. Tho 
patle,it's °""' will be e<ped!eoUy tnmsfertcd to rux approprlote physician. 
Pre$crlptlon Authority 
A physician ..,,istant Who wiskes ro apply for prescrlplion writi.og oofuorlly shall submit an application for 
such purpose to tho Board of Medkiru,. 
The drug cotegorles or spcoitfo legend d,ugs and eotllrol!ed drugs, Schedule ll through V Ula! will bo 
~ proridcd that the legeru! d,ugs and OODJrolloo d,ugs shall be COllJlistcnt wilb Ute regular 
prescriptive prooticc of the supervising physlclan. 
Current prosoriblng privileges, oow include Sonedule 2, 2N, 3, 3N, 4 and 5, afte; appUcotlon and approval 
through tho Idaho Board of Medicine and Fei!om! Drug &.fo1<:emeoi Administre!ion gul<lcllnes, 
DEA ii l-,IJ.l041!098l 
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CareRemw 
l'eriodic review of• reprosen1al:ivo sample of rocon!s and a perlodio review of lhe mt<lical scrvire,, being 
provided by the physlciao oslllSWll This review shall also mchulc an ev;iluation of rulherence to the 
delegation of services agreement. 
l'lcased<:saibo how1his wlll be acrompllsbed ot lhls pm<rtioo locanon: 
As the pnn,,uy supervising physici11l!, l will pctfunn pcriodlcooan reviews arul csse evaluarloru, of pafu,ils 
...u by the physician ssal-t ln addiuon, a """"""'1y supe,vlsb,g physician or I will be available 24 
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HALL, FARLEY, O:BERRECRT & BLANTON, P.A. 
702 W. Idaho, Suite 700 
Post Office Box l 2 71 
Boise, Idaho 83701 
.FACSIMIT.,E COVER SHEET 
October 11, 2007 
Telephone: (208) 395-8500 
Facsimile: (208) 395-8585 
TO: David E. Comstock 
Byron Foster 
FAX: (208) 344-7721 
FROM: 
RE: 
Steven J. Hippler 
Keely Duke 
Schmechel v. Byrne, et al. 
HFOB File No.: 2-404.53 
(208) 388-1300 
MESSAGE: Attached is Defendants' Exhibit 276. Thank you. 
PAGES: including cover page: 6 
HARD COPY TO FOLLOW: No. 
Sent by: Cathy Pontak 
1 'i -· c-
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EXHIBIT "5" 
1; G 
Schmechel v Dille & Byrne 
CV 2005-4345 
Page 1 
IN 'l'HE OISTRWT COURT OF 'l'HE FIFTH JUDIClAL DISTR1CT OF 
THE $Tl\TE OF IDAHO, IN AND FOR THE COUNT¥ OF TWIN FN.,LS 
VAUGHN SCHMECl-!BL, fodividudly I ) 
and as Surviving Spouse and ) 
Personal Representative of the ) 
Estate of Roaalie Schmechel, l 
Deceased, and ROBERT P. LEWIS, ) 
KIM HOWARD and TAMARA HALL, ) 
Natural Children of. ROSAL!E } 
CASE NO, CV 2005·4345 
11:li!POll.'rER' S 'l'RANSCRl !?'r 
SCHMECHEL, Deceased, ) 







CLINTON DILLE, M.D., SOUTHE:RN J 
!DAHO Pll.IN INSTI'.l;'UTE, an Idaho ) 
Corporation, THOMAS BYRNE, t' .A., j 





OCTOBER 17,, 2007 
PARTIAL REPORTER'S TRANSCRIPT 
JiJR~ TRIAL • DA.\' 2 
'rESTIMONY OF DR. STEPHEN LOR DON 
HON, G, RICHARD BINAM 
DISTRICT JUDGE, PRESIDI~G 
Reported By 
VIRGIN!/'>. M.. BAILEY, RPR, CSR no . .262 
Offici<il Court,: Report.ex 
1 APPEARANCES OF COUNSEL: 
2 MR, BYRON FOSTER, Attorney at Law, and 
MR. DAVID COMSTOCK, Attorney nt Law, 
3 Boise, Idaho, · 























MR. STEVEN HIPPLER, Attorney at Law, and 
MR, WILL VARIN, Attorney at Law, 
Givens Pursley LLP, Boise, Idaho, 
appeared on behalf of Defendant Dille & 
Southern Idaho Pain InS1itute. 
MS, KEELY ELIZABETH DUKE, Attorney at Law, and 
MR. CHRIS COMSTOCK, Attomey at Law, 
Hall, Farley, Oberrecht & Blanton, PA, 
Boise, Idaho, 
appeare(l on behalf of Defendant Thomas Byrne, P.A. 
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Testimony of Dr. Lordon 
October 17, 2007 
Page 3 ~ 
1 
WEDNESDAY, OCTOBER 17, 2007, ,i 
THERON WARD JUDICIAL BUILDJNG, i. 
. 425 SHOSHONE STREET NORTH, TWIN FALLS j 




10 STEPHEN PATRICK LORDON, M.D. 
11 produced as a wilness, being first duly sworn, was 
12 examined and testified as follows: 
i 
I 




t 15 Q. Hi, Dr, Lordon. Before we get started, the 16 last time we talked, you indicated there was something 
17 that you wanted me to tell the jury, I think I'll just i 
!i 
18 let you tell them, and then we'll get started, ' J 
19 A, Okay. I think there are basically two things ti 
;1 2 o r wanted to tell them. One is that I have stuttered ~ 21 ever ~ince I can remember, okay, probably since age two 
22 and three; and I've learned to deal with it, and l'm 
23 very relaxed with it, and sometimes it comes out, its 
24 ugly head, and sometimes r do just fine. Doesn't mean 























Page 4 ~ 
ij 
out. 
And the other thing I wanted to say is that 
1his is the first time that I have ever done something 
like this before and, please, bear with me. 
Q. Okay. Dr. Lordon, you're a medical doctor? 
A. Correct. 
Q. You practice in Salt Lake City? 
A. Actually in Murray, Utah, which is a suburb 







Q, And you're an anesthesiologist pain 
management expert; correct? 
A. Correct. j 
Q, And you have been -- first of all, I'll go , 
back to your education. You've got a degree in, I'm , 
assuming, some kind of science at U.C. Davis in 1978? j_ 
A. It was a bachelor or science in biochemistry 
in l 978, and I graduated with honors. 
(Discussion held off the record.) I 
THE WITNESS: My name is actually Stephen , 
with a P-H, middle name is Patrick, last name is Lorden, ! 
L-O-R.-D-O-N. l 
MR. FOSTER: Sorry about that. Okay. I 
23 BY MR. FOSTER: •; 
24 Q. And then in, after graduating from U,C. Davis l\,·.·.i 
2 5 in '78 and '79 and '80, vou started a 2raduate nroeram I! 
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1 it's truly an interdisciplinary service. 
2 Q. But from the standpoint of the physical 
3 examinations of patii,nts, that's done by other 
4 ri,edical professionals, and you have the benefit 
5 through the notes of their work-ups? 
6 A. Absolutely. I certainly could do this if 
7 necessruy. Advanced practice pharmacists, pharmaco-
B therapists frequently do that. But since it's 
9 already done, there's no need for me to do that. 
10 Q. All right. And as I understand it, you do 
11 not provide medical diagnoses for a patient's 
12 condition? 
13 A. Frequently I will come up with 
14 identification of drug treatment or drug-induced 
15 adverse effects, or I will identify problems witl1 
16 sleep hygiene, for example, which ln my note will 
17 explicitly recommend that this be evaluated by the 
18 psychologist, or I will. identify the patient 
19 presenting with what sounds like myofascial trigger 
20 points, in which case refer the patient to the 
21 physical therapist to inanage that. 
22 So frequently .. l'm identifying patient 
23 problems. Diagnosis, again, is a term of art. We 
24 refer to it more as an assessment. But it's all 
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physician, No, that's not correct. [n my examination 
I found such-and-sucb, which is -- which rules out 
what you're looking at as a potential diagnosis. So 
final diagnoses typically come out of the team 
setting rather than one individual. 
Q. Okay. With respect to treatment, do you l 
actually initiate pharmacotherapy treatment to a , 
patient, or do you make a recommendation to a medical I 
provider with respect to the initiation of a therapy? !.', 
A. Both. I will very frequently change the , 
patient's medication regimen. I will frequently 1 
recommend additional medications, in which case I go l 
to the responsible physician, discuss the case, and j 
recommend that the physician write the appropriate i. 
prescriptions, which almost invariably is done. J 
But quite commonly I will change the 
patient's dosing schedule based on the pharmaco-
kinetics of the medication and the patient's reaction 
to it, write the note accordingly, instruct the 
patient, and then inform the physician, for which the 
response is invariably, Thank you, that helps a lot. 
Q. Okay. And so you actually will adjust a 
patient's medication without first getting approval 
from the attending physician? 
A, Well, I do this in collaboration with the 
B 
Page 40 ~ ! 
rr 
1 interdisciplinary team staffing, which, as I 1 attending physician. l 
2 mentioned, is held each morning. 2 Q. Well -- ; 
" 3 Q. Okay. But with respect to a specific . 3 A. Chronic pain is not a medical emergency ff 
4 diagnosis for a patient as to whether they're 4 that you -- for which you intervene quickly. It's J 
5 suffering from fibromyalgia, I mean, is that a s clinically important to move step-wise and closely. ! 
6 diagnosis that you make, or is that made by someone 6 I will frequently a,J,;ise the patient of a change to , 
7 else within your interdisciplinary treatment team? 7 be made. [ will then advise the physician what I've 1 
8 A. That's a very. interesting question and e told the patient. j 
9 it's not a yes or no question because fibromyalgia is 9 Q. And that's where I'm getting to is the -
10 a very complex syndrome. So it might not be the best 10 timing of that. j 
11 example. But I woUld often identify because of what 11 A. And the physicians explicitly ask me to do ! 
12 the patient shares with me particular behaviors which 12 that. And the reason they refer patients to me -- ! 
13 would be more suggestive of, for instance, a 13 one of the main reasons they refer patients to me to l 
14 somatization disorder or an affective disorder as 14 see the patients is to make those adjustments. j 
15 opposed to a physical disorder. And because of what 15 Q. That's what I'm getting to -- ; 
16 patients share with us and because of the training 16 A. Correct. ;_, 
1 7 that we have and the ,_ what's often referred to in 17 Q. -- is wilh respect to those adjustments, . 
18 our terms of art as role blurring that occurs since 18 those aren't something that you go to the physician j 
19 patients determine what they're going to tell to 19 and say, Hey, before I tell the patient that I'm l 
2 o which clinician, I often will be identifying key 2 o going to do this, I want to run it by you first. Or l 
21 issues that will contribute to the final diagnosis. 21 there are times when you do that, there's times when , 
22 The diagnoses are not made by one 22 you don't do that? l 
23 individual in this setting. They're actually made by 23 A. The latter is co,rect. :_;,,,'.· 
24 the interdisciplinary team at team staffing. And not 24 Q. Okay. . 
25 infrequently the physical therapist will say to the 25 A. There are times that it's ve,y impo,tant , 
CitiCourt, LLC 
801.532.3441 
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1 CROSS EXAMINATJON 
2 BY MS. DUKE: 
3 Q. Dr. Lordon, good afternoon. 
4 A. Good afternoon. 
5 Q. Just to clear up a couple of things that l 
6 want to make certain we're all on the same page, you 
7 certainly do not feel that Mrs. Sclunechel was 
8 drug-seeking; correct? 
9 A. That is correct. 
10 Q. Meaning that she was not trying to switch 
11 providers and to try and get medication when she should 
12 not have been. 
13 A. There's no evidence of that whatsoever. 
14 Q. And there's also no evidence in the record 
15 that, or in Dr. Vorse's records, that she was 
16 noncompliant with her CPAP therapy; correct? 
1 7 A. That is corTect. 
18 Q. l think Mr. Hippler asked you this. But as I 
19 understand it, you are, -- you do not feel that edema is 
20 something that would be a side effect of Methadone or 
21 any other opioid; correct? 
22 A. Methadone, no. Other opiates, yes. When 
23 they are delivered, especially into the spine; they can 
24 cause lower extremity edema. But in this case, no. 
2 s Q. Right. Not Methadone? 
Page 66 
1 A. Not Methadone. 
2 Q. You also agree with the principle that there 
3 can be multiple treatment options that a provider can 
4 use that would be within the standard of care and it's 
5 up to the medical provider to use his or her judgment in 
6 detennining a treatment? 
7 A. Absolutely. 
8 Q. Let's talk about physicians assistants a 
9 little bit. Yon would agree that a physician assistant 
10 is a physician extender? Does that sound like a proper 
11 term to you? 
12 A. [ would use t_hat term. 
13 Q. Physician assistants evaluate and treat 
14 patients, and they do minor medical procedures; correct? 
15 A. That is correct. 
l. 6 Q. And that's all appropriate for them to do 
1 7 those things? 
18 A. Yes,itis. 
19 Q. l\ was ce1iainly okay, in your opinion, for 
20 Mr. Byrne to prescribe medications? 
21 A. Absolutely. 
22 Q. That's something that Idaho law permits him 
23 to do? 
24 A. Yes. 
25 O. And Idaho law also allows ohvsician 
Virginia M. Bail·ey, RPR, CSR No. 262 
Testimony of Dr. Lordon 
October 17, 2007 
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1 assistants to evaluate, plan, and implement plans of l 
2 care, and you have no problem with_ that; correct? ! 
3 A. I have no problem with that. I 
4 Q. So you are in no way critical of the fact ) 
5 that Mr. Byrne treated Mrs. Sclunechel; correct? ij 
6 A. No, none whatsoever. I 
7 Q. And actually, when we took your deposition, l 
B switching gears a little bit on you here, we were l 
9 talking about Dr. Vorse'$ change in the OxyContin from :.: 
1 o 40 milligrams to 60 milligrams on September 16th. Do 
11 you recaU that? ,\.i 
12 A. Yes, I do. • 
13 Q. And in that testimony, do you recall also l 
14 saying that you felt, given that there was a 50 percent l 
15 increase, and Mrs. Sclunechel was complaining of IO out l 
16 of 10 pain a couple of days later, that you really had [ 
17 to question whether or not OxyContin was the appropriat i 
18 drug; correct? , 
' 19 A. There were two answers, if! recall. There I 
' 2 o was either it was the appropriate drug or the right I
21 dose. l 
22 Q. You certainly agree that if Mr. Byrne spoke l 
23 with Mrs. Schmechel about how she was to take the !, 
24 Methadone, that would have been within the standard of l 
2 5 care; correct? } 
i 
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1 A. Oh, absolutely. 
2 Q. And I assume you also agree that 
3 Mrs. Schmechel wouldn't have seen the dictated history j 
4 and physical; correct? , 
5 A. There's no reason for her to have done that. , 
" 6 Q. That's not something you do in your practice? 
7 A. Very rarely. 
8 Q. And she also wouldn't have seen the 
9 handwritten notes that Mr. Byrne made in the medical 
1 O cha.rt; correct? 
11 A. Are you referring to Exhibit 1 O? 
12 Q. No. I'm referring to just the chart notes he 
13 makes in the chart itself, not to Exhibit 10. 
14 A. Oh, l see what you're saying. No, there's no 
15 reason for her to have seen those. 
16 Q. And obviously, Exhibit 10 is the handwritten 
1 7 note that she did receive? 
18 A. That's my understanding. 
19 Q. As I also understand it, you believe that 
2 0 Mr. Byrne complied with the standard of care -- well, 
21 strike that. 
22 As l understand it, you believe it's within 
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WHEREUPON, the following proceedings were he~ 
pursuant to the Idaho Rules of Civil Procedure: 1 
3 . JAMES KELLER f 
4 having been duly sworn to state the whole truth, testified ! 
l 
2 
5 as follows: I 
EXAMINATION .! ; 
BY MS. DUKE: l 
6 
7 
Q. Mr. Keller, my name is Keely Duke. We were jus I 
introduced off the record. lam one of the attorneys that :i 
lo is representing T.J. Byrne, the PA that provided care to j 
11 Ms. Scbmechel in September and October of 2003, " 
12 You are here today for your deposition. And this \
1
'. 
13 deposition is being taken pursuant to the Idaho Rules of 
8 
9 
14 Civil Procedure. i 
15 [fyou could please state your name for the ·i.· 
16 record, 
A. My name is Jimmie with an i-e, middle initial E. l 
18 Keller, K-e-1-1-e-r. l 







AQ.. For this case? i.'. 
No, any case? -
A Y 
n . es, 1: 
Q. So you're familiar with basically the process we li 
2 4 are about to go through today? ' 
Y ! 25 A. a • 
1 (Pages 1 to 4) 
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l because of her obesity I would kind of expect that because 
2 of the surgery she had on her knees, maybe on her back, I 
3 would assume that. 
4 But if it is getting worse -- and particularly I 
5 think her son Robert said she wasn't mentally alert on one 
6 of those weekend days, those are red flags to me that 
7 Mr. Byrne should have been aware of and seen her or 
B whatever. 
9 The phone calls, again, the phantom phone calls 
10 over the weekend or the documented phone calls that he says 
11 in his note that she was doing okay, what does okay mean? 
12 Did he ask her specifically, are you having any trouble 
13 breathing? 
14 The sleep apnea is a huge concern by using any 
15 narcotic whether it be Oxycontin, hydrocodone, oxycodone or 
16 methadone it has a potential affect. And then when you add 
17 them together and someone with a comorbid condition such aE 
18 sleep apnea, my goodness, you're decreasing the respiratory 
19 drive no matter what. And with her sleep apnea her 
20 respiratory drive is diminished anyway. And patients who 
21 use C-PAP are usually anywhere from 30 to 50 percent of 
22 them by literature are noncompliant because I hate to sleep 
23 in that stuff at night. Jt_is not very comfottable, 
24 So was she using·it on the couch1 I doubt it. 
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!! 
ii you think. Because here is Ms. Schmechel, never seen her ~ 
before but) gosh1 look at what all she has, what should we B g 
do? Should we consider this or not? ~ 
Q. Let me stop you there just real quick to follow up , 
with a question. Do you know whether Mr. Byrne ever talked ij 
to Dr. Dille about Ms. Schmechel's treatment? 1 
A. I can only go by what is in the depositions, and I { 
don't think there was anything that Dr. Dille signed off on i 
anything in his chart. i 
Q, lfDr. Dille were to testify in his deposition / 
that Mr. Byrne in fact did talk to him on that Monday after j 
Mr. Byrne did initiate the methadone therapy 1 wouldn't you ( 
agree that would have been appropriate? f .. l, 
A, For him to ta!k to him? , 
Q. Correct. ~ 
~ A. Yes. For the treatment, I still don 1t agree .with ~ 
the treatment. If Dr. Dille had any input in that l 
treatment, I don't think she was followed adequately, 
Q. But let me ask you this, it was okay, as I 
understand it, for Mr. Byrne to make the decisions as a 
physician assistant to alter the medication, correct? 
A. Sure. That's by any state regulation and 
supervisory dictorum that you have and the relationShip 
that you have with your supervising physician, a PA has the j 
authority to do that. Sure. . 
Page 56 ! 
l The other thing, with the edema that go back to what you l Q. You are not critical of him doing that aspect of I, 
2 said about the cardiomeglia and other kinds of things, tl1e 2 it? j 
3 concern that I have is what were her kidneys doing because 3 A. No, absolutely not. J 
4 we don't know. 4 Q. And what I understand you to be saying is once a a 
~ 5 Only, again, I'm going by an assumption ofa 5 physician assistant initiates that therapy, at some point ) 
6 patient similair to Ms. Schmechel being obese, hypertensive 6 after he's initiated that therapy you would like to see he 1 
7 and 60 years old by literature from the age of30 or 40 7 or she talk with their supervising physician and say, here , 
' a depending upon the individual's other comorbidities, wear 8 is what I did with Ms. Schmechel, is that all right with ,
9 los]ng anywhere from 3 to 10 percent of our kidney functio 9 you? I 
10 every decade over time. io A. There is the science of the medicine and there is j 
11 And when you add medications or other conditions 11 the art of medicine and there is the practice of medicine. i 
12 such as hypertension that C"'1 affect the renal function -- 12 All ofus who deal with medicine spend a lifetime or X j 
13 and she was obviously retaining fluid from something, wha 13 number of years perfecting our practice in medicine, ~ 
14 was her kidney function? Don't know. Did that have a 14 Science will always change. We learn something new about l 
ff 
15 contributing factor? Possibly. Don't know that, but that 15 diseases and illnesses every day, , 
16 is something that should have been monitored by Mr. Byrn ,16 So you have to keep up on the science aspect of [ 
l 7 Dr. Dille, somebody, in my opinion, should have rnonitore< 1 7 it. And there is some basic principles in science or j 
18 that. 18 pharmacokinetics and things that don't change, but you find / 
19 And I feel that if Mr. Byrne had talked to 19 out more about them. Like the knowledge of methadone toda \ 
2 0 Dr. Vorst or obtained those records that he would have 2 o is much different than it was, say, five or ten years ago. ~ 
21 hopefully -- there would been a lot of red flags about how 21 Q, · Or even in 2003 versus now? j 
22 he treated Ms. Scluneche!. 22 A. Correct. But the practice of medicine, the art of , 
23 The other thing was in a complicated patient, l 2 3 medicine is knowing' when you have limitations and knowing g 
' 24 would have probably talked to Dr. Dille. He was my 24 when you're stepping -- you're on a boundary here that \ 
2 5 supervising physician and said, this is my plan, what do 2 5 maybe you don't know everything about this patient but you j 
11, .• ,,,,.,.,...,.,,.,.,,,,,,"'-""='="='"'"-"·i;.;,;;""'"'.!!·"'"'~"~'""'~ .• -,,.-,,,,..,_,,,,_..,,_~,,,.-,,-,~.,,~.,,..,,m~t,w,.; ,.,..,..,._ ·'"''"'·'""""', <>,;, "'""~=,.."'l=c=,=--~ .. ,"-"J::.";.;;;:,,,;,;;,,i;.>,., " ""'"'""" , "'""""'"'"~'·""''''r-"'"=-'"'""""'"""'"'~ 
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' ' 1 should consult. I tell my students it is when the little 1 Q. Sure. I'm just trying to think of the most j 
2 hairs on the back of your neck stand up. It just doesn't 2 efficient way here to do that. Let me ask you a couple of i 
3Mri~ 3~~~~ I 
4 This is a patient whose hairs stood up on the back 4 ·1 would assume that you agree that Mr. Schmechel i 
' s of my neck. Whether I was seeing her in a general practice 5 was not drug seeking, correct? '
6 clinic for the first time or whether I was Mr. Byrne seeing 6 A. I agree. Nothing that I can find in anything · I.•. 
7 her in a pain medicine clinic. Hairs stood up on the back 7 would lead me to believe that she was a drug seeker. , 
s of my neck. This lady had problems, As l said, whether-- 8 Q. l would also assume that there's nothing -- well, · j 
9 ifhe talked to Dr. Vorst, that would have been perfectly 9 strike that. , 
10 fine and said this is what I'm doing, she is a pain 10 l would also assume that you are not saying she J 
11 medicine specialist. That's an opinion and you work on 11 wasn't a truthful, honest reporter of her condition to j_' 
12 opinions. 12 Mr. Byrne, correct? 
And Dr. Dille, from what I understand in reading 13 A. Again, nothing that I can find that would say that l 13 f 14 the testimony and so forth, he signed off -- as soon as he 14 she was not. "" 
15 signed that chart, he concurred with Mr. Byrne's treatment. 15 Q. And you would certainly agree, as I understand j 
16 That's the way it works, Docto1· Shirar in my practice and 16 from your last statement, that it is very important for a ! 
17 any PAs practice does not see every patient l see. And 1 7 patient to be honest and accurate with their medical 
18 that is understood. 18 provider? 
19 But implicitly as they read the chart and they 19 A. Yes. 
2 o review my chart or whatever and they say, you know, we 2 O Q. Is that part of their contract to the medical 
21 should have done this, we should have altered this type of 21 provider? 
2 2 treatment, that is how we do it. Ot· I'm going to call her 2 2 A. Yes. 
23 up or l'm going to go in the next room, depending upon ho1 23 Q. Aod a provider such as a physician assistant has 
24 we are working that day, and say, I've got this patient I 24 to be able to rely oit what the patient is telling he or she 
25 need you to take a look at. This is what I'm thinking 2 5 with respect to the patient's conditions? 
Page 58 Page 60 l 
~ 
1 aboutdoing,whatdoyouthink? Wouldyoucomeandlooka 1 A Yes Let ·ust let t Uy uwhatlteach 1 
2 them and consult. 2 my first ye~r stu'.;;,~ls. !-~on't~~o: "· ':,,can to sound I 
That is what physicians do. Physicians don't know 3 flippant, because it is not. It's any easy way for me to j 
4 evetything. That is why you have specialists. So you 4 get some levity when l teach them this but also to hone in ', 
3 
5 consult either telephonically or in person or you refer a 5 what I think is important in the practfce of medicine l 
6 patient to them. 6 across the spectrum of medicine and surgery. j 
7 That is, again, part of the implied contract that 7 The first rule I go by is there are dumb people j 
8 a provider has with a patient. The implied contract you 8 born to dumb parents. That is, again, what did the patient j 
9 have with a patient is that the patient is going to tell 9 hear. What are they capable of understanding that you're ! 
10 you everything you need to know to make a good, presumptiv 10 telling them and what is their ability to tell you the I 
11 differential diagnosis and treatment plan. 11 information you need to know. And it's incumbent as far al 
The co11tr.act the provider has with the patient is 12 that contract goes of that provider to glean out as much i 
13 you're going to find out everything you need to know and 13 information from the patient as they are capable. And if ! 
12 
14 you are going to do the right thing to the best of your 14 they're not, either their family member, their guardian or I 
15 knowledge. 15 another provider. ll 
I think that's all I have to add right now tltat_ I 16 The second thing is that patients lie. rt ls not j 
17 can think about of what I was going to say based upon what 17 that they always lie intentionally, some do. Some will lie ; 
16 
18 you asked me about in that disclosure and clarification. 18 to get secondary gain such as. you mentioned earlier, drug i1 a 
19 Q. As l understand it, have you articulated now all 19 seekers or whatever other kinds of things it may be. ; 
20 of the opinions that you hold in this case? 20 But they ·don't always lie intentionally, they just omit I 
21 A. I believe so. 21 things because either they didn1t think about it, you ~ 
22 Q. Obviously rm going to foHow up with you on some 
23 things. 
24 A, I expect that is -- that is why I'm here. I 
25 expect that, 
22 didn't ask the right question or whatever it is. So it is ; 
2 3 incumbent again on that practitioner to ask the right I 
> 
24 questions) open-ended questions so it leaves it for I 
25 discussion or get other infonnation from other mec1ns> as I It 
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l mentioned earlier. 1 
2 The third thing is that if you don't find it, it's 2 
3 not there. That is that when you do a physical exam or y, u 3 
4 do history taking and all you have are negatives, well, yo• 4 
5 assume everything is normal. Well, it may not be, but if 5 
6 it ain't there you assume, working on that diagnosis, that 6 
7 everything is okay. 7 
a And the final thing is that the conditions that 8 
9 are there, whatever is there, I'm too stupid to find it, 9 
1 o because I didn't look right. I didn't do the right test. 1 o 
11 I didn't ask the right person. I didn't ask the right 11 
12 question. I didn't do the right physical exam. I didn't 12 
13 order the right test. !'didn't order the right diagnostic 13 
14 study, whateveritis.. 14 
15 So those four rules kind of encompass the practice 15 
16 of medicine in my mind and in a case like this somewher< 16 
1 7 along those rules were violated. One way or the other 1 7 
18 between Ms. Schmechel and Mr. Byrne or Mr. Byrne and 18 
19 Dr. Vorst or Dr. Dille or whomever, Ms. Sclunechel, inn v19 
2 0 opinion, didn't get the care that she should have. 2 0 
21 Q. And going back kind of where we started -- 21 
22 A, Sure. 22 
23 Q. -- before you just provided that answer, you are 23 
24 certainly not saying that there is anything that you've 24 
2 5 read or observed with respect to Ms. Schmechel that wou d2 5 
Page 62 
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Dr. Vorst's records. With respect to the records that you i 
have reviewed, is there anything contained in those records i 
that you believe would have caused Mr. Byrne to alter his ! 
course of treatment for Ms. Schmechel? 1, 
A. I don't have an opinion. I can't say. I don't i! 
know. I don't know what he would have done. I wou!d ha ~ 
just felt comf011able in him taking a whole history of it. l 
Again, going back to not knowing her on that Friday j 
afternoon. Was she compliant? Was she drug seeking? I ! 
don't know. That is one thing I would have asked I 
Dr. V orst. ,, 
Q. But you don't know ofanything as you sit here J ., 
today that was contained within Dr. Vorsfs records that ~ 
would have or should have changed Mr. Byrne's treatment ,'f 
Ms. Schrnechel) correct? ! 
A, Not that rm aware of. ti 
Q. With respect to Dr. Harris -- strike that. I 
With respect to Dr, Hanis, I don't understand you B 
E to be saying that you believe Mr. Byme depa,ted from the , 
a 
standard of care in not obtaining Dr. Harris' records. I !i 
undersfand you to be saying it is something he could have j 
done but you are not critical of him in that regard? g 
A. Correct. Doctor Harris was the general I 
practitioner, the general family medicioe physician for j 
Ms. Schmechel. Be had a whole history of her. Jt is just , 
1 
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1 indicate that she was not capable and able of providing as 
2 best she knew it an accurate histoiy of her condition? 
3 A. To my knowledge that is correct. 
4 Q. There is certainly nothing that -- well, strike 
s that. 
6 
1 another reference that was there, ifnecessary. You know, l 
2 as an example, could he have called Doctor Vorst and not i 
3 got in contact with him, could he have and called ij 
4 Dr. Harris and said, hey, could you give me a background,~ 
5 Ms. Schmechel here. But, sure, it is another resource that j 
Ms. Schmechel reported to Mr. Byrne what 6 should have been considered before the treatment started, f; 
7 medications she had been 0111 correct? 7 in my opinion. j 
e A. Yes. 8 Q. But it's not a breach of the standard ofcare for ! 
9 Q. And did so accurately, conect? 9 him not to obtain those records or called Dr. Harris, , 
10 A. Yes. 1 o correct? _:,i 
11 Q. She also reported to Mr. Byrne that she had 11 A. Not a standard of care -- breach of care. l , 
12 obstructive sleep apnea? 12 wouldn't call it a breach of care. :,:_ 
13 A. As in his written note, yes. Not in that dictated 13 Q. Now, with respect to the records that Mr. Byrne 
14 note, 14 did obtain, are you aware of any prior treating physician j 
15 Q. But it's in the records? 15 records that he obtained with respect to Ms. Schmechel? I 
16 A. It is there, yes. 16 A. None that I'm aware of. I don't know of any than l 
17 Q. And she was using her C-PAP machine and was 1 7 what I have reviewed. ! 
18 compliant with it, correct? 18 Q. Are you aware that she was seeing an orthopedic j 
19 A. As far as I know, 19 surgeon with respect to her arachnoiditis? ; 
20 Q. WitbrespecttoDr. Vorst,lunderstandthatitis 20 A, Yes. ii ,, 
21 your opinion that Mr. Byrne should have done one thing, (21 Q. As I understand it, you're not aware that he in g 
22 another thing. And that is he either should have obtained 2 2 fact received those records from the orthopedic surgeon? j 
23 her records or picked up the phone and called Dr. Vars\? 2 3 A. No, not that I'm aware of. I 
24 A. That is correct. 24 Q. You would not be critical of him obtaining those j 
~,:,,~-~·r.:l·~~~::-~~2=~~,~~'-··~~ ~~?.~~~~:1!1~~~~:~~:~!~~'~:~~~ ,~!~ .. ~~, '"·~·~,~~.au~==::::~=.,,~~ f " ,...-h ,~rn~==-~-..--~~-''°'""~.,,==,~~=~~- --~"'~"~ ~,J 
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1 A. Critical of him obtaining or not obtaining? 
2 Q. Of obtaining the orlhopedic surgeon's records to 
3 determine if there is a surgical component to her pain? 
4 A. Again, as I said earlier, I think any resource 
Page 67 
1 standard of care that would be applicable to a physician 
2 assistant practicing chronic pain management medicine in 
3 Twin Falls, Idaho, in September and October of 2003, 
4 correct? 
5 that you can use to enhance yom knowledge of the patient 5 A. That's correct. 
6 is going to be eventually good for both parties, the 6 Q. And you certainly understand the concept that you 
7 patient and the provider. 7 have standard of care. That doesn't mean you can't go 
Q. That brings up a good point that you and 8 above tl1e standard of care, but there is a standard of care 
9 Mr. Foster are discussing there. Are there any documents 9 that you need to meet as a minimum threshold, correct? 
8 
10 that you have just seen but you don't have copies of that 10 A. Yes. 
11 are not contained within your file? 11 Q. With respect to your knowledge of the standard of 
12 A. Yes. Correspondence between Dr. Verst, the 12 care in Twin Falls, Idaho, as it existed in September and 
13 orthopod, and Dr. Vorst, the pain management physician, ir 13 October of 2003, for a physician assistant practicing pah1 
14 reference to Ms. Schmechel and her arachnoiditis. 14 management medicine, what have you done to fan1iliarize 
15 Q. Anything else? 15 yourself with that standard of care'/ 
16 A. Other than what I told you that arrived at my 16 A. I talked to a pain management physicillll assistant 
1 7 house today that l haven't seen. 17 by the name of Tom Robe. 
18 Q. Okay. With respect to seeing her on a Friday 18 Q. Rambo? 
19 afternoon and. changing her treatment, l understand that 19 MR. FOSTER: Rambo? 
20 that is something that you are critical of; is that 20 A. Rambo, sorry, 
21 correct'? 21 Q. (BY MS. DUKE) When did you speak to Mr. Rambo· 
22 A. Yes, ma'am. 22 A. I spoke to him on two occasions. The last time ; 
23 Q. ls that something that you're saying constitutes a 23 was last Thursday afternoon August 2nd. ' 
24 breach of the standard,of care? 24 Q. When was the first time you spoke to him? j 




1 It is -- as I mentioned to you, it is a flexibility of the 1 better idea than lhat. It was to qualify my expe,t l 
2 practice ofa medicine that a provider can do. ln my 2 testimony in talking to someone that had a like practice as , 
3 learned years as Jim Keller being a PA for 31 years, I've 3 Mr. Byrne did and that was Tom. And l apologize to you, ! 
4 just learned that there ·are things that you just don't do 4 just don't remember the date. I 
5 and this is one of them. Because of Schwartz laws, as I 5 Q. Was that amonlh ago, two months ago, back in ) 
6 mentioned earlier, It if it is going to go bad it is going 6 March when you were contacted on this ease, just a genera j 
7 to go bad over a weekend or a time that you don't have 7 time frame? l 
B access to that patient in a way that would be -- optimized 8 A. Time frame I think was May or June of this year. i 
9 the care to that patient. I think it was a poor decision 9 Q. And let's take the first time that you spoke to j 
10 on Mr. Byrne's pait. 10 him, whether it was May or June of this year. , 
11 
;t 
Q. But not a breach of the standard of care, correct? 11 A. Hang on a minute. The letter tliat you have, the j 
12 A. The standard of care for Jim Keller, yes. 12 exhibit, what date is that letter? j 
13 Standard of care in general, no. 13 Q. I have April 4. ,. 
g 
Q. And while we're on that topic with respect to 14 A. Okay. It was that time frame then because the , 
15 standard of care, what.do you understand that phrase to be, 15 telephone conversation says an hour long, that was a l 
14 
16 sta11dard of care? 16 combination of conversations I had with Tom at that time j 
17 A. It's a pretty open phrase. But generally it is 1 7 and Mr. Foster. So that should have been April. ! 
18 what a prudent practitioner in the same like practice or 18 Q. So sometime prior to April 4, 2007? i 
l 19 general knowledge or same profession, i.e., PA physician o 19 A. That's correct. -
20 whatever it may be would do in a similar situation, That 20 Q. But between March 3rd or 6th) whenever you were ~.:,"~ 
21 can be either local, state, national, international,just 21 retained in 2007? .. 
22 depends. · 22 A. That is correct. Mr. Foster told me he needed the 
23 Q. Okay. And you understand that the standard of 23 qualifications for legal purposes for the standm·d of care. j 
24 care that we're dealing with here is obviously not the 24 Q. In that first conversation that was either in late ; 
2 5 standard of care that you imply to yourself. It is the 2 5 part of March of 2007 or early part of April 2007, what wa, j 
,~;wa;, ,w;·-"1).r.:::c,:c~·--="''"'"'~''"'"~'~··" ,, ~ ·""'",.,.."' -"-'-""'""'~·~:~,"'-==="""'"'"'·'''"'"~;il;,.,. . ,, ,;,µ;~ '"'~",u;,.,...~,=•"'>=- ·"'"'-'-""""""""""'va;,~.,.,,... "'""""''ll"'""";,u,>1~,~=w.=---,,:,,,,;,;::#.l 
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EXHIBIT "7" 
1 ; ·••• r; 
Schmechel v Dille & Byrne 
CV 2005-4345 
l APP EA.RAN CBS OF COUNSBL: 
2 MR. BYRON FOSTER, Attorney at law, and 
MR: DAVID COMSTOCK, Attorney ;:it law, 
3 Boise, [daho, 
appeared on behalf of Plainttffs, 
4 
5 MR, STEVEN HIPPLER, Attorney at L'lW, and 
MR. VllLL VARIN,Auomcy at law, 
6 Givens Pursley LU1, BoL-re, Idaho, 
appeared on behalf of l)cfendant Dille & 
7 Southern Idaho Pain lnstitule. 
B 
MS. KEELY ELIZABETH DUKE1 Auomey at Law, and 
9 MR. CHRIS COMSTOCK, At!omey at law, 
Ha11, Farley, Oberrecht & Blanto11, PA, 
10 Boise, Idaho, 
11 
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8 JIMMIE ELLIS KELIBR, 
9 produced as a witness, being first duly sworn, was 
10 examined and testified as follows: 
11 DIRECT EXAMINATION 
12 BY MR. COMSTOCK: 
13 Q. Mr. Keller, good morning. You are a 
14 physician assistant practicing presently lhat trade in 
15 Colorado, and we have asked you to review materials in 
16 this case, study depositions, speak with P As from the 
17 state of Idaho, ,n order to form opinions as to whether 
18 or not Mr. Byrne, the PA in this case, fell below the 
19 standard of care in his treatment of Rosie Schmechel. 
20 Before we get into that, though, and your response about 
21 that, would you just take a moment, start first by 
22 introducing yourself and staling your full name for the 
23 record. 
24 A. My name is Jimmie, J-I-M-M-1-E, Ellis, 
25 Keller, K-E-L-L-E-R. 
.. .,,=~,· "· -~=-~,,,_.,.,,--_.,. .. , . .,,. 'v.,,... ,,.~, .... ~ 
Virginia M. Bailey, RPR, CSR No. 262 
'l'estimony of Jimmie Ellis Keller 
October 18, 2007 
Page 4 ' ., 
l Q. And can you tell us a little bit aboul ~ 
2 yourself personally, where you presently live, what you I 
3 are doing currently, and perhaps a little about your ~ 
4 family'! 1 5 A Sure. I am currently the Program Director ~ 
6 Por tlie Physician Assistant Program al Red Rocks w 
' 7 Community College in Lakewood, Colorado. Also, work ., 
j 
8 part time in a rural health clinic that we established ! 
9 through a grant two yean; ago in Idaho Springs, ~ 
10 Colorado, I work there on Tuesday afternoons as a ~ 
11 family practice PA. ~ 
~ 
12 l grew up in North Carolina, had intentions ~ 
ti 
13 of becoming a physician. Economically, things didn't ' 14 work out, so I enlisted in the Uniled States Army in t 
15 1967, lo get the GI bill to go back to school. t 16 1 was in Viet Nam. I was as medic in Viel ' 17 Nam, in 1969 to 1970, with two infantry battalions in i 
18 the 9th lnfantry Division in the Delta, Viet Nam. " il 
19 After I completed that tour of duty, I was at f ., 
20 Fitzsimmons Army Medical Center in Denver, Colorado. I i 21 was an assistant ward master on an orthopedic ward, 
22 taking care of returnees from the war. f 
" 23 And then I went lo teach in a program that I g 
i 24 had gotten additional training, !here at Fitzsimmons, 2 5 orior to ,roin,r a Viet Nam, that's equivalent to a 
Page 5 ; 
1 licensed practical nurse. The Army calls it a clinical ~ ' 2 specialist. I applied to and was selected in the sixth J 
3 class of the United States Army Military Physician ~ 
4 Assistant Prograrn, in association with Baylor i 
5 University, went there in 1964, graduated in 1976 with ti 
6 honors. ~ 
7 After that I was the first physician i 0 
8 assistant assigned to Fort Jackson, South Carolina, 1 
9 where I took care of active duty soldiers, male and l 
~ 
10 female, training at Fort Jackson. ~ 
11 Did a tour of duty in Germany for ' ~ 
12 three years, from 1979 to '82, with the 3rd Infantry I 13 Division. 
~ 14 After that I did assignments for physician e 
15 assistants in the Army Surgeon General's personnel 
~ 
16 office. And then I was selected to serve as the first l 
17 Army physician assistant in the White House Medical Unit 1 . 
18 with President Reagan and at that time Vice President :1 
19 George W. Bush from 1984 until 1988. 
20 After that I was selected to be the ombudsman ' ~ 21 for the Surgeon General of the United States Army as his l 
22 physician assistant consultant and helped transition ' ~ 
~ 23 physician assistants from being warrant officers at that ' 1 24 point in time in the Army to commissioned officers. :; 
25 1 retire<l in 1999. I went to &st Carolina 
2 (Pages 2 to 5) 
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Schmechel v Dille & Byrne 
CV 2005-4345 
Testimony of Jimmie Ellis Keller 
October 18, 2007 
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' 
1 in a pain mruiagement practice? 1 supervising physician never even sees the patienLs that 
2 A. I do. 2 you see; correct? 
3 Q. That he was managing people's pain? 3 A. Thal is correcL 
4 A. I do. 4 Q. And that's okay? 
5 Q. And that he was making decisions each and 5 A. That's okay. 
6 every day with respect t.o what he would do with a 6 Q. You are not here testifying that, with 
7 chronic pain patient? 7 respect to a c,iuse of death type opinion, are you? 
8 A. I understand that, yes. 8 A. I'm not an expert. I'm not a pathologist. I 
9 Q. You are certainly not agreeing with the 9 do have an opinion, though. 
1 o following: 1 O Q. But you agree you're nol a pathologist? 
11 First of all, you agree that physician 11 A. No. 
12 assistants perform many of the same functions as medical 12 Q. You're not a toxicologist? 
13 doctors? 13 A. No. 
14 A. That's correct. We practice medicine. 14 Q. And when I took your deposition in Denver, 
15 Q. And physician assistants deliver a broad 15 O:,!orado, you told me you were not going to provide an 
16 range of medical and surgical services? 16 opinion with respect to what caused Mrs. Scl1mechel's 
1 7 A. All the things you see here that we are 1 7 death? 
18 allowed to do by law in any state, territory of the 1 8 A. At that time I did. 
19 United States, and elsewhere, is a negotiated autonomy. 19 Q. Second, you're not critical of Mr. Byrne 
20 What that means is, is that we have autonomy of 2 O changing Mrs. Schmechel's Hydrocodonefrom 7.5 
21 independent decision-making as far as deriving and being 21 milligrams to lO milligrams, are you? 
2 2 able to do all those things that you see, deriving a 2 2 A. I am not. 
2 3 treatment plan and so forth; but we are dependent 2 3 Q. You are certainly not here saying that she 
2 4 practitioners, that is, that every PA is educated to 2 4 abused her Hydrocodone, are you? 
this knowled e in ever PA ro am that exists toda . I 2 5 A. Nol that I can -- not b an indication that ) 25 
' Page 51 Page 53 l 
t 
1 was. Mr. Byrne was. We all are. That when you reach a 
2 point of where you're unsure or the complication of a 
3 ease or patient is beyond your scope, then that's a 
4 point in time that you need lo consult with your 
5 supervising physician and/or refer to a specialist in a 
6 field, a consultant. 
7 Q. And thank you for that. 
8 A. And that's the same thing for physicians, 
9 loo, in their expertise, 
10 Q. And thank you for that, Mr. Keller. 
11 When you are unsure, as a physician assistant 
12 or as a physician, that's a time when you need to go to 













That is correct. 
But with respect to what [ have up there, a 
·an assistant, taking medical histories, 
ting physical examinations, prescribing 
lions, counseling and educating patients, 
ing patients, ordering diagnostic tests, 
· ng minor surgery, that's all within the scope of 
ian a.~sistant's practice; correct? 
Their practice and their education, yes. 
You yourself have a supervising physician? 
I do. 
And there are times, many times, where your 
Virginia M. Bailey, RPR, CSR No. 262 
1 I have researched, no. 
2 Q. TI1ere is absolutely no evidence of that; 
3 correct? 
4 A. None that I can find. 
5 Q. You're not critical that Methadone was used? 
6 A. That was a choice he made. As I said 
7 earlier, I would not have made that choice; but since he 
8 did, he used it. 
9 Q. Sure. And it was not a breach of the 
1 0 standard of care for him to use-Methadone; correct? 
11 Just the Methadone in and of itself. 
12 A. From my understanding, in his practice with 
13 Dr. Dille, that they use Methadone in substitution for 
14 the other long-acting opioids such as OxyConlin, yes, 
15 that was part of their practice. 
1 6 Q. And that was within the standard of care to 
17 do? 
18 A. It was in their standard of care, their 
19 standard of care. 
2 o Q, You agree that most practitioners are not 
2 1 experts in the phannacokinetics of Methadone, including 
2 2 -- or excuse me -- the pharmacokinetics -- pardon me. 
2 3 ['m going to start that over. 
2 4 You agree that most practitioners are not 
' i 
I 
2 5 experts in the phannacokinetics of medicines, including ! 
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l ) . . ~. 
Arthur Lipman 
lN THE DtSTRlCT COUfl.T OF THE FIPTH JUDICII\L OISTR1~7 
OP THE STATE OF IDJ:\HO, 
m 11.ND FOR THE: COUNTY OF nirn f,'Al,!,S 
VAUGHN SCHMECHEL, 
individually, and as 
surviving Spouse and 
Personal Representative of 
the Estate of ROSALIE 
SCttMEC!ili!L, deceased, and 
ROBERT P, LE:\'/lS, KIM HOWARD 
and JUANITA P~ERSON, 




CLINTON DILLf, M.D.; 
SOUTHERN IDAHO PAIN 
INSTITUTE, an Idaho 
corporation; THOMAS BYRNE, 
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JlllY 5, 200? * 11,00 a.m. 
Locacionr CitiCourt Reporting Gro~p 
170 South Main Street, Suite :mo 
Salt Lake City, Utah 
* July 5, 2007 
l EXHIBITS 
2 NO. DESCRIPTION !'AGE 
3 I Notice of Deposition 4 
4 2 Curriculum Vitae of Dr, Lipman 4 
5 3 Affidavit of Dr, Lipman 4 
6 4 Supplemental Affidavit of Dr. Lipman 4 
7 5 Second Supplemental Affidavit of Lipman 4 








8 More: current CV of Dr. Lipman 250 
10 Handwritten instJ~ction from BJ. Byrne I 
~3 given to Rosalie Schmechel 150 i 
14 11 Earlier version of notes of Dr. Lipman ' 
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~ 
PROCEEDINGS , 
(EXHIBITS-1-THROUGH-7 WERE MARKED. i 
~ 
ARTHUR G. LIPMAN, PHARM.D., 
called as a witness, being first duly sworn, was 
examined and testified as follows: 
EXAMJNA TION 
BY MS.DUKE: 
10 Q. Dr. Lipman, good morning, My name is 
12 FOR THE DEFENDANTS DlLLE nnd SO!JTI{ER.N lDAHO PAIN 
INSTITUTE: 
11 Keely Duke. We were just introduced off the record. 
12 We're here to take your deposition today. And that 
13 deposition will be taken"" 
14 MS. DUKE: r assume, Counsel, we can 13 
Steven J. Hippler, Esq. 
14 GIVENS PURSLEY 
60 J W. Bannock Street 
15 P. 0, Box 277.0 
Boise, Idaho 83701-2720 




19 ARTHUR G, LJP!YiAN, PHARM,D. ,o Examination by Ms, Duke · 4 





15 stipulate it will be taken pursuant to the Idaho 
16 Rules of Civil Procedure? 
17 MR. FOSTER: Yeah. 
18 Q. (BY MS. DUKE) If you could state your 





A. Arthur G. Lipman. 
Q. And where do you reside? 
A. Salt Lake City. 
24 
25 
Q. How long have you lived here? 
A. Be 30 years next month. 
Q. As I understand it when we were talking I 
• ;";" .,..., ..,.~,,.~,~...-""~ '"""'"""'····;_"""'"""'~"-~" ... ;, . --- "·-· - .....,, "'~'"'""""~"t'"'"""""'"''"="' 
CitiCourt, LLC 
801.532.3441 
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Arthur Lipman * July 5, 2007 
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1 through conversation? 1 methadone or the selection of the methadone. It's 
z 
3 
A. Yes. 2 the way that it was used that I fault. 
Q, Is it your contention that Mr. Byrne or 3 Q, And that relates, again, to the once-a-day 
4 Dr. Dille violated any applicable statute or rnle of 4 upward titration? 
5 law in the state ofldaho? 5 A. Correct, 
6 A. No. 6 Q. Are you knowledgeable enough about the 
7 MR. FOSTER: I'm going to object to the 7 scoring of sleep apnea to know whether her scores 
8 form. B qualified her for severe or moderate sleep apnea? 
9 Q. (BY MR. HIPPLER) One of the reasons that 9 A. No. 
1 O methadone is sometimes used is because it's felt to 1 o Q, You said you had a discussion with 
11 be an efficacious medication to give for neuropathic 11 Dr. Vorse. Did she indicate to you a belief, not 





" fi ; 
13 A. Yeah. There's not evidence to suppo1t 13 that this patient should not have been on methadone? 
14 that. Tb ere were a number of speculations on that, 14 A. Not that I recall. 
15 and I've actually published in this area also, It's 15 Q. And when you talked with the physician in 
16 a very-- one of the isomers of the molecule is a 16 Lewiston whose name I can't remember --
17 weak NMDA antagonist. We know that NMDA antagonist 17 MS. DUKE: Flinders. 
18 are useful in managing neuropathic pmn. There's 18 MR. FOSTER: Flinders. 
19 absolutely no real evidence that methadone is any 19 Q. (BY MR, HIPPLER) -- Flinders, did you 
2 o better th,m any other opioid for that purpose. There 2 o talk with him generally about the standard of care in 
21 was a speculation to that effect in the literature in 21 Idaho, or did you talk specifically about the 
22 the late 1990s which could have influenced people 22 standard ofcare in 2003? 
23 using it in 2003. Thinking that it's a better drug 23 A. The majority of the conversation on the 
24 than morphine or oxycodone or any other opioid is not 24 standard of care was between Dr. Flinders and 
25 valid, ft's just as good as the other drugs, 2 5 Dr. Lordon since they're both practicing j 
1--------"---"'-------":....;___ __ P_a_g_e_2_3_8+---------..:;....---=-----=---P-a_g_e_2_4_0_J! 
;; 
1 however, so there's no reason not to use it. 1 anesthesiologists. I certainly concurred with what 
2 Q. Okay. 2 they said. I don't remember much more detail about 
3 A. And it's cheap. 3 it. 
4 Q. It certainly wouldn't have been 4 Q. So you don't remember whether it was a 
5 inappropriate in 2003 for.Mr. Byrne working in a pain 5 general discussion or specific discussion related to 
6 management clinic to think that methadone might be a 6 2003? 
7 good drug of choice for neuropathic pain? 7 A, l suspect it was both. 
8 A. There's no reason to think it's a drug of 8 Q, Okay. And do you recall what Dr. Flinders 
9 choice. ft's certainly a reasonable alternative 9 indicated, if anything, about what his knowledge of 
10 opioid. I have no problem with the selection of 1 o the standard of care in Twin Falls, Idaho was in 
11 methadone. I've been very clear on that. I think it 11 2003? 
12 was a reasonable choice, 12 A. I don't recall. 
13 Q, I take it you don't feel it was necessary 13 Q. Or what his basis of -- or how much 
14 for him to first try to increase her OxyContin to see 14 coutact he had with providers in 2003 from the Twin 
15 if that worked better? 15 Falls region? 
16 A. She was already-- she was not taking a 16 A. That may )iave been part of the 
17 large dose. She was only taking 20 milligrams three 1 7 conversation. Again, I don't have a recollection. I 
1 B times a day, But that's still a reasonably expensive 18 do recall that he felt that there was fairly 
19 drug, and methadone is a lot cheaper. So for 19 consistent standard across the state ofldaho, and 
2 o economic reasons it would certainly be reasonable to 2 o that it was consistent between Idaho and Utah. 
21 try her on methadone. 21 Q. Okay. Do you know whether he practiced in j 
22 Q. It's at least, at a minimum, a matter of 22 Utah? , 
23 judgment, professional judgment? 23 A. I think he trained here. j 
24 A. Yeah, Neither I nor anyone else on either 24 Q, Okay. Do you know when that was? j 
25 side of this case, to my knowledge, faults the use of z 5 A. I don't recall. :i 
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HALL, FARLEY, OBER.RECHT & BLANTON, P.A. 
702 WEST IDAHO STREET, SUITE 700 
KF.Y FINANCIAL CENTER 
BOISE, IDAHO 8Jnl2 
POSTOFPICE BOX 1271 
B0l$E. IDAHO .8370! 
TELEJ>HONE. (208) 395-3100 
FACSil\fil..E (208) 395-8:SSS: 
W:\2\2-40453\Ctnm.sel OS.dot 
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VIA FACSIMILE 
Byron Foster 
Law Offices of Comstock & Bush 
199 N. Capitol Blvd., Ste. 500 
P.O. Box 2774 
Boise, Idaho 83701 
Re: Schmechel v. Byrne, et al., 
HFOB File No.: 2--404.53 
Dear Byron: 
June 20, 2007 
RICHARD 1:-. HALL 
DONALO S, f"IJU..F.Y" 
!'lllLLU> S. O:BI:RRECHI' 
1. CHARLF.$ IIU.ITTON 
RAYMOND D, POWERS 
C'I.NPYWAdo\UOffDAL"e 
J. K!:MN W!',S"f 
B,ui:r W. llMWOOD 
JOHN J. BllR,KE 
KEVINJ.SC/INl...l'IN 
TAMSE,N L. LUACWMN 
KEl?LY £.. DUKB 
JAMc.S S. THOMSON, JI 
BRYAN I>-. NIC'KEU 
CHlUSD. COMSTOCK 
JILL M. 'IWEDT 
PORTIA L, 18'NKINS 
KMEN'O,SI-II!E.IU),; 
KYLHM, i'EI.RSLEY 
DANA M. frelUIERHOU 
MAAA.1, ORi..£!1' 
W'liR$'l Il TOWNSEND 
WIOr.AfJamt:pklmlrr«f1', Pra,:/1CCMW in 
Jdah~ On:gon. Wa:ihtng(Cllland /JUI!, 
Thank you for discussing the deposition schedule in the above-referenced matter with Steve 
and I today. As we all agreed, Dr. Lipman's deposition wlll be held on July 5, 2007 in Salt Lake 
City, Utah at 11:30 a.m. As such, we wlll send out an amended notice of deposition duces tecum 
with the new 1 l :30 a.m. start time. In addition, you indicated that you wlll talk to John Bush to see 
ifhe can cover Jim Keller's already scheduled deposition on July 19. With respect to Dr. Lordon, 
you indicated that given the trial you and Dave have from July 9 through potentially July 31, you 
need to move Dr. Lordon' s currently scheduled July 20 deposition. As such, you are checking to see 
if Dr. Lordon can be deposed on August 2, 8, 9 or 13-17. Obviously, the earlier we can depose Dr. 
Lordon the better, given that Rich and I will be unavailable for depositions in this case from August 
20, 2007 through September 14, 2007 due to a medical malpractice trial we have in Rexburg, Idaho. 
We also discussed getting the pathologist and Dr. Vorse scheduled for deposition. Currently, 
Dr. Verse's deposition is scheduled for July 25, but understand from you that is not a deposition Mr. 
Bush will able to cover, as such, please provide us dates for Dr. Verse's deposition. fn addition, we 
need to get Dr. Graben scheduled. My office will contact his office to find a date and then work with 
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In the event we are able to get Dr. Vorse, Dr. Lordon, Dr. Graben, Dr. Lipman, and Mr. 
Keller deposed prior to August 3, we will Wk to our experts about seeing who can be deposed during 
the week of August 13th through the 17th. As we indicated today, we will likely not be able io get 
all of our experts scheduled that week, but will do our best to do so, If we are unable to get the 
individuals listed above deposed before August 3, then 1he majority ofour experts' depositions will 
need to occur during the week of September 17 ( as long as they are available). We would be willing 
to have you depose our toxicologist and Dr. Jim Smith during the week of August 13, even.if we m:e 
unable to complete Dr. Lordon's depo by August 3. 
On a final note, we agreed to extend the lay witness and expert witness depositions currently 
set by the court to an indefinite date. As for plaintiffs' disclosure of rebuttal experts, we will not 
agree to extend that deadline beyond July 18 due to your refusal to accommodate our request to 
extend our expert disclosure from June J 8 lo a laier date. 
Again, we appreciate you taking the time to have this phone call. Please let us know the 
availability of your witnesses as soon as possible so we can finish up the discovery in this case. 
Very truly yours, 
~(lk 
KED/cp 
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WEB PAGE: www.haUfarley.com 
VIA FACSIMILE 
Byron Foster 
Law Offices of Comstock & Bush 
199 N. Capitol Blvd., Ste. 500 
P.O. Box 2774 
Boise, Idaho 83701 
July 3, 2007 
RICHARD E. HALL 
DONALD J. PARLEY 
f>!ffi.l'...fl> S. OBER!U!Ctrr 
J. CHARLES 81..JI.NTON 
kA YMOND l), POWERS 
CANOY WAGAHOFF DALE 
I, KE.VIN WEST 
BARTW. HARWOOD 
lOHN J. DURKE 
KEVfi,,! J. SCANI.AN 
TAMS!::N!.,. LEACHMAN 
KEFil.YE.DUKE 
JAMES S, THOMSON, ll 
BRYAN A. NICKELS 
CHRIS D. COMSTOCK 
JlI.L M. TWEDT 
PORTIA!'.., JEl'iKfNS 
KAREN 0. SH!l.Ei-1.AN 
K.YLllM. Yl!ARSLEY 
DANA M. liERllERHOLZ 
MARK J. ORLER 
JEf'FREY R.. TOWNSEND 
Willi A.t1onmys Ar/milled to Prwtlce Law In 
Idaho, Or~g1m, Wa.;hington mid Ulah 
Re: Schmechel v. Byrne, et al., 
HFOB File No.: 2-404.53 
Dear Byron: 
We are in receipt of your letter ofJuly 2, 2007 regarding the scheduling of depositions in this 
matter. As you are aware, our office first requested depositions for plaintiffs' experts on April 24, 
2007. After hearing nothing from plaintiffs' counsel with respect to those depositions we sent 
another letter requesting the depositions on May 9, 2007. Again, having not heard from plaintiffs' 
counsel, we sent a third letter, dated May 23, 2007, requesting your experts' depositions. On May 
24, 2007, plaintiffs' counsel finally responded with proposed dates for plaintiffs' experts' 
depositions (with the exception of Dr. Lordou). As such, we scheduled the depositions as follows: 
Deponent 
Arthur Lipman 
Kimberly Vorse, M.D. 
Cornelius Hofman 
Jim Keller 
Stephen Lordon, M.D. 
Date 
July 5, 2007 
June 15, 2007, moved 
to July 25, 2007 
August l, 2007 
July 19, 2007 
July 20, 2007 
Location 
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However, you contacted us a week and a half ago indicating your office needed to reschedule 
all but one of those depositions. As such, we have worked with your office over the last week to 




Kimberly Vorse, M.D. 
Cornelius Hofman 
Jim Keller 
Stephen Lordon, M.D. 
Date 
July 5, 2007 
August 1, 2007 
September 18, 2007 
August 8, 2007 
August 2, 2007 
Location. 




Salt Lake City 
Unfortunately, we learned form your office on June 27, 2007 via e-mail from your assistant to 
my assistant that your office is no longer able to keep the July 19, 2007 date for Mr. Keller's 
deposition and that the first available date for his deposition is August 8, 2007. Given that your 
primary standard of care expert is not being deposed until August 8, 2007, we. are unable to provide 
our standard of care experts for deposition (Dr. Cox and Mr. Kottenstette) until they have had an 
opportunity to review and analyze Mr. Keller's deposition. As such, the depositions of Dr. Cox aud 
Mr. Kottenstette will need to beheld the week of September 17, 2007. If you are able to find a date 
that works for our office (such as July 19, 2007) for Dr. Keller's deposition, we will be able to 
schedule Dr. Cox's deposition the week of August 13, 2007. As for Mr. Kottenstette, he has been on 
vacation and we have been unable to reach him with respect to his availability, but anticipate we will 
speak with him in the next week or so. 
As we explained in our June 20, 2007 telephone conference, Dr. Phillips and Dr. Smith are 
not available for deposition until the pathologist in this case, Dr. Graben, is deposed. Unfortunately, 
Dr. Groben indicated he was available on August 14 and 15, 2007 for his deposition. However, our 
office has left another message with his office asking ifhe could attend a deposition sometime the 
week of July 30, 2007. In the event we are able to have Dr. Groben's deposition taken the week of 
July 30, 2007, we are able to have Dr. Smith deposed on August 16, 2007 (we have not yet reached 
Dr. Phillips with respect to his availability). If Dr. Groben is unable to provide us a date earlier tha11. 
August 14 or 15, 2007, that works foryouroffice, Dr. Smith's and Dr. Phillips' depositions will also 
need to occur the week of September 17, 2007 so that they both have time to receive and review Dr. 
Graben' s deposition tTanscript. 
With respect to Dr. Fakata, she is available for her deposition on August 17, 2007 in Salt 
Lake City, Utah. 
We are frustrated with respect to the timing ofmauy of these depositions but unfortunately, 
given your office's request to reschedule all but one of your experts' depositions, our experts' 
<I .,. .. ) (': 
l }. _·, ') 
. ' 
July 3, 2007 
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depositions have to be pushed into September. Please let us know if you can move Dr. Keller's 
deposition back to July 19, 2007, as that will resolve a number of these scheduling issues. 
KED/cp 
cc: Steve Hippler 
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Byron Foster 
Law Offices of Comstock & Bush 
199 N. Capitol Blvd., Ste. 500 
P.O. Box 2774 
Boise, Idaho 83701 
Re: Schmechel v. Byrne, et al., 
HFOB File No.: 2-404.53 
Dear Byron: 
July 6, 2007 
IUCf-wlD E. HALL 
DONALD 1. FARLEY 
f'Hll.Lll' s. ODlltlRfiCHT 
l CHAllES l!LANfON 
RAYMOND D. POWERS 
CANDY WAGAfiOFF DALE 
J.KEVI.NWESl 
BAATW, HARWOOD 
JOHN J. BURKE 
KEVIN 1. SC/\NLAN 
TAMSElfL. LEACHMAN 
KEELY a DI.IKB 
JJ\.MCS S. THOMSON, n 
Dll,Y AN A. NICKELS 
CHlUS D. COMSTOCK 
JILL M. TWEDT 
l'ORTrA L. JENKINS 
KAREN 0. SHEEHAN 
KYLE M. YaARSLBY 
DANA M. HE.RDERHOJ...Z 
MARK J. ORLElt 
JE.FfREY R. TOWNSBND 
With Attomcys Adtriilkd(o ProGlici law hi 
Jduho, Ot<J<)Qf'r, li'ash1J,[;U»1 w,d Utah 
Dr. Groben is available for his deposition on July 30, 2007, after 5:00 p.m. Ifwe are able to 
have Dr. Groben's deposition taken on July 30, 2007, we are able to have Dr. Smith deposed on 
August 16, 2007. Please Jet us know as soon as possible ifthls will work. 
KED/cp 
cc: Steve Hippler 
Very tmly yours, 
Dictated by Keely E. Duke and Sent 
Without Signature lo Avoid Delay 
Keely E. Duke 
-.-. ·=· ------------
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/7, 
199 N. Capito! Blvd., Suite 500 
POSoxi5M 
Boisa, ID 83701-1584 
Via Facsimile: (208) 395-8585 
Keely E. Duke 
Byron V. Foster 
Attorney at Law 
July 27, 2007 
HALL FARLEY OBERRECHT & BLANTON. PA 
702 West Idaho, Suite 700 
PO Box 1271 
Boise ID 83701 
Via Facsimile: (208) 388-1200 
Steven J. Hippler 
GIVENS PURSLEY, LLP 
601 W. Bannock St. 
POBox2720 
Boise, ID 83701-2720 
RE: Schmeche/ v. Dille, M. D, et al. 
Dear Counsel: 
le!eµhone: (208} 335-4440 
Facaim11c-: (208) 344-n21 
On further consideration, we will not be taking the depositions or your respective 
experts. Therefore, please cancel the deposition dates for those individuals. If you have any 
questions, please -feel free to contact me. 
Yours very truly, 
BVF/skp 
lZLL·vv£-SOZ Hsns ~ )IJ0lSH0J 
'/l 
100 N. Oapllo.! Blvd., Suite 500 
POBox1564 
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COMMENTS: Please see the attached correspondence of today's 
date. 
Including this cover sheet, this facsimile contains L page(s). 
CONFIDENTIALITY NOTICE 
FAX RECEIVED 
JUL 2 7 2007 
HALL, FARLEY. 
OBERRECHT & BLANTON 
The infonnatlon In this facsimile is confidential and intended only for !he use of the addressee. The data 
transmitted is attorney privileged and may be exempt from disclosure. Do not copy or distribute to anyone 
other than the addressee. Reliance on this data by other than the Intended recipient Is prohibited. Please notify 
us Immediately if you have received this communication ln error. Upon notification we will arrange for return of 
the faK copies to Comstock & Bush. Additionally, if you do nol receive all of !he pages of this facsimile, please 
notify our office as soon as possible. Thank you for your cocperatlon. lf you have any problems receiving this 
fax, please contact the operator at (208) 336-4440. 
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IN THE DISTRICT COURT OF THE FIFTH JUD:r.cnu. DISTRICT OF 
THE STATE OF IDAHO, 1N AND FOR THE COUNTY OF TWIN FALLS 
VAUGHN SCHMECHEli, Individually, 
and as surviving Spouse and 
Personal Representative of the 
Estate of ~osalie Schmechel, 
Deceased, u.nd ROBERT P. t,r,!WXS, 
KIM HOWARD and TAMARA HALL, 
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Plaintiffs, 
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CLINTON DILLE, M.D., SOUTHERN ) 
IDAHO PAIN INSTITDTE, an Idaho ) 
Corporation, THOMAS B¥RNE, P.A.'} 
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PARTIAL REPORTER'S TRANSCRIPT 
JURY TRIAL - DAY 5 
TESTtMONY 0~ DR, GLEN ROBERT GROBEN 
HON, G. RICHARD B'.E!VAN 
DISTRIC1 JUDGE, PRESIDING 
Reported By 
VIRGINIA M, BAILEY, RPR, CSR. No. 262 
official Court Renorter 
1 APPEARANCES OF COUNSEL: 
2 MR. BYRON FOSTER, Attorney at Law, and 
MR. DA VlD COMSTOCK, Attorney at Law, 
3 COMSTOCK & BUSH, Boise, ldaho, 
appeared on behalf of Plaintiffs. 
4 
s MR. STEVEN HIPPLER; Attomey at Law, and 
MR. WILL VARIN, Attorney at Law, 
6 GIVENS PURSLEY, LLP, Boise, Idaho, 
appeared on behalf of Defendant Dille & 
7 Southern Idaho Pain Institute, 
8 
MS. KEELY E. DUKE, Attorney at Law, and 
9 MR. CHRJS COMSTOCK) Atlomey at Law, 
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HALL, FARLEY, OBER.RECHT & BLANTON, l'A, Boise, Idaho, 
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TUESDAY, OCTOBER 23, 2007, Page 
3
1 
THERON WARD JUD[CIAL BUILDING, • 
425 SHOSHONE STREET NORTH, i 
TW!N FALLS COUNTY, TWIN FALLS, IDAHC i 
9 GLEN ROBERT GROBEN, 
10 produced as a witness, being first duly sworn, was 
11 examined and testified as follows: 
12 DIRECT EXAM!NA T!ON 
13 BY MR. COMSTOCK: 
14 Q. Dr. Graben, good morning, You are a medical 
15 physician and a forensic pathologist, and the jury has 
16 heard your name, and we have been referring to an 
17 autopsy report that was prepared by yourself regarding 
J. 8 the probable cause of Rosie Schrnecbel's death. 
19 Before we get into those matters and your 
2 o work and your conclusions in this case, would you take a 
21 moment, introduce yourself to the court, spell your last 
2 2 name for our court reporter and, if you wouldn't mind, 
23 review your background and your education that qualifie: 
24 you to do what you do for a living. 
25 A. All right. My name is Glen Robert Graben. 
Page 4 
1 My last name is spelled, G-R-O, B, as in boy, E-N, I am 
2 a forensic pati1ologist. l work at the Ada Coun1y 
3 Coroner's Office. 
4 I have a medical degree from the Universi1y 
5 of Colorado Health Sciences Center in Denver, Colorado 
6 in 1990. Following that J did a five-year residency in 
7 general pathology at the same institution in Denver, 
8 where [ studied basically all aspects of pathology, 
9 which includes forensic pathology, Following that I did 
1 O a one-year fellowship in forensic pathology where I 
11 specifically worked in a medical examiner's office, and 
12 that was the office of the Chief Medical Examiner in 
13 Richmond, Virginia, So I worked there for a year doing 
14 autopsies and studying under the medical examiners 
15 there, Then following that, I went to work, and I went 
16 to Texas, worked for three years, before coming here in 
17 2000. 
18 Q. Can you explain sort of what you have been 
19 doing since 2000 for a living, and explain if you can, 
2 O during that process, how it is that you got involved, 
21 even though you're primarily in Boise, in tenns of doing 
22 an autopsy for the coroner here in Twin Falls County? 
23 A. Well, I've been working at the Ada County 
24 Coroner's Office since June of 2000. We do all of the 
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l MR. HIPPLER: I'd be impressed if you were 
2 able to do it from up there. 
3 THE COURT: I would, too. 
4 BY MR. HIPPLER: 
5 Q. Mr. Comstock, well, before we get to that, 
6 the page we're at there on the second highlighted line, 
7 says, I'm of the opinion that findings, cause, and 
8 manner death, as follows. Do you see that? 
9 A. Yes, I do. 
10 Q. And it's true, is it not, that actually you 
11 don't determine the manner of death? 
12 A. No, I do -- not, well, on this case, I 
13 don't. Depends on where it comes from. 
14 Q. That would be in the coroner's office, in 
15 this case Ms., now Anton, then Shindle? 
16 A. Right. That's correct. 
17 Q. Now, Mr. Comstock touched on this, so I won't 
18 go into too much of it; but Mrs. Schmeche! had an 
19 enlarged heart, or what you medical folks call 
20 cardiomegaly; correct? 
21 A. That's right. 
22 Q, And it's true that cardiomegaly, as 
23 Mrs. Schmeche\ had, can in and of itself cause a fatal 
24 arrhythmia in a person? 
25 A. That's possible, yes. 
Page 26 
1 Q. In fact, there are times where you will get a 
2 body, and you'JJ do an autopsy, and you won't find other 
3 causes of death, you'll find an enlarged heart, and 
4 you'll call it a fatal arrhythmia, secondary to a 
5 cardiac -- cardiomegaly; correct? 
6 A. That's right. 
7 Q. And if they have a fatal arrhythmia from 
B cardiomegaly, there's no finding other than the enlarged 
9 heart itself that you typically will be able to find 
10 that shows you that that's what killed them; correct? 
11 A. That's right. 
12 Q. Now, Mr. Comstock had asked you about various 
13 parts of the report and had you point them out. 
14 lfyou turn to page five of, what we've 
15 numbered page five, on our document, under paragraph 
16 number four, gastroi1\testinal system. Pardon me. ! 
17 take that back. Number five. Sorry. 
18 And under number five, one of the things that 
19 you looked at was the kidney; correct? 
20 A. That's right. 
21 Q. And one of the things that you found in the 
22 kidney was granulation of the kidney; correct? 
23 A. That's right. 
24 Q. And granulation of the kidney is consistent 
25 with long-term hypertension or high blood pressure, is 



















































Testimony of Dr. Glen Robert Groben 
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fl 
Hoon 1 
A, That's right. I 
Q. And obviously, long-tenn hypertension or high j 
blood pressure, including to the extent of causing ! 
granulation of the kidneys can be indicative of coronary! 
artery disease 'I l 
A. Well, they can happen either/or. But l 
' certainly they can happen together. i 
Q. Sure. And in fact, in this case you found g 
what you indicated was coronary artery disease that was j 
I think you indicated, moderate to severe but trending j 
into the severe; correct? :l 
A. That1s right. ~ 
Q. And that would include a 75 percent occlusion l 
of -- is it the left descending main coronary artery? 1 
A. It's the left anterior descending coronary , 
artery. i 
Q, And like you said, that's one of the three U 
important vessels; correct? I 
A. Yes, it is. , 
Q. And you found a 50 percent occlusion, or i 
narrowing or stricture of the right coronary main j 
aitery; correct? l 
A. Yes, I did. j 
0. And I presume in your position as a 1 ., 
Page 28 l 
pathologist, you'll have patients who have similar 
findings in their heart, and you'll conclude that that I 
! 
is the cause of the death, that is, their severe i 
coronary artery disease may have caused a sudden cardia ~ 
death; correct? ! 
A. If there's nothing else, yes. j 
Q. And a sudden cardiac death might be an , 
arrhythmia, and it might be a sudden fatal heart attack? j 
A. That's right. J 
~ Q. If we have, for example, a sudden fatal heart l 
attack, often times on pathology, there won't be a sign .\ 
of that other than the coronary artery disease that you l 
see; correct? 
A. That's correct. 
Q. And just so that I am understanding 
correctly, that I understand what you're saying with j 
respect to Methadone, but if we had the same patient " 
with just the Hydrocodone and her other underlying, ! 
we've been using the term comorbid conditions -- and yo\ j 
understand what comorbid conditions are; correct? 1 
A. Yes. i 
Q. If we had the other underlying conditions, ! 
such as her heart disease, such as her high blood l 
pressure, such as her cardiomegaly, that you would have 
1
1 
found that it was her severe coronary artery disease 1! 
7 (Pages 25 to 28) 
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IN THE DISTRICT COURT OF THE FIFTF! JUDICIAL DISTRICT 
OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS 
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and as Surviving Spouse and Personal 
Representative of the Estate of ROSALIE 
SCHMECHEL, deceased, and ROBERT P. 
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CLINTON DILLE, M.D., SOUTHERN 
IDAHO PAIN INSTITUTE, an Idaho 
corporation, THOMAS BYRNE, P.A. and 
JOHN DOE, l through X, 
Defendants. 
Case No. CV-05-4345 
NOTICE OF TAKING DEPOSITION 
DUCES TECUM OF SHAIYENNE 
SHINDLE 
YOU WILL PLEASE TAKE NOTICE that defendant Thomas J. Byrne, P.A., by and thTough 
his counsel of record, Hall, Farley, Oberrecht & Blanton, P.A., will take the deposition of 







SHAIYENNE_ SHINDLE at the Twin Falls County Courthouse, }ury Room, 425 Shoshone St. N., 
Twin Falls, Idaho commencing at 9:00 a.m. on July 10, 2007, and continuing from time to time 
until completed, at which place and time you are invited to appear and take part in such deposition as 
you deem proper. 
The deponent is required to bring with her the following: 
1) All medical records, charts, reports or other documents reviewed by you or in 
your possession pertaining to the medical care and treatment of Rosalie Schmechel. 
2) A copy of any and all correspondence, medical records or other materials 
provided to you by plaintiffs or plaintiffs' counsel or which you provided to plaintiffs or plaintiffs' 
counsel. 
3) All documents, notes, writings, correspondence, recordings or reports, 
produced, created or written by you, including any p1ior testimony or statements given by you, 
whether recorded stenogtaphically or otherwise, which reflect your opinions in this case or relate to 
the issues in this case. 
4) A copy of your curriculum vitae. 
The above deposition will be conducted pursuant to the Idaho Rules of Civil Procedure 
before a Notary Public, or such other officer authorized by law to administer oaths. 
DATED this .f;!!ctay of June, 2007. 
HALL, FARLEY, OBERRECHT 
& BLANTON, P.A. 
.By~~ 
,f,.., Richru:d E. Hall " Of the Firm 
Q •' Keely E. Duke- Of the Finn 
Attorneys for Defendant Thomas J. Byrne 
NOTICE OF TAKING DEPOSITION DUCBS TBCUM OF SHAIYENNE SHINDLE" 2 
·t i r· n, 
J. ;:. .) .. 
CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that on 1he ~ Jdyday of June, 2007, I caused to be served a true copy of 
the foregoing NOTICE OF TAKIN DEPOSITION DUCES TECUM OF SHAlYENNE 
SHINDLE, by the method indicated below, and addressed to each of the following: 
David Comstock /4s. Mail, Postage Prepaid 
Law Offices of Comstock & Bush Hand Delivered 
199N. Capitol Blvd., Ste. 500 __ OvemightMail 
P.O. Box 2774 __ Telecopy 
Boise, Idaho 83701 
Attorney for Plaintiffs 
Fax No.: (208) 344-7721 
Steven J. Hippler 
GlVENS PURSLEY 
601 W. Bannock ST. 
POBox2720 
Boise ID 83701-2720 
~S. Mail, Postage Prepaid 
Hand Delivered 
__ Overnight Mail 
__ Telecopy 
Attorneys for Clinton Dille, MD. and 
Southern Idaho Pain Institute 
M&M Court Reporting via email 
in,~~ 
T5 . ' Keely E. Duke 
NOTICE OF TAKING DEPOSITION DUCES TECUM OF SHAfYENNE SHJNDLE. 3 
t 
,, , r~ ~ 1 _; J ) 
EXHIBIT "15" 






Cathy A. Pontak 
Thursday, June 07, 2007 9:50 AM 
Keely E. Duke; Richard E. Hall; Chris D. Comstock 
Kathy A. Savell; Kay L. Moorhouse; Cathy A. Pontak 
Schmechel v. Byrne 2-404.53 
Sarah from Dave Comstock's office called. She said Dr. Lordon is ohly available on Fridays and we have 
tentatively set his deposition for July 27 in Salt Lake. Also, Sarah said that their office is not available for 
the depositions of the coroners on July 10th as they are in trial. We are going to keep those on calendar 
for now, in case their case settles. 
1 




199 N, Capitol Blvd,, Suite 500 
PO Box 1604 
Sols~ 10 83701-1584 
Via Facsimile: (208) 395-8585 
Keely E. Duke 
Byron V. Foster 
Attorney at Law 
July 2, 2007 
HALL FARLEY OBERRECHT & BLANTON, PA 
702 West Idaho, Suite700 
PO Box 1271 
. Boise ID 83701 
Via Facsimile: (208) 388-1200 
Steven J. Hippler 
GIVENS PURSLEY, LLP 
601 W. Bannock St. 
PO Box2720 
Boise, ID 83701-2720 
RE: Sohmeohel v. Dille, M.D, eta/. 
Dear Counsel: . 
Last week, Ms. Duke's assistant, Cathy, emailed my assistant regarding 
scheduling/rescheduling the depositions of Mr. Hofman, Dr. Nicholson, Dr. Groben, Mr. 
Chambers and Ms. Shindle. In reviewing Ms. Duke's letter of June 20, 2007, it is indicated that 
if we were able to schedule Drs. Vorse, Lordon, Lipman, Groben and Mr. Keller prior to August 
3, 2007, we would discuss deposing your experts the week of August 13. Given 1hat we have 
set the majority of these depositions, Dr, Lipman on July 5, Dr. Vorse on August 1, Dr. Lordon 
on August 2 and gave proposed dates far Mr. Keller of either August 8 or 9, we would like to 
schedule your experts' depositions during the week of August 13, 2007. I feel it Is unreasonable 
to wait to schedule your experts' depositions until Dr. Groben's deposition has been taken. 
Therefore, please provide our office with your experts' avallabllity including, but not limited lo, 
.Mr. Kottenstette, Dr. Binegar, Dr. Cox, Dr. Fakafa, Dr. Smith, Dr. Phillips, Dr. Hare, and Dr. 
O'Donnell. 
Yours very truly, 
BVFf<>kP 
IUL-tts-soz Hsns ~ )l'.JO.lSNO:l 
zn: 
199N. CaplloJ l;IlvO,, S!Jlle 600 
POBox1584 , 






Byron V. Foster 
Attorney at Law 
FACSIMILE COVER SHEET 




Byron V. Foster 
July 2, 2007 
Schmeche/ v. Dflle, et al. 
Telaphone,: {208) 336-4440 
F1tCG.lm!l11: {208) 344-7721 
COMMENTS; Please see the attached correspondence of today's 
date, 
Including this cover sheet, this facsimile contains L page(s). 
CONFIDENTIAblTY NOTICE 
FAX RECJ;:IVED 
)UL Oc 2007 
. HAU.,-FARb!=,Y, _ 
OBERRECITT & "'""''ON 
The information in this facsimile is confidential and Intended only for !he use of tha addressee. The data 
transmitted Is atlomey priVllegect and may be exempt !rom disclosure. Oo not copy or dls\rlbute to anyone 
other than the addressee, Relianoo on this data by other than the intended recipient Is prohibited. Please notify 
us Immediately If you have received 1hls communlcatlon In error. Upon notlfioatlon we will arrange for return of 
th• fax copies to Comstock & Bush. Additionally, If you do not receive all ofthe pages of tills facs1m!le, please 
notify our office as soon as possible. Thank you for your cooperation. If you have any problems receMng this 
fax, please contact !he operator at (208) 336444-0. 
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Pagel 
IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRJCr 
OF THE STA.TB OF IDAHO, IN AND FOR 'rHS CO\JNTY ()F ·rwrn PALLS 
VAUGHN SCHMF.:Cl-iE:t,, individually, 
and as surviving Spouse and 
Pe:i.:sonal Representative of the 
Estate of nosALI8 SCHM8CHEL, 
deceased, and ROBERT P. LEWIS, 
KIM HOWARD and JUANITA PETERSON' 
natuzal cl1ildzen of ROSA.LIE 
SCHMECHEL,, deceased, 
PlaintiCfs, 
"· CLINTON L, D!LLE, M,D., SOU'J'IH?RN 
IDAHO PAIN INSTITUTE, an Idaho 
corpor.?ttion, THOMAS BYRN£, P ,A., 
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For the Defendant Hall Farley Oberrecht & Blanto, l 
Th01nas J. Byrne: BY: KEELY E. DUKE j 
702 West Idaho, Ste. 700 1 
P.O. Box 1271 ' 1 Boise, Idaho 83701-1271 , 
For the Deponent: Twin Falls County Prosector's 
Office 
BY: MATTHEWD. PEMBER 
P.O. Box 126 



















1 TI!E DEPOSITION OF SHAIYENNE ANTON was tal<e1 1 INDEX :,i 
2 on behalf of the Defend.ant Thomas J. Byrne at the 2 " 
3 law offices of Tolman & Brizce, 132 Third Avenue 3 TESTIMONY OF SHAIYENNE ANTON: PAGE J 
l 4 East~ Twin Falls, Idahot commencing at 12:00 p.m., 4 Examination by Ms. Duke 5 ~ 
5 on September 5, 2007, before Catherine Pavkov, 5 Examination by Mr. Hippler 96 . 
6 Certified Shorthand Reporter and Notary Public 6 Examination by Mr. Foster 105 I 
7 within and for the State ofldaho, in the above- 7 Further Examination by Ms. Duke 127 i 
8 entitled matter. 8 Further Examination by Mr. Foster 132 ' 
9 9 Further Examinatn by Mr. Hippler l 33 I 
10 APPEARANCES: 
11 For the Plaintiffs: Comstock & Bush 




P.O. Box 2774 
Boise, Idaho 83701-2774 
16 For the Defendants 
17 Clinton Dille aud 
GIVENS PURSLEY, LLP 
BY: STEVEN .l. HIPPLER 
18 Southern Idaho Pain ,601 West Bannock Street 






Boise, Idaho 83701-2720 


















Second Amended Notice of Taking 15 
Deposition Duces Tecum of Shaiyenne 
Shindle 
CD of photographs 134 
** To be provided later 
Twin Falls County Coroner's Office 19 
Autopsy Report with Attached Record 
of Death 
Twin Falls County Coroner's Office 19 
Autopsy Report 










(208) 345-9611 M & M COURT REPORTING SERVICE, INC, 
1 (Pages 1 to 4) 
(208) 345-8800 (fax) 
Page 41 
1 find any signs of struggle, bodily fluids, 1 Q. Rather, why don't you describe for 
2 sickness, anything like that. You know, just to 2 me in your own words what you believe, you know, 
3 indicate to me if she'd been sick prior to her 3 happened immediately prior to her death, at least 
4 death. And I didn't find anything to that effect. 4 from the standpoint of you being able to observe 




s Q. Okay. With respect to your s the scene. 
6 investigation of the area surrounding her, could 6 A. Okay. I believe from what I saw at 
7 you tell whether she had released her bowels or 7 the scene and what I later heard, you know, 
8 ber bladder at that point? 8 speaking with witnesses that were there, later 
9 A. I believe at that point, no. I 9 with Mr. Schmechel, the little bit I was able to 
1 O couldn't tell. It was later when we had moved her 1 o speak with him, he had seen her earlier that 
11 and was back at the mortuary that I noticed that. 11 morning, that she had been sleeping. I believe he 
12 Q. And it's also my understanding that 12 stated she was even snoring. 
13 the TV had been on when Mr. Lewis had come to the 13 By the way, the family members 
14 scene but that it had been subsequently turned 14 stated, you know, she didn't leave dishes in the 
15 off? 15 sink. She didn't leave the ashtrays. Those are 
16 A. Correct. And I can't recall what 16 things she did in the morning, part of her day. 
1 7 time, when in the time Officer Andrae told me 1 7 The bird cage wasn't taken off. The dog wasn't 
18 that, but he did say that when he got there the TV 18 outside. Those are things that she did, you know, 
19 and cable was on. I remember him telling me that 19 throughout the morning, I was told. That since 
2 o he did turn the cable off. 20 those things weren't done, I believe it was 
21 Q. So the TV and cable were off at the 21 sometime during the morning that maybe she woke j 
2 2 time? 2 2 up, you know, possibly had a cigarette or the -- : 
23 A. Correct. Uh-huh. Or I believe the 23 the coffee wasn't started or made, which they said I 
24 cable was off or they were having difficulty with 24 was one of the first things that she did, I don't j 




1 but he stated to me that he had turned them off. l Q. But you do think at the time of her l 
2 Q. But it's your understanding that 2 death she was awake? ' 
3 when he came upon her, prior to calling, 3 A. Correct, yes. And I believe that l 
4 obviously, nine-one-one, that the TV had been on? 4 dne to the fact with the cigarette, lit cigarette. l 
5 A. Correct. 5 Q. Right. And I would assume that you 1 
6 Q. And as I understand it, you didn't 6 also believe that just given the posture of her ! 
7 find any signs of any kind of other person unknown 7 body looking as if it kind of slumped to the I 
8 or trauma? 8 right, that she had been in a sitting position? j 
9 A. Right. 9 A. Yes. i 
10 Q. No sign of struggle? 10 Q. And then something occurred and she j 
11 A. Correct. 11 slumped to the right and that's where you found ] 
12 Q. And so you ruled this to be an 12 her? :: 
' 13 accidental death? 13 A. Correct, yes, :1 
14 A. Correct. 14 Q. All right. So after you performed fi 
15 Q. Is it fair to say that based on the 15 this investigation that brought you into the room, :.a,! 
16 fact that the TV was on, the fact that there was a 16 did you notice that there was a CP AP machine in u 
1 7 lit cigarette that obviously fell to the floor, 1 7 the room anywhere? · J 
~ 
18 and that it appeared Mrs. Schmechel slumped over, 18 A. Not that I recall, no. r; 
19 that immediately prior to her death she had been 19 Q. Do you remember anybody talking l 
20 sitting up? 20 about a breathing device which she would use if l 
j 
21 A. Correct. :Yes. I believe so. 21 she was asleep? j 
22 Q. And so it's not your opinion based 22 A. No. , 
23 upon your investigation that she bad been asleep 23 Q. Do you recall any photos of that ii 
2 4 at the time of her death,· is that con-ect? 2 4 device at all 7 a 
1\,' 
2 5 A. I don't believe so, no. 2 5 A. Not to my knowledge, no. ti 
•~'~"'-"-"'"'-"·""""-''"""'-- .. ,..,..,~.,~- '~"~""'"''""~'"'""'""'"'-"~-=~~,.,~~·-"'- ·="'-""'"-"'~\<r~"'"<~'"-''''-~""'"'"'"""' '~"'"""~"'~'""~" .. '""''~~""'"""~'~''-~"'"'-"""""'""'-''--.;,w,>,; "" =~· """"'""-'"'""-' =·=""' ·- ,,=.:..,.,,:.:! 
(208) 345-9611 M & M COURT REPORTING SERVICE, INC. 
11 (Pages 41 to 44) 
(208) 345-8800 (fax) 
16d 13aez .. 1417 -4e56-a964-12ed9bbae35_c 
1 1 C' ,. 
.1. -'· u ~-
EXHIBIT "18" 
OP ~~/~~A~iiS~li~J\~g~liI/!~~:I~ ~~~~/~I~1~k: 
VJIUGUN SCIIMECU&L, individually, and a13 ) 
Surv.Lv.fog Spo1rne llnd Pe:rsonal ) 
:~~:~~~~t~:~e~:el~e_._~~t;;:E~f :~s~~~~s. No, cv-os~4.34.! 
KlM !IOWARP and T.MIJIJ'!.1i. IUILL, natural 
children of ROSALIE SC'HMSCHEL, dece.ised, 
Plaintiffs, 
v,, 
Cl,lm'ON D'ILL'E, M.D., SOUTHERN lDAIIO l.'AlN 
INSTITUTE, 1111 ld"'ho (lOt:poration, TJIOMAS 
BYRNE, P-.h,' and JOHN DOE and JANE DOS, 
I through K, 
De.Cenda~ta. 
VWSO'l'J\PEO OEPOSl'l.'lON OF CLINTON l.J>.MAR PlLL£, M,D, 
JUNE :l, 2006 
REPOR.'T'ED B'f 1 
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i 
APPEARANCES (continued): ! 
· For Defendant Byrne: Hall, Farley, Oberrecht 8 i• 
Blanton, PA : 
BY: Richard E. Hall 1.· 
702 West Idaho I 
Suite 700 I 
Boise, Idaho 83701 ! 
I 
Also Present: John Glenn Hall, Videographer 
I 
~ ~-----------------+-----------------11 
Page 2 Page 4 ! 
l TIIEVIDEOTAPED DEPOSITION OF CLfNTONLAMAR DILLE, M.t, 1 INDEX ! 
;i: 
2 was tak!'n on belrnlf of the Plaintiffs at the offices of 2 l: 
3 Q;v,os Pu,sley, LLP, 60l West Bannock Stree, Bdse, 3 WITNESS CLINTON LAMAR DILLE, MD. PAGE!,: .. ~. 
4 Idaho, commencing at 9:15 a.m. on Friday, June 2, 2006, 4 Examination by Mr. Comstock 9 ~ 
; 
s before Maria D. Glodowski, Certified Shorthand Rc:port¢r 5 ~ 
6 and Notary Public within and for1he Stn.te ofldnho, in 6 ~ 




11 For P!l)lntiffs: Comstock & Bush 





199 North Cnpitol Boulevo.rd 
Suite 500 
Boise, ldid10 83701 
17 FotDefendnnts Dille and Give11s Pursley, LLP 








601 West Bannock Street 
Boise, Idaho 83701-2720 
8 1, Southern Idaho Pain and Rehabilitation 5 ~ 
f, 
9 Instilute chart, Bates stamped DILLEOOO l ~ 
10 through DILLE002S ij 
11 2, Curriculum Vitae of Clinton Lamar Dille, M.D. t4 ~ 
12 3, Hand-written note by T.J, Byrne 39 i\ 
11 I 
















09: 53 1 death? 
09: 53 2 A I think as physicians you always want to know 
09: 53 3 if any of your therapies or medications are involved, and 
09: 53 4 given that, then I was concerned, 
o 9 : 5 3 5 Q. Did you go back and look at her chart? 
09, 53 6 A. Yes, I did. 
09, 53 7 Q. Why did you do lha17 
09: 54 8 A. I wanted to review a!! the records and review 
09: 54 9 the care that had been provided by Mr. Byrne. 
09:54 10 
09;54 11 
Q. Diel you speak with Mr. Byrne? 
A. Yes, l did. 
o 9: 54 12 Q. Tell roe about that conversation. And this 
0 9 : 5 4 13 would be a conversation after learning about 









09: 57 5 
09:57 . 6 
09:57 7 
()9:57 8 




09: 57 13 
09,57 14 
Page 31 I 
A. I do not know that. I 
Q. Do you know whether Mr. Byrne had obtained any ~ 
records of her sleep apnea tests that they conduct to I 
determine whether or not your sleep apnea is mild, 
moderate, or severe? 
A. He had not. 
Q. Okay. After reviewing the record once you 
!earned Mrs. Schmcchel had died, and after talking lo 









iI Q. I note from the record whk:h ls Bates stamped 
' page 10 ofExhlbit l, that you wrote 1o the Twin Falls ~ 
County coroner on November 4th of 2003. Why did you d f · 
' 09:54 15 
09;54 16 
09,54 17 
A. And the.review of the chart. 
Q. Sure. 
09: 57 15 that? 1 o 9 1 s 7 16 A. It's a standard procedure when we have patients 
I A. After my review of the chart1 I told T.J. tha1 09,57 17 
o 9 : 54 18 it appeared that he had handled Mrs. Schmechel in an o 9 : 5 7 18 
09: 54 19 excellent fashioO and that I could not see where I would 09: 58 19 
o 9 ; 5 4 2 o have made any changes or done anything different than wh; to 9 : 58 2 o 
09:54 21 Mr.Byrnebad. 09:58 21 
09: 54 22 And, in fact, I thought Mr. Byrne had done an 09: 58 22 
who die unexpectedly and that have an autopsy, tha1 we 
would like to obtain that for her med -- completeness sake ! 
of her medical records. ~ 
ii 
'! 
to the coroner? Was that just routine practice, or did f 
you hear something about her death that caused you to mak~ 
Q, So you wrote to the·- what caused you to write 
09: 54 23 excellent job of obtaining the history and pulling out the D9: ss 23 that request? j 
09: 54 24 fact that she has obstrnctive sleep apnea when she didn't o 9: 58 24 A. We did not hear anything about her death. i,: ..
O 9 : 54 2 5 put it on her init_\al .intake, and that he was able to o 9 : 58 2 5 That-~ it was a routine practice. ~ 
1------~-----'---------------1--------------------------1~ 
Page 30 
09 : 5 5 1 address that and fonnulate a plan and to follow up with 09: 5 8 1 
09:55 2 
09, 55 3 
09, 55 4 
09, 55 5 
09, 55 6 
09: 55 7 
09: 55 8 
09,55 9 
09:55 10 
it, and with his concern, also, had made appropriate 
telephone calls and follow up with the patient J thought 
that Mr. Byrne had done an excellent job. 
Q. Why i& obstructive sleep apnea a significant 
piece of her history when providing this type of 
Schedule II narcotic treatment? 
A. Because if the patient has obstructive s[eep 
apnea that's not appropriately treated, it could -- the 
narcotics, not just methadone, but any narcotics, could 
09, 58 2 
09, 58 3 
09:58 4 
09: 58 5 
09:58 6 
09, 58 7 
09: 59 8 
09, 59 9 
09,59 10 
o 9 : 5 5 11 cause some respiratory depression and increase the -- the 09 : 5 9 11 
chance of an -· of an adverse outcome. 
Q, Did you !earn from T.J. Byrne whether or not he 
had - be had attempted to contact Dr. Vorse to determine 
the extent of Mrs. Sc;:hmechel1s sleep apnea disturbances? 













don't think thattilat's particularly relevant since the 09, 59 17 
patient was already being treated with potent long acting O 9 : 5 9 18 
09 : 56 19 narcotics that have essentially the same side effects as 
O 9 : 56 2 O methadone, and that tbe patient was being treated with 
09, 56 21 CPAP. 
09: 56 22 Q, From your discussions with Mr. Byrhe, do you 
O 9 : 5 6 23 have an understanding as to whether or not 
09: 56 24 Mrs. Schmechel's sleep apnca was by history mild, 
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~ 
1 Q. Did you subsequently receive a copy of the 
toxicology report relative to her autopsy? ~ 1 
A. I beHeve so. 
Q. Did you review that? ~ 
i A. I have reviewed it. ~ 
Q. Did you place a copy of what you received into J 
Mrs. Schmeche!'s chart? I'll represent to you, Dr. Dille, . 
ill 
that it ls not part of the chart that has been produced to if 
me, and that's why I ask the question1 did you put a copy! 
of her toxicology autopsy report-into her chart? fl 
A. I am not sure about that. 3 
' Q. ls tliere some kind of separate chart being kept f_~_ 
relative to RosaJic Schmechel in your office? . 
" A. We have a-- probably a folder that relates to  I ongoing legal issues related to her that we've received 
from my attorney, as well as T.J.'s attorney. i 
Q. Okay. l 
MR.,H!PPLER: A11d -, and, Counsel, for lhe ! 
record1 it was my understanding when I obtained the ~ 
records from Ms. Davies, that the cha.ti was in there and j 
it may be a -- just a matter of my staff having separated i\ 
that out when they gave me what they thought was tbe f, 
' record when they went through it, but you're welcome tO :(
look at the original chart at some point to see whether '· 
it's in there? 
8 (Pages 29 to 32) 
55e00f49-6131-48fb-a72b-!2a671283842 
1 
" ,, " 
). Ur; 
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IN THE DISTRICT CO~RT OF THE PIPTH J\JDlCIAL DISTRICT OF' 
TH8 STATS OF IDAHO, IN AND l'OR 'rHE COUNTY OP TWIN FALLS 
VAUG!:IN SCHMECl-iEL, Individually' 
and as Surviving Spouse and 
Personal Representative of the 
tstate ol: Rosalie sclimechel, 
Deceased, and ROBERT I?, UEWlS, 
KIM HOWARD and 'l'AMAAA HALL, 
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THURSDAY, OCTOBER 25, 2007, , 
THERON WARD JUDICIAL BUILDING, J 
425 SHOSHONE STREET NORTH, TWIN FALLS i 
COUNTY, TWIN FALLS, IDAHO. I 
* * * * * * * * * 
8 CLINTON LAMAR DILLE, 
9 produced as a witness1 being first duly sworn, was 
10 examined and testified as follows: 
11 DIRECT EXAMINATION 
12 BY MR HIPPLER: 
13 Q. Dr, Dille, could you introduce yourself to 
14 the jury and spell your name, including your last name 
15 for the court reporter? 
16 A. My name is Clinton Lamar Dille. That's 
17 spelled C-L-1-N-T-O-N, L-A-M-A-R, last name, Das in 
18 David, l-L-L-E. 
1~ Q. And Dr, Dille, could you take some time to 
20 introduce yourself to the jury in terms of where you 
21 grew up, where you1re from? 
22 A. I was born in Jerome, spent much ofmy youth 
23 in the Magic Valley and graduated from Murtaugh High 
24 School. r was involved and worked on our family farm 









' ' ~ 
Page 4 ij 
• 1 changed on the farm, and I went to college. I went to l 
2 Brigham Young University and obtained a bachelor's of !.;, 
3 science degree and 1hen went to medical school at the 
4 .University of Washington in Seattle. Because I was an ] 
s Idaho resident, Idaho has an agreement with University j 
6 of Washington to educate ldaho students, and it's called , 
' 7 the WAMI Program, which stands for Washington, Alas a, 
8 Montana, and Idaho; and in 1his program, the first year I 
9 is, of education, is performed in your home state, and I, 
10 so the first year ofmy medical education was performed 1, 
11 at University ofldaho in Moscow as well as at ! 
~~ :~s~~~~t~~e~~t~~;::fr~~ro:;~e":~~~~;s~t 1~:d I 
l.4 Washington School of Medicine in Seattle, where l 
15 graduated with a medical degree. 





Q. Okay. And are you married? 
20 A. Yes. rm~~ I've been married to Anna, my 
21 wife, for 30 years. 




A. I do. I do. I have six children. 
Q. What are their names and ages? 
A. The oldest is Brock; he's 28. He lives here 
1 (Pages 1 to 4) 
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1 Q. Okay. And we talked earlier about what you 
2 understood the conversion starting dose to be, and I 
3 think you indicated it was 30 milligrams or 15 
4 milligrams twice a day; correct? 
5 A. Yes. 
6 Q, And you understand that Mr. Byrne, from his 
7 testimony, as well from your review of the records, had 
8 elected to conservatively initiate her into that 
9 conversion starting dose; is that right? 
10 MR. COMSTOCK: Objection, Your Honor. 
11 Leading. 
12 MR. HIPPLER: Setting up another question, 
13 Your Honor. 
14 MR. COMSTOCK: It is leading, Your Honor. 
15 THE COURT: It is leading, counsel. Would 
16 you try to 1·ephrase it? 
17 MR. HIPPLER: Okay, Sure. 
18 
19 BY MR. HIPPLER: 
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' ~ 1 to do what he did with Mrs. Schmechel? 
2 MR. COMSTOCK: Objection, Your Honor. Call l 
3 for this man to make a legal conclusion as to what's ; 
4 required by the Board of Medicine. ] 
THE COURT: Overruled. The question I 5 
1 6 referenced his understanding of what he believed the i 
7 agreement would require rather than what the law would 
8 require, I'll allow that. 1
1
, 
9 THE WITNESS: Our intent was to allow 
10 Mr. Byrne to practice medicine and to do the things that j 
11 he had been trained for and was obviously authorized to I 
12 perform by the State of Idaho, the Board of Pharmacy, as , 
13 well as the DEA; and in that respect, we had no intent I 
14 of trying to limit Mr. Byrne's ability to practice. I j 
15 think that our intent was to try to meet the Board of a 
16 Medicine's requirement that we have this agreement, j 
l 7 which is a general outline and the contents of which are j 
18 not specified by the Board of Medicine. s 
19 W11at is important here is that I recognize j 
20 
21 
Q, How would you describe Mr. Byrne's dosing of 20 that [ am his primary physician who is supervising him, , 
Mrs. Schmechel with respect to her conversion starting 21 and Mr. Byrne recognize that I am his supervising l 
2 2 dose and the doses below that? 2 2 physician, and that I recognize if there are anything j 
23 A, I think that the conversion starting dose of 23 that I do not want Mr. Byrne to do that I think is I 
24 30 milligrams was -- was conservative and was a 24 outside his scope of medicine, and our intent here was l 
2 5 reasonable conversion starting dose. l think that he 2 5 not to limit Mr. Byrne on this -- on this piece of I .------------"----------+-------~---------'.-------;,•! 
Page 40 ~ 
I 
1 took it even more conservative and started the patient 1 paper. j 
Page 38 
2 with a decreased dose, which, from my review of the 2 ! 
3 charts, appears to be 5 milligrams twice a day, which he 3 BY MR. HIPPLER: , 
4 was trying to elicit if the patient had any adverse side 4 Q. Okay. Was this something that you guys would I 
5 effects from the medication, that, with the long 5 have out on your desk and look at every day in tem1s of j 
6 half-life of this medication, it would be best to have a 6 the exact wording ofit? }.' 
7 small amount on boa;d and have an adverse reaction than 7 A. I don't think I ever saw this again until ·· 
8 to have a larger amount on, on board. And so he was 8 this trial. I 
0 
9 starting with a smaller starting dose and was working 9 Q. Okay. And there was something raised in J 
1 O the patient into the starting conversion dose. 1 O opening. I just want to cover it real quick. Ms. Duke, ! 
11 Q. Did you have any problem or concern with 11 can you pull up the signature page of the delegation of i_".·, 
12 that? 12 services agreement? I believe that's Exhibit 40 in the 
13 A. No. 1-- l may have done things differently. 13 jury notebook. l 
14 I may have started the patient right on 15 milligrnms 14 Doctor, I don't mean to embarrass you about I 
15 twice a day or 10 milligrams three times a day. But 15 your handwriting, Do you see where you signed under, ; 
16 that was very a reasonable and conservative approach to 16 supervising physician? j 
1 7 the medication management that Mr, Byrne approached. 17 A. Yes. j 
18 Q, And you were here yesterday; correct? 18 Q. And you dated it? , 
19 A. Yes, I was. 19 A. Yes. j 
2 0 Q. And you had. -- you've seen the job 2 o Q. Can you read your handwriting? 'l 
21 description and the delegation of services what were in 21 A. Yes. I 
22 effect in 2003; correct? 22 Q. What does it say for the date? j 
23 A. Yes. 23 A. 4/15/03. , 
L
2"""4"""'""'Q"'"'. "B"'a"'siiie"'d"'u"'p"'on=y"'ou"'r"i"'n"'te"'n"'t "'in"'t"'h"'at~'a"'g"'r"'ee"'m"'e"'n"'t"', -~~2"'4"""""'""Q"'. """O"'k"'a"y .""'A""n"d"a"'ft"'er~y""o""u""'sia,g"'n"'ed""'th"'is"'o"'n"'4"'/"'1"'5""/0""3"', """,Ji·,i,I_  5 under that agreeme t, .did Mr. Byrne h ve the authority 2 5 do you recall seei g i  again until this trial? ii 
,..,.,~'"m"""'~""'""''"""":-c,· =•· , .,,,.,,.,,.,,,.,,...,,.,,=="--~""'"'·"='"''" ··:.:;a.,=··•-""' , . •,-, , . ~,,,.,,,.,.,,., ..•. ,,,,,._=_.,,.,'"~"'""~"''"'"~-.,=,=,;1.,,.,,...,,,,,.,,.,,,.,..,.,,,.,._..,,,,,,,,,.,,,,.=-:.•..:"'='-"·"='"""""""~ · ,..;; 'I 
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Attorneys for Defendants, Clinton Dille, M.D. and Southern Idaho Pain Institute 
IN THE DISTRICT COURT FOR THE FIFTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS 
VAUGHN SCHMECHEL, Individually, and : 
as Surviving Spouse and Personal 
Representative of the Estate of ROSALIE 
SCHMECHEL, deceased, and ROBERT 
P. LEWIS, KIM HOWARD and TAMARA 




CLINTON DILLE, M.D., SOUTHERN 
IDAHO PAIN INSTITUTE, an Idaho 
corporation, THOMAS BYRNE, P.A., and 
JOHN DOE and JANE DOE, I through X, 
Defendants. 
STATE OF IDAHO ) 
)ss. 
County of Ada ) 
Case No. CV 05 4345 
AFFIDAVIT OF STEVEN J. HIPPLER 
IN SUPPORT OF CLINTON DILLE 
AND THE SOUTHERN IDAHO PAIN 
INSTITUTE'$ RESPONSE TO 
PLAINTIFFS' MOTION FOR NEW 
TRIAL 
STEVEN J. HIPPLER, being first duly sworn upon oath, deposes and states as 
follows: 
AFFIDAVIT OF STEVEN J. HIPPLER IN SUPPORT OF CLINTON DILLE AND THE SOUTHERN 
IDAHO PAIN INSTITUTE'S RESPONSE TO PLAINTIFFS' MOTION FOR NEW TRIAL -1 
·. r 
1. J. G 8 
1. I am an attorney in good standing licensed to practice law in the state of 
Idaho. I am one of the attorneys for Defendants Clinton Dille, M. D. and Southern Idaho 
Pain Institute in the above-referenced action and have personal knowledge of the facts 
of the matters contained herein. 
2. I represented my clients at the May 18, 2006 deposition of Mr. Byrne. A 
true and correct copy of Mr. Byrne's deposition is attached hereto as Exhibit A. Prior to 
the deposition, Mr. Byrne's counsel, Mr. Hall, asked if I could provide him with any 
documents responsive to the Plaintiffs' duces tecum deposition notice for Mr. Byrne that 
were in my clients' possession. In reviewing my clients' records, I found a job 
description for Mr. Byrne dated 2001. A Delegation of Services Agreement dated 2004, 
was also produced at the deposition. ·· Copies of these documents were then provided to 
Mr. Cor:ns.tock at the deposition pursuant to the duces tecum notice. 
3. During Mr. Byrne's deposition, Mr. Com,;tock, sought to question Mr. 
Byrne on the 2004 Delegation of Services Agreement. I interjected an objection to 
clarify the record and in an attempt to clarify everyone's understanding of these 
documents and their purpose. It was my understanding that the version of IDAPA § 
22.01 .03 et seq in effect in 2003 required a written document defining the working 
relationship between the supervising physician and physician assistant. It was further 
my understanding from my client that the 2001 job description fulfilled this function as 
they had no copy or record of a "form" Delegation of Services Agreement until 2004, the 
first time that the Board of Medicine prescribed a specific form and required the 
Agreement to be submitted to the Board for review and for the Board to maintain a 
copy. At that time, my client believed he and Mr. Byrne had been using the 2001 job 
AFFIDAVIT OF STEVEN J. HIPPLER IN SUPPORT OF CLINTON DILLE AND THE SOUTHERN 
IDAHO PAIN INSTITUTE'S RESPONSE TO PLAINTfFFS' MOTION FOR NEW TRIAL· 2 
description to serve as their "Delegation of Services Agreement" until 2004 when the 
Board of Medicine provided a required form Agreement and required it to be filed with 
the Board. This is what I communicated to Plaintiffs' counsel at the deposition. (See 
Exhibit A at p. 32, I. 1 - p. 33, I. 23.) This, however, was merely an objection and a 
good faith expression of my understanding of the facts and the _requirements that were 
in effect at the relevant time. 
4. Later in the deposition, Mr. Comstock sought to question Mr. Byrne with 
the IDAPAs that became effective in 2004, after Mrs. Schmechel's death. Your affiant 
objected to these questions to the extent they were based upon a document not in 
effect in 2003 (Exhibit A, p. 95, II. 12-22). Mr. Comstock replied that his questions were 
not based upon the actual IDAPAs; but rathsir were .general questions that utilized 
language that mirrored language from.the·post 2003 IDAPA regulations. 
5. On October 4, 2007, Defend~nts ·received a letter from plaintiffs' counsel 
indicating that based upon his understanding of the IDAPAs, a Delegation of Services 
Agreement was required in 2003, and requesting a copy of that document ( See Affidavit of 
Byron Foster in Support of Plaintiffs' Motion for New Trial, Ex. D). After receiving this letter, 
your affiant again inquired of Dr. Dille's office whether they had an Agreement other than 
the job description and then inquired of Mr. Byrne's counsel whether Mr. Byrne knew of any 
purported 2003 Agreement other than the job description. It is my understanding that Mr. 
Byrne's counsel again inquired of Mr. Byrne whether he had a copy of a 2003 Delegation of 
Services Agreement. It is my understanding Mr. Byrne then conducted a search of his 
records in storage and discovered the 2003 Delegation of Services Agreement and 
provided it to his counsel, who then immediately produced the document to Plaintiffs' 
counsel on October 10, 2007. (See Defendant Thomas J. Byrne, P.A.'s Fourth 
AFFIDAVIT OF STEVEN J. HIPPLER IN SUPPORT OF CLINTON DILLE AND THE SOUTHERN 
IDAHO PAIN INSTITUTE'S RESPONSE TO PLAINTIFFS' MOTION FOR NEW TRIAL" 3 
Supplemental Responses to Plaintiffs' First Set of Requests for Production of Documents, 
Foster Aff., Ex. E). As such, the 2003 Agreement was produced to Plaintiffs upon its 
discovery. Indeed, Mr. Byrne's counsel produced it to Plaintiffs prior to your affiant ever 
seeing the document. 
6. Attached hereto as Exhibit B is true and correct copy of Mr. Byrne's 200i 
job description and the 2004 Delegation of Services Agreement between Dr. Dille and 
Mr. Byrne, which was Exhibit 4 of Mr. Byrne's deposition and which contain identical 
language to the 2003 Delegation of Services Agreement that was found and produced 
to Plaintiffs prior to trial. 
7. Attached hereto as Exhibit C is true and correct copy of the deposition of 
Dr. Lipman. 
8. Attached hereto as Exhibit D is true and-,correct copy of the deposition of 
Mr. Keller. 
9. Attached hereto as Exhibit E is true and correct copy of the trial testimony 
of Mr. Keller. 
10. Attached hereto as Exhibit F is a true and correct copy of the trial 
testimony of Dr. Lordon. 
11. Attached hereto as Exhibits G and H are a true and correct copies of the 
October 19, 2007 and the October 24, 2007 trial testimony Mr. Byrne. 
12. Attached hereto as Exhibit I is a true and correct copy of the trial testimony 
of Dr. Dille. 
13. During the depositions of all of Plaintiffs' experts, Defendants' counsel 
asked to, and did, review every document the experts had received and relied upon in 
developing their opinions. None of Plaintiffs' experts had a copy of, or had been sent a 
AFFIDAVIT OF STEVEN J, HIPPLER IN SUPPORT OF CLINTON DILLE AND THE SOUTHERN 
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copy of any IDAPAs (regardless of year) or the 2001 job description or the 2004 
Delegation of Services Agreement and its attachments. Further, none of the experts 
relied upon any of the IDAPAs, Idaho statutes or other regulations, job description, or 
Delegation of Services Agreements in forming their opinions. None of the experts 
opined that Mr. Byrne and Dr. Dille should have had a Delegation of Services 
Agreement in 2003 or that either of the Defendants violated the standard of care with 
respect to the scope of Mr. Byrne's authority under Idaho law or otherwise. 
Further your affiant sayeth naught. 
Dated this~ day of December, 2007 
SUBSCRIBED AND SWORN TO before me, a Notary Public, this .3~ day of 
December, 2007. 
Notary Public fo~o 
Residing at , J JD 
My Commission Expires: Y;x,t.) '3
1 
&Pl\ 
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CERTIFICATE OF SERVICE 
I hereby certify that on this~ day of December, 2007, I caused to be served a 
true and correct copy of the foregoing by the method indicated below, and addressed to 
the following: 
David E. Comstock 
COMSTOCK & BUSH 
199 N. Capitol Blvd. #500 
P.O. Box 2774 
Boise, ID 83701-2774 
Attorneys for Plaintiff 
Richard E. Hall 
Keely E. Duke 
. Hall Farley Oberrecht & Blanton PA 
702 W. Idaho Street 
P.O. Box 1271 
Boise, ID 83701-1271 
Attorneys for Defendant, T. J. Byrne P.A. 
__ U.S.Mail 
-~ Overnight Mail 
__:;;;,_ Hand Delivery 
Fax 344-7721 --
__ U.S.Mail 
__ Overnight Mail 
Y:, Hand Delivery 
Fax 395-8585 --
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(208) 345-9611 
IN THE DISTRIC'f COURT OF TH:E FIF'TH JUDICIAL DISTRICT 
OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS 
VAUGHN SCH:MECHEL, individually, ) 
and as Surviving Spouse and ) 
Personal Representative of the } 
Estate of ROSALIE SCHMECHEli, 
deceased, and ROBERT P. LEWIS 1 
KIM HOWARD and TAMARA HALL, 







Case No. CV-05-4345 
Plaintiffs, ) VIDEOTAPED DEPOSITION OF 
VS, ) THOMAS J. BYRNE, P.A. 
CLINTON DILLE, M.D,, SOUTHERN 
IDAHO PAIN INSTITUTE, an Idaho 
) MAY 18, 2006 
) 
corporation, THOMAS BYRNE, P.A., } 
and JOHN DOE and JANE DOE, I ) 
through X, ) 
Defendants. ) 
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1 
Page 2 
THE VIDEOTAPED DEPOSITION OFTHOMAS J, BYRNE, 
2 P.A., was taken on bchnlfofthe Plnintiffs at 
3 the offices of Hall, Farley, Obcrrechl & B!;m!on, 
<! PA, 702 W. rdaho, Suite 700, Boise, Idaho, 
5 commencing at 9:26 a.rn, on Thursday, May 18, 
6 2006, before Emily L. Nord, Cenified Shorthnnd 
7 Reporter and Notary Public within nnd fur the 












Law Office$ of Comstock & Bush 
BY MR. DAVIDE. COMSTOCK 
199 N. Capitol Boukva.rd 
Suite 500 
P.O. Box 2774 
Boise, 1D 83701-27/4 
19 For Defendan1 Hall, rarley, Oberrccht 
20 Thomas J. Byme, & Bltmton, PA 
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TESTfMONY OF THOMAS J, BYRNE, P.A. PAGE 
Examination by Mr. Comstock 6 
EXHIBITS 
9 NO, DESCRTPTION 
10 J. Index of Medical Records, 
MARKED/PAGE 
I 
11 Rosalie Schmeche!; Tabs I through 6 
12 2. Handwritten nofatlons/inslructions S 
13 3. Rules for the Licensure of Physici~n 5 
14 Assistants 
15 4. Provider Contrnc1 1 dated 1 !/14/2001; 32 
16 
17 
Job Description for PA Services; 
Delegation of Services Agreement 
18 5. Medication and Dosing sliect, with 47 
19 additional documents/con-espondence 
20 6, Curriculum Vitae of Thomas J. Byrne, 







































M.D., and the 
Southern Idaho 
Pain Institute: 




BY MR, STEVEN J, HIPPLER 09: 26: 10 4 
601 W.BannockStreet 09:26:39 5 
P.O. Box 2720 09: 26: 40 6 
Boise, ID 83701-2720 
Christy Davies 


















09 :27: 2924 
09:27:3125 
THE V1DEOGRAPHER: On the record. 
MR. COMSTOCK: For the record, today's • 
date is May 18th of 2006. My name is David 
Comstock, I represent the Schmechel family, 
Mr. Byrne, and we are here today to take your c, 
deposhion with regard to medical care) or the ;; 
provision of medical care, that came from the f 
Southern Jdaho Pain Institute between September 
26 of200} and Rosalie Schmechel's death on 
October 2nd of 2003, 
Before we do that, though, I would ask 
each of the counsel here to represent, for the 
record, who they arc and who they represent. 
MR. HALL: I'm Rich Hall. I represent 
Mr.Byrne, 
MR. HIPPLER: I'm Steve Hippler. l 
represent Dr. Clinton Dille and the Southern 
Idaho Pain Institute. 
MR. COMSTOCK: Mr. Byrne, in order to .'. 
get this process sta,ted> we first of a!I need to 
have the court reporter give you the oath, and 
we'll do that al this time. 
M & M COURT REPORTING SERVICE, INC, 
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09:27:33 l THE WTTNESS: Okay. 
2 
3 THOMAS J. BYRNE, PA-C, ATC, 
4 first duly sworn to lei! the truth relating to 
5 said cause, testified as follows: 
6 
7 EXAMINATION 
8 QUESTIONS BY MR. COMSTOCK: 











trainer, and I was there a little over five 
years. I went to Portland State Univer.dty from 
there; and then frotrl Portland State, went to 
Brigham Young University, again as an athletic 
trainer. And then I went back into -- back to PA ,; 
school from Brigham Young University, .:;_ 
Q. Whal motivated you to go to PA school, 
having been an athletic trainer for all those 
years? 
09 : 2 7: 4 5 10 wouldn1t mind, would you introduce yourself to 
09: 2 7 : 4 7 l l the record, and to whoever is going to watch this 
09, 3 o, 111 o A. Oh, I guess I wanted a professional 
09 :27: 50 12 





































09 :29: 4225 
o 9 , 3 o , 15 11 challenge, and had met a couple of physician I'' 
at some point, by stating your full name, {elling 
us where you presently live, an<l telling us what 
you are presently doing for a living? 
A. Yes, sir. My name i$ Thomas Joseph 
Byrne. I !ive in Post Falls, Idaho: 5120 West 
Hedgewood Avenue. And I work in Spokane Valley, 
in the Valley Hospital Emergency Department. 
Q. What are you doing in the emergency 
department? 
A T work as a physician assistant there. 
Q, You have been a physician's assistant 
for appl'oximately how long? 
A. l graduated from physician assistant 
school in l 995 and have been a practicing PA 
Page 7 
since that time. 
Q. Would you review for me your education 
leading up to graduating frorn physician 
assistant's school? 
A. I went to Boise State University. I 
graduated there with a bachelor of science degree 
in 1980 in physical education/athletic training. 
I went on and got a master1s degree at Brigham 
Young University> and l finished that in l 982, 
And that was !n exercise physiology) also with an 
emphasis in athletic training and sports 
medicine. 
Then J worked as an a!hletk trainer 
for about 17 years, and then went to PA school at 
Travecca College in Nashville, Tennessee, from 



























09: 31, 4013 
09:31:4314 
09: 31: 4615 
09:31:5016 
Q. Working as an athletic trainer1 can you 09: 31: 5217 
review that employment for me? Who did you wort09: 31: 5618 
for, and what did you do during those years? 09: 32: 02 19 
A, Sure, I finished my degree in '80 and 09: 32, 05 20 
then worked at a graduate assistantship as an 
athlet!C trainer at Brigham Young Univer.sity, 
until I finished my degree th~re. 
Then I went to southern California and 




09: 32: 14 24 
09:32:J,625 
assistants in my interaction with team -- our 
team physicians; and it seemed interesting and 
challenging professionally, and! liked the idea 
of working closely with the physician and the 
·experience that it enabled. 
Q, Describe for me, ff you can, the PA 
program that you went through. 
A, It was about a 28-month bachelor's of 
science program. Tbe first year of the program 
is clinical didactics; you1re in the classroom 
the majority of the time. And the second year is 
out in the ~- doing clinical rotations out in the 
different settings; family practice, emergency 
medicine) pediatrics, psychiatry, internal 
Page 9 
medicine, those settings. 




Q. And from that point forward, up to your 
employment at the Southern Idaho Pain lnstitutc, , 
can you summarize for me the jobs that you've 
held? 
A. Sure. ln 1995, I went to Gooding, 
Idaho, and was employed by Gooding County 
Memorial Hospital & Associates in Family 
Practice, and I worked in family practice in the 
emergency room at Goodjng Hospital. And I wm 
there, I think, roughly two years and then went 
to the Twin falls Clinic and Hospital in Twin 
Falls, where I also worked as a physician 
<1sslstant in family practice, internal medicine, 
and emergency room. And then I let\ that 
facility to work with Dr. Dille. 
Q. In what year did you st.art working with 
Dr. Dille? 
A, l believe that was in January of 200 I. 
Q. And you left employment with Dr. Dille 
when? 
A. October of2004; September or October 
(208) 345-9611 M & M COURT REPORTING SERVICE, INC. 
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Q. for what reason? 
A. I just was ready for a change. My wife 
and l had property in northern Idaho, and we 
wanted to relocate. And we had stayed in 
southeastern Idaho primarily until our two older 
boys bad graduated from high school, and when 
that was ~- when -they had finished school, we 










has family in northern Idaho, eastem Washington 09: 35: 4210 
and we wanted to get up to thal area. 09: 35': 45 11 
Q, In the PA program under which you were 09: 35 t 50 12 
trnincd1 was there any aspect of that program 09: 35; 53 13 
that afforded you some type ofsubspecialty, if 09:36: oo 14 
you will 1 in pain management or administration o · 09: 36: 07 15 
narcotic medications for management of pain? 09: 36: 0816 
A. In the didactic training, we had a 09:36: 10 17 
semester of pham1acology training. And then in 09: 36: 17 1a 
each ofrny clinical rotations -- family practice, 09: 36: 20 19 
internal medicine, and emergency medicine-- 09: 36: 24 20 
there was ample experience in the prescription of O 9: 3 6: 26 21 
pain medications. It wasn't exclusive to a pain 09: 36: 32 22 
management practice, 09: 36: 35 23 
Q. So in other words, the PA program that 09: 36, 42 24 
you attended waS not a program specialized or 09: 36: 45 25 
Page 11 
designed to graduate PAs who are golng to go into 
pain management medicine? 
A. No. 
Q, It was more general than that; is that 
correct? 
A. That's co1Tect. 
Q, When yoo wenl lo work with Dr. Dille, 
was it your understanding that the area of 
m~dicine that you were going to be working in was 
going to be in the area of pain management? 
A. Yes. 
Q. Was thai an area of interest for you, 
and did you seek that out? Or how is it that you 
got that job? 
A. l knew both Dr. Dille as well as 
Christy Davies, his office manager, through my 
years in Twin Falls, and had had opportunity to 
meet Dr. Dll!e on many occasions and found him to 
be an interesting physician and was intrigued and 
interested by the work that he was doing at his 
-~ in his practice. And the opportunity came up 
for inc to move into his practice, and I took the 
opportunity. 
Q, Priol' to going to work within 



























experience and/or training in the medical process 
of converting a pain management patient from an 
OxyContin-based pain con1rol to a methadone-based : 
pain control? 
A. I don't have specific recollection, you 
know, of specific patients. But during the 
course of my work leading up to my employment at r 
Southern fdaho Pain fnstitute, J certainly had 
patients that 1 worked with who were on those--
on those medications. However, at that time in 
my career, l did not prescribe those medications. 
Q. Did YO\! have training, education, or 
experience with opioids, such as mcthadone1 
during the period of time of your PA trai11ing? 
A. Yes. 
Q. Explain that to me. 
A. Through my training in my program of 
pharmaceutical training, in our program we 
learned about al! of the opioids, including the 
long-acting opioids, 
Q, What is your understanding as to the 
uses to whlch methadone has been put over the 
years in terms of the management of patients? 
A. Its multiple uses, or are we talking 
just specifically abou1 pain management here? 
Page 13 
Q. That's a good point. Multiple uses 
first. 
A. Okay, I know of its use in the 
withdrawal of patients from illicit drugs and 
so~called n1ethadone programs that are available 
within1 you know1 most large metropolitan areas, 
Pve never been involved in one of those program 
or patticipated in one of those programs, but l 
know that1s one of the uses of methadone. 
And then methadone has become a widely 
prescribed medication within prima1y carcj famil, 
practice, internal medicine, as well as pain 
management centers for the use of chronic pain, 
in treating patients with chronic pain, 
Q. By September of 2003, when Rosalie 
Schmechel came to lhe Southern Idaho Pain 
Institute ~~ 
A. Yes. 
Q. -- for care, had you familiarized 
yourself with the statistics relative to the 
rising number of deaths that occuffed following 
the initiation of methadone pain management 
therapy? 
I 
MR. HALL: Object to the fonn. 
MR. Hil'PLER: Join; assumes facts. Ii 
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THE WITNESS: I was aware of the risks 
of all of the long-acting opioid medications and 
hn<l made a concerted effort to work closely wilh 
Dr. Dille t_o familia1fae myself with the 
medications in that drug class. 
09, 38, 2 9 6 Q. (BY MR. COMSTOCK) What understanding, 
09:38:30 7 ifany,didyouhavc,asofSeptemberof200J, 









09 :38 :44 9 occurring with the initiation of methadone 09 :41: 2-5 9 
09:38:IJ.710 therapy? 09:41:3010 
09: 38: 48 11 MR. HALL: Object to the form again, 09: 41: 34 11 
09: 38: 4 9 12 MR. HIPPLER: Ponn and foundation; 09: 41: 38 12 
09:38:5113 assumesfacts. 09:41:4113 
09:38:5614 THEWITNESS; Again,lwasawareofthe 09:41:4214 
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09 ,40 ,2719 
09,40,2820 
09,40,3221 




myself with those medications and, I think, had a 
good understanding of those risks. 
Q. (BY MR. COMSTOCK) You understand, or 
understood in September of 2003, that methadone 
was a long-acting pain medication? 
A. Yes, 
Q, You understood that it was a powerful 
pain medication with a long half-life? 
A. Yes. 
Q, And you understood a!so that methadone 
Page 15 
had the capability of gradually increasing its 
level of toxicity. if you will, in your system as 
you administered it'? 
A. Yes. 
Q. And is that because of its long 
half.life? 
A. Yes, it is. 
Q. What risk, if any, does that present to 
a patient who is being converted from a 
short-acting pain medication, like OxyContin, to 
a longer"acting pain medication, like methadone, 
with a long half-life? 
MR. HIPPLER: Object to the fo1111 and 
foundation. 
MR. HALL: Join. 
THE WITNESS: I guess I'd want you to 
clarify the question for me, if you could, 
please. 
Q. (BY MR. COMSTOCK) What is the 
significance of the fact that methadone, with its 
long half~Hfe, can accumulate within your 
system1 in terms of patient risk? 
A. Okay. Methadone, by its 
characteristics, has a long halfwlife, as you 




















09, 42, 5110 
09, 42, 57 11 
09:43,0012 
09,43,0513 
09: 43: 08 14 
09 ,43, 1115 











does accumulate in rhe patient1s system. And 
that1 in essence, is why the medicine is 
effective and valuable as a long-acting opioid 
pain medication, because it does stay in the 
system. 
And as the patient1s level of methadone 
is safely and slowly elevated, the medication 
hopef1-1lly has a benefit of decreasing their pain, 
and once that pain level has decreased to an 
acceptable level, then the dose of the methadone :· 
is then leveled off and -- and possibly even •·· 
lowered, depending upon how the patient is 
responding, 
Q, ls there a risk, because of its long 
life and because of the fact that it can 
accumulate, that a patient will get levels that 
are too high and dangerous to the patient? 
A. There's a level w~ there are tisks with 
all of the !ong .. acting opioids, whether it1s 
OxyContin or methadone, certainly; but ln 
methadone -w in the case with methadone, in 
pa1tlcular1 you have to be aware of that 
characteristic; and for that reason, a gradual, 
slow progression in the dose of the medication, 
· again1 to a level ·ofimprovem·ent in pain for the 
Page 17 
patient. 
(Ms. Davies enters deposition room,) 
Q. (BY MR. COMSTOCK} ls the risk to the 
patient ofdeveloplnga toxic level of methadone 
increased during the period of time that they are 
titrating up the dosage to get to a therapeutic 
level? 
A. I don't think that a general 
characterization can be made such as that. I 
think that if the practitioner is aware of the 
characteristics of methadone and takes that into 
account and makes it, again) a gradual, slow 
titration with close monitoring of the patient, 
making sure that, A, their pain level is 
decreasing and they're not developing any 
problems, then il1s ... 
Q. When converting a patient from an 
OxyContinMbased pain management program to 
methadone, is it incumbent upon the practitioner 
monitoring that to do so slowly? 
MR. HIPPLER: Object to the form. 
MR. HALL: Join. 
THE WITNESS: And are you referring to 
the titration of the methadone, or the removal of 
the OxyContin? 
I 
.... ,, . 
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Q. (BY MR. COMSTOCK) !'m referring to --
A. I didn'l understand. 
Q. rm refen·ing to the titration of the 
methadone, and 1 apprecii::ite the clarification, 
A. TI)e ~w again, I would just go back to 
the same thing tha1 I said before, It is 
impo1iant to monitor, obviously, and I guess it 
would be impo11anl to start at what would be 
considered safe early doses; and again, elevating 
the dose as indicated by the patient's pain level 
and how the patient feels subjectively. 
Q. Long-acting opioids, like methadone, 
have1 do they not, a risk inherent in them in 
terms of their capacity to decrease respiratoi·y 
drive? 
A Yes. I ,would like to also say that 
that's not ex.elusive to methadone, All of the 
long-ac1i_ng opioids in that drug class --
including OxyContin, MS Contin, which is a 
morphine-based, long-acting opioid -- ail have 
!-hose same characteristics, 
Q. Then we agree that the characteristic 
can be that it will decrease respiratory drive? 
A. Of that drug class, yes. 
Q. And that1s one of the risks that are 
Page 19 
inherent when you arc titrating a patient up in 
lerms of their dosage of methadone, is it not? 
A. Yes. 
Q. And because of that risk that's known, 
it's incumbent upon the practitioner who is 
monitoring this medication to understand the 
baseline that this patient brings to the tab{e, 
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MR. HIPPLER: Object to the form. 09, 48, 0510 
MR. HALL: Join. 09, 48, 0911 
11-lEWITNESS: Yes. 09:48,1112 
Q. (BY MR. COMSTOCK) So, for example, i 09 ,48, 1413 
you have a patient who has decreased respiratory 
drive during their sleep, such as a sleep apneic 
patient, 1hat's something the practitioner should 
be keenly aware of when titrating up their 
medication such as methadone? 
A. Yes. 
Q. Why is that? 
A. Again, as with all of the narcotics in 
the long-acting drug dass, as well as the 
short-acting opioids, for that matter, that is 













decrease respiratory drive. So that1s inherent 
within the narcotic class in general. 
Q. What are the symptoms that you would •• 
you mentioned that, during this process of 
titrating up, when using methadone as a means o 
pain management, you need to do that slowly, 
carefuily, and monitor it; correct? 
A. Yes. 
Q, And in the process of monitoring, what 
are you doing? 
A. Essentially describing, prior to 
prescribing the medication to the patient, the 
potential side effects of the medication as well 
as the risks of medications. And again, these 
are risks that are inherent to a!! of the 
opioids, but in particular, you know, with 
methadone, discussing the -- as that was -- your 
question is specific to methadone; is that right? 
Q. Yes. 
A. Discussing, again, the long hatf-life 
of the medication and its risks of respiratory 
depression, as well as other side effects 1 which 
could include dizziness, headache, nausea1 
potentially vomiting, There's an abundant numbf '.. 
of side effects with all of the opioids. · 
l?age 21 ; 
Q. What side effects would be present if a 
patient were developing a dangerous level of 
methadone in their body? 
A. You know, I think that really would be 
depending-· dependent upon a1 you know1 
case-by-case basis. Each individual responds 
differently to different medications, and to 
generalize would be fairly difficult, r think. 
Q. If a patient1 during the process of 
titrating up methadone, ex.pressed to you that 
they were having problems with their mentation 
and their thinking1 would that be one of the 
symptoms that you as the practitioner would wan;'. 
to know about and be concerned with? 
A. I think that potentially would be a 
concern with any of the long-acting opioids, or 
the opioids in general1 yes. 
Q. Same question with respect to reduced 
breathing, if they were having difficulty 
breathing. 
A. I1m not sure I understand your 
question. 
Q, ff1 in fo Bowing a patient that you're 
titrating up, the patient says to you, 'You know, 
o 9 : 4 6 : 08 2 5 general, is that they tend to potentially 09: 48: 48 25 ljust11 -- 11 I'm not breathing very wel\.u 
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Q. Is that something that you as a 
practitioner would want to be concerned about? 
A. I would certainly want to be aware of 
any potential complaints that the patient had, 
certainly. 
Q. How about swelling or edema in the 
lower extremities? 
A. Yes. 
Q. ls swelling in the lower extremities or 
edema in the lower extremities a symptom of 
developing toxic or dangerous levels of opioid or 
methadone in your system? 
A. You know> J don't have specific 
knowledge of that as an exclusive side effect or 
adverSe effect. I would assume that somewhere h 
the -- it's been reported that~- I don1t know 
that it1s exclusive to methadone or the opioids. 
Q, lf a patient reported to you -- and 
again, this is a patient that you were titrating 
up their methadone to get to therapeutic levels 
~" repo1ted to you that they had experienced 
swelling in their feet and a discoloration of 
their feet are you telling me that that is not 
something that you would equate to acoumulatillf 
Page 23 
dangerous levels of methadone? 
A. And we're talking about a hypothetical 
situation here, then? 
Q, Sure, 
A. Okay. If this was a new problem that 
the patient reported with the prescription of a 
new medication and they reported it to me, 
whether it was methadone or OxyContin or a higl 
blood pressure medication, I certainly think at 
that point that you would want to involve their 
primary care provider to determine whether or no 
there was another issue> medical issue with that 
particular person that potentially could be 
contributing to the edema, as well as the 
medication 1 certainly. 
Q. Is methadone contraindicated fol' use 
with patients who have a hislory of severe sleep 
apnea? 
A. And we're talking about in 2003? 
Q, Yes. 
09, 51, 26 21 A. Not-· not to my knowledge, 
0 9: 51: 28 22 Q. How about thereafter? 
o 9: 51: 3 3 23 A. I don1t have specific knowledge of a 
09: 51: 37 24 contraindication, no. 








qualified your answer to uin 2003." Has there 
been some information disseminated since 2003 
that would lead you to believe that methadone ma) 
be contraindicated for use in a patient with 
severe sleep apnea? 
A. No. I just wanted to make sure that J 




Q. In September of 2003, you were 
practicing as a PA at the Southern Idaho Pain 
Institute in Twin Falls! Idaho; is th&t correct? 
A. That is correct. 
Q. And during that time frame, you were 
employed by the Southern Idaho Pain Institute? 
Or by Dr. Dille? How did that work? 
MR. !IlPPLER: Object to the form; calls 
for a legal conclusion, You can go ahead and 
answer. 
MR. COMSTOCK: l don't know if it's a 
legal conclusion, by whom you're employed, but M 
MR. !IlPPLER: Well •• 
THE WITNESS: I guess -· yeah, I guess 
09,52,0810 












09, 52, 42 23 
09,52,45 24 
09,52,5125 
I would say I considered them the same. I worked { 
with and for Dr. Dille, who, for all intents and 







Q, (BY MR. COMSTOCK) Your checks, when 
you would get paid, were your checks on Southern i.; 














Dr. Dille1s check to you? 
A. I think it was Southern Idaho ·Pain. 
Q. I'm going to talk to you somewhat about 
standard of care applicable to PAs practicing in 
Twin Falls, Idaho, in September and October of 
2003; and 'f:'hen·J use the phrase 11standard of 
care,11 I'm talking about the standard of 
healthcare practice applicable to a PA in the 
community of Twin Falls in September of 2003, 
A. Okay. 
Q. Do you understand that? 
A. Yes, I do. 
Q. Would you agree that the standard of 
09: 53: 42 18 care, when taking a new patient into the Southern 
09: 53: 4 7 19 Idaho Pain Institute for potential management of 
09: 53: 50 20 their pain problem, required~~ required you to 
09: 53: 55 21 obtain a complete histo1y from that patient 
09: 53: 58 22 before a~ministrntion of opioid medication? 
09: 54: 02 23 MR. HALL: Object to the form. 
09, 54, 04 24 MR, HIPPLER: Join. 
09; 54: 06 25 THE WfTNESS; Yes, it was our routine 
. 
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09: 56: 44 23 
09:56:4624 
09: 56: 4725 
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to take a comprehensive history of the patient on 
their initial visit to the facility. 
Q. (BY MR. COMSTOCK) And in that process, 
you would want to obtain an accurate history so 
that you understood what the patient was actually 
bringing to your plate to manage; correct? 
A. Yes, to the best ofmy ability, 
Q. In that process, and before changing a 
long~~enn fonn of pain mi:magcment1 did the 
standard of care c11ll for you to consult with any 
pain management physicians who had been caring 
for this patient before coming to the Southern 
[daho Pain Institute? 
A, Did il call for me to do that? ls that 
what you asked me? 
Q. Was that the standard of care? 
A. No. 
Q, Why no!? 
A. Why not ... l guess, could you just 
rephrnse ¥• 
Q. Why is it not the standard of care lo 
contact the physician, who has been managing the 
pain of this patient for a number of years, 
before implementing a change in the long•tenn 
management protocol? 
Page 27 
A. Again1 it's really relatively a 
case~by-case situation based on the patient's 
circumstance and what their individual situation 
is. 
Q. In what circumstance would you, as the 
PA intaking a new patient) believe it would be 
incumbent upon you to contact the prior care 
physician who had been managing their pain for 
years? 
A. I don't know when it would be incumbent 
upon me to do that. Again, it would just be an 
individual decision with an individual patient. 
Q. Well, if, for example1 you had a 
patient who had been under the care of a 
well--trained and qualified pain management 
physician for five or six years and they came to 
you saying, "You know, you're closer to me than 
they are, and I'd like to come for pain 
managemcnt,1' and you decided that you wanted t 
change the pain management protocol; under that 
circums!.ance, would the standard of care call for 
you to at least consult with the prior physician 
before doing that? 
A. No. 
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A, Are we talking specificaHy now about 
Mrs. Schrnechel? 
Q, Sure. 
A. Okay. I felt, in my process of 
interviewing Mrs. Schrnechel during her-· the 
history taking and the time that I spent with 
her, that she was able to articulate to me, both 
in a written and verbal fonn, her chief 
complaint, her past medical history, her current 
medication regimen, her medication allergies, he 
w. again, her chief complaint un<l her pain !eve!1 
her satisfaction with her current treatment 
program in terms ofits ability to control her 
pain, and her quality of life. 
Q. And under those circumstances, you're 
telling me the standard of care for a PA 
practicing in Twin Falls, Idaho, in September of 
'03 would allow for the PA to not contact the 
physician who had been providing the pain 
management for years? 
A. Yes. 
Q. Did the standard of care call for you, 
as the PA intaking a new patient, to obtain the 
prior medical records before changing the pain 
management protocol? 
Page 29 
A. Coul<l you state that for me once more, 
please? 
Q, Sure. Did the standard of care call 
for you, as the PA taking ln a 11ew patient for 
pain management) to obtain the prior records of 
the patient before changing the pain management 
protocol? 
A. No, I don't believe it did. 
Q, Would it be effective~- an effective 
and efficient way for you to familiarize yourself 
with a patient1s past pain management to obtain 
the records? 
A I think the most effective and 
efficient method of attaining that information is 
I 
to interview the patient, who is an excellent ,, 
historian, was lucid, and was able to communicate} 
that information to me, Tiie patient was there 
and was able to communicate those -- that 
Information quite effectively to me. 
Q, Does !'he standard of care call for the 
PA to carefully consider any change in pain 
management when ii involves narcotic medication : 
such as methadone? 
A. Yes. 
Q. Does the standard of care cal! for the 
...... ,.,,, .. , ., .. ,.,., ..... " '"•' -,·.;,·.-.·:. ,,,, .. _., .... ,._ •.. """' , ........ _.,,.,__,.,, ......... ·.· ...... ., .,,, .,,... '""'""'"' ·-· .... ,, .. ,.... . .... , .... ~,·: ,. . ._,, ... ,..,.,,,,., , ........ , "· .. ,.,,_,,.,, 
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P A to consult with the supervising physician 
before implementing a change in the narcotic pait 
management for a new patient coming into the 
clinic? 
A. Again, case by case, depending upon the 







sometimes no. 10: 02: 53 7 
Q. In Rosalie Schmechel's case, did you 10: 02: 54 8 
consult with Dr. Dille prior to implementing the 9 
change in her pain management program? 10: 03: 04 10 
A. No,ldidnot. 10:03:0511 
Q. Why not? 10: 03: oa 12 
A. I was confident in my experience with 10: 03: 12 13 
-- in pain management and with my previous 10: 03: 1914 
prescribing of medications that Mrs. Schmechel 10: 03: 2115 
was prescribed, as well as the medications that 10: 03: 22 16 
she had been prescribed previously1 to make thos. 10: 03: 24 17 
adjustments without consulting Dr. Dille on that 10: 03: 29 18 
day. 10,03:3419 
Q. We'll be going through the chart here 10: 03, 3 7 20 
in a little bit --
A. Okay. 
Q. -- and at some time later on, did you 
actually consult with Dr. Dille relative to 
Rosalie Schmechel? 
l?age 31 
A. Yes, I did. 
Q, We'!! get into that later. 
A. Okay. 
Q. Would the standard of care require a 
physician's assistant to work under the 
supervision of a physician? 
A. Yes. 
Q. In that regard, did the standard of 
care call for the PA and the physician to have an 
agreement relative to the duties and obligations 
between the two of them, and the supervision? 
A. Yes. 
MR. HIPPLER: Object to the form. 
Q. (BY MR. COMSTOCK) Did you have a fonn 
of an agreement with Dr, Dille during the period 
of time that you were providing medical services 
to Rosalie Schmechel? 
A. Yes. 
Q. Was it in a written fonn? 
A. Yes. 
Q, Have you brought that document with you 
here today to produce as part of this deposition? 
A. Yes. 






























10: 05: 06 24 
10:05:0825 
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MR. COMSTOCK: l'vejust received a 
five~page ·- a four•page doc- -- a five-page 
document from Mr. Ha!!, and ['rn going to have 
that marked as Exhibit 4 to the deposltion, if 
you will. 
(Exhibit 4 marked.) 
Q. (BY MR. COMSTOCK) Mr. Byrne, l've just 
handed you what's heen marked as Exhibit 4 .. , 
(Interruption.) 
Q. (BY MR. COMSTOCK) l'vejust handed you 
What's been marked as Exhibit No. 4, and is this 
a copy of the agreement that was in effect 
between you ond the Southern ldaho Pain & 
Rehabilitation Institute .• 
A. The·· 
Q. •• in September of 2003? 
A. The top copy is a contract, an 
employment contract. The second pnge ls a --
kind of a rough job description. And then the 
rernalnder of the documen! is the Delegation of 
Services Agrnement document that is provided for 
the Board of Medicine, as required. 
MR. HJPPLER: Counsel, if I can 
interject here-~ 
MR. COM STOCK: Sure. 
Page 33 
MR. HIPPLER: •• I ,night be able to 
help out. Jusr so the record is clear, because 
Mr. Byrne didn1t have possession of these 
documents, in order to facilitate this deposition 
! nonetheless acquired them through my client for 
today's deposition. 
I want to point out that, with regard 
to the Delegation of Services Agreement, this was 
not in effect in 2003, as the Board of Medicine 
did not require them in -¥ until 2004. But we 
produced the one that was in effect thereafter. 
And in addition to the docmnents that 
you have ~wand perhaps Mr. Hall1s assistant can 
make a copy of it -- on the delegation it says 
"Sec atrnchcd,11 and I have the pages that are 
supposed 10 be attached that go with the 2004 
delegation agreement. 
MR. COMSTOCK: Okay. So you have just 
handed me three more pages lhat are the 
attachment to the Delegation of Services 
Agreement that you're representing was in effect 
in 2004? 
MR. HIPPLER: Correct. 
I 
MR. COMSTOCK: Would you mind if! mark : 
these three pages -· 
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MR. HIPPLER: That's fine. 
MR. COMSTOCK: -- or add them -- I'm 
going to add these three pages to Exhibit 4 so we 
don't have so many multiple exhibits. 
MR. HIPPLER: That's fine. 
Q. (BY MR. COMSTOCK) Mr. Byrne, because 
of that clarification r want to get·~ back up 
just a little bit. First ofal!, did you have a 
Delegatioti of Services written agreement between 
yourself and Dr, Dille and the Southern Idaho 
Pain Institute in effect in September of2003 













Schmechel? 10, 08, 1813 
A. ! believe there was a job description, 10, 08: 20 1.4 
which is enclosed. 10: 08: 2215 
Q. But in terms ofa Delegation of 10: 08: 2316 
Services Agreement, such as the one that's 10: 08: 24 1 7 
attached to Exhibit No. 4, was there such an 10: 08: 2518 
agreement1 in writing, in effect in September of 1 D: 08 : 3 2 19 
2003 between yourself and the Southern Idaho Pain 10: 08: 39 20 
InsHtuteand Dr. Dille? 10: 08: 42 21 
A. l think there was a-~ was some 10: 08 :44 22 
documentation that was with the Board of 10: 08: 45 23 
Medicine, bui not necessarily a Delegation of 10: 08: 48 24 
Servkes Agreement. 1 O : O 8 : 51 2 5 
Page 35 
There was, at some point during 1hat 
period, a change in the board 1s recordkeeping 
process, per se. So documentation was with and 
through the Board of Medicine rather than tl1rough 
the office, So the documents went to the Board 
of Medicine rather than ~. the documentation was 
kept with the Board of Medicine in -- Boise? 










Q. And Rosalie Schmechel, r take it, was 
not a patient, at least on September 26 of 2003 
when she first came in the clinic and you changec 
her pain management regimen, that you believed 
you needed to talk to Dr. Dille about? 
A. I didn't believe that I needed to talk 
lo him about Mrs. Schmechel on that day. Bul I 
did review the case, her case with him 
subsequently. 
Q. Did you review her case with him after 
she <lied? 
A. No, before. 
Q. And again, we'll go through the chart 
and perhaps you can help me with when that 
occurred. 
A, Okay, 
Q. Getting back to standard of care 
questions, would you agree that the standard of 
care called for the PA to carefully instruct a 
patient whose paifl management was being shifte J 
from OxyContin to methadone? 
A. Yes. 
Q. And would that include an obligation lo 
:J 
carefully instruct relative to any increases in f 
the dosage that were going to take place over the / 
subsequent days? 
A. Yes. 
Q. And we call that 11titrating it up"; 
correct? 
A. l'm sure that that is a tenn that can 
Page 37 
be used. There1s probably other terms that can 
be used as we!!. 
Q. Would you agree that !n this process of 
10:06,54 9 understanding of how you and Dr, Dille worked 
10: 06: 58 10 together with respect to any particular patient 
10, 07, 00 11 in September of 2003. 
converting a patient from OxyContin to methadone 
1 o : o 9: 14 10 and titrating it up, the standard of care called 
10i09:09 9 
10: 09: 18 11 for the PA to follow that patient closely in 













Q. You 1ve told me that the standard of 
care didn't necessarily require you to consult 
with Dr. Dille before irnpl~menting a change in 
chronic pain management? 
A, On a casewby-case basis. 
Q, Was that understanding in writing 
anywhere between you and Dr. Dille? 
A. No, 
Q. A11d ls that the pt'actice that you and 
Dr. Dille had engaged in from the time you 
started as a PA up to September of 2003? 
A. To the best of my recollection, we 
1 0 : 07 : 3 7 2 5 communicated regularly about patients. 











10: 09: 57 23 
10: 09: 59 24 
progl'ess? 
MR. HALL: Object to the fonn. 
MR. HIPPLER: Join. 
THE WITNESS: Yes. 
Q. (BY MR. COMSTOCK) Would you agree tba1 
the slandard of care also would reguire the PA to 
change the regimen of pain management in the face 
of any reported syrnp!oms that would evidence a 
dangerous level of methadone accumulating within 
the patient's system? 
A. r guess I'd need you to clarify the 
question. Are we talking specifically about 
10; 10; 01 25 Mrs. Schmechel now? 
. .,_ ... ,,, .... ,...,. ,..... . .. ~,. . ............ ,., .... , -.. -. 
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Q. J'm talking about any patient and 
standard of care. 
A. Okay. 
Q. If you're in the process of converting 
a patient --
A. Okay. 
Q, •• from OxyContin to methadone; you're 
in those days where you1re titrating it up. 
A, Okay, 
Q, As part of your following with them, 
it's reported to you symptoms that would lead yot 
to believe that perhaps this patient is 
developing a toxicity or a dangerous level or a 
dangerous accumulation of methadone; does the 
standard of care require for you to change that 
regimen immediately? 
A. I would certainly want to get all 
infonnation available from the patient that --
their concerns and prob!ems1 and determine, to 
the best of my ability, whether or not it sounds 
like a side effect from the medication that had 
been prescribed; or, again, if this patient had 
other medical problems that could potentially be 
producing_those side effects, that the patient 
may need to be seen by their primary care 
Page 39 
physician or in the emergency department at the 
local hospital for evaluation in the interval 
between their next visit. 
Q. With respect to Rosalie Schmeche!, it's 
fair to say that on September 26 of 2003, the 
first day she came into the pain institute and 
met yo\l --
A. Yes. 
Q, -- ym1 made the decis'ion to change her 
pain management control, did you not? 
A. Yes. 
Q, And you changed part of it, at least, 
from OxyContin to methadone; correct? 
A. Yes, I did. 
Q, Give me each and every reason why you 
did that. 
MR. HIPPLER: Object to the form. 
THE WITNESS: During the course ofmy 
history with Mrs.·· of Mrs. Schmechel, she 
expressed to me her reason for being at Southern 
Idaho Pain Institute and her chief complaint as 
being ongoing chronic pain, and that was her 
priority for being in our facility, was that she 
was having ongoing pain lhat she rated a 10 over 




















































And the predominant factor in making a 
change at that time was her expression of pain, 
but also her concerns that her existing pain 
management program, though it had been adjusted "i. 
within the last month, was not providing her with 
adequate pain control, and that it was affecting 
her quality of life; her ability to sloop, her 
ability to function 1 her bi!- -- abil- --
ability, rather, 1o perform her activities during 
the course of the day, 
Q. (BY MR COMSTOCK) If, during the 
process of obtaining this history from 
Mrs, Schmechel, you learned from Mrs. Schmeche! > 
that her pain was a 10 on a scale of 10 --10 
over 10 --
A. Yes. 
Q. -- that is something you would chart, 
is it not? 
A. The documentation that she provided for 
me indicated that she -- that was her pain 
rating, and she expressed it to me. 
Q. In talking with her, would you have 
written that down because of its significance to 
you? 
A. I may or may not have. It was 
Page 41 
communicated to me in a verbal and a written fom ·. 
by the patient, 
Q. What consideration did you give, if any 
at a11, to Rosalie Schmecbel's history of sleep 
apnea and the fact that she was using a CPAP 
during hei· sleeping hours? 
A. What consideration did J give to it? 
Q. In making your selection of methadone. 
A. I) during the course of my history 
taking, again, and her past medical history, she 
indicated to me that she did have obstructive 
sleep apnea, and that this had been diagnosed and 
had been treated by Dr. Kimberly Vorse, and that 
the patient had been prescribed CPAP and that she 
was compliant with her CPAP and used it as she 
had been instrncted by Dr. Vorse. 
Q, Other than that, did you have any 
information relative to how severe her apnea 
events were during her sleeping hours? 
A. The patient indicaled to me 1hat she 
had obstructive sleep apnea and that she was 
compliant with her medication. That was the 
informaiion {hat I needed. 
Q. Did the standard of care call for you 
to determine whether or not her sleep apnea was 
I 
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mild, moderate, or severe, before changing from 
OxyContin to methadone? 
A. No. Her pain ~" her sleep apnca was 
being managed, according to the patient1s 
history) effectively, and she was compliant with 
her treatment. 
Q. Based on the history that you took of 
Rosalie Schmechel1 <lid you conclude that she wa 
a patient who was fairly knowledgeable about her 
ongoing condition and the medications t!1t1t she 
had been treated with? 
A. She appeared Lo me to be alert and 
lucid and communicated effectively, both in a 
written as well as a verbal fonnat, her past 
medical history, her CUJTent family/social 
situation, her current pain level, and her 
current treatment. 
Q. And because of that, you chose to rely 
upon her history rather than contacting Dr. Vorse 
who had been her pain management physician for 
the past number of years; correct'! 
A. I felt the infom1ation that 
Mrs. Schmechel provided for me was -- was clear 
accurate, and was what I needed. 
Q. Did you at that time know Dr. Vorse? 
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A, I did not know Dr. Vorse personally. I 
had never met her. I had seen communications, 
written communications, chart notes and such, 
from -- from other patients, but I don1t believe 
that I had ever met her or talked to her. 
Q. A( that time did you know -- did you 
know of Dr. Vorse and what her specialty was? 
A. Yes, I did. 
Q. So when you made the decision to change 
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regimen, you knew that Rosalie had been undertht 10: 19: 5111 
care of Dr. Vorse, a pain management specialist 
practicing in Sun Valley; correcl? 
A. During the course of my history taking, 
Mrs. Schmechc! indicated to me verbally that she 
bad been under the care of Dr. Vorse for her 
chronic back pain and her obstnictive sleep 
apnea. 
Q. And you knew at that time that Dr. 










correct? 10:20:43 21 
A. Yes, I did. 10; 20, 45 22 
Q, Yet you chose not to contac1 Dr. Vorse 10: 20: 49 23 
before making a change from the OxyContin-base< 10: 20: 57 24 
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MR. HIPPLER: Object to the fom1; 
asked and answered. 
THE WITNESS: Yes, I did. 
Q. (BY MR. COMSTOCK) If you had contacted 
Dr. Vorse and said, "You know, Dr. Vorse, I've 
got one of your patients here; she's in our 
clinic becnuse it's closer to her home than Sun 
Valley, and l want to change, you know, the basis 
of her pain management from OxyContin to 
methadone," and Dr. -Vorse had indicated 10 you 
that she would not recommend that, would you have 
done lt? 
MR. HIPPLER: Object to tl1e fonn; 
foundation. 
MR. HALL: Join. 
THE WITNESS: l guess (hat would be 
speculation. f don'l have the infonnation that l 
would need-to -- you know, to make that decision. 
l didn1t contact Dr. Vorse and didn't fee! that 
it was at that time necessary for me to contact 
her to ma~e the changes that were made based on 
my pl'evious experience with these medications. 
Q. (BY MR. COMSTOCK) Prior to Rosalie 
Schmechel's death on October 2nd of 2003, had you 
experienced the death of any other patients that 
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you were treating with methadone? 
A, Yes. 
Q, Tell me about that. 
A. Do you have a specific question? 
Q. Howmany? 
A. One. 
Q, Under what circumstances? 
A, It was alleged that one individual had 
-- had died from the use of methadone, 
Q. I'm going to hand you what we have 
marked as Exhibit No, I, Mr. Byrne1 and Jld ask 
you just to flip through that quickly. 
A, (Examining document,) Okay. 
Q. There1s an index and some tabs1 but 
other than the index and the tabs and the Bates 
stamp numbers, does that exhibit appear to 
comprise the chart, if you will, from the 
Southern Idaho Pain Institute relative to Rosalie 
Schmechel? 
A. Yes. 
Q. Have you had a.n opportunity to review 
that chart prior to the deposition here today? i 
A. Yes. 
MR. HIPPLER: And, Counsel, for the 
10: 17: 46 25 mode of therapy to methadone; correct? 10: 20: 58 25 record 1 I will note that the chart that you had 
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prodticed previously, which J1m assuming is the 
same one, was not complete and identical to the 
chart that I have for the institute, 
MR. COMSTOCK: Well, then, perhaps 
sometime you can get me a complete and accurati 
chart. 
MR. HIPPLER: I did give Mr. Hall a 
comp!ete copy of it. l think he has that 
available. 
Q. (BY MR. COMSTOCK) As pa11 of the •• 
MR. HALL: Just a second --
Q, (BY MR. COMSTOCK) As part of the 
deposition notice, Mr. Byme, we asked you to 
bring with you a copy ofRosa!ie1s chart or any 
notes you might have with respect to Rosalie. 
Have you done so? 
MR. HALL: I've got a copy of the 
chart, I believe. 
MR. HIPPLER: And again, Mr. Byrne is 
not in control of that chart. As a courtesy, 
however, J did provide that to Mr. Hall. 
MR. COMSTOCK: !'m not whining about 
it, but Mr. Hall is now in control of it, so l 
gather I can get it. 



























A. Yes, sir. 
Q. And the subsequent page behind it, 
which is 6 --
A. Okay. 
Q. -- so we1ll refer to those two pages, 
What are those two pages? 
A. These are handwritten notes from 
Southern Idaho Pain Institute that are dated 9126 
of 2003, in reference to Rosalie Schmechel; and 
in particular, lhis is her part of the document 
from that day's visit. 
Q. And the first day she came to the 
institute was September 26th of 2003; is that 
correct? 
A. Yes. 
Q. And on that day she was seen by 
yourself; correct? 
A Yes1 she was, 
Q. Was she seen by Dr. Dille on that day? 
A, No, she was not, 
Q, Was she seen by anybody else on that 
day? 
A. She was seen by our front office staff, 
who see all of our patients1 as well as one of 

















10: 22: 4117 
10:22:4418 
10:22:4719 
10 :22: 5520 
10: 22: 58 21 





MR. HALL: Sure. That's why we brought 10: 24: 1 7 1 
~ 10:24:21 2 
MR. COMSTOCK: So that we have a 10: 24: 25 3 
complete record, Mr. Byrne) rm going to go ahea 10: 24: 28 4 
and mark this as Exhibit 5, what has just been 10 :24:32 5 
produced. 
(Exhibit 5 marked.) 




Q. (BY MR. COMSTOCK) If you wouldn't 10, 24: 42 9 
10:24,4610 
A. -- when we refer to~- which copy? 
Q. We're going to rcferto Exhibit l, 
because there are things l want to ask about 
documents that are contained in Exhibit I. But 
just for a moment -- and bear with me -- if you 
would just look through Exhibit 5 and tell me if 
you recognize that as being the complete chaii 
from lhe Southern Idaho Pain Institute for 
Rosalie Schmechel, 
A. Yeah, to the best that I can tell, it 
appears to be the complete document. 
Q, Now, getting back to Exhibit I, would 
you refer to, under the first tab -- there's 
Bates stamps in the lower-right-hand comer of 
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above1 which is in her handwriting) as well as 
the vital signs section that1s up there. 
Q, Okay. So the initial paragraph, which 
begins '1Paticnt is a 60-year-old female" was 
written by? 
A, Sharon Willmore1 medical assistant. 
Q. How about the vital sign information 
above that and to the left. where it has Rosalie 
Schmechel's name and the weight of 203 and the 
pulse and the blood pressure. ls that written by 
her as well, or is that written by you? 
A. No1 those are written by Ms, Willmore. 
Q. The writing on the right-hand upper 
side, 11 OxyContin, 11 "Lortab," is that handwriting 1· 
yours'? i.: 
A. That is my writlng1 where it says 
OxyContin, 20 milligrams, Q8; and Lortab, 5 to ( 
per day. 
Q. When you wrote that down, was that 
because that's what you were infonned 
Mrs. Schmechel had been taking under the care o 
Dr. Vorse? ·. 
A. Yes. fn talking to her, r }ust wrote 
that up there so 1 wou Id know specifica!!y what 
the dose was on those meds, as it didn't indicate 
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it specifically in the medication !ist that was 
written by Ms. Willmore. 
Q. All right. Approximately how long did 
you spend with Rosalie Schmechel that day'? 
A. [ would say probably 60 to 70 minutes. 
Q, And during that 60-to-70-minute period 
of time, I'm assuming therets some verbal history 
taking that you do, but what else did you do? 
A. A fairly extensive discussion with the 
patient in tenns of her chief complaint, her 
medical history, family/soCial histo1y, as well 
as a physical examination which was performed by 
myself. 
Q. The writing on this page from the top 
all the: way down to near the bottom where it says 
9/30/03 --
A. Yes. 
Q. -- is all from September 26th; ls that 
cmTect? 
A. That1s correct; up to the point where 
it says 9/30, patient phone cal! advised; that's 
from a different day. 
Q. And that's your initial off to the 
far-right-hand side just above that? 
A. That is correct. 
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Q. And so these are the handwritten notes 
that you took during !"he course of talking wlth 
Rosalie Schmechel? 
A. Yes, sir. 
Q. And doing your examination and 
evaluation? 
A. That's correct. 
Q. I don11 see anywhere in here that she 
was complaining to you that her pain was a 10 on 
a scale of 10, do you? 
A. Additional document- -- on the initial 
visit, the patient also was asked to fi!I out a 
pain questjonnaire form, tlrnt1s a comprehensive 
fom1 that the patient fills out in reference to 
their reason for being al the institute. That1s 
00007, which was completed by Mrs. Schmcchel. 
And during the course of my interview 
process and history taking with Mrs. Schmechel, 
had this fom1. with me and wa,; reviewing it while 
I was talking to her, and actually confi1111ing a 
lot of the information that was on here, as there 
are some notes that I made on th.is document in 
addition to the notes that she had made on there 
us well; and again, to clarify, from my 
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Q. In the pain questionnairc1 when it gets 
to the section of "Level of pain" -- I see it on 
00008? 
A. Yes, sir, 
Q, There's a circle around '110." Did you 
place that circle, or did Mrs, Schmechel place 
that? 
A. No, that was placed by the patient. 
I 
Any docurnen1ation that l made on this chart would'.,: 
be off lo the side. I think there's only really 
one -- one spot where I wrote --
Q. And on what page is that? 
A. 009, on the surgical hislory,just 
clarifying that she had arthroscopic surgery in 
'03 of her right knee, and that Dr. Widell had 
done her back surgery. 
Q. The inforn,ation that you wrote down by 
hand on September 26th also became part of a 
dictated char! note, did it not, for that day? 
A. Yes. 
Q, And l want to foHow that process for _a 
minute. 
A. Okay. 
Q. You meet with Mrs. Schmechel; you're 
Page 53 
writing notes while you meet with her; you 
develop a plan for her care. 
A. Yes. 
Q. And implement that plan. After she has i. 
gone, and al the end of the day, did you sit down ; 
and dictate what had gone on that day with 
respect to Mrs. Schmechel? 
A. [ -- my typical routine was to dictate 
· the patient's chart after I saw the patient, in 
order to keep it fresh in my mind and try to be 
as accurate as possible, 
Q. If we look at page. I under lab 1 of 
Exhibit 1, that's a dictzited note for September 
26th, is it not? It's page l and page 2. 
A. That is correct. 
Q. ls that what you dictated on September 
26th? 
A. Yes. ·; 
Q. Now, with respect to the process of 
getling lhat document back, the typed document, . 
how long did that typically take at the Southern 
Idaho Pain Institute? 
A. It was variable; several days, 
typically, by the time the recording went to the 
transcriptionist and came back. 
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Q. Is there any way we can determine when 
the typewri1ten chart note actually came back to 
!he institu\·e7 
A. Not to my knowledge. 
Q. Let me represent to you that September 
26th of2003 was a Fridayi and again, wi!h 
respect to what you remember being typical during 
thal time frame, would it have been typical for 
the transcription to come back the following 
Monday if you had dictated it on Friday, or would 
it have been several day~ after that? 
A. I don't have specific recollection of 
when it came back. It cou Id have been Monday; it 
could have been !ater. I don't recall. 
Q. I do note on page 2 thel'e are 
signatures there for yourse!fand Dr, Dille on 
the typewritten document; and ccln you (eli me, 
from looking at this document or any other 
document, on what day those signatures were 
actually placed on the typed chart note? 
A. I dont 
Q. Fair to say )t would have been several 
days after September 2<5th? 
A. Yes. 
Q. Going back to your handwritten note of 
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that day, look at the plan, and can you just tell 
me whal the plan was for methadone? 
A. Yes. The plan was to initiate 
methadone at five to ten milligrams every 12 
hours. 
Q. And how was that explained to Rosalie 
Schmechel? 
A. l explained to Mrs. Schmechel in detail 
after we had spoken at length in the early palt 
of her history and physical examination in 
reference to her chief complaint of ongoing pain, 
and her interest in changing her pain managemen1 
program and the ineffectiveness of her existing 
program had suggested that we try different 
medicaticins, and she was amenable to that. 
I then discussed with her at lenglh the 
medication methadone, its characteristics as we 
had -- you an.d l had discussed earlier in the 
deposil!on, in terms of its long-acting nature 
and its use in chronic pain and its risks and lts 
benefits. And we discussed those al length. 
And then prior-~ after discussing 
those things and noting lhat she understood those 
completely, I then discussed with her the 
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instructions that we had set forth, which was 
initiating the methadone at five milligramst and 
theni with my instruction, advancing the medicin 
as determined by her -- her level of pain. 
And we also at that time discussed the 
use of a short-acting pain medication for 
breakthrough pain. 
And in addition to that as well, we 
discussed the lowering of one of her medications '.! 
that she was on, which potentially could produce 
some sleepiness, as well as its ineffectiveness1 
essentially, and I felt that we needed to lower 
that dose, 
So the methadone was discussed at 
length with her in reference to the dosing -- the 
dose, the dosing interval, the changes, how they 
would be made, and as well as, again, we~- 1 
focused on talking to her about the potential 
problems with th.e medicine. 
Q. Was the prescription that she was given 
for ten~rnilligram tablets? 1--
A. That's correct. 
Q. And so if you wanted her to rake five 
mil\igrams1 you instructed her to break one of 
them in half? ls that what you did? 
Page 57 
A. Yes. 
Q. And was she to start lhat day, start 
off with five rni11igrams? 
A. Yes, 
Q. And is that how this is written? 
A. Yes. 
Q. Explain that to me. This looks to me 
Hke it's ten milHgrams ~-
A. -- one-half --
Q. -- hyphen, one-half --





-- POQ 12 hours. , 
And that means every 12 hours; correct,;: 
A. Correct. 
Q. So isn't this written that she could 
take as much as one whole pill, or ten 
milligrams, right off the bat? 
A. No. She was instructed to take a half. 
Q, ls that instrnction written down here 
anywhere? 
A. Right there, one-half to one. 
Q. But when you write one-half lo one, 
doesn1t that indicate to you that she can take 
one-half of one or one? 
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A. The chart itself, both in the 
handwritten notes as well as the dictated forrn, 
are notes that I made essentially for myself, for 
completeness in the patient1s treatment program, 
as well as to~¥ so I would understand and 
remember what treatments were rendered for the 
patient. 
So in ils entirety, the chart was a 
document for me and for Dr, Dille to understand 
the initial evaluation and treatment of the 
patient. 
Q. So it was her inst1uction, according to 
you 1 to take five milligrams as soon as she 
picked up the prescription? 
A. Can J review the document? 
Q. Of course. 
A. Okay, thank you. (Examining document.) 
The dictation, as we!! as the written note, 
indicate that I gave her inslruction in reference 
to the initial starting dose being at five 
milligrams, and then gave her an idea of what we 
would be doing in tenns of titrating the 
medication up to control her pain. 




























Q. And it1s your testimony that she was 
clearly instructed on that? 
A Yes, she was. 
Q. With respect to the hydrocodone, which 
is the short-acting, if you will, you changed 
that somewhat from what she had been taking undc , 
the direction of Dr. Vorse, did you not? 
A, Yes,ldid. 
Q. Dr, Vorse had her taking what? 
A. Dr. Vorse had her on -- and you want to 
know just specifically the short~acting 
medication~-
Q. Yes. 
A. -~ right now? L01iab, which is one of 
the trade names for hydrocodone; and she was 
taking a 7.5 500 Lortab, 
Q. What does that mean? 
A. 7.5 indicates the millig1·am amount per 
pill of the narcotic, which in this particular 
case is hydrocodone. The 500 indicates the 
amount of acetaminophen that is in the same pi!l. 
So it1s a combination pill using hydrocodone and 
acetaminophen. 
Q. And she was to take it on what 
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A. Vh-huh. 
Q. -- were you giving Mrs. Schmechel the 
pem1ission to go up to as much as one tablet or 
ten m.illigrams every I 2 hours over the weekend? 
A. I believe so, yes. 
Q. And what were her instructions relative 
to doing that? l mean, did you tell her that if 
you're not getting any pain relief, just go ahead 
and take more? 
A. Well --
Q. What did you tell her about that? 
A. One of the factors with any medication 
is a slow elevation in the dose, and so we wanted 
to make sure that, A, she didn1t have any 
immediate side effects of nausea or anything sud 
as that; and we talked about those things, as l 
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10: 3 s: 56 19 methadone and how it was dosed and her previou• 10: 41; 19 19 
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A. I believe the record indicates 
Mrs. Schmechel told me she took five to six per 
day. 
Q, And so what was your pre.scrjptiqn 
relative to hydrocodone? You changed it to 10 
slash 500? 
A. That1s correct. 
Q, So that would be increasing the amount, 
would it not? 
A. Increasing the amount of the 
hydroeodone per pill from 7.5 to JO milligrams, 
Q, And how about the dosage, as to when 
she could take it? 
A. Every four to six hours, one pill. 
'· 
Q. So you were giving her instruction that 
she could actually take more hydrocodonc than , 
what she had been under the care of Dr. Vorse; 
correct? 
A, The dose pet pill was, in fact, 
increased, yes. 
Q. Now, you had her decrease the 
amitriptyline. Why was that? 
A. Probably the single most jmportant 
reason was that this medicine really wasn1t 
giving her any benefits that she could tell. It 
.. " .... , .. ,., ._,,._ . .,._,, .... ~.,.,,.,."·"·' ........ , ... c"".,-.-.,·c; , .. ,,..,, .. , .. ,.·· 
' 
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wasn't benefitting her sleep, a:nd it didn1t seem 
to be benefitting her pain. 
So my determination on that day was 
that ifit wasn1t working, then I wanted to 
decrease it to avoid potential side effects; 
sedation, dry mouth, those types of things. But 
most importantly, because it just wasn1t 
effective, 
So there wasn't, in my mind, a reason 
to maintain the substantial dose of(he 
amitripty!ine that she was taking. 
Q. You wa11ted her to continue the Bextra; 
correct? 
A. Yes. 
Q. At the same doses; correct? 
A. I did not make any changes to the 
Bextra. 
Q. Discontinue the OxyContin? 
A. T)mCs correct. 





















handwritten instructions relative to the 10: 44: 5121 
medications she was to take when she left your 10: 44: 53 22 
office that day? 10: 44, 56 23 
A. [ don't have a specific recollection of 10:44: 5924 
a handwritten riote1 but! did, on some occasions) 10: 4 5: 02 25 
Page 63 
write -- write down some instructions for rny 
patients just so they understood dosing and the 
medication. I don1t recal11 you know) 
specifically if I did on that day with 
Mrs. Schmechel. 
Q. And your handwritten note would have 
clearly said just take five milligrams initially? 
A. I don't have a recollection of the 
handwritten note, 
Q. But it was your intent, though, that 
she only take five milligrams initially? 
A. At least ti1e first day, yes. 
Q, On the first day -- would it have been 
your intent that on the first day, September 
26th, that she take only five milligrams? On 
that day? 
A. I don't have specific recollection of 
-- of.the amount, but five to ten milligreim$ 
certainly was a reasonable starting dose in a 
patient who was on a substantial amount of 
another long-acting opioid medication. 
Q. I'm going to hand you what I've marked 
as Exhibit No. 2. 
A. Okay, 

























10: 52: 4.2 25 
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Exhibit No. 2? 
A, Yes, that is my -- my handwriting. 
Q, And that's handwriting on a Pfizer pad, 
is it not'! 
A. That's correct. No intended 
advertisement there. It1sjust what I had in 
hand. 
Q, I understand, Let me represent to you 
that this is something that Mrs, Sch~ncchel had al 
home; and Vaughn Schmechel, her husband, kep1 i ): 
and gave it to me. 
A. Okay. 
Q, Do you recognize this as a-~ as the 
instructions that you gave her in writing when 
she left your office on September 26th? 
A. I would say that is, correct. 
Q. And ifl read it correctly, on 
methadone it says one-half to one piff every I2 
hours; correct? 
A. Thafs correct. 
Q. And it doesn1t say fake only five 
milligrams initlally? 
A. It says one-half to one pill every 12 
hours. Five milligrams is a half a pH!. 
Q. Right. Looking at the -- what's marked 
Page 65 
as Exhibit No. J , • , 
MR. HWPLER: We've been going for a 
while. Can I take a break? 
MR. COMSTOCK: Sure. 
THE V!DEOGRAPHER: Off the record. 
(Recess held.) 
THE VJDEOGRAPHER: On the record. ,, 
Q. (BY MR. COMSTOCK) Mr. Byrne, we're 
back, having just taken a short recess to stretch 
our legs. I'd like to refer you to what's under 
tab 3 of Exhibit l; Ws page 1 l. 
A. Okay. 
Q. Just for a moment. Do you recognize 
tha1 document? 
A. Yes, l do. 
Q. What is it? 
A. It is essentially a medication !og 
that's kept in our office, which a!!ows us to 
keep a running track of the patient's date of 
visit, refills, an<l'.what medications were 
prescribed. 
Q. Is the handwriting on this log yours? 
A. The mc.dications, tbeir dosages, amounls 
written, arid !'he date are mine, The name is.not 
my handwriting. 
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Q. So if I read this correctly, 
Mrs. Schmechel was given a prescription for 90 
tabs of methadone? 
A. Yes. 
Q. And those are the ten-milligram tabs; 
is that correct? 
A. That*s correct. 
Q. And then you write n1 Q 12." What does 
that mean? 
A. One te1Hnilligram tablet every 12 
hours. 
Q. And what's thew~ what's written 
undemealh the number 90? 
A. No refills. 
Q. And hydrocodone is l O slash 500, and 
we1ve talked about that before; correct? 
A. Yes. 
Q. And what's written under the number70? 
A. One refill. 
Q. And I gather the prescription that she 
was given al the time she came in to see you on 
September 26 called for 70 of the hydrocodones t 
be deliver1;;d to her? The number 70? 
A. Yes. 
Q. Does that mean she can get 70 of those 
Page 67 
pills at one time? 
A. Right. 
Q. All right. Let's get back to page 1 of 
Exhibit l, which is the transcribed typewritten 
note for September 26 of 2003. 
A. Okay, 
Q. I want to go through the history that 
you dictate there. And this is your dictation, 
is it not? 
A. Yes, it is. 
Q. You write, under "Chief Cornplainf1 '. 
"Her chief complaint at time of presentation is 
central low back pzdn status post two surgeries, 
the last of which was 199 ! "; correct? 
A. Yes. 
Q. And then you have a history section 
where you discuss the pain that you and she 
talked about; is that correct? 
A. Yes. 
Q. And it indicates that she rarely gets 
pain in her leg; correct? 
A. Yes. 
Q. Occasionally gets numbness and a duU 
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Q. Otheiwfse no significant leg pain; 
correct? 
A. Correct. 
MR. HALL: Well, you left out part of 
the first sentence. 
Q. (BY MR. COMSTOCK) You continue: "Her': 
pain is typically constant, worse wllh lying down 
and has disrupted her sleep"; correct? 
A. Yes, 
Q, Did you write <mywhere in here tha( her 
painisal0ona !0? 
A, No, but in the documentation of her 
intake form, she ex.p1essed to me at th.it point, 
in a written fonn as well as verbally, that her 
pain was a 10 over 10. 
Q. You write: "She also has increasing 
pain with activities. 11 And then1 "If she gets in 
a flexed position) her pain improves"; correct? 
A. Correct. 
Q. So with some manipulation of her spinal 
column, her pain is improved? 
A. Yes, She indicated that if she bent 
forward, and when she was lying down, If she bent 
forward a lilt!e bit, she could get a Uttle more 
comfortable that way. 
Page 69 
Q, You did not include, in the Past 
Medical History section, any information relative 
to her sleep apnea and the use of a CPAP; is tha1 
COlTeCt? 
A. I would consider the dictated document 
as well as foe handwritten document the same in 
terms ofmy - my record and my recordkeeping. 
It's documented in the written por1ion. 
Q. The reason I ask it, it's not here in 
the typed portion, is it? 
A. No, it's not. 
Q. And the reason I ask it is that 
Dr. Dille signs off on the typed portion, bul Ito 
didn't sign off on your handwritten notes. So 
did you tell Dr. Dil!e that this was a woman who 
had a history of sleep apnca and was on CPAP 
therapy at some point in time? 
MR. HALL: Object to the form, 1 
MR. HIPPLER: Join. 
11lli WITNESS: You know, J don't have a 
sped fie recollection of the details of our 
conversation, but I do recall speaking to him at :; 
length in reference to Mrs. Schmechel, because he 
was going 1o be seeing the patient in follow-up, 
and I wanted him to know that I had seen ber and !_ 
........... , ... ,,,.·., , ....... ,, .. ,, 
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what had been done. 
Q. (BY MR. COMSTOCK) And as you sit here 
today, you can't recall if you actually talked 
with him about her CPAP therapy and her sleep 
apnea? 
A. I can1t recall. 
Q. Let's look at the Physical Examirn.1tion 
portion of your dictated and typed chart note. 
A. Okay. 
Q, What I don't see in this section, under 
Musculoskelcta!, ls anything that would indicate 
to me that you are finding that her pain is 
severe. Do you see anything that would indicate 
to you in tllis section that her pain is severe? 
A. You know, I1m assessing clinically her 
range of motion and pain, and her pain complaint 
is a-~ ls a subjective thing that she relayed to 
me verbally as well as in a written format. 
Q. But is there anywhere in here relative 
to your physical examination of her 
muscu!oskeletal system that would indicate to 
someone reading il, Hke Dr. Dille, that she was 
indicating that she had pain on a~¥ al a 10 on a 
scale of IO? 
A You know, there's indications that she 
Page 71 
had limited range of motion in her back as well 
as palpable lenderness, 
Q. So the answer to my question is, there 
is no indication here that she had s~vere pain or 
pain on a -- at a 10 on a scale of 1 0? 
A. There is -~ 
MR, HWPLER: Object to the form. 
THE WITNESS: .. an indication in the 
intake form where the patient indicated to me in 
a written as well as, later on in the evaluation, 
in a verbal form that she was still having 
cum;lanl pain. 
Q. (BY MR. COMSTOCK) I understand your 
answer, Mr. Dille~- or Mr. Byrne, but this 
document, which is your typed dictated note for 
the visit of September 26th, and looking under 
thls section, doesn't say that, does h? 
A. It does not, but I would also again 
stale that this -~ the document, the written, the 
transcribed, as we!! as the intake form, was 
something that was considered as the entire chart 
·and was used for our reference, and M~ and for 
10: 59: 13 23 that purpose, the information is there. 
10: 59: 16 24 Q. Under Assessment, you write: 
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with minimal radicular symptoms.!J There's 
nothing in that section to indicate to the reader 
that this is a patient who has severe ongoing 
back pain, is there? 
MR. HIPPLER: Object to the form. 
MR. HALL: Join. 
THE WITNESS: Again, you know, the 
patient indicated to me that she <lid have ongoing -'. 
back pain, and the record indicates that 
Q. (BY MR. COMSTOCK) Under the Plan 
section, there1s some discussion here about why 
she came to you. 
A. Uh-huh. 
Q. And it reads: "The patient has been 
under the care of Dr, Kimberly Vorse to this 
point but feels like it is more convenient for 
her to come to Twin Falls for her pain 
management, and she also wants some new 
information in reference to pain management. 11 
Did she come to you for you to actually 
take over her care, or did she come to you just 
for a second opinion and some information 
relative to what else could be done in terms of 
pain management'? 
A. She came to us to establish for pain 
Page 73 
management. 
Q. Did you make any statements to her 
relative to Dr. Vorse and your view of whether 
Dr. Vorse was adequately carjng for her chronic 
pain patients? 
A. Could you repeat the question 1 please? 
Q. Yeah. Did you make any comments to her 
about Dr. Vorse which would be construed as 
negative comments in terms of her ability to 
treat chronic pain patients? 
A. No. 
Q. What was the new information that she 
wanted? 
A, If you read on, it basically says that 
"She feels like her medicines arc currently not 
working 11 well -- as we!! as they should-~ as 
they used to. And that's not the quote, "She 
feels like her medicines are currently not 
working as well as they should or they used to.11 
And that was the information that she 
wanted, what other options were there for her in 
terms of improving her pain and her.quality of 
11: 01: 33 23 life, in addition to the convenience of seeing a 
11; 01: 36 24 pain management provider in Twin Falls which wa~ 
11: 01:4025 closer to her residence than driving to the Wood 
(208) 345 9611 M & M COURT REPORTING SERVICE, INC. 
19 (Pages 70 to 73) 




























Q. Again, with September 26 being a 
Friday, did you expect that by the following 
Monday, that this patient would have titrated up 
to as much as one and one-half pills every 12 
hours? 
A. No. I very clearly instructed her that 
len ml!ligrams twice a day would be the maximum 
dose. And that's indicated on the note dictated 
on 9/29, that 111 spoke to Ms. Schmechel today in 
reference to her medication change to methadone. 
She was doing wel!. 11 I advised her that she 
could go ahead and increase to methadone, ten 
milligrams twice a day1 and continue the program 
and recheck as schcdl!!ed, So .. 
Q. Your handwritten note to her-, however, 
which is marked as Exhibit 2, says "may increase 
to maximum of one and onewhalf pills every 12 
hours.'1 
A. The patient •• 
Q, Does it no!? 
A. It does Indicate that, but what was 
indicated to the patient verbally was that she 
would sta1t at five milligrams, up to ten 
milligrams:, 
Page 75 
11 : o 3 : 15 1 Q. Well, if 1 take your handwritten note 
11 : o 3: 1 7 2 literally, you were giving the patient pennission 












MR. HIPPLER: Object to the form; 
argumentative, asked and answered, 
Q. (BY MR. COMSTOCK) Correct? 
MR. HALL: Join. 
THE WITNESS: No, 
Q. (BY MR. COMSTOCK) Isn't that what "May 
increase to maximum of one and onew!ialfpi!!s 
every 12 hours" eqlmlcs lo? 
A. I think it's all about the time frame 






the written note but was very clearly indicated 
to the patient when l talked to her. 
And is also w~ 
Q. So you-· 
A. And is also pretty clear in the note on 
11: 04 : 03 20 9/29 as far as the dose that she was taking at 
11: 04: 06 21 that time. 
11: 04: 06 22 Q, So would you agree with me, then, that 
11: 04: 08 23 your handwritten note that the patient left your 
11: 04:10 24 office with is incorrect? 
11: 04: 15 25 MR. HIPPLER: Object to the fonn. ft 1s 
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11: 04: 16 l argumentative and misstates his testimony. 
11: 04: 19 2 THE WITNESS: The patient had verbal 
11; 04 :21 3 instructions that were very clear; and I felt, in 
11 : 04 : 26 4 talking to the patient in fo!low-up, that she was 
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milligrams every 12 hours. 
Q. (BY MR. COMSTOCK) But you would agl'Ce 
that your note that you gave to her isn't the 
same thing as what you told her verbally? 
A. lt is --
MK HALL: Asked and answered. 
THE WITNESS; -~ the same thing. It 
says a half to one pill every ! 2 hours. 
Q. (BY MR. COMSTOCK) But it does go on, 
Mr. Byrne, to say, "May increase to maximtlm of 
one and one-half pills every 12 hours," docs 'it 
not? 
A It states that, but the patient was 
given instructions that sl1e obviously was 
11: o s : 02 20 following tha1 indicated the appropriate time 
11: o 5 i o 5 21 frame for the titration from five to ten 
11 : o 5: 08 2 2 milligrams; and then another note that's in the 
11: os: 10 23 chart that indicates the titration beyond ten 
ll 1 os: 15 24 milligrams. 












11, 05: 5912 
11,06:0313 
Page 77 
point in time over the weekend? 
A. No. 
Q. Did Dr. Dille telephone and talk to 
thls patient at any point in time over (he 
weekend? 
A. Not to my knowledge. 
Q. lfthat had occurred1 would there be a 
no1e in your chart to that effect? 
A. Yes. 
Q. From your review of the chart, when did 
you next have contact with Rosalie Schmcchel? 
A. I spoke to Mrs. Schmechel on 9/29 of 
103. 
Q. And if we -- that would be a Monday; 
correct? 
A. That is c01Tect. 
Q. And if we look at the handwritten log 
of patient contact, again under tab 11 page 5 --
A. Yes. 
Q. WW I don1t see uny entry in there 
reflecting patient contact on 9/29 of'03, do 
you? 




11: 06: 04 14 











contact and called Mrs, Schmeche! pcrsonaUy, and'. 
for that reason, as soon as I hung up the phone, 
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I dictated this note, that J had spoken to her. 
Q, All right, but on 9130 there's another 
phone conversation that bas, not only a dictated 
note, but also a corresponding handwritten note? 
A. Correct. 
Q. So is the practice, when you call a 
patient, you don 1t enter a handwritten note but 
rather just a dictated note? 
A. I think that there was no specific 
practice, but it was availability of the chart at 
the time. When I spoke to her on the phon_e, I 
may not have had the chart in front ofme on the 
29th when I decided lo dictate the note in terms 
of efficiency. 
Q. The chart notes -- the dictated note of 
9129 of'03, which is Monday, indicates that 
Mrs, Sohmechel was doing well. It doesn't 
indicate. however, what doses ~he was taking, 
does it? 
A. !fl advised her to go ahead and 
increase the methadorn~ to ten ml tligrams at 
bedtime and ten milligrams daytime, then I wouk 
say she was ,taking less than len milligrams twice 
a day. 
Q. And that is what you advised her, was 
Page 79 
the ten milligrams at bedtime and ten milligrams 
in the daytime? 
A. That1s correct, every 12 hours. 
(Clearing thrnat.) Excuse me. 
Q. So would it be your understanding that 
she started that protocol on Monday the 29th? 
A. She may have been taking five 
milligrams on one dose and ten milligrams on 
another dose, I don1t have specific recollection 
of that, but I indicated to her that at that 
point she could take ten milligrams twice a day. 
Q. At that time was she to continue the 
hydrocodone as you had previously prescribed to 
her? 
A. As needed for breakthrough pain. 
Q, When you met with her on September 26 
of 2003, did the two of you depart with an 
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A. No. 11: 11: 30 20 
Q. Did you have an understanding as to 11: 11: 34 21 
when you would next communicate so that you, a 11: 11: 36 22 
the PE, could continue to -- the PA, could 11: l l : 3 9 23 
continue to monitor the progress of her titration 11: 11: 4 0 24 
of methadone? 11: 11: 41 25 
.. '""' .. , .. "·".-'''·· · ... -., , .. 
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A. My intent was to check with her on 
Monday. 
Q. And on Monday the 29th, it's your 
te...i:;timony that you called her? 
A. That's cort"ect. 
Q. From the office? 
A. That's correct. 
Q. In the office when you would contact ;:; 
patients1 did you use a ceH phone or did you use 
what we call a landline? 
A. It would have been the office !andline. 
Q, How do we know and how do you know th, -
this is a contact from you to Mrs. Schmechel as 
opposed to Ivfrs. Schmechel caHing you? 
A. I don't specifically know1 other than I 
just~~ 111 spoke to Ms. Schrnechel today." 
Q, It doesn 1t say ~M 
A. I have a recollectioh of calling her on 
9129, 
Q, Why did you eleet to increase the 
methadone, if you will 1 to ten milligrams at 
bedtime and ten milligrams daytime? 
A, Based on the information that she had 
given me on the phone, that was the next logical 
step in the management of her pain. 
Page 81 
Q. When Mrs. Sclunechel was speaking to 
you, was she under the impression that you were a 
medical doctor, or a physician1s assistant, or do 
you know? 
MR. HALL: Object to the fonn. 
Q. (BY MR. COMSTOCK) You may not know.: 
what wa$ in her mind, but did she ever reference 
you as 11 Dr. Byrnen and those kinds of things? 
A. In my presence? 
Q. Yes, 
A. She did not reference. me as 
nor. Byrne. 11 It was my routine, typica!ly upon 
presenting to a patient in an exam roorn, lo 
introduce mysetfas HTJ Byrne, physician 
asslstant. 11 And I also wear -- wOre a name badge 
which also indicated my name as well as my title. 
I believe at that time it said "Physician 
assistant, <.1th!etic trainer." 
Q. {n your experience in taking care of 
patients, you know, wherever, and including the 
Southern Idaho Pain Jnstitute, th~y often would 
confuse whether or not you were a doctor, would 
!hey not? 
MR. HIPPLER: Object to the fonn. 
MR. HALL: Join. 
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Page 82 Page 84 
THE WITNESS: I don't have specific Mrs, Schmechel 1s information to him, and he 11:14:16 1 
recollection about Mrs. Schmeche!, but certainly agreed, 11:14:20 2 
I've had patients on occasion who would refer to Q. That's not anywhere in the written 11,14:22 J 
me as "Doctor/' And when possible1 I would try record, though, is it? 11:14,24 4 
and correct them and make sure they understand m A, No, 11: 14, 27 5 
role and duties. Q, Let1s turn next to the -P your office 11,14:37 6 
Q. (BY MR. COMSTOCK) Thank you. In thi note of September 30, '03. 11:14:40 7 
note of September 29 of'03, you end it by A. Okay. 11:14:42 8, 
saying: "She will continue with this program Q. And first of all, let's go to the i: ,11:14:45 9 
until we recheck as scheduled." 11: 14: 47 10 handwritten note on page 5 of tab 1 of Exhibit 1. -f 
A. Uh-hub. 11, l.4: 54 ll That's your handwriting there, is it not? 
Q. So at that point in time, did she have 11: 14: 57 12 A. That's correct. 
a scheduled follow-up appointment? 11: 14; 59 13 Q. And would you read that handwriting for 1, 
A. I don't know a specific date, but it 11: 15: 02 14 me so that I know what all ls writ!en there, \ 
was my intent for her to be seen in follow-up two 11: 15; 04 15 because there's -- in parentheses there1s an 
weeks from the original vi.sit with Dr. Dille. 11: 15: 07 16 11crr01J1 and things of that --
Q, As of September 29th, which is Monday, 11: 15: 08 17 A. Right. Essentially [1ve written here, 
had you consulted with Dr. Dille? 11: 15: .1. O 18 npatient phone caH, advised methadone, 5 to 10 
A. I believe I spoke to Dr. Dille on 11: 15: 13 19 to 15 milligrams a.m.1 5, 10, 15 milligrams p.m." -:: 
Monday, 11: 15: 18 20 And then I made an error1 and so 1 initialed that 1,, 
Q, Before or after you had this 1:l.: 15: 22 21 I wrote 11error,'1 that I had crossed something out 
conversation with Mrs, Schmeche!? 11: 15: 25 22 and initialed it. 
A, I don1t recall specifically. 11: 15: 26 23 nDecrease Elavi1
1 
mlnimize hydrocodonei 
Q. Under your practice with Dr, Dille, 11: 15: 33 24 call Monday for any problems. 11 
would you have had the authority to increase her 11 : 15 : 3 6 2 5 Q. What was the enor? 1 1----------------------,----------------------I 
11: 12: 54 1 
11: 12: 59 2 
11:13,02 3 
ll: 13: 03 4 
11,13:07 S 
11,13,12 6 
11 :13: 17 7 
11 ,13: 21 8 
11:13:25 9 
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methadone to ten milfjgrams at bedtime, ten 
milligrams at daytimet without first consulting 
with Dr. Dille9 
A. Yes, I would. 
Q. Was it Dr. Dille1s practice to come 
back and initial chart notes where medication 
changes were made to show that he was supervisin, 
your actions and activities? 
A. f don1t have a specific recollection of 
11:13:2610 that. 
11: 13: 28 11 Q. And the reason I ask that question ls, 
11: 1313012 as I look at 1he chart note for September 29, I 
11,13,3413 
11:13:3714 









11, 14: 08 24 
11: 14, 13 25 
see your inhials on it, and assuming it takes 
several days to come back --
A. Right. 
Q. -- after being typed up1 you initial 
it; but f don1t see an initial there for 
Dr. Dille, Do you see one? 
A. I do not. 
Q. How, Mr. Byrne, am 1 to develop an 
understanding from this record as to whether or 
not Dr. Dille approved of your increase in the 
methadone on September 29th of '03? 
A. I spoke lo Dr. Dille at an interval 
after her initial visit and relayed 
11:15,39 1 

























A. I don't specifically remember. I think 
maybe I wrote the wrong mifligrams behind it or:, 
something. I don't -- I don't recall. 
Q, I mean, I can't tell from looking at 
this what's been crossed out1 can you? 
A. I don't. It's-milligrams and then my 
initials behind that, where I signed, so -- its 
5/10/15 ~~ and I may have written -- I dodt know·;: 
what I wrote, but it was an error and it was 
crossed out, and I initialed -~ wmte llerror'i and 
initialed my -~ put my initials there to make j'. 
sure that it was understood that it was an error 1 
that I had made in the ~- a clerical error that I 
had made there. 
Q. When did you make that change? 
A. At the time that I wrote the note. 
Q. And how do we know that? 
A. Because there's no other date on it 
If I would have done it on a differeni time, 
whjch isn't likely, I would have written a date. 
But certain[y once this is written_, I wouldn1t 
make a change. 
Q. You write here 11 minlmlzc hydrocodone," :: 
Why that change'/ · 
A. My anticipation with the patient on 
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long-acting medicine, as the dose increc1ses and 
her pain level improves, is that the necessity 
for the short-acting medicine for breakthrough 
pain is decreased, and so less medication is 
needed. 
Q. Again, with respect to your typical 
practice1 would it be your testimony that on this 
day, September 30th, you wrote the handwritlen 
note that we see on page Bates stamp 5, and then 
on that same day you dictated the transcribed 
note that we see on page 4? 
A. Yes. 
Q. But it would be several days later that 
the transcribed note comes back and you initial 
it? 
A. Yes. 
Q. In the transcribed note, it slmis off, 
0 Mrs. Schmechel called in as instructed.n 
A. Okay. 
Q. And what J don1t see in the note from 
the day before, September 29 1 '03, was that 
Mrs. Schrnechcl was instructed to call in; other 
limn the line that says '*Follow up sooner if 
there are problems." So was Mrs, Schmechel 
instructed to call in on September 30th, even in 
Page 87 
the absence of problems? 
A. I oftentimes asked m>1 patients to call 
in and check in with me and let me know how they 
were doing. 
Q. Why did you change the methadone 
protocol on September 30th from that which you 
had prescribed for her on September 29th? 
A. She just seemed to be doing better, was 
tolerating the medicine well; and a safe, gradual 
increase again ln the methadone to, again> try 
and improve her underlying pain complaint and to 
reduce the amitriplyline an<l the ::.hort~at:ting 
hydrocodone. (Clearing throat) Excuse me. 
Q. I'm a little confused, and maybe you 
can help me here, but on September 29th you ~~ 
you wrlte in your dictated, typed note~¥ 
A. Uh-huh. 
Q. ~- she is to go ahead and increase 
methadone to ten milligrams at bedtime, ten 
milligrams a1 daytime. 
A. Okay. 
Q. On September 30th your transcribed note 
says, 1'She is taking 10 milligrams a.m., 15 
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A. Yes, it does. 
Q, So is this note an indication that 
Mrs. Schmechel was taking five more milligrams ir 
the p,m. than you had authorized her to the day 
previously? 
A. You know, I think that she understood 
the mode of increase with the methadone and that 
certainly with the low starting dose of the 
methadone at five mil1igrams, again, a ve1y ~w I 
would actually consider probably a low dose of 
the methadone at ten milligrams, with t11e 
substantial amount of the long-acting opioid 
OxyContin that she had been taking prior to that, 
that those medicine doses were fine. 
Q. Well, if she had1 on her own. gone up 
to one and a half pills or 15 milligrams al 
night, that would be consistent, would it no1, 
with your handwritten note to her that you gave 
her on September 26th? 
MR. HALL: Object lo the fonn. 
MR. HIPPLER: Join. 
Q. (BY MR. COMSTOCK) Conect? 
A. Yes. But again, I think it was 
understood by the patient the gradual, slow 
increase in the medication, that 1he initial 
Page 89 
doses were low intentionally, and that a 
significan·t period of time was taken to gradually 
increase the dose of the methadone with a good 
dosing interval in between the two doses. 
Q. What I don1t understand1 Mr, Byrne, is 
that·- and maybe I'm just thick-headed, but what 
l don1t understand is that you write on September 
29th that it's ten milligrams in the morning and 
ten milligrams at night, at bedtime, and that 
nshe will continue this program until we recheck 
as scheduled/ and you1ve testified that that 
,. 
would be several weeks down the road. And the1 ,: 
the next day·· 
A. I don1t think I said several weeks down 
the road. I said from the day that she was seen 
by myself on Friday the 26th, that she would sec 
Dr. Dille In two weeks. 
Q. Right 
A. Okay. 
Q. I didn 1t mean to misrepresent anything 
on that. 
A. No prnblem. 
Q. My question, though, is that il looked 
to me like you were planning, at 1east on 
September 29th, that she would slay al l O and l 0 
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mil Ii grams, and then on September 30th you1re 
telling her to go ahead and up it to 15 and 15, 
if she chooses? 
A. Again, the patient was tolerating the 
medication well; her pain was improving; there 
was no other, you know, concerns about the 
medicine at that point; and she understood how 
the medicine worked and our intent in the dosing 
schedule. She was doing well, 
Q. Again, with respect to your 
conversations with Mrs. Schmcchel1 was lt ever 
reported W you by Mrs. Schmeche! that she was 
having cdcrna in her legs and pain in her legs? 
A. No. 
Q. ls h your testimony that you never 
talked to her on Sunday the 28th? 
A. I did not. 
Q. After talking with Mrs. Schmechel on 
September 30th of 2003, did you speak with her 
again? 
A. No, I did not. 
Q. In talking with her on September 30th 
of 2003, is it fair to say that you had given her 
the authority to take up to 30 milligrams of 
methadone in a given 24Nhour period? 
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A. Yes. It also indicates in the note 
that on -· on the handwritten note on the 30th, 
that !:'\he could call Monday if there was any 
problems. She also understood that she could 
call at any time if she had any concerns. 
Q. And I had one question about that, that 
writing, "CaU Monday for any problems." We know 
from the calendar that September 30th was a 
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September 30 as Tuesday, and then at the end of 11: 27: 57 10 
that note it says, "Ca!) Monday for any 11: 28: 00 11 
11: 25: 15 12 problems." 11, 28: 0112 
11: 25: 16 13 What was the significance of Monday? 11: 28: 10 13 













Was there going to be a vacation that you were 
going to have and you weren't going to be back 
until Monday? Or. , . 





communicating with Mrs. Schmechel from the onset, J: 1 : 2 8 : 2 5 18 
she understood that we were always accessible and 
iha1 she could call us with problems jf 
necessary. 
Q. At any point in time, hllve you reviewed 
the iiutopsy report with respect to 
Mrs. Schmechet1s death? 
A. Y cs, I have. 








Q, Having done so, do you have an 
understanding as to wha~ the cause of her death 
was? 
A. 1n reading the autopsy report, it was 
alleged that lt was combined 
methadone/hydrocodone poisoning, l believe, was 
how it was -- it was inte:rpreted. 
Q. Do you have any reason to disagree with 
that finding? 
A. rm not a forensic pathologist or a 
toxicologist. I don1t have specific information 
as to what her cause of death was. 
Q. From your review of thal document and 
from your dealing with Mrs. Schmechel) do you 
have an opinion, one way or the other~ over 
whether or not Mrs. Schmechel had been following·; 
your instructions with respect to the taking of 
methadone? 
A. I feel like she was following my 
instructions in the dosing of methadone. 
Q, How about with respect to the taking of 
the hydrocodone? 
A. I'm not sure that she was following my 
instruc1ions in reference to the hydrocodone. 
Q. And why do you say that, Mr. Byrne? 
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A. The·· I would have to •• can l look at 
that record as well? Do we have that? 
Q. You know, I didn't bring that with me 
here today) Mr. Byrne. 
A. I would probably need to read that and 
review it in order to answer that question. 
Q. But when you did read it, there was 
something about the information contained in 
there that caused you to wonder whether or not 
Mrs. Schmechel had followed your instructions 
relative to the hydrocodone? 
A. No, I wouldn't say that. 
Q. What was it, if you can recall, that 
causes you to wonder about that? Just in 
general? Was it the pi!! count? Was it the 
level of toxicity found in her blood? 
A. Just -- though I don't have a complete 
recollection of the report, as it's been some 
time that l reviewed it, I did note lhat the 
levels -- on the toxicology report, the level of 
methadone was within therapeutic range and the ;. 
level of hydrocodone wus ul or -- at the higher 
end of thernpeutic range or higher. 
Q. Did you attempt to break down the 
investigation) the coronets report, the autopsy 
. ,., •........ ,, .. ,., ..... ' .. , ... ,.,,"''''""·''''' .··,_., ... ,,,. 
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report, in tem1s of calculating the number of 
pills that she had been taking? At any point·· 
A. I did not. 
Q. -- in time? I1m going to hand you what 
I've marked as Exhibit No. 3, and I'll represent 
to you that this comes from the Idaho 
Administrative Code, and its the Rules for 
Li censure of Physician Assistants. 
A. Okay. 
Q, Have you ever seen this document 
before? 
A. I believe) when I applied for a license 
in the state of Idaho, this was part of the --
the packet that I received, yes. 
MR. HIPPLER: Do you have a copy there, 
Counsel1 for me? 
MR. COMSTOCK: (Handing document to 
Mr. Hippler.) 
Q. (BY MR. COMSTOCK) ln terms of your 
practice as a PA within the state ofldaho, at 
various points in time did you ~- were you called 
upon to study the Rules for Licensure of 
Physician Assistants? 
A. Was I called upon to review the rules 
of --
Page 9S 
Q, Yeah; did you ever study these at any 
point in lime? 
A. I believe J reviewed them a.t ~" at some 
poinl1 yes. 
Q. With respect to practicing as a PA in 
the state of Idaho under the supervision of a 
physician in September of 2003, was it your 
impression that there needed to be a written 
agreement between you, as the PA, and the 
supervising physician in order for your Hcense 
to be effective? 
MR. HIPPLER: Are you refen-ing to the 
provisions that have a 2004 date next lo them, 
Mr. Comstock? 
MR. COMSTOCK: 1 haven't represented 
one thing or the other, Mr. Hippler, with respect 
to the exhibit. I've got a question pending in 
front of the Witness that deals specifically with 
his understanding in September of 103. 
MR, HIPPLER: I'll object to the extent 















































the document not in effect in 2003, 11:37 :39 22 
MR. COMSTOCK: The question didn't call 11: 37: 45 23 
for him to relate it to the document, and the 11: 37 :48 24 
reason 1 asked that was, I don't know whether the 11: 37: 5125 
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document is '04 or 103. 
THE WITNESS: Can you repeat the 
question or can she read it back, please? 
MR. COMSTOCK: I think what we'll do at \ 
this point in time is1 since I've been advised by ;. 
the videographer that we need to change the tape, 
we1ll take a short recess and change the tape. 
THE VIDEOGRAPHER, This is the end of 
Tape No, I; off the record. 
(Recess held.) 
THE VIDEOGRAPHER: On the record. 
Q. (BY MR. COMSTOCK) Mr. Byrne, I'm no . 
directing this question -- and we are back on the 
record, having changed the videographer1s tape, 
This question is not directed to the Rules for 
Licensure that I had you look at. Frankly, I'm 
not sure if those are 2004 or 2003 rnles. 
The question, though, is stilt before 
you, and that is, as of September of 2003, was it 
your understanding, as a PA practicing in the 
states of Idaho, that you needed to do so under a 
written agreement with the physician who was 
providing the supervision? 
A. I believe there was documentation that 
was provided to the State Board of Medicine1 as 
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required by them1 for that working relationship 
between the physician assistant and the 
supervising physician. 
Q. As you recall those documents -- and 
whether the Board of Medicine will give us those, 
documents or not~ I don1t know -- but as you \ 
recall them; do they get so specific as ro define 
when Dr, Dille has to approve the actions that 
you1re taking on behalf of a patlent? 
In other words, can Dr. Dille come back 
in a week later and simply sign off on a chart1 
or is there something that would define how soon: 
after your decisions he needs to review that? 
MR. HALL: Object to the fonm of the 
question. 
MR. HIPPLER: Join. 
MR. COMSTOCK: It's a poor question, 
but it's still a good one, 
THE WITNESS: Again, I don't have a 
specific recollection of the fonn or the 
documentation, but to my recollection, there was 
a section that tatked about the physician 
ovc:rsccing the physician assistant and chart 
review and such. And that's -- I don1t have a 
speci fie rec a II there. 
25 
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Page 98 Page 100 
Q, (BY MR. COMSTOCK} Y m11ve told me that 11: 40 : 59 1 cei1ainly had other medical problems and some 
you remember visiting with Dr. Dille about 11: 41: 02 2 
Rosalie Schmcchel on that Monday, although 11: 41: 07 3 
there's nothing in the chart which would indicate 11: 41: 11 4 
that happening. Did you talk with Rosalie -- 11 : 41: 14 s 
with Dr. Dille about Rosalie Schmechel on Tuesday 11, 41: 15 6 
when you changed the medication up to as much as 11: 41: 18 7 
15 rnil!igrams twice per day? 
A. I don't have a recollection ofa 
conversation on Tuesday. 
Q, So in terms of Rosalie Schmechd and 
conversations you had with Dr. Dille about this 
patient, you recall one conversalion and that 
conversation occurring on the Monday following 
her initial presentation to the client? 
A, To the best ofmy recollection, yes. 
other health issues that, I guess, potentially 
could have caused problems, but l don't have any 
information-" other infonnation in reference to 
that. 
Q. What were those other issues? 
A. She had high blood pressure; she was a 
smoker. 
Q, Anything else? 
A. I think that the recm·d indicates i1er 
past medical history. 
MR. COMSTOCK: Cnn f have this marked 
as the next exhibit in !ine? What arc we up to, 
6? 
COURT REPORTER: Yes. 
(Exhibit 6 marked.) 
I 
Q. Did you dictate the letter, tha1 ls 













Q. (BY MR. COMSTOCK) !'ve handed you what i 
we've marked as Exhibit No. 6. Ts that a copy of 
A. Yes. 
Q. And thal letter is at page 13 tinder 
tab 5? 
A. Yes. 
Q. Would that have been diclation that you 
did on September 26th, or sometime thereafter? 
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A. This letter would have been dictated at 
the same time or just after I finished the-~ the 
other dictation, the history and physical 
examination. 
Q, Now, the date on the letter is 
September 26th, and so my obvious question is, 
you know, was this transcribed and prepared for 
your signature by September 26th, or was it 
likely sometime later? 
A The dictation was, in fact, September 
26th, which is indicated. I would say that the 
transcription was subsequent to that.. 
Q. Even though the letter bears the date 
of September 26? 
A. That's when it was dictated, yes. 
Q, Have you formed an opinion -- and I'll 
object to my own question. Have you formed an 
opinion relative lo what killed Rosalie 
Schmeche!? 
A. No. 
11 :41: 55 19 yout· Curriculum Vitae whk:h you provided to 
ll:4L57 20 Mr. H~!l, which has now beenprnvided tome? 
11: 42: oo 21 A. Yes, it is. 
11:42:0122 Q. Isthatcurrent? 
11 :42: 02 23 A. Yes, it is. 
11: 4 2: 04 24 Q. Are there any additions, changes, or 






















make it accurate? 
A. There actually is. From probably -- [' 
for about two months in between January alld March~ 
or April of'05 1 I worked fill-in at a local t 
family practice clinic in Spokane. lt1s actually 
a-· Community Health Association of Spokane ls 
the name of this facility. It provides health 
care for indigent people within the community, 
people that don't have health insurance. And 
that's -- that's not on here. And Jim not sure 
why, but it's not. 
Q. Any other additions, corrections, or 
deletions? 
A J'll just take a second to review it. 
Q. Sure. 
A. (Reviewing document.) My ldaho license 
is designated as an inactive \icense1 but I do 
have a license within the state of Idaho as a 
physician assistant. lt1s just an inactive 
Q. Do you think she died from something 11: 43: 38 21 
license because l don't have a supervising 
physician in the state of Idaho. And the same 
would ho!d for rny athk:fo; trainer registrntion, other than methadone and hydrocodone toxicity? 11 : 4 3 : 4 3 22 
A. As I sit hcrc1 I guess I don1t have the 11: 13: 4 s 23 
information that I would need to accurately 11: 43: 52 24 
respond to that question. Mrs. Schmechel 11: 43: 54 25 
as I don'! have !I supervising physician in the 
state of Idaho, 
So those are both essentially inactive, 
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though I do have those licenses, 
Q. Other than the lawsuit involving 
Mrs. Wil!iams1 husband and this particular 
lawsuit, have you been named as a defendant in 
any other cases that would relate to medical --
provision of medical care and services? 
A, Not to my recollection. 
Q. Have you ever had your license as a PA 
investigated, suspended, or revoked at any point 
in time? 
A. No, sir. 
Q. Other than teslifying here for this 
deposition and testifying for a deposition in 
that Williams case, have you testified, eithei· by 
deposition or in a court of law, relative to 
provision of medical care and services? 
A. Yes, There were two other occasions 
where I was called as a witness in the 
prosecution of two criminal cases, and that's the 
only time that I've ever been in a courtroom, 
And I dontt believe at that point that I gave a 
deposition, l was just-~ I was called to 
testify. 
Q. Okay, and l won't go into that. Those 
are criminal matters that probably relate to a 
Page 103 
patient and what happened with a patient, I'm 
assuming; correct? 
A. They were related to -- one was to a 
patient that falsified information in a work comp 
isst1e, and the other was a-~ actually a 
vehicular manslaughter case when -- I was working 
in an emergency room when this event took place. 
Q. Any other testimony that you've given 1 
either by way of deposition or in a court of law? 
A. Not that I can recall at this time. 
Q, Have you ever been asked by a law firm 
thal Joes work, 8l!Ch as my firm does from time to 
time, to review the conduct and activities and 
services of another PA to determine whether or 
nol that PA met the standard of care? 
A. No. 
Q. Have you talked wilh any of the 
Schmechel family since Rosalie Schmeche!1s death~ 
A. No, I have not. 
Q. Have you told me all of the 
conversation that you had with Dr. Dlflc relative 
to Mrs. Schmechc!? 
A, 1 believe I indicated that I didn 1t 
recall word for word the conversation, but that I 
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with him in reference to Mrs. Schmechel and the 
changes that I made to her treatment plan. 
Q. When did you firsl learn, if you 
remember~ that Mrs. Schmeche! had passed away? 
A. I think it was on or about October 3rd. 
Q, So it was shortly after her death, 
which was recorded as being October 2nd; correct?.'. 
A. I believe those were the dates, yes. 
Q. Who di{l you learn from? 
A. I believe I was told by Christy Davies, 
our office administrator, 
Q. Di<I you then talk to Dr. Dille? 
A. I think at some point in time we did 
talk, yes. 
Q, When did you talk to Dr, Dille? 
A. I don1t have a recollection of the 
specific date or time, 
Q, Where were the two of you when this 
conversation took place? 
A, We were in our office. 
Q, And did you talk about Rosalie 
Schmeche! and the care thal was provided to her? 
A, I believe we had a discussion, yes. 
Q. What did you talk about? 
A. I don 1t have a specific recollection of 
Page 105 
the conversation. And part of the conversation 
may have been, you know, that she had passed 
away. And that was about it, because I didn't 
really have any other information available at 
that time, nor did he, 
Q. At that time was it known to either of 
the two of you that Rosalie Schmechel had died, 
according to the autopsy report, from methadone 
and hydrocodone toxicity? 
A. No, 
Q. When you talked with Dr. Dille, was 
there any concern ofyourS relative to whether or 
not she had died because of the provision of 
medical care that you had provided to her? 
MR. HALL: Object to the fonn. 
MR. HIPPLER: Join. 
TI-IE WITNESS: You know, my -- details 
of the conversation, I don1t recall. It was just 
basically that we had had a patient that I had 
seen and_ that she had passed away and I didn't 
have any other information at that point in time, 
and that was really the extent of it. 
Q. (BY MR COMSTOCK) Were any of the 
chart notes that I had you go through, both 
handwiilten and dictated and then transcribed1 
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signed by you after Rosalie Schmechef1s death? 11: 51: 45 1 
A. That's possible, I1m not sure when the 
-- what the time frame was for those documents t< 
come back from the transcriptionist and the date 
of her -- of her death, 
Q. Who was providing the transcription 
services, if you know? I mean, as the PAyou ma 
not have any idea of the --
A. r don't have any idea. 
Q, Okay, Were you interviewed by anybody 
from the coroner1s office relative to 
Mrs. Schmechel death? 
A. No. 
Q. interviewed by anybody from the 
sheriffs office? 
A, No. 
Q. Did anybody come and talk to you 
relative to investigating the cause of Rosalie 
Schmeche!1s death? 
A. No. 
Q. Other than talking with Dr. Dille, did 
you speak with anybody else about Rosalie 
Schmechc! and the care and provision of medical 
services you had given to her? 
A. Not to my recollection. 
Page 107 
Q. When did you learn that the cause of 
her death was being linked to methadone and 
hydrocodone? 
MR. HALL: Object to the form. 
THE WITNESS: l don't have a specific 
recollection of that date. 
Q, (BY MR. COMSTOCK) Was it -- if you 
remember, was it before or as a result of the 
filing ofa petition for prelitigation screening 
in these matters? 
A. Could you restate that for me --
Q, Sure. 
A. -- or repeflt that? 
Q, What l really want to know is whether 
you learned from some source in the Twin Falls 
community that the cause of her death was being 
linked to methadone and hydrocodone before the 
point in time when1 you know, this litigation 
process sta1ted and the prclitigation was filed. 
A. Again, I don'l haven specific 
recollection of that sequence of events or the 
time -w the time lherc, 
Q. At some point in time, though> 
Mr. Byrne, you did learn that -- that the death 










11: 52: 07 J.1. 
11:52,1012 
11:52:1213 
11: 52: l.614 
11:52:2015 
11,52:2416 
11: 52 :2617 
11:52:3118 
11:52.3419 






























1l :56: 14 25 
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hydrocodone? 
A I reviewed the-· the documentation. 
Q. Okay, And that's how you learned? 
A. Yes. 
Q, After you reviewed that documentation, 
did you do anything to investigate the matter 
further yourself? 
A. No, 
Q. Did you go back to the chart and review 
the chart again? 
A. I have reviewed the chart subsequently, 
Q. And that's a bad question. I meant as 
a result of your reviewing the autopsy as opposed: 
to trying to get ready for this deposition, 
A. l don't recall specifically; l'm sorry. 
Q. Other than the attorneys involved in 
representing you 1n this matter, have you 
discussed the alleged cause of Rosalie 
Schmechel's death with anybody? 
A. No, 
Q. Rave you had any conversation with 
Dr, Dille regarding the cause of her death after 
you learned that it was being linked to methadon 
and hydrocodone? 
A. l don't recall specifically. 
Page 109 , 
MR. COMSTOCK: I believe those are all 
the questions I have. At this point I would like 
to take just a moment to go through my notes and 
~- but l do think Pm done. 
THE WITNESS: Okay, 
MR, COMSTOCK: We can either have these 
gentlemen ask questions tf they choose to do so 
while I do that, or we can go off the record 
briefly, 
Whatis your pleasure, gentlemen? 
MR. HIPPLER: We'll go off the record, 
l guess, 
MR. HALL: We'll just go off the 
record, 
Tl-IE V!DEOGRAPHER: Offlhe record. 
(Recess held.) 
THE VJDEOGRAPI-IER: On the record. 
Q, (BY MR. COMSTOCK) The last questions r; 
have for you relate to a kind of just 
administrative matter, and it involves questions 
of insurance, Did you have a policy ofinsurance 
tha! covered you for your provision of medical 
care and services ln effect at the time you were 
treating Rosalie Schmeche!? 
A. Yes, 
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11:56:16 1 Q, And to your understanding, is that 1 CHANGE SH~ET FOR THOMAS J. BYRNE, P.A. 
11:56'18 policy of insurance a different policy from the ' Page_ Line_ Reason for Change 2 Reads 
11:56:21 3 one which covers the clinic itself? Or do you 3 Shotild Read 
11:56:27 4 know'? ' Page_ Line _ Reason for Change Reads 
11:56:27 5 A I believe it is independent, yes. res 5 Should Read 
11:56:31 6 a policy under my name, ' Page_ Line _ Reason fot Change Reads 
11:56:35 7 Q, As l review the care that you provided 7 Should Read 
11:56:39 8 Rosalie Schmechel, it would look to me as thoug s Page_ Line _ Reason for Change : 
~ ... and this is more lawyerly w- that everything 
Reads 
11:56:43 9 9 Should Read 
11:56:4-610 you did was within the scope and course of your 10 Pnge_ Unc __ Reason for Change 
11:56:4811 nonna! duties as a PA working for Dr. Dille and 
Reads 
11 Should Read 
11: 56: 5212 the institute, Can you think of anything that 12 Page_ Line _ Reason for Change 
l1: 56: 5513 you might have done, relative lo Rosalie Reads 
13 Should Read 
11:56:5714 Schmechcl, that would fa!! outside the nomrnl 14 Pag:e_ Line _ Reason for Change 
11:57:0115 realm of your duties that you would provide to Rends 
15 Should Read 
11:57:0316 any patient? 16 Page_ Line _ Reason for Change 
11:57:0517 A No, sir. Reads 
MR COMSTOCK: Okay, Those are all 
17 Should Read 
11:57:0818 ]S Page_ Line _ Reason for Change 
11:57:0819 the questions I have, Thank you. Rends 
11:57:1120 MR. HIPPLER: No questions at this " Sliou!d Read 20 Page_ Line _ Reason for Change 
11: 57: 12 21 time. Reads 
11 :57; 13 22 MR. HALL: I have no questions. 21 Should Read 
22 Page_ Line _ Reason for Ch,mge 
11 :57: 15 23 TI1E VlDEOGRAPHER: Off the record. Reads 
24 (Deposition concluded at 11 :57 a.m.) 23 Should Read 
24 Please use n separate sheet if you need more room. 
25 (Signature requested.) 25 WITNESS SIGNATURE } 
Page 111 Page 113 
ii 
1 CERTIFICATE OP WITNESS 1 REPORTER'S CERTJFICATE 
2 I, THOMAS J, BYRNE, P.A., being first duly 2 l, EMILY L. NORD, CSR No. 695, 
3 sworn, depose and say: 3 Certified Shorthand Reporter, certify; , 
' That l am the witness named in the foregoing 4 That the foregoing proceedings were 5 deposition, consisting of pages ! througli l IO; 5 taken before me at the time and place therein set 
6 that I have read said deposition and know the 6 forth, at which time tile witness was put under 
7 contents thereof; that the questions conrnined 7 oath by me; 
8 therein were propounded to me; and that the 8 That the testimony and an objections ' 
9 answers contained therein are true and correct, 9 made were recorded stenographically by me and were ·'. 
10 except for any changes that l may have listed on 10 thereafter transc1ibed by me, or under my direction; 
11 the Change Sheet attached hereto, 11 That the foregoing is a true and correct 
12 DATED this __ day of ,200_. 12 record of all testimony given, to the best ofmy 
13 13 ability; 
14 14 I further certify that I am not a 
15 THOMAS J. BYRNE, P.A. 15 relative or employee of any attorney or party, : 
16 SU8SCRJBED AND SWORN lo before me th)s--: 16 nor am I financially interested in the action, 
17 day of , 200 17 - IN WITNESS WHEREOF, I set my hand and 
18 18 seal this __ day of May, 2006. 
19 19 
20 NAME OF NOTARY PUBLIC 20 
21 21 EMILY L. NORD, CSR, RPR 
22 NOTARY PUBLIC FOR 22 Notary P11blic .. 
23 RESIDING AT 23 P.O. Box 2636 
24 MY COMMISSION EXPIRES 24 Boise, Idaho 83701-2636 " 
25 25 My Commission expires November 5, 20 ! !, 
····-·· ····· .. - .. -......... ,., .. ,, .. .............. , ...... ,., .... "' .. , .. '• """'"'''"'" ,,-,vA,-, . ... ,, ..... .. _..,, ... , ,., ...... ,., . ..... _,,,.,., •.. 
29 (Pages 110 to 113) 
(208) 345-9611 M & M COURT REPORTING SERVICE, INC. (208) 345-8800 (fax) 
') I) n I') 
-1. C, ·.1 ,.., 
Provider contract 
o'<.>uthern Ida.ho Pain & Rehabilitation Institute 
Climon L. Dille, M.D. 
Michael f;(. Schabacker, M.D. 
236 Martin Street 
TWIii Falls, ID 83301 
2()8,733-3181 ph 
208-733-3)/iQfax 
As of the date of: / I It 1/ IO / , 2001, this contract wlll become effective. 
J 
The Plrysician Assistant, Thomas J. Byrne hereafter to be known as employee will be entering into a provider agreement 
with the Southern Idaho Pain & Rehabilitation hlstitute hereafter to be known as employer. 
SALARY: 1:he employee will be paid on an holll']y basis of $45.00 per hour. After January l, 2002, the employer 
guarantees at least 3:t hours per week. Prior to that date, the eniployee will be paid on a per diem basis, Aftirr 90 days of 
full time employment the employer and employee w!l) review hourly salary and performance at that time and consider a 
possible monthly salary or changes i11 rate of hourly salary. 
HEAL TH INSURANCE BENEFfTS: On January l, 2001, the employee and family will be eligible for lrealth insuraitce 
benefits, The appropriate fo1ms must be filled out by the employee in order for the employer to apply for said insurance. 
A medical savings account will be set up ln the employee's name for the patient to use for medical expenses relating to 
non-covered health bendits, vision, dental etc. The amount placed in the account will be 75% ofthe maximum deductible 
for the family. 
RETIREMENT BENEFrfS: Toe employee is eligible for retirement benefits after 1000 hours of employmet,t. The 
accounts are set up on January!" annually. The employer contributes the maximum amount for this. The employee is also 
free to set up payroll deduction accounts and other investment plans on his own. The emph:,ye:e is eligible at any time 
during his employment to discuss investment options with our financial counselor as a benefit to the company, 
VACATION: The employee is eligible,.for 2 weeks (80 hrs) of vacation time within the 1" year of employment. This time 
will not be rolled over into the next year unless previous arrangements have lleen made, Thfo will be reviewed annually 
for negotiation of more time. 
SICK SALARY: The employee is elisfble for 1 week (40 hrs) of sick time. Further time for surgeries, or extended 
illnesses will be reviewed on an individual basis. Notice for sick time needs to be as quickly as possible to arrange for 
coverage, 
PROFESSIONAL FEES: The employer is responsibfo to pay annual dues for malpractice insrn·atice, NATA dues, lditlto 
license and any Physician assistant licenses. 
MEDICAL EDUCATION: The employer highly recommends to the employee to remain current on changes in medicine. 
If a conference or education seminar comes up that the employer or employee wishes to attend, it will reviewed on a case 
by case basis for funding, time scheduling etc, 
By signing this contract, I agree to the above statements, with the understanding that this contract will be revfowed on 




August 28. 2001 
Southern Jdaho Pain & Rehabilitation Institute 
Clinton L. Dille~ M.f). 
236 Martin Street*496 Shoup Ave E 
Twin Falls, fl) 83301 
208-733-3181 ph 
208-733-3168/ax 
JOB DESCRJPTION FOR PHYSICIAN ASSISTANT (PA) SERVICES 
IN1TTAL EVALUATION 
The physician assistant employed with Southern Idaho Pain Institute will be utilized in 
the initial evaluation for patients seen in this facility. Tbese patients stem from a 
physician referral b3se and also patient self referrals. They wlll require a full history and 
physical on it1itial visit and will be documented with appropriate findings and 
recommehdations. This wiJl include the ordering of appropriate tests and prescribing of 
tnedication8. These results will be reviewed by the supervising physician to determine 
and confirm findings and form a treatment plan for the patiei1t · · 
RE-EVALUATION 
The PA will be utilized in the re-evaluation of existing 'patients for medication 
management & renewal and recommendations. for further treatment within our facility. 
The PA will perform appropriat<' system exams based on the patient's chief complaint. 
Upon this exam, the physician assistant will recommend the type of therapy and/ot 
procedure that the supervising physician will review and perfomi. 
SURGICAL ASSlSTANT 
The physician assistant wiH assist the supervising physician with cases presented in our 
surgery center. These cases will include but are not limited to, epidural procedures under 
fluoroscopy, epidurograms, discograms, stellate ganglion blocks, lumbar sympathetic 
block$ and Medtronic intrathecal trials. The ,,upervising physician will train (he PA to 
assist him on aII of the above procedures. 
MINOR PROCEDURES 
The PA wil! perform several small office based procedures based on the medical findings 
on clinka! exam within this facility, These include, but are not limited to; trigger point 
injections, small joint injections, occipital injections, and manipulations, 
DELEGATION OF SERVICES AGREEMENT 
DEUiGATION OF 81::IWICES AGREiM.eNT 
A t>e!egatlo11 of S$rvlcet Agrc,omont ia to be maintained at eael) prai::tlce site1 at the addreati ot record of the 
supi,rvlsin9 pllya!olan and at the BMrd of Medicine. The Dol&gation ·of Sel'\llce$ Agreement j3 o written doo~nt 
mutueUy agr~&d upon and -aigned end datsd by the physic!an aiutistant end supervislnt, phyi,:Jclan that lists the 
physician assiatal'lt' o training, experience and education and. definoe the working relationship ~nd deleg~tlon of 
duties batweel'l. tho supervising physician and the physician -~~l:£lt1mt att flpeoifiad bV BQard rule. 'rh& Board at 
Medinine will review the written Delegation of Servlcas Agrqement end may review job de90rlptlori.s_ polii::y 
statement$, or other dooumanta that define tht1 fl)sp0Mlbllltl1;ts of the physician as.')iatent !n thi, practlo& setting, 
and may re~uira st.ioh changes as needed to aohiave oomp!ianca With thane rules and to safeguard th& public. 
The following mutt be b;glbl&, Uso ~ddltl6~al ihosb if neca111!1ry. SUBMIT YOUR DELEGATION OF SERVICE$ 
AGREEMENT TO THE BOARD WITH YOUR APPLICA'rloN Fon LICEN8URE AND WffH ANY CHANGE IN PRACTICE 
OR SUPSAVISION. 
Phy.$iclan Assistant N.ame; __ -+~~-..:....s,;---.,,__,__..;,....,,_"*~:.--"":,,,,...:r;..,_.._..,_.L...... _______ ~ 
Supervising Physician Name:~-~c::.,....;;...;...---'-.c;-"---,~'--..---"'-"--c;;-.G-.w;........:_--;.-_,_,.;~----,__.--




2, Name of Feoitlty: __________ ..,.._ _ _,_ ___ ,;.._ __ ..;.__,_~-·-----------
. · ·~ddre.ss: ______ ~--~---------~---~----~--~---~-
THE FOI.LOWINS CQRE CQMPETl:NCY MEPICAL AND SURGICAL SEr!tVtCE$ ARI; APPROVeD FOR ALL IDAHO 
UCENSED PHYSICIAN ASSISTANTS. rna supervising phy$lotan may ra.qvest Board ravtaw and approval of 
speolatized procedures not Jiste\';I ln the core oornpatenr.:ies by cQmpfetln9 Form 6 Page 5, 
.. Administration of medications .. Non-ablative la$&r procedures 
" Anoscopy 
. ., Joint l~3eot\ons/aspiration 
• Apply/remove casts & splints • Laceration r-epalr tmd management 
• Ass:iit in ottic0 procedures & surgt'lfY "' Local anesthesia including digital block 
• Assist in surgery ii Menagern-0nt of slmpla frectures exeluding 
• SladdEir catht:iterlzatton rnd1.1ctions 
" Advanced Cardlao Llfe Support • Naso9astria tube insartion and removal 
• CL!A waived lab prncedures • Order durabf a medical equipment 
• cc;insultation with ref erra-1 to approprie.t~ • Perform pulmonary function te:it 
health car!,'! resources • Skin cir .subcutaneous excision/biopsy 
• Di~therrny/Ulttasound • Superflaial foreign objei;;t rernovaf 
• Fulguration/cryQtherapy superficial lesions • Treatment of thrombosa.d hemorrhoids 
• Ganglion cyst aspiration • Vanipunoture 
• Incision & Drainagll • Wound management 
• lngrow11 toenail removal 















DELEGATION OF SERVICES AGREEMENT 
PRESCRIPTION AUTHORITY 
A physician asslstaot who wishes to apply for prescription writing authority ~hall submft an application for such 
purpose to the Board of Medicine. 
The drug categories or specifio legend drugs and controlled drugs, Schedul& ll through V that may be prescribed 
shall be consistent with the regular preserlptlva practice of the supervising physician, 
Grodu11t8 p/Jy/1/clan 11ss1,m1,1ts shall not ba 1111tltkld ta fs11.11& llny pll1k¢ptlo1111. 
Please tlst the drug natagorieu of specific legend drugs and oontroll&d drugs that will be prescribed, .,,, 
~f' 7i2rc"T /-,:- t'4> ,r. I 
~ 
.... 
Note, Tha phf/$1Clan. Mflstant · wtrh spproll8d prascrfptlv11 authol'lt'I ~om tli<> lfoard of Madfclne r,;r Scheduh) n 
through V drug* mwst obtaftt reg1'rt,,.tlon ftom tJw Federal Drug l!nforo11m1111t Adminlatratlan and th11 Jdaht;> lJ"4rd of 
Phsrm11cy. Form, and a link to thfl DEA may hs flCCfl!ts11d an tbs Board of Pharmscy',; W/Jbs/tB at 
www.accw/dt,ho.w,lbap, 
MEDICAL SERVICES REVIEW 
Please des¢rlb$ the procedures or protocols for periodic r~view of a representative sample of record& and e periodic 
review oi the medical servloe• being provided by the physloian assistant. This review shall also Include an 
eva!ua\lon of adharenot1 to the Delegation of Service$ Agreement, . 
~ ~~H+c ~- r1.' 
Noto: Graduttti, phy1tlclsn aYslstllnts nro (l)qufrer/ to h•v• (f WfJ9kly rocord rovfew by their quporvfsfng pbysiman, 
Rev. 4/04 
DELEGATION OF SERVICE:$ AGREEMENT 
ACTIVITY AND LOCATION 
Plaase list the specific activities and patian.t service$ whioh will be porformed by the physician assistant and the 
specific locations and facilities Ii'\ which the physician assistant will funoUon. · 




DIRECTION AND CONTROL 
Please describe the methods to be used to ensure re$pon$ible direction and. control of the aotMties of the physician 
assistant Including an on-site visit at least monthly, regularly soh-,duled conferences between the supervising 
physician and the physiolan assistant, and eva!lablllty of the aupervlsing physlolan to tho phy$!Clan a•slstant in 
parson by telephone at thl$ practice site, 
5 t"'{" &t:. ""C!.' ,;,..,,,( .--
Rev. 4/04 
a 
Form 6 Paga 2 
·1 ') r": •·'1 
J. r~ .. , ' 
Dlrection and Control 
The methods to be uood to insure responsible dlrection_ aud eontiol of the acliv.ities of the ph)'llioian 
assistant whioh ,bllll provide for an on·site visit at l"*'<! monthly, reg,,J,,tly !lbheduled wnlbtences between 
!l!e Sltp<n'islng physician and the physician ~t, and availability oftbe nupervW,,g phyn!Clllll to the 
physician a.sistant in person or by telephone, 
Please de~Jt:,e how llils will be =mplish«d ut this prac~ll'I ,;ite; 
As they physician US6iBlnnl's supervlsing physiclm:! I will be avi!llable for collUUltatfon, guidance, and 
s!lpervision on most business days, in my infrequent ahsonces n s«iorulru:y supervising p\zysioian will \,e 
11vaill!b!e. 
l will pm:forn, at !""81 monthly periodic chart and ca,,: rev!ows, and wm wo!k wlth my phynician assistant 
to cstablish m:ld maintain muttwlly ~ upo/1 Jm>CUCO protocols & guidcl1-. 
Emergency Procedures 
A vailablllty of the sui,,ervising physician to the physician 11BSistant Jn pef$0n or hy telephone and 
prooeclures for providinf, backup for the physician !ll)$i6lant ln emergency situations. 
Plel!Se describe how this wiU l?e accomp!ioblod m; this prn,:,tice am, 
When a serJoi,.jy ill or il\iurnl patiellt present to South= l<lltho Pil!n ruJd R,:,J;abililllllon the physician 
assistant will mltfate.stabllizixig care lllld malntaltt strict ad.her= to ACLS, ATLS, lllld PALS su\delinell, 
Tl:te physician assistant will move e,qieditiow,ly to 1mJ1sfor the= of1he patient to an appropt¼te 
physician or physioiatl spocW.ist. A pru:mu:y or secondary phyeicillll will be a\'l>ilol:,\e 2~ hourn per day 1:o 
provide consultlltion, smdruloo wd supervision to the pby8ician ru!Sistimt. 
Addressing Sitn11tions Ontside the ~cope of Prn11tlce 
Procedures for addressing situstioll!! outside the scope of practice o( ihe physlchro assistant. 
Please dw:ribe how this will be occomplisbed at this practice aite 
Should a situa1lon ()(X)llr tlw is outside the scope ofpmctice for the pb)'lllcliln assisint)t be will i.nlmNiately 
contact a pri.ml,zy or secondary supervlsiug ph)'llician for coosuliation, guiUllllce and im,tru,;rtior,. The 
patient's care will bo ""JlC(lie,1tly tnmsrerrod to an appropriate ph)l1'idan. 
Prescription Authority 
A ph;Ysicinn asslstuut who wish<"ll to apply for prewriptio!l mi ting ~uthorlty $hall submit M oppl!catlon for 
such purpose to the Board of Medicine. 
Tue drug categories or specific legend drugs and contl'Olled drugs, Schedule n throlljlb V !bat will be 
p~cribed provided that the legend (hugs and controlled drugs shall be consisoont with the regular 
prescrlptiv~ pmct\ce of the supervising physician. 
Cl!l'rent p~ribmg privil~os, ,ww inclll!le Schedule 2, 2N, 3, ,N, 4 and S, Thfa ~henge =e after 
applicatiQn and '\P!'lOYlll iliroug/,. lb.e l<Ulho B-Oard of Mclicine and Federol Drug Enforoemern 
Admi.n.istrntion ~lines. 
DEA II M.80480981 
Issued 8/14/02 
Expires 7/31/05 
Delt1g11U1:m of Sertices Ag-ment. 
&eh Jioo!ll!ed' physician assfollll:it "'1.ull malntai.tl a .:nrrent copy of 1M Deb,tp,tion of Se,-vloos (006) 
Agr.em!l/lt between tlw ph)'llician U!18lstant and each ofhl,; or her•ilpetvilling pby,;iclm:lJI. This ag,ecment 
.llb,;;\l not t,,;, sent I.<> the Boom, but =i be mmmalned on lite at ~ localion m whlcl! the physidar, 
llSSISUl!ll is prnctioiug, This agre,,ment shall be made i:mm;xllllicly available 1'> lhe Board ,ipon roqllel>t arui 
sball lnelude: 
Activity aud LOORtlon 
A li>tillg of the ll)'Ocillc aotMtiO>l, will-Oh will be perfonned by 1he physician ll.'!Sislanl and tho specific 
Jocatlollll and fueillt!e, in which tho ph)l>lcian IIS/lIB!m!t will llu.,won. 
f&AAtlon <>Uooi;e 
Southern Idaho Pain and R,,bahilita1lon 
236 Mat1in St. 
Twin l'lllls, !dab<, 83301 
Initial Eyj!)Ullljon of P!ltlents 
The phy,riolm fll!~istani emp!oyi,d with Soothi,"tl;! !<Wm Pain &: Rel:mbillwtion will be utilized in the initial 
evalimtlon for pa~tt seen ln tltl• .illcillty. Tb.ea.e Jllfflenlll 3tlrol irom a phy!!iclim refenal i,..., and ,ilso 
patient se!f0ll:f=!s, Pali1Wts wUl requlnrn full history and p)lysiw on initial vlmt. Perunmt iindingx will 
be doo\tn,lented m;d N>OOttm:1.,..datious made. 'l'lll, recommondallons will be """"'"';,ii by lhi, supervising 
phylllcitm w conflrro .li.t>dllll!ll ru:id det.et'ttrln,, a ~t pl1111. 
R&·Eva!Jllliirul 
The l' A will be u!iJiz,,d in th<; "7-eVrullallon of ox:i~ Jllffle!l~ :fur ~ ~ & mwwal tlfid 
remmn\eodmlons f.br further ll'ellltnimt within our !1w!lily. Tho PA wl!l petfurm "l'Pl'Ojlrin!e system= 
l,,,sed on !l:le Plfflent's cllief complniul. Upon fhls eiwn, will recomm¢nd -thezype of therapy aod/,;r 
procedure that ls needed, The sUp<1tViliing phyrliellm will review &:Id pecl\,nn llll.d lndi~ 
$u,rg;cal Assistant 
TJ,~ physician mlii!llnt will MS!st llw supenising physielall with - p~ In our Slml<llY """ll<o:, 
These C8ll<!$ will incln<le but w:e nQ\ limited to, epiducal ~s ~ .tl~l?Y, tpi~, 
disoogl'lllll.!l, s«ollate gIDJglim.1 blookll, lUlllOOt ~pa!hotio 'blocks and Medlll:>nm  twls. Toe 
suporvfal.ng physlcilm will lnlln the l'A to l!Mi!lt him oo .U of !he ai;Qve procedures. 
Minor ~ 
The PA -will perform several small office booed J)ro<1<)dll!'e!I blllled on tho mediCld ~ on cllnicru exrun 
within this :111\Jlll!y. These itwlude, '(,µtore not lintl~ tu: trigger point miootions, mUllljol.nt li\ioctions, 
occipital mJeclJoru,, and manlpulatiou,. 
fi:~ will assist in lllllllaging and evruoofulg J)lltients for physiool therapy wltbm our fuoility, 
!Jeneml Quidl'Jm 
Tue Pbys!cl,m A..,.ls\ot\llS ~. bnck&round l1ll6 i,xpen"""" mm him q;,,,lified to func1ion in !his 
C11pfi(lify. HTu pl'f!fltle<: will bi, augme!lted by 24-hour btwlrup and S\l!lport from hi{; derugrurted J>tUlllllY ""d 
seco~dacy ,mpe,.visll;t_g Physician. 
' 
P'eriodio revlew of tt represoo!lllive llll!:llple of !1000.-d:l .md a periodic i:evlew of tho medlcul ~ being 
provided by tru., plzy,,iclan assltru1nt. This wvl.nv sball Jlloo Include an eva!uotton of adhorence 1n the 
dcleijllllim of ecn-ices ~eni 
Pl- desctibe how this wlll be l\Ct:Omplll!hod at thi• ptaQtk:,: looatl,:,n: 
AJJ the prinlaly ouJl()fl'ising pbyrucJ..o, l wiU perform p!lrlo&c ®rJrt m-i- !ll!d = ovid\W.lio.llll of patlonts 
seen by the p!t;r,l!clru:i MsisnmL In nddltlon, l or a •eoondll!y oup¢rvi5lng phyl!ioirui will be ,rvllilllble 23 
hours a day to pr-Ovide the pbyll!cilm ""1iil!Ulllt whl, medleal guldilnce !ll1d "1lpervi•ion. 
Lipman, Arthur * July 5, 2007 
IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT 
OF THE STATE OF IDAHO, 
IN AND FOR THE COONTY OF TWIN FALLS 
VAUGHN SCHMECHEL, 
individually, and as 
Surviving spouse and 
Personal Representative of 
the Estate of ROSALIE 
SCHMECHEL, deceased, and 
ROBERT F. LEWIS, KIM HOWARD 
and JlJANITA PETERSON, 
natural children of ROSALIE 
SCHMECHEL 1 deceased, 
Plaintiffs, 
vs' 
CLINTON DILLE, M.D.; 
SOUTHERN IDAHO PAIN 
INSTITUTE, an Idaho 
corporation; THOMAS BYRNE, 
P.A.; and DOES I through X, 
Defendants. 
Deposition of: 
ARTHUR G. LIPMAN, 
PHARM.D. 
case No. CV-05-4345 
July 5, 2007 * 11:00 a.m. 
Location: CitiCourt Reporting Group 
170 South Main Street, Suite 300 
Salt Lake City, Utah 
Reporter: Lynne L. Shindurling, CSR 1 RMR 
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(EXHIB!TS-1-THROUGH-7 WERE MARKED. j 
4 ARTHUR G. LIPMAN, PHARM.D., 
5 called as a witness, being first duly sworn, was 
6 examined and testified as follows: 
7 
8 EXAMINATION 
9 BY MS. DUKE: 
10 Q. Dr. Lipman, good morning. My name is 
11 Keely Duke. We were just introduced off the record. 
12 We're here to take your deposition today, And thal 
13 deposition will be taken --
H MS. DUKE: I assume, Counsel, we can 
15 stipulate it will be taken pursuant to the Idaho 
16 Rules of Civil Procedure? 
17 MR. FOSTER: Yeah. 
18 Q, (BY MS. DUKE) If you could slate your 
19 foll name for the record. 
2 o A. Arthur G. Lipman. 
21 Q, And where do you reside? 
22 A. Salt Lake City. 
23 Q. How long have you lived here? 
2 4 A. Be 30 years next month. 
25 Q. As I understand it when we were talking 
Page 
1 off the record, you were raised in the East? 
2 A. Correct. 
3 Q. Okay. And where was that? 
4 A. Massachusetts. 
5 Q, Based on infonnation contained within your 
6 curriculum vitae, I've noticed that you've been 
7 deposed a couple of times, so you're obviously 
8 familiar with this wonderful process. 
9 A, Yes. 
10 Q. I'll just go through a couple basic ground 
11 rules which are important just to have on the record 
12 here. 
13 If I ask you a question that you don't 
14 understand, will you please let me know? 
15 A, Yes. 
16 Q, And if you're answering my questions, I'll 
17 assume that you're understanding them. Okay? 
18 A. Yes. 
). 9 Q, It's also impo11ant tl1at you and ! not 
20 talk over one another as best we can. It's sometimes 
21 difficult for me nut to cut you off, not meaning to, 
22 bu! to think you're done with your answer and, in 
23 fact, you're not, So please let me know if I cul you 
24 off and that you have more to say. 
25 And same for me wilh my questions. A lot 
5 
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of times you're going to know exactly what my l 2 as well, which is: "A copy of any and all 
question is, and in good old American conversation we 2 correspondence, medicals records or other materials 
always finish one another's sentences. But if you 3 provided to you by plaintiffs or plaintiffs' counsel 
could try to let me get the question out for the ease 4 or which you provided to plaintiffs or plaintiffs' 
of the court reporter here and also for cleanness of 5 counsel." I would assume that any of those types of 
the record. 6 documents are here as well. 
As I understand it) you1ve been (1eposed ·7 A. Correct, 
six times? Would this be the seventh? 8 Q. And then the third section discusses items 
A. I can't recall the exact number. 9 that relate just generally to the case of any 
Q. Okay. 10 statements you've made or anything like that that 
A. Approximately. 11 relate to the case. I would assume that all of those 
Q, Maybe around five to ten? 12 are here today as well. 
A. In the last two or three years, yes. 13 A, Yes. You saw my typewritten notes. 
Q. Okay. And what I've done -- I guess we 14 Q, And your notes> yes, Your curriculum 
can do a little bit of the house cleaning first -- is 15 vitae, I have a copy of what I believe to be, which 
I'm going to hand you what's been marked as Exhibit l6 is item No. 4i your most current cuniculum vitae 
Number 1 to your deposition. And that is the Second 17 which is marked as Exhibit 2, if you want to just 
Amended Notice of Taking Deposition Duces Tecum of 18 confirm for me. 
Arthur G. Lipman, Pharm,D. And as I understand it, 19 A. Well, this is a dynamic document so--
you have seen a previous one of those, but you had 20 Q. l understand. 
not actually seen Exhibit 1. 21 A. This is reasonably up-to-date, I've had a 
A, Correct. 22 few things since then. Nothing that would 
Q. Okay. What I'd like to do and what we did 23 substantially change anything that I'm doing here. 
with respect to Exhibit l is delineated certain 24 Q. Anything related to issues that are in 
documents. We went through your curriculum vitae and 25 this ease with respect to methadone or anything like 
Page 7 Page 9 
delineated certain documents, some of which we may be 1 that? 
able to obtain through, you know, our medical 2 A, Well, I am frequently invited to speak 
sources, but others thal will be more difficult. 3 around the world on various topics. I don't know 
And so, if you could, I guess, take just a 4 if -- Twas just in Brazil last month. That's not-· 
glance through that list and you'll see what we're 5 well, this actually only has invited presentations 
looking to. And then I can ask you some questions 6 through 2004. Surprises me, So this is an older 
about it. 7 version. 
A. Yes. 8 Q. Okay. 
Q. Okay. So let's start ,with item No. I, 9 A, I've had a number of invited presentations 
which was: "All medical records, charts, reports or 10 at international pain meetings since then, but my 
other documents reviewed by you or in your possession 11 opinions and the science -- it reflects the current 
pertaining to the medical care and treatment of 12 science, but my opinions have not changed from what's 
Rosalie Sehmechel." You have brought all of those 13 reflected here. 
documents with you here today, correct? 14 Q, I understand. Would it be easy for you to 
A. Correct. 15 provide an updated cuniculum vitae? 
Q. And with respect to this case and your 16 A. Sure. 
retention in this case, is it fair for me to assume l 7 Q. Okay, 
that every piece of paper or document that you have 18 A. If I get an e-mail requesting that, I'll 
reJated to this case is here in front ofus in these 19 be happy to respond. 
three stacks? 20 MS. DUKE: Perfect. We'll ask for that, 
A. Correct. 21 Mr. Foster, if you could do that. And we will mark 
Q. I would assume there's no e-mails, nothing 22 that updated CV as Exhibit Number 8 to this 
like that? 23 deposition. 
A. Nothing that I've kept. 24 MR. FOSTER: Send me a letter. 
Q. Okay. And that, l think, would cover item 25 MS. DUKE: You need a letter for that? l 










2 MR. FOSTER: Yeah. 
3 MS. DUKE: Okay. Well, it's Exhibit 8 to 
4 the deposition. 
s Q, (BY MS. DUKE) With respect to item No. 5, 
6 we asked for copies of the following, and the 
7 following were items thal we noted in your curriculum 
8 vitae. And [ guess what I'd like to do is talk to 
9 you about each of those from the standpoint of 
1 o whether you would have a copy of those referenced. 
H And we might be able to more quickly do 
12 that by just saying, you know, you do keep a copy of 
13 the materials that you'll provide at various 
14 symposiums and lectures that you provide. 
15 A. Not necessarily, 
16 Q, Okay. And so what we'll do is go through 
l 7 item 5 here. 
18 MR. FOSTER: You want to go through each 
19 oneofthese? 
2 o MS. DUKE: Correct. 
21 MR. FOSTER: Why? 
22 MS. DUKE: And see if --
23 MR. FOSTER: Why? 
24 MS. DUKE: To see ifhe has them in his 
25 possession, ifhe knows ifhe does or doesn't. 
Page 11 
1 MR. FOSTER: Why don't you just send me a 
2 letter, and I'll find out from him and you can cut 
3 out about an hour of the deposition that way, 
4 MS. DUKE: It's not going to take that 
5 long, Mr. Foster, and it's my deposition. 
6 MR. FOSTER: So that's really the way you 
7 want to do it'/ You want to go through each one of 
B these and ask him ifhe has a copy? 
9 THE WITNESS: I may expedite this by 
1 o stating that l have copies of the books in which 
11 l've -- which I've written. l have copies of most of 
12 the books in which I've written chapters. I only 
13 have single copies of those. So they're in my 
14 personal library. These -- most of these are 
15 available through any standard health sciences 
16 library, academic medical library, and could be 
1 7 obtained there. · 
18 You have a number of items here which are 
19 not particularly important, such as Grand Rounds at 
20 various hospitals. l certainly don't keep those. 
21 Invited presentations, I don't -- I have probably 
22 5,000 slides in my computer which I sort according to 
2 3 what presentations I'm doing, and l don't keep copies 
24 of those. 
2 5 l would refer you to the first tier 
* July 5, 2007 
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1 literature, the Medline indexed journals in which 
2 ['ve published from my CV, and those will give you a 
3 good handle of the major medical textbooks in which 
4 I've published on opioids. Warfield, 
5 W-a-r-f-i-e-1-d, which is a Harvard University 
6 based -- Harvard Medical School based book; Tollison, 
7 T-o-1-1-i-s-o-n, which is another leading textbook; a 
8 couple of books that I've published myseU: Those 
9 will give you a good handle on what my positions are 
10 on this, and it's all public record. 
11 Q, (BY MS. DUKE) Okay. 
12 A. And I'm happy to discuss any of these in 
13 whatever detail you'd like. 
14 Q. No, That's helpful. You indicated you 
15 had slides, that when you go to a presentation, 
16 you'll pull from these approximate 5,000 slides to 
17 cover whatever it is that you're going to discuss. 
18 A. Right. The 5,000 may not he an exact 
19 number. I don't know. I --
20 Q, Sure. l understand. 
21 A. I have several hundred presentations which 
22 I've sorted over time, and I adapt from those. 
23 Q, And what we would be looking for with 
24 respect to these requests would be hand011ts, slides, 
25 whatever you want to ca:11 them, related to issues in 
Page 13 
1 this case, such as the use of methadone) for 
2 instance, 
3 A. I'll be happy to refer to the appropriate 
4 publications from my CV on anything to back up what 
5 I'm talking about today, if that would be helpful to 
6 you. 
7 Q, That is helpful in a way, but what you 
8 might believe backs you up our experts might feel 
9 differently or they might feel certain things that 
J.O you have done actually support them. And so that's 
11 why my question is much broader versus just saying, 
12 Tell me what you're relying on, which I will ask you, 
13 But that's why I'm expanding it to this, you know, 
14 this database you basically have of information that 
15 you can compile when you go and speak in San 
16 Francisco at the International Pain Symposium. 
:l 
17 That's the kind of information I'm looking for. ; 
18 So with respect to the preparation of 
19 handouts for those types of things, what l would be 
20 interested in obtaining is any information that you 
21 have in those slides related to methadone. 
2 2 A. Well, J'm not really willing to share 
2 3 those slides. Those are my personal property. I 
24 don't copyiight them, but this is my own intellectual 
2 5 property and this is not infonnation that I pass out 
....... ,, ... V 
4 (Pages 10 to 13) 
CitiCourt, LLC 
801.532.3441 
": ;·) , f 
I •1· ....., ( ~ ~. 
Lipman, Arthur * July 5, 2007 
Page 14 Page 16 
1 routinely. I am happy to refer you to the published 1 pay him to get you things that you can get otherwise. 
2 papers and firs( tier journals, which will-· or the 2 MS. DUKE: Okay, Mr. Poster, I think that 
3 published textbooks, both of which are available 3 you're not understanding exactly--
4 through standard medical libraries as back-up. 4 MR. FOSTER: I think I fully understand. 
5 And I think that my credentials and my 5 MS. DUKE: No. If you'd please let me 
6 federal consultationships and such speak to my 6 finish, I let you finish, Mr. Foster. If you'd let 
7 expertise in this as opposed to the people who you 7 me finish. 
B obtained as your experts. 8 MR. FOSTER: l think I fully understand. 
9 Q. And I'm not in any way trying to disparage 9 MS. DUKE: The issue is we're looking for 
1 O your experience or anything like that. I think 10 things that were disseminated --
11 you're misinterpreting what I'm saying, What I'm 11 MR. FOSTER: I know what the issue is. 
12 saying is we'd like information and, quite frankly, 12 MS, DUKE: That were disseminated --
13 we're entitled to information that you have put out 13 MR. FOSTER: I know what the issue is. 
14 there in the public, whether it be through literature 14 MS. DUKE: ·- at his lectures, 
15 or be it through a slide at a presentation that you 15 MR. FOSTER: And you can get them off his 
16 shared with people at a lecture related to methadone. 16 CV. 
17 A. And if you ask specific questions, I'm 17 MS. DUKE: Mr. Foster, please settle down. 
J.8 happy to respond to those with specific answers, 18 MR. FOSTER: You can get them off his CV. 
19 Q. Well, and so with respect to methadone, do 19 MS. DUKE: Settle down. 
2 O you have slides contained within your database that 20 MR. FOSTER: I'm not -- don't tell me --
21 involve the use of melhadone in chronic care non- :n MR. HIPPLER: Can we no( talk over each 
22 malignant patients? 22 other? One person at a time, 
23 A. Yes. 23 MS, DUKE: Just let me finish. 
24 Q, We would be interested and are requesting 24 MR. FOSTER: Steve, hold your water. 
25 acopyofthoseslides. 25 Your-- :· ~----'-'-------------------1----------------------"" 
l?age 15 
1 A. Again, I'd be happy to send those to you 
2 electronically, if you'd just send me an e-mail 
3 message regarding that. 
4 MR. FOSTER: Wait a minute. Wait a 
5 minute. 
6 THE WITNESS: Okay. 
7 MR. FOSTER: Are you going to pay him to 
B do this? 
9 MS. DUKE: I think it's your obligation to 
10 provide it, Mr. Foster. 
11 MR. FOSTER: I don't think so. 
12 MS. DUKE: Well, then, we can-· 
13 MR. FOSTER: So if you want to get this 
14 stuff, you move for a Motion to Compel. 
15 MS. DUKE: We!J, let me ask you --
16 MR. FOSTER: Because this has now become 
1 7 oppressive because you're asking him to take a 
18 considerable amount of time to give you information 
19 that you can get from the public sector from his 
20 publications. So-~ no. Just wait a minute. So 
21 he's not going to do this unless) one1 [ see them 
22 first; and, two, you pay him to take the time to do 
23 that because Pm not asking him to do it You 1re 
24 paying him for his time in his deposition here today. 
2 5 That's not my obligation, It's not my obligation to 
Page 17 
1 MS. DUKE: Let me finish. 
2 MR. FOSTER: First of all, this notice is 
3 invalid because you didn't give reasonable notice for 
4 this. So you shouldn't even be going through the 
5 thing. 
6 MS. DUKE: I ask can whatever I want. 
MR. FOSTER: You should go to court and 
B ask the judge if this is reasonable notice. 
7 
. 9 Secondly, he's fully willing to give you 
10 what you want but not in this context. If you want 
11 these things and ifl determine that they're 
12 discoverable, you're going to pay him for getting 
13 those things. 
14 MS. DUKE: Are you done? 
15 MR. FOSTER: Because that's not his 
16 obligation. 
MS. DUKE: Are you done? 17 
18 MR. FOSTER: And it's not my obligation to 
19 pay for them. 
MS. DUKE: Are you done? 20 
21 MR. FOSTER: Say whatever you want. Are 
22 you going to ask him any questions? 
23 MS. DUKE: Are you finished so that I can 
24 actually say something? 
25 MR. FOSTER: Go right ahead, 





1 MS. DUKE: Okay. What we're discussing 
2 is not as siniplistic as you1re attempting to 
3 characterize it, Mr, Foster, The infonnation that 
4 we're seeking> I undetstand that we can make an 
5 effort to obtain texts. I understand we can make an 
6 effort to obtain chapters out of medical books that 
7 have been disseminated through a publisher. What I 
B am talking about and I think what Dr. Lipman and I 
9 had an understanding with respect to what was being 
1 O discussed are materials that he will compile for the 
11 numerous and various lectures that he provides, you 
12 know, on these topics, specifically methadone in 
13 chronic care nonmalignant situations, and he's 
14 indicated that's something he can do. 
1 S Whether the cost of it is something that 
16 you want to bicker about and have us go to the court 
17 for, that's a separate issue. What I'm trying to 
1 B establish at this point, assuming all of the issues 
19 related to cost are handled, is if you're willing to 
2 o undertake that endeavor, whatever it may entail, to 
21 obtain those materials. 
22 THE WITNESS: Perhaps I can, again, 
23 expedite this process in the interest of everybody's 
24 time, Pm here for one reason and one reason only1 
2 5 and that's to present the science that backs up my 
Page 19 
1 positions. I believe that I have a good grasp of the 
2 science and that I do have some slides that express 
3 these, many of which are referenced -- some of which 
4 are referenced in papers that I've published in 
5 referee journals, and I'd be happy to provide that. 
6 All I need is a simple request, an e-mail request, 
7 and I will provide those electronically. 
8 I don't expect that I'd provide an 
9 extensive amount of infonnation beeause you really 
10 need some very specific information having to do with 
11 tho, pharmacokinetics of methadone. That's what's 
12 pertinent to this case. This was a tragic outcome. 
13 It hurts me greatly to see this type of thing happen. 
14 Unfortunately, it was highly avoidable: 
15 Q. (BY MS. DUKE) Okay. And I understand 
16 your position with respect to that. But going back 
1 7 to the documents and whatnot, what type of time 
18 commitment do you think it will take you to identify 
19 slides and materials that you have that are related 
2 0 to the use of methadone in a chronic care non-
21 malignant setting? 
22 A. It will take me less than an hour. 
23 Q. Okay. Thank you, 
2 4 MR. FOSTER: Don't send anything to them 
2 5 unlil you send it to me. 
* July 5, 2007 
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1 THE WITNESS: Anything I send I would send 
2 through Mr. Foster. 
3 MS. DUKE: And nor would I ever ask for 
4 that, Mr. Foster. I know what the rules are. 
5 THE WITNESS: And I'm happy to provide 
6 this. I'm not providing opinion. I'm providing 
7 science. 
8 Q. (BY MS. DUKE) I understand. Sol guess 
9 an example would be when we are talking about these 
10 slides, I note that you've gone to the worldwide pain 
11 conference several years in San Francisco? 
12 A. No. That was one international thing. 
13 Which number are you on? 
14 Q, w. 
15 A. Oh, yeah. That was called the Worldwide 
16 Pain -- that's the world society of pain clinicians 
17 meeting. 
18 Q. Correct. 
19 A. Yeah. I was asked to present that 
20 particular topic, That was seven years ago. I would 
21 not have that set of slides. 
22 Q. I understand that. But what I'm asking is 
23 just that's the kind of material we're looking for is 
24 when you're asked to go and speak at something like 
25 that. 
Page 21 
1 A. Absolutely, 
2 Q. That's just so we're on the same page, 
3 A. And the key is you want the slides that 
4 explicitly relate to methadone pharn1acokinetics and 
s dosing, and r ean get those together. 
6 Q, All right. lfwe could, whal did you do 
7 to prepare for your deposition today? 
8 A. I looked through the notes that I have 
9 of which you have a copy. I looked through the 
i O affidavits from defense experts which I recently 
11 received and the disclosure of what was to be said 
12 by-· or what was to be presented by defense experts. 
13 And then l had a brief meeting this morning with 
14 Mr. Foster. 
15 Q. With respect to your meeting with 
16 Mr. Foster this morning, how long did you two meet? 
1 7 A. Less than an hour. 
lB Q. And during that conversation, what was 
19 discussed between the two of you? 
:i o A. Simply reviewed the records and my · 
21 opinions about the experts' statements and the 
22 disclosure of experts' testimony that you folks 
2 3 provided. 
24 Q. Okay. Anything else that you and he 
2 5 discussed that you can remember the specifics of? 
" ........ ,."·~-" ',J. '• •· ..... _ .. ,,.,._ •.. ,.,,_.,_, .•. ,.,,·.,:. " ...... . 
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A. I think we reviewed a few of the time 1 Q. Twice a day. And then what do you believe 
relationships and what occurred. 2 it was titrated up to? 
Q. And what are you referencing there? 3 A. Mr. Byrne said in his testimony that he ' 
A. The number of days that Mrs. Scl1mechel 4 instructed her 5 to 10 milligrams but that the 
received methadone, and we discussed the doses that 5 prescription label explicitly read 10 milligrams. 
she received. 6 Now, this is outside of the standard of practice of 
Q. And with respect to that, what have you 7 the Federation of State Medical Boards of the United 
concluded were the days she received methadone and 8 States, which is the parent body to all medical 
the dosage she received each of those days? 9 boards, both allopathic and osteopathic, including 
A. That she was prescribed the methadone on a 10 the Idaho State Board. And the original 1998 
Friday; presumably she began it Friday night or 11 statement in 2002, I believe, was changed to a mo<lel 
Saturday, most probably Saturday; that her dose was 12 policy in which there's a call for explicit 
titrntcd up again Sunday and Monday and then probably 13 instruction to the patient. 
again Tuesday; and that she received the methadone, 14 Now, the fact that Mr. Byrne testified 
as I recall -- we didn't talk about this -- but l 15 that he told the patient one thing and that he wrote 
recall it was either six or seven days in total that 16 another thing on the prescription causes me some 
she received the medication. J. 7 concern. That's not my major concern, That1s 
Q. And what do you understand the doses to 18 indicative of less than optimal care and one might 
have been on Friday through Thursday? 19 argue below the standard of practice. ' 
A. Well, there's extremely poor documentation 20 My major concern that l believe is well 
and there's conflicting information presented in 21 below the standard of practice and is clinically 
Mr. Byrne1s records, the prescriptions that were 22 unacceptable is to titrate the drug up, to increase 
written and the labeling that was on the 23 the dose with the rapidity with which he did that. b 
prescriptions from The Medicine Shoppe pharmacy and 24 Q. Okay. And the question was: What do you I':" 
his testimony. So the documentation of what was done 25 understand the titration to have been, the actual 
Page 23 Page 25 
is not of high quality. 1 milligrams? 
The initial dose, as I understand it from 2 A. That the patient was told that she could 
the testimony, was twice daily, dosing probably of 10 3 take between 10 and l 5 milligrams, one to one-and-a-
milligrams of methadone. And l have absolutely no 4 half I 0-rnilligram tablets up to three times a day by 
objection to that. 1 note that four of your experts 5 Monday or Tuesday. 
all said that they had no objection to that, that 6 Q. And we'll come back to that, obviously. 
that was a very reasonable starting dose. They're 7 Any other specifics that you recall you and 
incorrect in that pharrnacokinetically it should have 8 Mr. Foster discussing during your meeting this 
been given three times a day, but that's not a risk 9 morning? 
factor for toxicity. That's a risk factor for lack 10 A. l think that presents the flavor. 
of efficacy because of the duration. 11 Q. And have you spoken to Mr. Foster at any 
My problem is that the titration was so 12 other time prior to today? 
rapid, that the dose was increased on a daily basis. 13 A. On the telephone. 
Of explicit note none of your experts addressed that 14 Q, Are those telephone conferences reflected 
in any way, which suggests to me either that they did 15 in what I've marked as Exhibit Number 6, which it 
not receive full records, or if they did receive full 16 looks like is your complete compilation of notes? 
records, that they didn't pay much attention to them 17 A. Yes, April 6th, also April 30th. 
because my concern is not the initial dose. My 18 Q. All right. Do you recall just the general 
concern was the rate of titration, 19 nature of what you and Mr. Foster discussed on April 
Q. And the rate of titration being what? 20 6th? 
A. That the dose was increased on a daily 21 A. I believe that all of our conversations 
basis the first few days of therapy. 22 related to my reaction to the testimony provided by 
Q. So you believe she started at I 0 23 Dr. Dille and Mr. Byrne and the dosing regimen for 
milligrams on either Friday or Saturday. 21 the medication that was used. 
A. Twice a day. 25 On April 301:h it was a teleconference that . • ' < ........ _. ... ""'',~-,.,-.,,.-, .... ,., .... , ........ '" 
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was held between Mr. Foster, two of his physician 1 international meeting in the last week and a half, 
experts, and myself. 2 and I haven't put those in yet. 
Q. Okay. And who were the physician experts? 3 Q. Okay. At least we'll be much more updated 
A. One was Dr. Steve Lorden in Salt Lake 4 than Exhibit 2. 
City, and I can't recall the name of the physician in 5 A. And, again, I don't think it's going to 
Idaho. I'm sure Mr. Foster can. 6 reflect •• a couple of book chapters but really 
Q. And what was the nature of the 7 nothing that would change any opinions. 
conversation? 8 Q. Okay. But with respect to your training 
A. The·· our opinion of the care that was 9 and whatnot, if you could first just describe for me 
provided by Mr. Byrne for Mrs. Schmechel. 10 what your practice is. 
Q. Do you recall any details in that April 11 A. Training or practice? 
30th discussion? 12 Q. Practice right now. Then we'll get into 
A. My position, of course, is that the 13 the training to --
medication was titrated too rapidly. Concern was 14 A. ['m professor of pharmacotherapy at the 
expressed, as I recall, by the physicians about the 15 University of Utah in the College of Pharmacy and 
documentation that Mr. Byrne requested. And there 16 adjunct professor ofanestl1esiology in the School of 
was discussion of the standard of practice and the 17 Medicine. My practice is as director of clinical 
commonality or differences between Utah and Idaho. 18 pharmacology at the Pain Management Center, which is 
Q. Any other specifics that you recall? 19 the refeJTal center for the five-state lntermo·untain 
A. Again, I think that reflects the flavor of 20 Region. 
the conversation. 21 Q. And as the director of clinical pharmacy 
Q. And so, as l understand it, in Exhibit 6, 22 at the University of Utah-· •. 
that reflects the time that you've spent on this case 23 A. Clinical pham1acology at the Pain 
from the time that you were initially contacted by 24 Management Center. 
Mr. Comstock's office and up through yesterday? 25 Q. At the Pain Management Center? 
Page 27 Page 29 
A. Correct. 1 A. CoJTect. 
Q. And I'm trying to recall what your hourly 2 Q. ls that related or affiliated to the 
rate is. What is it? 3 University of Utah? 
A. Four fifty. 4 A. It is. It is of University Health Care, 
Q. Is it 450 per hour regardless of whether 5 which is the hospitals and clinics of the University 
you're traveling to Idaho for the trial or you're 6 of Utah. 
sitting in the courthouse waiting for trial? I mean, 7 Q. How long have you held that position? 
is there some different charge for trial testimony? 8 A. Well, I started ·• I was actually one of 
A. No difference between testimony, record 9 the founders of the Pain Management Clinic 28 years 
review, and consultation. 10 ago on a part-time basis, and I think I was named 
Q. And deposition? 11 with that particular term about 12 years ago. Could 
A. Time is time, And deposition. And that 12 be 15. 
will be my charge for this morning also. 13 Q. And what are your job duties and 
Q. Have you already been paid? 14 responsibilities in that position? 
A, No. I haven't presented a statement. 15 A. I'm involved in the active teaching and 
Q. Okay. !fwe could·· obviously, Exhibit 2 16 training of medical students, anesthesiology 
is a little older. But we'll have Exhibit 8 that 17 residents, and other residents who rotate through the 
provides your most current, at least as of today-- 18 service, and pain management fellows. Those are ' 
A. Okay. 19 trainees for the subspecial!y board of pain 
Q. -- curriculum vitae. 20 management. I also have undergraduate doctor of 
A. Oh, as of two weeks ago. 21 pharmacy students, post-doctoral pharmacy residents, 
Q. Or as of two weeks ago. 22 and my own post-doctoral research fellows who rotate 
A. I haven't updated it. 23 through the service. 
Q. There we go. 24 My responsibilities are to teach 
A. Jive just been to two, one national, one 25 appropriate phannacotherapy. I see patients two days 
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l a week on consultation from the attending physicians 
2 who are requesting my assistance in defining 
3 appropriate phannacotherapy for their patients. I 
4 explicitly recommend medications, commonly opioids, 
5 medication regimens 1 educate patients, and provide 
6 consultation to staff. 
7 Q. And so twice a week is the frequency in 
8 which you see patients? 
9 A. l see patients Tuesdays and Wednesdays. 
1 o I'm involved in research, teaching and administration 
11 other days. 
12 Q. And with respect to an average number of 
13 patients that you'll see every Tuesday and Wednesday 
l.4 each day, what do you think an average is? 
15 A. Well, there are two ways in which I see 
16 patients. One is on formal consult, and I'll have 
1 7 typically two to four patients each day that I'm in 
18 clinic who I'm asked to see on a tertiary consult. 
19 These are difficult advanced patients in whom the 
20 physicians are explicitly seeking help. 
21 When I have students and residents on 
22 clerkship, I'm in clinic more oflen and will see 
23 patients more frequently because that's a teaching 
24 role for my students and residents. And they will be 
25 seeing patients also infonnally. We may see six or 
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l eight patients a day in that setting. 
2 Q. Okay. 
3 A. I also get a large number of telephone 
4 calls and what we call cribside consultations where a 
5 member of the medical staff will say, Hey, Art, can 
6 you help me with this particular patient problem? 
7 Those typically happen two or three times a day when 
8 Pm in clinic. 
9 Q. Okay. And so, as I understand it, 
10 obviously, you're not a medical doctor, 
11 A. That's c01Tect. 
12 Q, You're not a physician assistant. 
13 A. No. I'm a doctor ofphannacy. 
14 Q. Right. And under Utah law you're not 
15 pennitted by law to prescribe medications. 
l. 6 A. That's not true. 
17 Q. Okay. 
18 A. Under Utah law under the Collaborative 
19 Practice Act I have full prescriptive authority if I 
20 seek that. I make a point of not seeking that 
21 because I think that my far more important role is to 
2 2 teach physicians in training, ranging from medical 
23 students to subspecialty follows, the proper way to 
24 prescribe. And they learn more if they actually do 
2 5 the prescribing with my consultation. I can fill out 
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1 a simple form which gives me prescriptive authority. 
2 Q. So Utah Jaw, if you fill out this simple 
3 form, you could have prescriptive authority? 
4 A. Correct. 
· 5 Q. That's not something that you've done? 
6 A. By choice. 
7 Q. And so you are unable in Utah, based on 
8 that choicef to prescribe medications to patients, 
9 correct? 
10 A. Using the legal term "prescribe," you arc 
11 correct. Rather, my role is to teach people, to 
12 teach physicians and physicians-in-training how to 
13 prescribe. 
14 Q. Okay. Would you agree that with respect 
15 to your treatment of patients, that practice is 
16 limited to pharmacology workup? 
17 A. No. 
18 Q. Okay. 
19 A. l consult with the interdisciplinary team. 
2 o We have what we call team staffing where the 
21 interdisciplinary team of physicians, psychologists, 
22 physical therapists, and pharmacotherapists meet 
2 3 first thing in the morning and go through all of the 
24 new patients having been seen in the past week on 
2 5 that pa11icular day or by that particular attending 
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1 physician, and we also carry out a good review of 
2 continuing patients. And that's very much of an 
3 interdisciplinary interaction where we discuss all 
4 aspects of care. And there's complete input by all 
5 members of the team. 
6 I've been on medical school faculties 
7 first at the Yale University School of Medicine in 
8 the I 970s and at the University of Utah since I came 
9 here now for well over 30 years arnj have been 
10 teaching medical students and trainees how to 
11 optimally use medication during that full period of 
12 time. 
13 Q. Okay. But taking aside an 
14 interdisciplinary type treatment of patients, you 
1s know, meetings that you might have with other medical 
16 professionals who are providing treatment, what is 
1 7 the time spent with you being the primary care 
18 provider for a patient with respect to the provision 
19 of pharmacology services? 
2 o A. I'm sorry. I don't understand your 
21 question. 
22 Q. Let me try to think ofa better way to say 
2 3 this. With respect to direct interaction with 
24 patients -- so T1m not talking about conversations -M 
2 5 A. Correct. 
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Q, -- with other providers who might be 1 through the attending physician for future 
seeking guidance or your opinions with respect to 2 consultation as needed. 
treatrnent. 3 Q. And so do you examine the patient? 
A. Uh-huh. 4 A. J take a history. I don't physically 
Q. -- how frequently do you aclually do the 5 examine them. Certainly, if we need to assess vital 
hands-on patient evaluations? '6 signs, if I want lo know what the impact of the 
A, Each Tuesday and Wednesday. 7 patient's care is on heart rate and such, we have all 
Q, And is that on your own or is thal with a 8 that information, which is typically taken by a 
student? 9 medical assistant or a nurse when the patient first 
A. Both. If l don't have a student on 10 comes into clinic. So l have access to that. 
service, l still have palients. I have a schedule of 11 Q. Sure, 
clinic -- it's listed as pharmacotherapy clinic -- 12 A. And, of course, I'm working off the very 
just as each of the attending physicians has his or 13 same medical record. My notes go in the same record 
her clinic listed, and I come into clinic and have my 14 as the physicians, physical therapists, and 
schedule. 15 psychologists. So we all have access to each other's 
Q. And if you could just provide an example, 16 notes. We eaCh have a section in the chart. And, 
then. If you were going to be there on your own, 17 clearly, I'm not going to redundantly do what's 
let1s say you don 1t have a medical student that1s 18 already been done by a physician or a psychologist. 
there with you on that Tuesday or Wednesday and you 19 But frequently in this setting the patient will 
have a patient scheduled on your pham1acotherapy 20 report things to one clinician which are actually 
schedule, what would you be doing for that patienl? 21 more aj)prop1iate for another, but, for some reason) 
A. Initially, I'd evaluate the patient's pain 22 the connection is not there, And, therefore, I often 
intensity and complaints to validate what has been 23 will be told things that are important for the 
reported to other members of the team because 24 physical therapist or the physician or the 
consistency of report is important in an inter- 25 psychologist to know and vice versa, which is why 
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disciplinary setting. I'll take a complete 1 it's truly an interdisciplinary service. 
medication history, current and past medications, 2 Q, But from the standpoint of the physical 
including nonprescription medications, dietary 3 examinations of patients, that's done by other 
supplements. I review sleep pattems 1 diet, use of 4 medical professionals, and you have the benefit 
substances such as alcohol, caffeine, illicit drugs, 5 through the notes of their work-ups? 
tobacco. I assess patients' compliance with their 6 A. Absolutely. l certainly could do this if 
treatment regimen, detennine who all of the 7 necessa,y. Advanced practice pharmacists, pharmaco-
prescribers are who are seeing the pa1ient, including 8 therapists frequently do that. But since it's 
both primary care and consultation physicians and 9 already done, there's no need for me to do that. 
other presclibers, and then I come up with a drug 10 Q, All right. And as I understand it, you do 
therapy management plan. I educate the patients. 11 not provide medical diagnoses for a patient's 
l then typically meet with the other 12 condition? 
members of the interdisciplina,y team, just as all of 13 A. Frequently I will come up with 
the other providers in the clinic do on a routine 14 identification of drug treatment or drug-induced 
basis, and together we develop a h·eatment plan. 15 adverse effects, or I will identify problems with 
We then meet with the patient and share 16 sleep hygiene, for example, which in my note will 
the treatment plan because it's important for the 17 explicitly recommend that this be evaluated by the 
patient to be comfortable with the plan for the 18 psychologist, or I will identify the patient 
patient to be compliant with it. 19 presenting with what sounds like myofoscial trigger 
[ often will see patients on follow-up if 20 points, in which case refer the patient to the 
there is complexity in their pharmacotherapy. If 21 physical therapist to manage that. 
it's straightforward and it's simply required 22 So frequently I'm identifying patient 
education, I will often opt not to see that patient 23 problems. Diagnosis, again, is a tenu of art. We 
again because of the limited number of hours that I 24 refer to it more as an assessment. But it's all 
have to see patients, But l'm always available 25 really the same thing, and that's all shared in the 
.. . ......... 









1 interdisciplinary team staffing, which, as I 
2 mentioned, is held each morning. 
3 Q, Okay. But with respect to a specific 
4 diagnosis for a patient as to whether they're 
5 suffering from fibromyalgia, I mean, is that a 
6 diagnosis that you make, or is that made by someone 
7 else within your interdisciplinary n·eatment team? 
8 A. That's a very interesting question and 
9 it1s not a yes or no question because fibromyalgia is 
1 o a very complex syndrome. So it might not be the best 
11 example. But I would often identify because of what 
12 the patient shares with me particular behaviors which 
13 would be more suggestive of1 for instance, a 
14 somatization disorder or an affective disorder as 
15 opposed to a physical disorder. And because of what 
16 patients share with us and because of the training 
1 7 that we have and the -- what's often referred to in 
18 ounerrns of art as role blurring that occurs since 
19 patients determine what they're going to tell to 
20 which clinician, I often will be identifying key 
21 issues that will contribute to the final diagnosis. 
2 2 TI1e diagnoses are not made by one 
2 3 individual in this setting. They're actually made by 
24 the interdisciplinary team at team staffing. And not 
2 5 infrequently the physical therapist will say to the 
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1 physician, No, that1s not con-ect. In my examination 
2 I found such-and-such, which is,_ which rules out 
3 what you're looking at as a potential diagnosis. So 
4 final diagnoses typically come out of the team 
5 setting rather than one individual. 
6 Q. Okay. With respect to treatment, do you 
7 actually initiate pharrnacotherapy treatment to a 
8 patient, or do you make a recommendation to a medical 
9 provider with respect to the initiation of a therapy? 
1 O A. Both. I will very frequently change the 
11 patient's medication regimen. I will frequently 
12 recommend additional medications, in which case I go 
13 to the responsible physician, discuss the case, and 
14 recommend that the physician write the appropriate 
15 prescriptions 1 which almost invariably is done. 
16 But quite commonly I will change the 
17 patient's dosing schedule based on the pharmaco-
18 kinetics of the medication and the patient's reaction 
19 to it, write the note accordingly, instruct the 
20 patient, and then inform the physician, for which the 
21 response is invariably, Thank you, that helps a lot. 
22 Q. Okay. And so you actually ':'ill adjust a 
23 patient's medication without first getting approval 
24 from the attending physician? 
25 A. Well, I do this in collaboration with the 
* July 5, 2007 
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1 attending physician. 
2 Q. Well --
3 A. Chronic pain is not a medical emergency 
4 that you -- for which you intervene quickly. lt's 
· s clinically important to move step-wise and closely. 
6 I will frequently advise the patient of a change to 
7 be made. l will then advise the physician what I've 
8 told the patient. 
9 Q. And that's where I'm getting to is the 
1 o timing of that. 
11 A. And the physicians explicitly ask me to do 
12 that. And the reason they refer patients to me --
13 one of the main reasons they refer patients to me to 
14 see the patients is to make those adjusunents. 
·J.5 Q. That's what !'m getting to --
16 A. Correct. 
1 7 Q. -· is with respect to those adjustments, 
18 those aren't something that you go to the physician 
19 and say, Hey, before I tell the patient that I'm 
20 going to do this, I want to run ii by you first. Or 
21 there are times when you do that, there's times when 
22 you don't do that? 
23 A. The latter is correct. 
24 Q, Okay. 
2 s A. There are times that it's very important 
Page 
1 that we speak, for example, to the psychologist about 
2 changes before making them because of the 
3 psychosocial implications. If it's a straightforward 
4 phannacokinetic issue, the physicians typically defer 
5 to me as the expert in clinic for that, and they come 
6 to me for help and ask me to do that. 
7 Q. And you certainly don't need their 
· 8 approval to do that within the regimen that you have? 
9 A. Well, I -- I have blanket -- I have a 
10 priority blanket approval to do that. I'm being 
11 requested to do that. 
12 Q, And then once you make those types of 
13 changes on your own, you'll infonn the inter-
14 disciplinary team of, you know, I went ahead and 
15 increased the OxyContin to 20 milligrams every 12 
16 hours? 
1 7 A. Absolutely. And I wiite a note 
18 accordingly which goes in the medical record. 
19 Q, So do you actually make the decisions of 
2 O what medications cenain patients will actually be 
21 on? 
22 A. Often. 
23 Q. But you've got to go to somebody and say, 
24 rm recommending X for patient Y. I need you to 
2 5 prescribe that to patient Y? 
41 j 
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A. Well, again, I don't have to. I choose to 1 commonly which result in their making the changes 
because 1 see my role as a senior faculty member to 2 accordingly, 
teach. 3 Q, And when you get a cribside or telephone 
Q. I understand. 4 type call, you 1re making a recommendation based on 
A, So I could easily do this without 5 them reaching out to you, the physician reaching out 
involving the othermembers of the team, but then I'd 6 to you and saying, you know, What do you think about 
be abrogating my responsibility as a professor. 7 this, Dr. Lipman, and you saying, I would recommend 
Q. Okay. So my question was -- and I'm not 8 doing X. That would be a recommendation that you're 
meaning it in a have because you're not pennitted to 9 providing to those medical providers, correct? 
do so, You've made a choice not to fill out what you 10 A. That's correct. Frequently they'll call ;-
call simple paperwork to have the ability to write 11 and say, Here's the situation. l'd like your 
prescriptions. And so if you decide that you're 12 opinion. Do you think you need to see this patient? 
going to put a patient on something, you have to go 13 Sometimes, if it's complex, I'll say, Yes, put the 
to someone else and say1 I need you to write thfa up 14 patient on my schedule. Other limes it's just going 
for me, correct? 15 to be a question on how to adjust the dosing regimen 
A. Frequently what I'll do, just in the 16 to optimize desired effects versus adverse effects. 
interest of time, is I'll actually write the 17 Q, And so in your clinic if you -- well, do 
prescription, then run it by the attending physician 18 you use methadone? 
or the fellow, if it's a senior fellow who already 19 A. Absolutely. 
knows the patient, saying, This is what so-and-so 20 Q, And you'll use it in a nonmalignant 
needs. And they say) Thank you very much, sign it) 21 chronic care setting? 
and it goes in the chart. 22 A. Absolutely. 
Q. But you don't sign the prescriptions? 23 Q. And when you use methadone and you see a 
A. That's correct. And, again, that's by my 24 patient on a Tuesday and you place that person on 
choice. 25 methadone, would you follow up with tl1at patient or 
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Q, So with respect to your clinical role at 1 would someone else? 
the pain clinic, you do make decisions as to what 2 A. Could be either. 
medications to place a patient on'? 3 Q, Okay. 
A. Yes. 4 A. The point is that the team will follow up 
Q, What dosages should be used with a 5 with the patient. And more often than not I will 
patient? 6 actually define what the dosing regimen would be, the 
A. Yes. 7 rate of titration, and then we would discuss the 
Q, What titration of those dosages is 8 patient at the next team staffing to assure that all 
appropriate? 9 members of the team are aware of the issues that 
A. Yes. 10 should be monitored. 
Q, And then you provide follow-up care to 11 Q. But the patient will start that regimen 
those patients? 12 prior to that conversation with the interdisciplinary 
A. If indicated. And for the record, I am 13 teami correct? 
not doing this routinely for all patients. I'm asked 14 A. There will nonnally be an informal 
by the physicians to see the more difficult patients 15 discussion among the team members in the clinical 
with whom they are having difficulty. 16 conference room that we all work out of. There will 
Q. How many patients a week do you think you 17 be a fonnal staffing of the patient and completion of 
do those things for? 18 the interdisciplinary team note within the next week. 
A. Well, as I mentioned, I see two to four 19 Q, Okay. And when you do that, and, again,, 
patients a day on Tuesdays and Wednesdays, When I 20 just using as an example someone that you'll place on 
don't have a student or resident in my service, that 21 methadone, what would be the follow-up protocol with 
number will increase by a factor of two to three, and 22 respect to a patient that you place on methadone? 
also more days per week when I do have a trainee in 23 A. Well, the important issue is that 
service. I also receive telephone calls commonly 24 methadone is a medication that takes up to IO days to 
from members of the staff and ctibside consultations 25 reach steady state serum levels. That's the level --
' . ' 
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1 the point at which the amount going into the body is 
2 equal to the amount going out of the body. There has 
3 been an alarming increase in the number of deaths due 
4 to methadone, which, as you know, has been well 
5 documented in the literature, most recently in 
G Morbidity and Mortality weekly reports. However, 
7 this problem has been in the literature since the 
8 1990s. And, indeed, in one ofmy publications in the 
9 journal Oncology in the late l 990s I desctibe the 
10 phannacokinetics of this in some detail with a 
11 graphical presentation of how the serum levels 
12 increase. 
13 The biggest concern that I have is that 
14 the physicians not titrate the drug too quickly 
15 because of the risk of respiratory depression 
16 occurring prior to the patient achieving the desired 
1 7 effects. 
18 Q. But going back to my question, if you were 
19 to start a patient on methadone, what would be the 
2 o follow"up protocol to see that patient again? 
21 A. We would nonnally give the patient a 
22 limited amounl of medication, advise the patient to 
23 call if there's any question, and schedule the 
24 patient to be reseen in the clinic usually in two 
25 weeks, 
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l Q. And when you say 11 1imited medication,° 
2 would that be like a two-week supply? 
3 A. Correct. 
4 Q, Whatever supply to get them to the next 
s visit that you want them to have? 
6 A. If we have a patient who we feel is 
7 compliant and who has been taking opioids in an 
8 adherent manner, then we may give a month's supply. 
9 That1s not the issue, and that1s not the issue in the 
10 case of Mrs. Schmechel. The issue is the rate at 
11 which the medication was increased. 
12 Q. And, trust me, we're going to definitely 
13 get there. I promise that .. 
14 A. I trust you completely. 
15 Q. ·· you're going to get to talk about that. 
16 Are there times where you will take a 
17 patient off of OxyContin and put them on methadone? 
18 A. Certainly. 
19 Q. Okay. And I think-- I mean, I'm trying 
2 o to do this in a logical structure, so we'll gel to 
21 your opinion so we1re not jumping all around. So I1m 
2 2 going to switch gears on you real quick and we1ll 
23 come back to this. 
24 If you could,just give us a general 
2 5 description of your medical education and background. 
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1 MR. FOSTER: Before we go on, let's go off 
the record a second. 2 
3 (A discussion was held off the record,) 
4 Q. (BY MS. DUKE) Okay. So if you could go 
5 into your medical education and background. 
6 A. I have an undergraduate degree, a 
7 Bachelor's degree in pharmacy, from the University of 
Rhode Island. I have a Doctor of Pha1macy degree 
from the University of Michigan. 
8 
9 
10 Q, And the Doctor of Pharmacy you obtained in 
11 1968? 
12 A. At that time it was strictly a post-
13 graduate degree with a major research phase. That 
now has become the entry level degree for phamiacy in 
the very recent past, but it's a very different 
14 
15 
16 degree now from what it was at that time. 
17 Q, Okay. But you obtained your Doctor of 
18 Pharmacy in '68? 
19 A. Yes. 
20 Q, Okay, And I noticed when we looked 
21 thro\lgh your curriculum vitae a number of honors that 
22 you have, academic appointments, teaching coordinator 
23 positions, professional experience, pharmacist 
24 licensure. 
25 A. That's because I'm old. 
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1 Q. With respect to all of those, I just want 
2 to make sure there1s no significant or relevant 
3 update that you feel we can talk about today since 
4 we're actually here for your deposition. 
5 A. l was just designated university 
6 professor. Big deal, you know. In academics you get 
7 honors in lieu of salary, 
8 Q. Other than that, any other achievements? 
9 I guess I should limit that to professional 
1 o achievements. 
11 A. Things are always happening. They're not 
12 really significant. You reach a point-- I was just 
13 appointed as a member of a study section, which is a 
14 peer review panel for federal grants for the agency 
15 of Health Care Research and Quality, but I have a 
16 number of those NIH appointments on there already. 
'.!- 7 Ifs just more of the same. 
18 Q. If you could, I understand that you've 
19 been in Utah for 30 years, or almost 30 years next 
20 week. 
21 A Next month. I 
22 Q, Or next month. 
2 3 A. I'm underoatl1. 
2 4 Q. But if you could just describe what your 
2 5 practice has been over tl1e last ·· you know, well, 
13 (Pages 46 to 49) 
CitiCourt, LLC 
801.532.3441 
,~ ·(1 , .. ) V"') 



















































Lipman, Arthur * July 5, 2007 
l?age 50 Page 52 
since 1968, of what you did after you obtained your 1 board certified a dog some phannacists have taken. 
Doctor of' Pharmacy. 2 That's the Diplomate of the American Academy of Pain 
A. In 1968 I accepted a commission in the 3 Management, which I consider a silly credential. So 
U.S. Public Health Service, and I spent two years on 4 that's the only one that 1 would be technically 
active duty in the Indian Health Service. I 5 eligible to take. 
maintained my commission and am now a senior inactive 6 Q. And then just broadening that out to the 
reserve officer in the Public Health Service, consult 7 Pham1,D. world, not necessarily specializing in pain, 
with the Surgeon General periodically, 8 what tyPes of board certifications are available in 
1 made the decision to move into academics 9 that? 
after that and accepted a position at the Yale New 10 A. Oh, there are a number of boards: 
Haven Medical Center with the title of drug 11. Oncology phannacy, psychiatric pharmacy. As! 
information director, and in 1971 was invited to join 12 mentioned, there's a board certified pharmacothempy .. 
the faculty of die Yale School of Medicine, 13 specialist, which is the primary care board, if you 
· explicitly in the Department of Surgery where l 14 will, or the basic board. These have been 
taught and did research until I was made an offer I 15 established in the last 10 or 12 years. And the 
couldn't refuse by the University of Utah, Made the J.6 young graduates who have gone through residency and 
decision to come here for no more than five years, to 17 fellowship typically take those today. 
leave New Haven for Salt Lake City, discovered it was 18 Q. And tl1en do you obtain privileges like a 
a wonderful place to live, and after 10 years J 19 physician would when you practice at a hospital? Is 
retired from the chainnanship of the department for 20 that something that you have to go through? 
which I was brought here to create a new clinical 21 A. It varies from hospital to hospital. 
department in the College of Pharmacy. I went 22 Typically, once you receive an appointment on the 
overseas, got my research back up, and have been 23 hospital staff and you're accepted by the clinic 
doing pain and palliative care work ever since. 24 staff, that takes care of it. There's not a 
The rest of what I do is written in 25 privileging process such as there is forphysieians. 
Page 5 J. Page 53 
excruciating detail in the document in front of you. 1 Q, Okay. Then if we look at almost the rest 
Q. Are there any board certifications that a 2 of your curriculum vitae, if you could,just any 
Doctor of Pharmacy has or that you have? 3 literature or publications, you know, whether it's 
A. There are now. At the time that l trained 4 textbooks, medical articles, journals, treatises that 
there were not. There's .. there are things such as 5 you've authored or participated in the authming of 
board certified phannacotherapy specialist and such. 6 with respect to issues related to this case that you 
I actually serve as consultant on a number of the 7 feel are relevant and pertinent. 
board examinations and such. But because I'm one of 8 A, Well, you have my textbooks. There's the 
the •. in the days that l received my Doctor of ·9 Pain Management Primary Care, which 1 was requested 
Phannacy degree, there were only five universities in 10 to do five years ago or so, which is written for 1: 
the country that granted the degree. It was strictly 11. primary care physicians and other clinicians as ;, 
post-graduate, very small numbers, and those things 12 opposed to pain specialists. And that gets into .. 
didn't exist then. So I was literally one of the 13 issues such as the risks of methadone. My chapters 
founders of the field that was then called clinical 14 in the Warfield book, in the Tollison book. 
pharmacy. Now it's more commonly called 15 l was one of the chairs of the panel that 
pharmacothernpy. So I've never taken any of those 16 wrote the American Pain Society Principles of 
board examinations. J. ') Analgesic Use in Acute Pain and Cancer Pain, the most 
Q. And what are the board certifications that 18 recent edition. Now, that does not expHcitly 
exist now with respect to the type of work that you 19 include nonmalignant pain, but there is a large 
do? 20 amount of transferability of the methadone section 
A. There's nothing $pecifically related to 21 from chronic cahcer pain to chronic nonmalignant 
pain. 22 there. 1 was on the Federal Clinical Practice 
Q, Okay. 23 Guideline appointed by the secretary of HHS that 
A. Nothing that's broadly respected. There 24 wrote both the acute and cancer pain management 
is one board, which I would not take, that literally 25 guidelines published in '92 and '94, respectively, by 
................ , .. ,,,,,,.,.. 
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1 the Departmenl ofHealfh and Human SeiYices. There 
2 are numerous other chapters in my CV, but probably 
3 the American Pain Society Principles and the most 
4 recent textbook and textbook chapters summarize the 
5 infonnation nicely. 
6 By definition textbooks and book chapters 
7 are a review of the literature. They1re not original 
8 research. I have not done original research in 
9 methadone, per se. I've done a lot of original 
10 researc.h with other opioids. But the principles of 
11 pharmacokinetics apply across opioids. They differ 
12 greatly. TI1at is, the pharmacokinetics differ 
13 greatly among the opioids. But in order to do the 
14 research that I did, for example, on the 
15 phannacokinetics of Sufentanil, the same principles 
16 would apply there as they did in methadone. 
1 7 Q. Any others that you think would be 
18 relevant or pertinent to the issues in this ease that 
19 you haven't already stated? 
2 o A. No. r think that pretty much summarizes 
21 il. Hopefully, there's a consistency in what I've 
2 2 written over the years. 
23 Q. With respect to your opinions in this 
24 ease, are you relying on any specific piece of 
25 literature or journal with respect to issues in this 
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1 case? 
2 A. Well, realize, all I do is pain and 
3 palliative care, and I read this literature 
4 regularly. I contribute to this literature 
5 regularly. I edit a journal that is Medline listed 
6 that publishes this type of literature regularly. 
7 And, therefore, I'm continually updating my knowledge 
8 base based on what's published. But there is not a 
9 particular reference that I refer to. I've written 
10 numerous chapters in some books that summarize my 
11 understanding. 
12 Q. And what's the journal that you edit for? 
13 A. Journal of Pain and Palliative Care 
l4 Pharmacotherapy. 
15 Q. But, as you sit here today, I understand 
16 that there's a breadth ofinfonnation and 
1 7 publications that you've been involved in that do 
18 relate to methadone. But is there any one or two or 
19 three, or however many, that you would be walking a 
20 jury through saying, you know, here's what I've said 
21 here or here1s what someone else has said with 
2 2 respect to methadone? 
23 A. No. You will be requesting my slide set 
21 on methadone, and that will pretty much summarize 
2 5 what I talk about. 
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1 Q. Okay. 
2 A. You can't talk about methadone in 
3 isolation. You have to talk about methadone as one 
4 of the range of opioids that we use clinieally. 
5 Q. But other than this slide set on 
6 methadone, there's no other item that you could 
7 identify here that you would be taking the jury 
8· through or referring to? 
9 A. You know, I've written so much over the 
10 years it's hard to remember. lfyou refer to my 
11 textbook for primary care cliniciansi whatever we 
12 called the silly tbing, I coauthored the chapter on 
13 opioids with one ofmy former post-doctoral fellows. 
14 I think that's what I did. And I'm sure l discussed 
15 methadone in there. l don't recall the details. 
16 Q. Okay. 
l 7 A. There's a -- there's not one thing that 
18 ['d refer on. I'd refer on 30 years of experience 
19 and consultation and literature and expertise. 
2 O Q. And I'm just trying to get to the heart of 
21 the matter, if there's any that we're relying on, 
22 because we would obviously want to review it. 
23 A, Certainly. And those are the things I've 
24 cited. 
25 Q. Okay. . 
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1 A. l certainly would refer to the Grey and 
2 Caravati Morbidity/Mortality weekly reports paper 
3 from January 21st or 23rd of 2005, albeit that 
4 occurred after Mrs. Schmechel's event. But it 
5 summarizes the previous decade ofliterature, And 
6 that's an important summation of the problem. 
7 Q. And what is that called, Grey and 
8 Caravati --
9 A. They were the two authors. Todd Grey is 
l O the chief medical examiner of the state of Utah. 
11 Marty Caravati is the medical director of our Poison 
12 Control Center, which is part ofmy departmeot. And 
13 they-· l think Caravati was the first author. 
14 Morbidity and Mortality, MMWR -· it's available on 
15 the Web -- publication of the Centers for Disease 
16 Control and Prevention of the Public Health Service. 
17 H's a major publication of reportable diseases and 
18 medical events. And the lead article in that 
19 January -- third week of January 2005 was on deaths 
2 O due largely to methadone legitimately prescribed for 
21 patients with chronic nonmalignant pain. 
22 MR. HIPPLER: Keely, if! may, just so I 
23 can clarify, is that what you previously referred to 
24 as the MMW Utah report on methadone deaths? 
2 s TI{E WITNESS: Yes, yes. 
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1 MR. HIPPLER: Okay, Thank you. 
2 THE WITNESS: You can easily find it just 
3 by Googling. 
4 MR. HIPPLER: [ have. 
5 THE WfTNESS: Yeah. Good. 
5 Of note, Todd had actually discussed this 
7 with me as a clinical observation that he had made 
8 from the autopsies he was doing over a year before 
9 that was published. But I do want to stipulate that 
10 was, of course, published after 2003, 
n Q, (BY MS. DUKE) Right. 
12 A. But it reviews years of experience. And 
13 there was literature, and [ gave you the example of 
14 what I published in· the journal Oncology in the late 
15 nineties that's in my CV on the pharmacokinetics of 
16 methadone in there and the risk oflethality if it's 
17 titrated up too quickly. 
18 Q, I know we talked earlier about your April 
19 16th and April 30th conversation with plaintiffs' 
20 counsel's office, and you had indicated that on the 
21 April 30th conversation you spoke to Dr. Lordon and 
22 another Idaho physician with respect to this case, 
23 Other than those two individuals, have you spoken to 
24 any other experts retained by the plaintiffs in this 
25 case related to this case? 
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1 A. I spoke to Dr, Vorse at one point. And 
2 that's all I can recall. I don't think there was 
3 anyone else, But all of my conversations are listed 
4 on the notes that you have. 
5 Q. Okay. 
6 MR, HIPPLER: Keely, can we take a 
7 two-minute break? 
a MS, DUKE: Oh, sure. 
9 (A short recess was taken,) 
10 MS, DUKE: Back on the record. 
11 Q, (BY MS. DUKE) With respect to grants and 
12 honorariums that you've received, I noted through 
13 some research that you1ve received a number of grants 
14 and honorariums from a number of different companies, 
15 and I'm going to read some off and just ask if they 
16 ring a bell. 
17 Abbott? 
18 A. l can't remember what I did with them, 
19 Q. Okay. Endo'/ 
2 O A. How many years ago was this? 
2 l Q, I have no idea, It was just a list. 
22 A. Is that~- I'm not sure where that1s 
2 3 corning from. 
24 Q. I pulled it off the fntemct off of 
25 some--
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1 A. Oh. When we do --
2 Q. -- literature that --
3 A. -- medical education, we always have to do 
4 disclosures of companies with whom we1ve consulted, 
s Q, Right. 
6 A, And we're on speakers' bureaus, And so 
7 I've consulted with most of the companies that are in 
8 the pain management field simply because I've 
9 published in tl1e area. That's pretty normative for 
1 o the thought leaders in the field. 
11 Q. And l understand, And that's why -- I 
12 mean, Glaxo SmithK!ine was one of them, 
13 A. l did some research with them a few years • 
14 ago, a couple years ago, 
15 Q. And what was that research? 
16 A. It was with a peripheral opiate antagonist 
1 7 for opiate-induced constipation. 
18 Q, Janssen Phamiaceutica? 
19 A. l did some consultation with them. I 
2 o can't remember. I think it was probably related to 
21 their transdermal opioid. 
22 Q. McNeil? 
2 3 A. I'm on a speakers' bureau with Ortho-
24 McNeil, and I've consulted with them and did research 
2 5 when it was part of J&J and when Alza was handling 
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1 their iontophoretic fentanyl patch, We did some 
2 studies on that. 
3 Q, Merck? 
4 A. Merck, I consult with them "- did consult 
5 with them when they were in the nonsteroidal anti-
6 inflammatory business and now do some speaking with 
7 them on prevention of post-herpetic neuralgic with 
8 their new shingles vaccine. 
9 Q. Novartis? 
10 A. Novartis has a COX-2 selective non-
11 steroidal anti-inflammatory, lumeric oxid, I 
12 consulted early in clinic,il development on that. 
13 Q. Okay. Pfizer? 
14 A. Pfizer, I've been involved in Celecoxib 
15 consultation speaking, 
16 Q. Farossia, does that ring a bell'/ 
17 A. l don't know, 
18 Q. No idea what tlrnt is. 
19 Purdue Phanna? ' 
2 0 A. They are obviously heavily into opioids, 
21 OxyContin, 
2 2 Q. Has that been research that you've done 
2 3 for them or --
24 A. I was -- I spoke to them, I consulted with 
2 5 them, and I was heavily involved in the OxyContin 





















































Lipman, Arthur * July 5, 2007 
Page 62 Page 64 
product liability defense. 1 enough science to make intelligent decisions. 
Q. What do you mean by very involved in the 2 Q. Okay. With respect to other testimony, we 
liability defense with respect to OxyContin? .3 talked just briefly earlier about other work that 
A. There were a number of egregiously 4 you've done in other cases. And at least in the 
offensive plaintiff suits against OxyContin that had 5 research that I did, it looked like you had four 
absolutely no scientific basis, and 1 was involved 6 medical malpractice cases that you've been involved 
in, among other things, Doberting out one of their 7 in plus this one. ls that a --
major witnesses and providing the science upon which 8 A. Well, you've got a listing. I've only ,· 
OxyContin was based. OxyContin was marketed 9 started keeping records on this two or three years •. 
terribly, but it was -- it's a good product and 10 ago. 
product liability on it is silly. 11 Q. Okay. 
Q, And then UCB Pharma? 12 A. The vast majority of work that I have done 
A. l actually did some studies on the anti- .13 has been defense. I've done very little plaintiffs 
epileptic that they were looking at in neuropathic 14 work. I feel ethically that if I'm going to be a 
pain. 15 strong advocate of opioid therapy, which 1 am, and 
Q. Have you done any research or anything 16 I'm on the record nationally and internationally as a 
like that for methadone's producer, Methadose Tyco? 17 strong advocate of using opioids and using them 
A. No. 1 did one consultation with one 18 aggressively when clinically indicated, if I'm going 
company that was interested in marketing methadone, 19 to do that, then J foci l have a moral obligation 
but l can't even remember the name of the company. 20 also to speak up when 1 think opiates are being used 
Q. And when you say a consultation, what is 21 dangerously or inappropriately. 
involved in that? 22 So probably three-quarters or fourth- ' 
A. Advisory board. They'll bring six to ten 23 fifths of what I've done has been defense of 
thought leaders in from around the country, around 24 physicians or clinics or hospitals in their opioid 
the world, and sit you down in a hotel for a day or 25 use when there have been unanticipated, unavoidable 
:i 
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; 
two in typically New York to really brainstorm what's 1 adverse outcomes of opioid therapy, frequently 
happening with the medication and what its potential 2 wrongful death, allegations of wrongful death. And ;: 
uses, adverse effects, and regulatory issues are. 3 only a small percentage has been plaintiffs. ~ 
Q. And was that in the last five years, ten 4 Q. And have you ever been involved in a 
years? 5 medical malpractice case that involved methadone 
A. Last five years, l believe. 1 cannot even .6 other than this one? 
remember the name of the company. I don't even know 7 A. l honestly don't recall. It's possible. 
who markets methadone now. It's probably somebody 8 Q. How about morphine? 
who markets methadone. 9 A. I'm sure I1ve been involved in morphine 
Q. I think it's Tyco is what the PDR said. 10 cases. I know J1ve been involved in meperidine 
A. It wasn't Tyco. 11 cases. 
Q. It's not? Okay. 12 Q. And do you recall being involved in a 
A. At one point it was Mallinckrodt, and this 13 pretty significant plaintifi's case that involved 
was AA Pharma, or something like that. J.4 morphine that went to trial? 
Q. Okay. And then with respect to any other 15 A. One in Wisconsin? 
grants, anything notable to this case -- 16 Q. Yes. 
A. No. 17 A. l think, yeah. J make a point of both 
Q. -- with respect to -- 18 physically and mentally shredding the file as soon as 
A, People don't fund research on methadone. 19 I'm done with a case and I've got other things to 
It's a generic drug. The NIH will lypically not fund 20 think about. And J recall it was in some small town 
research on something that's commercializable1 and 21 in Wisconsin, I think right on the -- was it the ' 
the phanna industry will not fund something unless 22 Mississippi River? And beyond that I can't recall a 
it's going to be a patented product, which ls one 23 thing. 
reason that the research, the science on methadone) 24 Q, Okay. None of the details of facts of 
has been so slow to come out. Bui now we do have 25 that case that you recall? 
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A. I don't even recall the outcome of it. 1 Q. But you don't recall here? 
Q. And I think you've already answered this 2 A. But I don't recall in this case. 
question with some of what you just said. But do you 3 Q. I would assume you don't have any 
keep any copies of depositions ~- 4 acquaintance with their finm other than this case, 
A. No. 5 though, or the people at their firm? ,, 
Q. -- that you have in other cases? 6 A. l believe that's the case. 
A. No. I look forward to shredding the file 7 Q. And with respect to ptior testimony, does 
in front of me right now. 8 it sound tight to say that you've testified in Utah, 
Q. Okay. Do you register with any type of 9 Wisconsin, and Ohio with respect to vatious cases 
legal service or referral agencies, anything like 10 that you1ve been in an expert position? 
that, with respect to your services as an expert? 11 A. And Atizona -- !! 
A. No. You see, phannacy is the second 12 Q. Okay. i, 
oldest profession in the world. Prostitution is the 13 A. -- California. Those are what come to 
first. The second is fine for me. I don't need the 14 mind. Georgia. Georgia. Sorry. 
first. 15 Q. Okay. Where was the OxyContin case where 
Q. Okay. 16 you Doberted out the witness; do you remember? 
A. l consider that grossly offensive, and l 17 A. He was Doberted out in Oklahoma Federal 
think anybody who does that type of thing ought to be 18 Cou1t. 
taken out, drawn and quartered. But l don't have any 19 Q. When was that case? 
opinions on that. 20 A. Oh, three or four years ago. There were 
Q. l was going to say you don't feel strongly 21 over 370 OxyContin cases, not one of which was lost. 
about that at all, do you? 22 One we settled without prejudice because it was an 
A. That's one reason l enjoyed Doberting out 23 AG's case in West Virginia. Everything else was --
a colleague in Federal Court who was just selling 24 MR. HIPPLER: Off the record. 
himself as a plaintiffs' whore on the OxyContin 25 (A discussion was held off the record.) ·, 
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cases. l shouldn't say that on the record, but 1 MS. DUKE: Okay. Back on the record. 
that's how l feel. 2 Q. (BY MS. DUKE) Have you ever been sued for 
Q. Okay. Have you worked with plaintiffs' 3 medical malpractice? 
counsel's firm before? 4 A. No. 
A. This finn? 5 Q. Okay, And this is a standard question we 
Q. Co1Tect. 6 ask. It's not meant to offend you in any way. Have 
A. You know, I think I was called about 7 you ever been convicted of a crime? 
another case, and l have no idea what the status of 8 A. No. 
that is. And I don't know -- l can't recall which 9 Q. Okay. What were you asked to do in this 
one came first. And I don't even know what's 10 case? 
happened on the other case. 11 A. I was asked to review the use of the ' 
Q. Is that another methadone case? 12 methadone and provide my opinion as to whether it was 
A. I don't believe so, but I don't recall. 13 approptiate and within standard of practice. I 
Q. Do you know if it's in Idaho? 14 should say methadone and other opioids that this lady 
A. I'm not sure. I assume so. The only 15 received. 
reason l know that is because when I was going to 16 Q. And l would assume that's what you've j 
' pull up my file to bring it here, that there was . 17 done . 
another one there that was -- that was named. But l 18 A. Yes. 
have no idea what's happened to the other case. 19 Q. You had made a comment earlier, and now 
Q. Any idea how plaintiffs' counsel's finn 20 that we're really into your opinions with respect to 
located you? 2l. methadone, that the research has been slow with 
A. No .. They-.. I usually ask that question, .. 22 respect to methadone. I guess what do you mean by 
and usually they say that they were referred by a 23 that and why has it been slow? 
physician who I helped to a·ain or they found my name 24 A. Methadone has been available since the 
in the literature. 25 I 940s and in this country since the l 950s. lt was 
18 (Pages 66 to 69) 
CitiCourt, LLC 
801.532.3441 
"! () ;··, $): 
1 (, ,',., 
Lipman, Arthur 
Page 70 
1 actually developed as an alternative to morphine in 
2 Germany at the build-up to World War I! when they 
3 didn't have access to morphine because of the stuff 
4 going on _in Europe. And from day one it1s been an 
5 excellent analgesic. 1110 problem is that, as you 
6 know, there's a 17-year patent life on drugs as other 
7 products; and,_therefore, it is by definition a 
8 generic drug. And there's not a source of funding 
9 for the research, particularly in the pham,aco-
1 O kinetics. This has taken place. It's taken place 
11 because there's been a need for it. And it really 
12 evolved more from initially clinical observation and 
13 then the research that came accordingly. But you 
14 don't have big phanna or the NIH, which are our two 
15 major sources of fonding, available to support this 
16 wo.,'k. Therefore, the work was not available. We 
17 didn't have good phamiacokinetic data on this drug in 
18 the fifties and sixties or even the seventies. ll 
19 wasn't really until the l 980s that this started to 
20 become available. By the mid- J 990s we did have the 
21 data, Had it been a new drug coming out, we would 
22 have had the data within a couple of years. 
2 3 Oxycodone is a drug that's been available 
24 since 1915 in this country. It wasn't until 
2 5 OxyContin was developed that the data were done --
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l. the data were generated because the FDA insisted that 
2 this new fom1 of Oxycodone had to have phannaco-
3 kinetic studies. And we now have superb infomiation, 
4 which we didn't have for the first 70 years that drug 
5 was used. 
6 The point is we have the infom1ation now 
7 on methadone and it's got to be used accordingly. 
8 Q. I've done my best to sort through the 
9 disclosures that were provided by plaintiffs' counsel 
10 with respect to what you will testify to and the 
11 bases for those opinions based out of your affidavits 
12 as well. 
13 A. Uh-huh. 
14 Q. And I guess what I'll do is just have you 
15 provide a description of what your opinions are in 
16 this case, and then we'll go through those and I'll 
1 7 follow up with any that I'm curious about to see 
18 whetl1er you have an opinion or not. 
19 A. Sure, 
2 O Q. So if you want to go ahead and just, you 
21 know, as you feel best with respect to describing it, 
2 2 what are the opinions that you hold in this case? 
2 3 A. Okay. There were four of your experts: 
2 4 Chris v~ I can never remember his last name. 
2 S Q. Kotenstette. 
' .. 
* o·u 1 y 5 , 2 o o 7 
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1 A. I-le was my student in the B.A. program at 
2 Utah, which is the irony. And I know Chris, and he's 
3 a leader in P.A. pain management. Dr. Cox, Dr. Hare, 
4 Keri Fakata, who was my post-doctoral fellow, and 
s Dr, Bender, l believe. 
6 MR. FOSTER: Binegar. 
7 THE WITNESS: Binegar. All of whom 
8 commented correctly that a starting dose of 10 
9 milligrams twice a day was a conservative dose for an 
10 individual who had been receiving OxyContin at a dose 
11 of250 milligrams every eight hours plus short-acting 
12 hydrocodone. Absolutely conect statement. The 
13 problem is that none of them commented in their 
14 affidavits on the titration schedule, which is the 
15 issue here, 
16 Now, whether that is because they did not 
1 7 see the full record or, if they received it, did not 
18 review it, or they were asked only to comment on the 
19 initial dose, I do not know. But I have no argument 
2 o with what each of them said there. They're 
21 completely correct. 
22 lf, however, any of them was asked under 
2 3 oath to comment on tile appropriateness of the 
24 titration, l can assure you of the individuals l 
2 s know, that they would agree with my opinion that this 
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1 medication was titrated much too rapidly. If they 
2 did not reach that conclusion, anyone who did not 
3 reach that conclusion is either ignorant or dishonest 
4 in his or her answer. 
5 I don't know the level of sophistication 
6 of some of the experts. r do know the level of 
7 sophistication of some of them. The ones who know 
s the medication and know its pharmacokinetics will 
9 clearly tell you, as will anybody knowledgeable about 
1 o this medication, that you cannot safely increase the 
11 dose of methadone rapidly. And the reason for that 
12 is, as I mentioned to you earlier and as l published 
13 in that Oncology article, is that it takes several 
14 days to reach steady state. 
15 Now, two or three of the experts commented 
~6 on the dose conversion from Oxycodone to methadone. 
1 7 The literature is very clear. The expert opinion is 
18 very clear on this that we don't have good conversion 
19 data on methadone. This is one of the problems with 
2 O the medication. We have very conflicting data. 
21 There is universal agreement among the lmowledgeable 
22 individuals that·there is a huge amount ofinter-
23 patient variability in response to different opioids, 
2q and that mandates when we're rotating from one opioid 
2 s to another -- and Dr. Hare, who is a friend and 
I 
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colleague, explicitly talked about opioid rotation in 
his affidavit -- when we rotate from one opioid to 
·another, we always give a lower dose of the new 
medication. 
Ten years ago Dr. Kathy Foley, one oflhe 
leading physician phannacologists in this area in the 
world .. she's at Memorial Sloan-Kettering in New 
York, another old friend -- suggested a 20 percent 
reduction. With methadone today the general 
consensus is that we should probably have closer to a 
50 percent reduction. 
The reason that we must reduce the dose of 
the new opioid to which we're rotating is there is 
incomplete cross-tolerance to the respiratory 
depression. But the more important finding, which, 
again, any knowledgeable person can speak to, and 
this is work thal has largely come out of Dr. Gabriel 
Pasternak's laboratory at Memorial Sloan-Kettering --
Gab is a neuropharmacologist/neurologist. I last 
spoke to him about this about three weeks at a 
meeting in New York -- is that genetically we're all 
different. There are many different subsets of the 
opioid receptor, [n genetics we refer to these as 
slice variance. So 1 may be more responsive to 
morphine. You may be more responsive to methadone. 
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Steve may be more responsive to Oxycodone. Byron ma 
be more responsive to hydrocodone. It's just this is 
our genes, what we get from our parents, And it has 
to do with different densities of these receptors 
and, therefore, different responsiveness. 
Now, what this comes down to is that you 
cannot ever safely convert a patient from opioid A to 
opioid B at an equally analgesic dose knowing that 
that's safe a priori. lt may well be, and in the 
majority of cases it will happen. But in a 
significant portion of patients, maybe 15 percent of 
patients -- I don't know the number, but that might 
be a good guess, and Gab Pasternak agrees with me in 
our most recent conversation it's probably 15 
percent, or at least that1s a starting point u~ 
you're going to get into real big trouble because 
somebody .is going to be exquisitely sensitive to drug 
B who was not very sensitive to drug A. 
Now, that's why the teaching -- and this 
is what I have taught for many years to students in 
medkine, in physician assistants 1 and in phannacy, 
is that you have to make these conversions very 
conservatively. But most importantly -- this is the 
key -- you have to do dose increases after you have 
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morphine that's easy. Morphine has a half-life .. 
that's !he time it takes for the body to eliminate 
half of the medication. The half-life of morphine is 
two hours. The half-life of oxycodone immediate 
release tablets is two hours. So in ten hours 
literally it would be safe to increase the dose. How 
do we routinely increase the dose on these? For 
convenience, once a duy. You couJd do it twice a 
day, but we do it once a day. That makes very good 
clinical sense. It's consistent with the science. 
Methadone, conversely, and tbis is well 
published in the literature, can have up to a 10-day 
time to reach steady stale because your half-life can 
be up to 60 hours. It's typically around 30, maybe 
40 hours. Now, what that means is that you have to 
wait a much longer period before you can safely 
jncrease the dose, 
At a recent opioid thought leader 
conference the docs around the table were all asked, 
How often will you increase methadone? And the 
answer consistently among these six or seven thought 
leaders was once a week. We don1t increase methadone 
more than once a week. Now, that's today in 2007. 
We didn't know as much about this in 2003 when 
Mrs. Schmechel received this medication. And it was 
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fairly common in 2003 to increase the dose every 
three or four days, not every day. Maybe once every 
day, but not every day. Where's the science? 




article in MMWR which clearly documents the number o : 
deaths. 
Now, there were deaths due to other drugs, 
but methadone was way up there, Why was methadone 
way up there? Because Medicaid programs in Idaho, 
Utah, and other states, and third-pa1iy payers went 
to the primary care docs and said, Hey, OxyContin is 
very expensive, We don1t want you using OxyContin 
until you've at least tried something cheap. And the 
docs had all been saying to the monitors who called, 
Well, what's cheap? They'd say methadone. And so 
the doc would use methadone and titrate ii the way 
that these physicians had typically used morphine, 
increasing the dose every day, which, as I said, for 
morphine is fine. And guess what? A bunch of people 
woke up dead, which is why Todd Grey came to me in 
2004 and said, How come I'm seeing all these patients 
coming in to my medical examiner1s office on the 
fourth to sixth day of methadone therapy when they've 
died when they're getting this prescribed drug? And 
I said to him, Absolutely understandable according to 
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1 the pharmacokinetics. And then you have the 
2 publication. Now, the --
3 Q. The publication being the 1999 --
4 A. No, the 2005 thing that he wrote. 
5 Q. Oh, okay. 
6 A. Now, what is the standard of practice? 
7 The Federation of State Medical Boards has been very 
8 clear on this. When you go to your doctor, you 
9 absolutely want your doctor to understand the drug 
10 that he or she is prescribing. The standard of 
11 practice is that if the physician does not understand 
12 both the phannacodynamics, which is the mechanism of 
13 action, and the phannacokinetics, whjch is the way 
14 that the body disposes of the drug, what we call the 
15 fate of the drug in the organism, if your doctor 
16 doesn't understand that, that doctor has no place 
17 prescribing that drug. The standard of practice says 
18 that the doctor bas to find that out. How do you 
19 find it out? You read the package labeling, which is 
20 not the best source, but it's the one that's approved 
21 by the FDA, 
22 Physician assistant has absolutely the 
23 same obligation under the Physician Assistant 
24 Practice Acts of Utah and ldaho and all other 
25 jurisdictions. And the physician assistant has an 
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l additional obligation to consult with his or her 
2 supervising physician, and the supervising physician 
3 has a legal obligation and a standard of practice 
4 obligation to assure that the P.A. under that 
5 physician's supervision is knowledgeable in what lie 
6 or she is prescribing. 
7 Now, I was involved with the American 
8 Academy of Physician Assistants in writing the whole 
9 defense for which most jurisdictions have allowed 
10 P.A.s to prescribe opioids. I wrote the original 
11 curriculum, which is used now by most P.A. programs 
12 in the country for teaching pharmacology to P.A.s,, 
13 and I taught in the P.A. program at Yale and at Utah 
14 until Utah -- Utah till about live years ago, Yale 
15 from '70 or '71 till the late seventies when I moved 
16 to Utah. So l've been involved in P.A. education and 
1 7 practice and helping to define these standards of 
18 practice. They have the same obligations as the 
19 physician, pl11s the supervisory physician has 
2 o additional obligation, which is the problem here, 
21 Let me be very frank and open. This is a 
22 tragedy. I feel terrible when this happens, and I 
2 3 feel terrible (a) for the patient and her survivors. 
24 I also fbel tenible for society because it scares 
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we need to use in a lot of people. And I'm not 
interes.ted in any witch hunts. I'm not interested in 
any chasing people down. l'rn interested in improving 
the way that we treat patients in pain. And this 
tragic event was avoidable if there had been an 
appropriate titration. 
Does that mean that Mrs, Schmechel would 
not have died of something else9 I don't know, I 
can only comment on the medical probability, the 
scientific probability that the way in which she was 
titrated on her methadone -- and 1 can calculate out. 
We have computer simulation, very accurate computer 
simulation programs which will actually plot out how 
a drug is going to be disposed of in a body. You and 
I dispose of drugs by the same laws of thermodynamics 
and mechanics that regulate how a waterfall or steam 
engine works. This is the scienceofpharmaco-
kinetics. Most physicians don't know tl1e science of 
phannacokinetics. They get a couple lectures in 
medical school. That's all. They're not pharmaco--
kineticists. That's not their job. We have a whole 
group of scientists who do that full time for a 
living. We know the laws ofpharmacokinetics. We , 
know the pharrnacokinetics of methadone. We know tha ' 
a lot of people will get methadone too rapidly, and 
Page Bl :· 
1 they usually get away with it. But, you know, every 
2 once in a while they don't get away with it. It is 
3 the absolute obligation, and the standard of practice 
4 is very clear on this, of the physician to know the 
5 PK, the pharmacokinetics ofdrugs that he or she 
6 prescribes. Same for a P .A, And, tragically, that 
7 science was not applied in this case. 
8 Now, the temporal relationship, the time 
9 relationship of her dosing, of her titration and of 
10 her death, are such that there is a high probability, 
11 certainly far greater than not, that methadone was 
12 the major contributing factor to her death, Had she 
13 been a robust, healthy individual with no a priori 
14 respiratory impairment, which, of course, she had 
15 with her obstructive sleep apnea, chances are that 
16 she may have survived this, That doesn't single out 
1 7 methadone. There's nothing worse about methadone 
1 B than any other opioid. 
19 If she died of a -- largely due to a 
2 o cardiac arrhythmia1 as one of your experts contends, 
21 which is a possibility but a lower probability than 
22 respiratory depression, then methadone would have 
23 actually been a contraindicated medication because, 
24 as I'm sure yot11re aware from your research, 
2 s methadone has been clearly implicated in some 
····"",'<",., ... ,_,.,., .. ,, ... : ... ................. ,,, 
21 (Pages 78 to 81) 
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1 significant cardiac rhythm dist11rbances leading to a 
2 recent FDA Dear Doctor notice that went to every 
3 prescriber in the country •• or an FDA -- l should 
4 say an PDA safely bulletin, rather, that was 
S published recently on EKG interval changes with 
6 methadone. l don't believe that was the case. 
7 But if the defense is that it was a 
B cardiac arrhythmia, you've got a whole new area of 
9 exposure there that hasn't even been explored, And 
10 the dose that she received and the duration at which 
11 she received it, I think that that's highly 
12 improbable that that was the major contributor. I 
13 think the major contributor was direct respiratory 
14 depression due to accumulation. Patients will 
15 increase the dose of medication when they're getting 
16 little effect, not enough. Thafs intuitive. Any 
17 intelligent person would do that unless they are 
18 explicitly warned that that's potentially lethal, 
19 which it is with methadone. And that explicit 
2 O warning not only was not given by either Mr. Byrne or 
21 Mr. Dille, but she was instructed to continue to 
2 2 increase her dose. Go ahead and take l O to 15 
23 milligrams and increase it. That's scary, 
24 I have stopped physici,ms who have written 
2 5 orders like that when they've come to my attention, 
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1 and I've gone and warned the physicians and said, you 
2 know, that's a wonderfol order to wtite if you would 
3 like to end up in a malpractice defense, which is 
4 much more effective than telling them it's dangerous 
s to the patient. 
6 That's basically my opinion. We could 
7 spend hours teasing it out ofme, but that's what I 
8 have to say about it. And I can produce the 
9 mathematical models and the graphics that will 
1 O clearly demonstrate this. I hope that saved about an 
11 hour. 
12 Q, Okay. Let's go through these and further 
13 flush them out. We'll see how well l did. First of 
14 all, I guess, just so J understand what you're not 
15 critical of, first of all, is the use of methadone 
16 here. You're not critical of that. 
17 A. No. 
18 Q. Okay. Are you ctitical of the switch from 
19 OxyContin to methadone? 
20 A. No. 
21 Q. No. Okay. Are you critical of Mr. Byrne 
22 making the switch on thal Friday? 
2 3 A. I have taught for over 20 years you never 
24 start an opioid on a Friday, you never change an 
2 5 opioid on a Friday, and you don't change the dose on 
1 a F1iday, because you know the rule. The problems 
2 always happen alter 5:00 p.m. on Friday, You 
3 start·· when we taper patients, when we do things 
4 like that, we invariably start them on Monday or 
5 Tuesday, no later than Wednesday so that we at least 
6 know where we are by the weekend. But l'm not overly 
7 critical of him for that. l think it was an unwise 
8 decision. l think it showed a lack ofclinical 
9 sophistication. Certainly, with a drug like 
1 0 methadone that has a very vatiable phannacokinelic 
11 pe1i111eter it was a dumb thing lo do. 
12 lfhe hadn't titrated it loo quickly, if 
13 he told her, This is the dose to take and don't 
l4 increase it at all until at least Tuesday, I wouldn't 
15 be critical ofit. 
' 
16 Q. Okay. So let me just take that part of , 
17 il, though, switching her from the OxyContin to --
18 A. That's fine. 
19 Q, to the methadone and doing it on a 
20 Friday. r understand what your training is with 
21 folks, but is that something you're saying is below 
2 2 the standard of care? 
2 3 A. I wouldn't pick on that. 
24 Q. Okay. 
2 5 A. We have much more important things to 
Page 85 
1 address. 
2 Q. Okay. So then let's move on from that 
3 portion and then go to the dosing. You indicated IO 
4 milligrams was fine. You're not ctitical of that 
5 from a--
6 A. Well, I'm critical of it clinically. It 
7 should have been three times a day, but I would not 
8 have had strong objection to 5 milligrams three times 
9 a day. I might even be comfortable with 7-1/2 
10 milligrams three times a day. Clinically, it was 
11 wrong to prescribe it twice a day, In your experts' 
12 affidavits they did not address the efficacy. 1l1ey 
13 only addressed the safety, I'm sure that's what they 
14 were asked to address because that's the basis of 
15 this case. It was indicative of ignorance of the 
16 pharmacokinetics of the drug, It's a huge red flag 
17 to anybody looking at pharmacokinetic issues. But 
18 I'm not concerned about the safety of l O milligrams 
19 twice a day initially, 
20 Q. And ifit had been 5 milligrams twice a 
21 day, again, that's not necessarily a criticism. You 
22 might not agree with that approach. 
2 3 A. It would be inefficacious, but it wouldn't 
2 4 be dangerous. Now, there is an inherent danger in 
2 5 lack of efficacy. And that is when people don't get 
22 (Pages 82 to 85) 
CitiCourt, LLC 
801.532.3441 
·~ q ,·) " 



















































Lipman, Arthur ·* July 5, 2007 
Page 86 Page 88 
pain relief from taking two pills, what do they 1 of the blood. So you've got a reabsorption 
typically do? They take three. If they don't get 2 phenomenon occurring from the urine back into the 
enough relief with three but they're starting to get 3 bloodstream. So as people's renal function, kidney 
a little bit, what do they do? They take four. 4 function decreases, the drug sticks around longer. 
Welt, with methadone, that's ve1y, very dangerous. 5 This was a relatively young woman with 
Sol guess there is an inherent risk, but 6 other morbidities, but renal failure was not one of 
that's not the major risk. The major risk was the 7 those. 
titration schedule. 8 Q, What other morbidities did you note? 
Q, Okay. But looking at that, and we'll get 9 A. Well, obviously, she had obstructive sleep 
to the titration schedule, ifit had been 5 10 apnea. She obviously had some significant lower limb 
milligrams twice a day or if it had been I 0 11 edema, discoloration. She apparently had some 
milligrams twice a day, as 1 understand it, that's 12 decreased cardiac function. 
not what you would have done, but you're not saying 13 Q, On that Friday that Mr. Byrne saw 
that's below the standard of care; is that correct? 14 Mrs. Schmechel, what was your understanding of, first 
A. That not what a knowledgeable clinician 15 of all, what he determined would be her treatment 
would have done, but it was not -- it was below the 16 regimen? 
standard of care for efficacy, not for safety. The ,17 A. He reasonably determined that it would be 
basis of this lawsuit is safety. It is noteworthy 18 appropriate to rotate to an alternative opioid since 
that there had been several very high profile 19 she was not obtaining optimal or desired results from 
criminal suits as well as civil suits for lack of 20 the OxyContin. He also determined that he would 
adequate pain relief, the Chen case in California 21 decrease the dose of her amitriptyline. Clinically, 
being the most notorious, which I'm sure you know 22 I would consider that an unwise decision. He should 
about. So it was below standard of practice, but it 23 have rotated her to desipramine, but that's beyond 
was an efficacy, not a safety issue. 24 the level of sophistication that I would expect in a 
Q, So is that an opinion that you'll render 25 primary care physician assistant. 
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at trial? 1 Of particular concern to me is that he had 
A. If asked, l would. 2 a lady who he knew had obstructive sleep apnea and 
Q. Okay. And so with respect to twice a day 3 had been treated by a dually boarded physician, 
versus three times a day. as I understand it1 it1s 4 boarded both in sleep medicine and in pain medicine. 
your opinion that if you're going to prescribe 5 Now, your experts opined that it is the 
methadone, it should be three times a day, not twice 6 prerogative of any clinician to determine which prior 
a day? 7 medical records that clinician will seek. That's an 
A. Well, it's not just my opinion. It's the 8 absolutely true statement in the broad generic sense. 
science. 9 But when you have a patient who you're putting on a 
Q. But that's your opinion -- 10 profound respiratory depressant, which an opioid by 
A. Yes. 11 definition is, particularly when it's a new opioid to 
Q. -- in this case? 12 that patient, and when this patient has been under 
A. Yes, for a patient with good renal 13 the care of a physician with this type of credentials 
function. And this lady's renal function was 14 previously and the patient comes !o you as a 
perfectly adequate. 15 relatively low level •• well, as a midlevel 
Q. And what's your basis for that opinion? 16 practitioner, whereas the patient had already been at 
A. I refer you to my chapters. 17 a tertiary level practitioner with the dual 
Q. But if you could just provide an 18 subspecialty boards, it is certainly unwise and, in 
explanation. 19 my opinion, below the standard of practice no! to 
A. This drug is eliminated through the 20 obtain the records from that other clinician. 
kidneys. If your kidneys are functioning 21 Q. And why is that? 
inefficiency, then by defini lion the drug will 22 A. Because this is a patient with multiple 
recirculate through the body. The kidney is the 23 morbidities who has been under the care of a 
valve that lets the -- lets the body eliminate what 24 special -- a dual subspecialist for relatively 
is dissolved in the blood. The urine is the filtrate 25 complex disorders who has a severe chronic pain 
' .. ,., 
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disorder, which is by definition very difficult to 1 medications. I know that she had a cardiologist, I 
treat, who is coming to the new clinician, Mr. Byrne, 2 believe. I know she a primary care physician. The 
not because of dissatisfaction with the prior doctor 3 concern, obviously, that any knowledgeable clinician 
but because of geographic convenience. Very 4 would have is respiratory depression from the new 
reasonable thing. rt's not only good medical 5 opioid because of the incomplete cross-tolerance when 
practice, it's just plain common sense and intuitive 6 changing from the OxyContin to the methadone. 
sense that you would want to get the opinion of this ·7 Q, But it's Dr. Vorse's records th.at you1re 
other specialist so that you will get a more complete 8 critical of Mr. Byrne not obtaining? 
history. 9 A. At least her opinion. I'm not saying he 
Of note, in the records that I reviewed 10 needed to get medical records, I'm saying he at 
there was concern expressed by, I believe, a plimary lJ. !east needed to communicate with her, if not medical 
care physician of Mrs. Schmechel, or was it a 12 records, at least, you know, how's she doing? What 
cardiologist, about her not being able to 13 are the concerns? I mean, these are conversations we 
particularly well tolerate the pressures -- the CP AP 14 have in our clinic with referring physicians every 
pressures that Dr. Vorse had ordered. 15 day, and not just referring physicians, but prior 
As I'm sure your aware, as any clinician 16 care givers for patients who come to our clinic, 
is well aware, a CPAP is a relatively uncomfortable 17 Q, And he should have had that conversation 
device, and noncompliance with CP AP and ill-fitting 18 with her or obtained her records prior to making any 
masks is a very common confound. It's absolutely 19 change to her treutment, correct? 
essential for any clinician to know that the patient 20 A, Certainly, 
is compliant with the CPAP, is tolerating the CPAP, 21 Q, Okay, With respect to Dr. Verse's 
is using ii as prescribed, not simply to know that it 22 records 1 have you reviewed those records? 
was ordered. Yet, in the simplistic reductionist 23 A. Yes. 
affidavits that your experts presented, they 24 Q, And do you believe that you have a 
indicated that there's no problem with using an 25 complete copy of those records? 
Page 91 Page 93 
opioid i11 a patient who has obstructive sleep apnea 1 A. I believe so. 
as Jong as the patient is on CPAP, 2 Q, Was there anything in her records that you 
Well, that's an absolutely true statement 3 believe would have changed the course of what was 
as far as it goes. But the essential part of this 4 done? 
that would clearly come out in trial, if asked, is 5 A, Possibly, The bigger issue·· the biggest 
does everybody wear the CP AP mask easily? ls it 6 issue is Dr. Vorse's records were -- reasonably well 
everybody compliant? ls it essential to know whether 7 documented the fact that this lady had a severe 
the patient is compliant with and tolerating the CPAP 8 chronic pain disorder, She had degenerative joint 
before determining that it's adequate to support the 9 disease. Her pain was not going to be cured. Her 
patient's respiratory function dming sleeping hours? 10 pain was going to be managed at best. And the goal 
That's not addressed. And I don't know whether 11 of-therapy, as Dr. Vorse documented it, and indeed as 
Mrs. Schmechel was able to use her CP AP properly. I 12 the testimony supports, was to make her as 
don'l even know if she felt thal she should continue 13 comfortable and as functional as possible with the 
using her CP AP when she changed her care from 14 recognition that she was going to have significant 
Dr. Vorse to Mr. Byrne. So these are all confounds 15 chronic pain the rest of her life. 
that really concern me, 16 Now, this was impo11ant information for 
Q, Okay. And with respect to that, as your 17 any o1her clinician addressing Mrs. Schmechel's pain 
opinions pertain to records from another provider1 as 18 to have in hand before making any decisions. I have 
I understand, it's Dr. Vorse that you felt Mr. Byrne 19 no idea, because of the paucity of the documentation, 
should have at least called and had a conversation 20 the very poor quality documentation of Mr. Byrne 
with and/or obtained her medical records? 21 that -- you know, what was discussed with her. 
A. Correct. 22 There is a clear standard of practice 
Q, Okay, No other physician? 23 here, As l mentioned earlier, the Federation of 
A. That's the one of most concern to me 24 State Medical Boards in the United States has 
because Dr. Vorse had been the person prescribing the 25 published initially model guidelines, now model 
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policy on use of controlled substances for management 1 that you believed Mr. Byrne should have had. 
of chronic pain. You can find thoseon FSMB.org, the 2 A. The history of medications that the 
publications, policies. It's public info11nation -- 3 patient received, how she responded to them) the 
evety state medical board in the country has those -- 4 difficulty in managing her problems, and the 
that clearly spell out what should be documented in 5 difficulty in managing her sleep apnea. Those are 
the record. 1t wasn1t done. So there1s not enough 6 the major issues that I recall. There may be other 
infotmation from Mr. Byrne's records for me to know 7 minor issues thal I might find ifl were to go 
what he actually discussed with the patient. 8 through the records again. 
I'm fu11her concerned that Mr. Byrne's 9 Q. Are you aware, in reviewing Dr. Vorse1s 
documentation is terribly inconsistent. What he 10 records, if Mrs. Schmechel did not adequately or 
wrote on the prescription, what he says he told the 11 accurately provide an oral history to Mr. Byrne 
patient, what the family says he told the patient 12 related to what she had been on, you know, as her 
differ. And this is well below the standard of 13 pain regimen over the last couple of years? 
practice because patients get confused easily. There 14 A. He did not document a long-tetm pain 
has to be a consistency in what they're told in 15 regimen. He documented what she was on presently. 
writing and what they're told verbally and what their 16 And he did -- and what she reported there to him, 
support system is told ifwe want a potentially 17 what Mrs. Schmechel reported to Mr. Byrne was 
dangerous medication to be used with the best 18 consistent with what Dr. Verse's records reflected. 
possible safety. 19 What is not documented in Mr. Byrne's records is the 
Q. Let's go back to Dr. Vorse's records. Is 20 difficulties that Mrs. Schmechel had had with her 
there anything in her records that, in your mind, 21 CPAP previously. 
should have caused Mr. Byrne not to start her on the 22 Q. Okay. So other than the difficulties tl1at 
dose that he did? 23 she had had with her CPAP previously, is there 
A. Not the starting dose, no. 24 anything else contained in Dr. Vorse's records that 
Q. Okay. Is there anything in Dr. Vorse's 25 you believe Mr. Byrne should have known? 
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records that you believe Mr. Byrne should have 1 A. Well, he needed to know how she had 
identified related to increasing the dose of the 2 responded to the opiates over time and how the doses 
methadone? 3 had been titrated. The biggest issue is what are 
A. Yes, the issue that -- well, the fact that 4 reasonable expectations of care. His records do not 
CPAP had been ordered and that there were variable 5 reflect that in any way, 
pressures. Several months ago since I read 6 Q, And so when you say that he had no idea of 
Dr. Verse's records. And my recollection now, which 7 how she was titrated on other medications, would that 
may not be complete, is that there were concerns 8 be, for instance, the OxyContin? 
about her sleep apnea management, and there certainly 9 A. Yes. 
were concerns about how well her pain could be 10 Q. What other medications? 
managed. 11 A. She also was taking a hydrocodone 
A critical issue in chronic pain is 12 acetaminophen which he immediately increased from a 
patient expectation. \Vhen patients go to a new 13 7-1/2 milligram hydrocodone dose to a 10-milligram 
clinician, they always go with a new hope. I've got H hydrocodone dose. That's not a major issue, and I'm 
a new provider. Can 1 get better care? That's 15 not critical of that, per se. But it would have been 
perfectly appropriate and reasonable and 16 very helpful for him to know what her history was 
understandable. ll's very impot1ant that Mr. Byrne 17 there. Had there been an increasing trend, had she 
have a realistic picture of what a well-trained pain 18 been on a higher dose to which she had responded 
specialist has learned in, I believe it was several 19 bet1er pain-wise but had had adverse effects, which 
years of treating this patient. If you don't know 20 would have resulted in Dr. Vorae lowering the dose. 
the history, you're going to make the same mistakes 21 The more history that we get with a chronic pain 
over again, to quote Santayana. And he didn't obtain 22 patient, the more we understand the gestalt and the 
the information that he should have obtained. 23 better we can manage the patient's care, 
Q. But that's what I'm trying to get to is 24 Q. With the hydrocodone, thafs not a 
what information is contained in Dr. Vorse1s records 25 criticism, though, that you have saying that that was 







l a breach of the standard of care for him to increase 
2 the hydrocodone, correct? 
3 A. Co1Tect. 
4 Q. Okay. You've talked about missing 
5 documentation and inconsistent documentation. I'd 
6 like to take those two items and separate them out 
7 and first talk about missing documentation. In 
8 talking about that you had talked about the FSMB.org 
9 site. 
10 A. Correct. 
11 Q. Do you know what Idaho provided for with 
12 respect to documentation in these types of situations 
13 in 2003? 
14 A. I don't. I assume (hat Idaho, like most 
15 jurisdictions in this part of the country, simply 
16 adopted the FSMB model policy, or some significant 
17 part thereof. Many state medical practice acts do 
18 not go into lot of detail, and then the legal 
19 standard de facto becomes what is published by the 
20 PSMB. And so lam working under the assumption that 
21 that would be applicable since the Idaho State Board 
22 of Medical Practice, or whatever it's called in 
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clearly spelled out in that document. 
Q. (BY MS. DUKE) And which areas do you feel 
that he was lacking in with respect to his 
documentation regarding Mrs. Schmechel? 
A. His notes are very, very cursory) very 
outlined. He indicates what she was on previously, 
that she wasn't responding to it adequately. The 
pain is not quantified using any of the standard pain 
quantification instruments that we use. TI1ere1s no 
statement of expectation. And there's no statement 
of his having disc\JSsed the risk/benefit ratio with 
her of using this medication. 
Again, that's recollection. It's a while 
since I've looked at his records. 
(EXHIBIT-9 WAS MARKED.) 
Q. (BY MS. DUKE) I've handed you what's been 
marked as Exhibit Number 9 to your deposition, and 
!'II represent to you that this is a copy of the 
medical chart kept by Southern Idaho Pain and 
Rehabilitation Institute that was provided to us. ls 
this the chart that you reviewed? 
A. Yes. 
Q. Those are all the documents that you had? 
A. Yes. , 
Q. And if we turn, first of all, to-- see r, 
1----'----'---"--------------+----"---------'----'---------t>> Q. Okay. But you don't know that for 
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1 certain? 
2 A. No. 
3 Q. And in 2003, September of 2003, what did 
4 the FSMB model policy provide with respect to the 
s documentation in a scenario such as Mr. Byrne seeing 
6 Mrs. Schmechel? 
7 MR. HIPPLER: Object to the form. I 
8 believe in 2003 it was guidelines, not policies. 
9 Q. (BY MS. DUNE) Or guidelines. 
10 A. No. Jt was policy in 2003. It was 
n changed. In I 998 was model guideline. I believe 
12 2002 was the year it was changed to model policy. 
l3 But it's the same document. Policy is just a much 
l4 stronger document within the taxonomy of the 
15 Federation of State Medical Boards. 
16 . There are eight explicit things that are 
17 desc1ibed there. I can't recite them verbatim off 
18 the top ofmy head. They're in the document. 
19 Specifically, complete medical history, a complete 
2 o description of all interventions, discussion of 
21 risk/benefit ratios) consultations that are obtained 
22 or are going to be obtained 1 obviously any 
23 interventions, which would be what he did document, 
24 what he prescribed, and plan for fo]low-up care. 
25 Those are the ones that jump out at me. But this is 
., •• ., •• • •••"[ T "'"' • •• •'"•','''",'•"' •.:•·cv;,, -,, . ., 
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l the little Dille 00 numbers? 
2 A. Yes. 
3 Q. Okay. If you turn to Dille 00 --
4 A. Eleven. 
5 Q. -- 11, it looks like you're there. And 
6 then also to Dille 15 and l 6 along with the pain 
7 questionnaire of 17 through 20. In looking at those 
8 documents, which I understand to be the primary 
. 9 substantive documents that contain information tl1at 
1 O was relayed to and from Mr. Byrne and 
11 Mrs. Schmechel --
12 A. Correct. 
13 Q, -- if you could point out what you believe 
14 is inadequate. And take your time to read those. We 
15 can go off the record, if you'd like, just to refresh 
16 your recollection. 
17 A. Okay. 
18 Q. Okay. So based on your review of those 
19 records, what do you believe is lacking, if anything, 
2 O from the standpoint of Mr. Byrne's documentation 
21 regarding his initial evaluation with Mrs. Schmechel? 
2 2 A. The major issue which is directly relevant 
23 to this case is discussion of risk/benefit ratio 1 
2 4 which is explicitly described in the Federation model 
2 5 policy. He states here in his plan that he is going 
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1 to discontinue OxyContin, start her on methadone I 0 
2 milligram q 12 titrated from 5 milligram up to a 
3 maximum of J 5 milligrams within the next 72 hours, l 
4 don't see any statement in here about the lisk of 
5 increasing more rapidly. l don't see any clear plan 
6 of titration. He says titrated dose from 5 to a 
7 maximum of 15, Is that five twice a day? Five three 
8 times day? Five four times day? Over the next 72 
9 hours? No discussion of the risk ofrespiratory 
1 o depression, no discussion of the issue of incomplete 
11 cross-tolerance, which is what presents the risk to 
12 her. This is specifically the issue that l believe 
13 led to her demise, 
14 Q. Any other items that you believe were left 
15 out that should have been put in? 
16 A. Well, it would have obviously been very 
1 7 useful, as f have described, to have a more complete 
18 history from Dr. Vorse. We have history of present 
19 illness, past medical history. He mentions that 
2 o she'd been under the care of Dr. Vorse for pain 
21 management. He doesn't mention anything about her 
2 2 being under the care of Dr. Vorse for her obstructive 
2 3 sleep apnea. 
2 4 Let's look in here and see. Chief 
2 5 complaint. I'm looking for comorbidities. 
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1 Neurological. What do we have under respiratory? 
2 lsn't that interesting. Nothing. All systems 
3 reviewed and otherwise unremarkab1e? This is 
4 incredible. l hadn't picked this up until you 
5 brought it to my attention. There's nothing about 
6 her sleep apnea here under respiratory1 review of 
7 symptoms, directly relevant to this case, 
8 There's a very incomplete history on her 
9 diagnostic studies. She had had sleep studies, at 
10 least one complete one, nothing previously, and 
11 that's not mentioned at all. I'm absolutely--well, 
12 let me say I'm very surprised to see that there's no 
13 mention in here at all of her sleep apnea, which says 
14 to me he took a very incomplete history. 
15 Q. Okay. Any other criticism of his 
16 documentation? 
1 7 A. Those are the ones that I see at this 
18 poinl. 
19 (Witness confers with Mr. Foster off the 
2 o record.) 
21 A Counsel refers me to page Dille 11 here, 
22 but l'm reading the typed summary, which is what 
2 3 people typically would look at. Okay. Had epidural 
24 injections, low back pain, Dr. Vorse. Okay. He has 
2 5 CPAP and has it down stable on his handwritten notes 
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1 on page 11. 
2 Q. Right. He also says sleep apnea light 
3 before that. 
4 A. I'm sorry? 
5 Q. He also says sleep apnea right before 
6 that. 
· 7 A. Right, Yeah. So --
8 Q. Okay. So that is documented? , 
9 A. I did see that previously. So that's -- I 
10 guess that's why I didn't react to it previously. I 
11 am1 however, surprised that it's not in the typed 
12 summary because the typed summary~- normative 
13 medical practice is we rarely, if ever1 go back and 
14 read the handwlitten notes which are the basis for 
15 the dictated or typed summary. We always go back and 
16 read the typed summary previously. So was it in the 
17 record? Yes, Was it where itbelonged--whereit 
18 was needed in the record for future review? No. 
19 One could argue that. 
20 Q, With respect to these criticisms that you 
21 have of documentation, the failure to document 
22 something in and of itself, obviously, does not cause 
23 hann to the patient, correct? 
24 A. No. Failure to document unfortunately 
25 often does cause hann because at future visits we 
Page 10s 
1 don't have the information we need. 
2 Q. Well, let's take Mrs. Schmechel. In her 
3 instance any of the failure to document, as you call 
4 them, none of those caused her injuries} correct? 
5 A. This is a different question than you 
6 asked me previously. I believe that her death was 
7 due to too rapid titration of methadone. Failure to 
8 document is not what caused the death. 
9 Q. Right, 
·10 A. It was the way the methadone was titrated. 
11 Q. Okay. That's what I'm getting to. So you 
12 might have criticisms as to not including something 
13 in the records, but at the end of the day that's 
14 certainly not what you're saying led to her ultimate, 
15 you know, death. 
16 A. Y cs, I was answering the question you 
1 7 asked, which was whether tile note was within standard 
18 ofprnclice. And my answer was no. Now you1re 
19 asking a different question, is the failure of that 
·2 O note to meet standard of practice causation here, and 
2 J. the answer is no. 
22 Q. Right Okay. So now going to what you 
23 understand Mr. Byrne discussed with Mrs, Schmechel 
24 regarding the risks, benefits, alternatives 
2 s available, what's your understanding of what 
... , ... .,, .. , .. ,,.,.,,, .. 
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1 conversation occurred? 
2 A. Well, r don't have a good understanding 
3 because I have inconsistent records. I have his 
4 saying one thing in testimony and his writing 
5 something else in his note and his writing something 
6 else in his WM the sam·e as the note as what he wrote 
7 on the prescription, which says to me that there is 
8 either an intentional or unintentional inconsistency 
9 in what he is saying, He did not document the 
10 concems that l would have. l write notes on this 
11 type of thing regularly. I always put down, under 
12 plan, explicitly discussed with the patient the risk 
13 of this medication and the importance of adhering to 
14 the presctibed regimen and not taking additional 
15 doses. That's standard of practice. You are 
16 required to both educate the patient on that and to 
17 document what education you gave to the patient. 
18 Q. And do you have an understanding as to 
19 whether or not he has testified in this case that he, 
20 in fact, did have that conversation with 
21 Mrs. Schmechel on that Friday? 
22 A .. Well, as I have said more than once 
23 previously, what he wrote and what he said I find 
24 inconsistent> and now I'm concerned about that. I 
25 don't know what he said to Mrs. Schmechel. 
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1 Q. Have you read his deposition? 
2 A. Yes. 
3 Q. And what do you recall him saying in his 
4 deposition as to what he discussed with 
5 Mrs. Sclunechel regarding the treatment plan that he 
6 was initiating for her on that Friday? 
7 A. My recollection is that he told her what 
8 she should take and that she shouldn't exceed that. 
9 But what he told her to take was a rapid titration 
1 O from what he said was 5. What he wrote was 10 to 15 
11 milligrams twice a day, that she could increase that 
12 to three times a day. And I have some recollection, 
13 this may be incoITect, that he also talked at some 
14 point about four times a day -- that may not be 
15 coITect -- of taking her methadone, and that she 
16 would titrate up basically on a daily basis. 
1 7 So if she started on Saturday, she could 
18 go up on Sunday, go up again on Monday. 
19 Q. All right. But you do understand that 
20 it's Mr, Byrne's testimony that he had a conversation 
21 with Mrs. Schmechel in that regard? 
22 A. Yes. 
23 Q. I understand that you're ctitical of that 
2 4 not being written in the notes, 
25 A. Yes. 
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1 Q. But other than that, are you critical of 
2 what he told Mrs. Schmechel regarding the initiation 
3 of the therapy that he would be instituting on that 
4 Friday? 
5 A. Yes. 
6 Q. Okay. And what is that criticism? 
7 A. That the titration was inappropriately too 
8 rapid. 
9 Q. Any other criticism of what he has 
10 testified that he told her on that Friday regarding 
ll the initiation of therapy that he was providing? 
12 A. Initiation is not the issue, It1s the 
13 continuation that1s the issue. And I don1t recall 
14 anything else at this point. 
15 Q. Based on your reading of the records, 
16 based on your review of Mr. Byrne's deposition, what 
17 did you understand to be his initiation of therapy 
18 with respect to methadone and then his titration of 
19 that drug over the next couple of days? 
20 A. Initiation> as I understand it, was at 10 
21 milligrams twice a day, although his testimony says 5 
22 to l O milligrams. His testimony also said that the 
23 patient could increase it to as high as 15 
24 milligrams. And, indeed, in his -- l don't recall if 
25 it was testimony or records, I think it was 
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1 testimony, he said that in a conversation with her 
2 two or three days hence that he had approved 
3 increasing it to 15 milligrams. J think that answers 
4 the question. 
5 Q, Okay. So it was your understanding that 
6 she was to start at l O milligrams a day? 
7 A. Yes, twice a day. Not once a day, twice a 
8 day. 
9 Q. And then to titrate up --
10 A. Daily. 
11 Q. And what did you understand -- for 
12 instance, if she were to staii on Friday at bedtime, 
13 what did you understand he communicated to her with 
14 respect to what she should do Saturday? 
15 A. Pm not clear on that because, again, J1m 
16 finding inconsistency. I saw a prescription record 
1 7 from The Medicine Shoppe that indicated a 30-day 
18 supply of90 tablets, and the mathematics says that's 
19 three tablets a day for 30 days. 
2 O From what he said or what I read in the 
21 documentation, I understand that he told her that she 
22 could titrate up from 5 to 10, 10 to 15, perhaps from 
2 3 two to three times a day, maybe to four times a day, 
2 4 in a daily manner, in a very rapid step-wise manner. 
2 5 Q. But you would agree that's in his 
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1 documentation and also in his deposition? 
2 A. I believe so. 
3 Q. And so ifwe look, then-- I mean,just 
4 based on what your evaluation is as to what she was 
5 to do, what did you understand that she should do 
6 Friday? Let's say she takes an evening dose. What 
7 should that evening dose be? 
s A. Ten milligrams. 
9 Q, Saturday? 
lo A, Ten milligrams twice a day. 
11 Q, Sunday? 
12 A. I'm not clear whether it was an hicrease 
13 to three times day or whether it was an increase to 
14 l 5 milligrams twice a day or maybe even 15 milligrams 
15 three times a day. That's where I don't have a clear 
16 picture, 
1 7 Q. And what makes you think that he increased 
18 her to three times a day? 
19 A. The fact that he ordered 90 tablets for a 
2 o 30-day supply. And, again, I'm sorry, my 
21 recollection on this is not crystal clear. But I 
22 thought there was a mention at some point of 
2 3 increasing the frequency to three times a day, I may 
2 4 be incorrect. 
25 Q, Okay. And please, you know, if you'd like 
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1 to look at the records, you can certainly look at the 
2 records we've already guided you to. You can also 
3 look at the ·· 
4 A. And feel free to guide me ifl'm incorrect 
s on where it should be. 
6 Q. The 29th and 30th. For instance, let's 
7 take the 29th, which is at Dille 0013. That says, "l 
B spoke to Ms, Schrnechel today in reference to her 
9 medication change to methadone. She was doing well. 
10 I advised her to go ahead and increase her methadone 
11 to 10 milligrams at bedtime and 10 milligrams 
12 daytime.'1 
13 A. This is one of the areas where I have 
14 confusion because on Friday J believe his records 
15 said he told her to take 5 to 10 milligrams of 
16 morning and evening. And I understood she was taking 
17 that, When I look at Dille 0012 dated 9-30, she's 
18 taking 10 milligrams a.m., 15 milligrams p.m., and 
l 9 advised her to titrate dose on a variable dose 
20 between 10 and 15 milligram a.m. and 10 to 15 
21 milligram p.m, This is the rapid titration to which 
22 I refer. 
23 Q, l understand that, but l'm on something 
24 different at this point. With respect to the dosing 
2 5 frequency, you've alluded a couple oftirnes .. 
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1 A. Yeah. 
2 Q. •• that you had thought that he had 
" 3 increased that to three times a day, and l guess l 
4 would like you to show me where you believe that says 
5 that. 
6 A. Okay. I may have drawn that conclusion 
7 from the fact·· from the prescription .. the 
8 pharmacy printout that listed 90 tablet.s for 30 days. 
9 Q, Well, you'd certainly agree that they're 
10 10-milligrnm tablets. 
11 A. Yes. 
12 Q. And if she's ultimately going to take 15 
13 milligrams a day, that would require·· or twice a 
14 day-- excuse me. 
15 A. Fifteen milligrams twice a day requiring 
16 three tablets, that's correct. 
17 Q. Exactly. Okay, So other than·· 
18 A. So may be the case. But it's the total 
19 number of milligrams of drug. Because of the long 
20 half-life, this drug will, by definition, accumulate. 
21 lf it were a shorter-acting drug such as morphine or 
22 oxycodone, not OxyContin but short-acting oxycodone, 
2 3 taking it two or three times a day would make a 
2 4 profound difference in the elimination from the body 
2 5 because of the short half-life, With its long half-
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1 life, whether you take a total of 30 milligrams as 
2 one, two, or three doses a day, the net effect of 
3 what's remaining in the body is going to be very 
4 similar. So from a toxicological perspective Ws 
5 the same. 
-6 Q. Okay, 
7 A. So, as I said earlier, I may have been in 
8 error on the three times a day. That was an 
9 assumption I made. 
10 Q. Okay. And I just wantto make sure that 
11 there's not something I'm not seeing that you're 
12 seeing, and J want you to show me it if you believe 
13 that she was on three times a day. 
14 A, Sure. That's why we're here, 
15 Q. All right. 
16 A. Okay. 
17 Q. So based now upon your review, it looks 
18 like he was continuing to have her on a course of 
19 twice a day with varying milligrams. 
2 O A. And 1 again, that1s concerning to me 
21 because of the relatively short duration of the drug 
22 in the first few days of therapy. Because of the 
2 3 variable kinetics, this is a drug that after a week 
24 or so would probably work fine twice a day in many 
25 patients, not in everybody, but in many patients, 






1 But in the first week of therapy it's a much shorter 
2 duration. 
3 That would also cause me concern from the 
4 risk of her taking additional doses, which we do not 
5 know whether that was the case. 
6 Q. Right. 
7 A. But that certainly would have been 
8 consistent with her demise. 
9 Q. And l was going to ask you about that 
1 o because l saw it in your disclosure. You certainly 
11 don't know whether or not she followed Mr. Byrne's 
12 instruct.ions or if she increased her hydrocodone and 
13 her methadone, correct? 
14 A. CoITect. 
15 Q. It would be speculation for any ofus to 
16 testify to that? 
1 7 A. It would be. But r did express concern, 
18 and, again, you can help if I'm missing something 
19 here. I'm only interested in getting the truth out. 
20 And that is whether he explicitly cautioned her not 
21 to exceed the prescribed dose. 
22 Q. Okay. Do you recall reading his 
2 3 deposition? 
24 A. l do, but l don't remember the details. 
25 lt was a while back. 
Page 115 
1 Q. Okay. But ifhe were to testify that he, 
2 in fact, did inform her that it's very important that 
3 you don't take over the amount that I've prescribed 
4 you, you would feel that that's reasonable for him to 
5 tell her, coITect? 
6 A. I would think it's essential for him to 
7 tell her that. But at the same time it's essential 
8 for him not to prescdbe an amount that would have 
9 been potentially excessive. 
10 Q. Ifhe had started her off on 15 milligrams 
11 a day -- excuse me -- 15 milligrams twice a day, once 
12 in the morning, once in the evening) would you be 
13 critical of that? 
14 A. That is not a black-or-white issue. This 
15 is a shades-of-gray issue, I'd be more concerned 
16 about starting her on 30 milligrams a day than 20 
17 milligrams a day. As l mentioned previously, we do 
18 not have good dose conversion numbers for methadone. 
19 It's uniquely difficult. It's a uniquely difficult 
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1 milligrams, let's say that that was the course of 
2 action he look, and he said, I want you to take 15 
3 milligrams of' this twice each day, would that be 
4 something that you would be critical of him from the 
5 standard of care standpoint? 
6 A. I'd be more concerned about 15 twice a day 
7 on 30 a day than I would be initially 20 a day. Nol 
8 a black-and-white issue. 
9 Q. Okay. 
10 A. I would want to see documentation in the 
1l record on why he did that. 
12 Q. You're saying you would be more concerned. 
13 But does that mean that you would be critical of him 
14 from the standpoint of 15 milligrams twice a day is a 
15 breach of the standard of care period? 
16 A. There's not a clean cutoff here between 
1 7 one and the other. If! wanted to be as hyper-
18 critical as I could be, I would be more concerned 
19 about starting with the drug on a Friday. I'd be 
20 more concerned about giving her a month's supply. 
21 Neither of those by itself is outside of standard of 
22 practice. If you take each of these elements 
23 individually, which is what you do and what you're 
2 4 supposed to do, and try to dissect them and say is 
25 this a violation of standard of practice, is that a 
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l violation of standard of practice, those are 
2 perfectly reasonable and appropdate questions. 
3 You're asking me as an experienced pain clinician who 
4 teaches this and who does this whether the overall 
5 care was within standard of practice, whether the 
6 entire package that you put together was one that 
7 presented an unreasonable risk to this patient. My 
8 conclusion is yes) it di.d present an unreasonable 
9 risk to the patient. 
10 Now, has it ever been done with patients 
1.1 not having adverse outcomes? Of course1 it has, 
12 But, tragically, this patient did have the worst 
13 possibly adverse outcome. And everything in this 
l4 pattern of care points to the fact that it was the 
15 way in which this medication was used that was the 
16 major contributor to her death. 
17 Q. Okay. And !understand that that's your 
18 opinion. But with respect to ifhe had initiated her 
19 at 15 milligrams twice a day, as I understand it, 
I 
2 o drug to convert from other opioids, which is why wise 
21 clinicians do this very conservatively. And that 
2 o that is not something that you would be here saying i 
22 was, indeed, what the IO milligram initially was as 
23 Dr. Hare and Dr. Binegar stated in their affidavits. 
24 And I concur with that. 
25 Q. But ifhe were to have started her at 15 
21 that's a breach of the standard of care; is that 
22 correct? 
23 A. You 1re asking me, again, to assign a yes 
24 or no answer to a gradation issue. [ would bernore 
25 concerned aboutsta11ing heron 15 milligrams twice a 





l day than l would be on starting her on IO milli&>rarns 
2 twice a day. I think the 10 milligrams twice a day 
3 was a reasonable dose. Would 25 milligrams a day or 
4 30 milligrams a day be grossly unreasonable? I can't 
5 answer that yes or no. I would be less comfortable 
6 with that. I am comfortable with What be did --
7 Q. Okay. So --
8 A. -- initially. 
9 Q. .. as you sit here today, you do not have 
l O an opinion whether that would be a breach of the 
11 standard of care or within the standard or care to 
12 have started her on 15 milligrams twice a day and 
13 just kept her on that? 
14 A. I'm not trying to be difficult and I 
15 understand what you're asking and l understand why 
16 you're asking it. And l can't answer that question. 
1 7 What l can state unequivocally is that the risk to 
18 this lady of giving -- of starting at 15 twice a day 
19 as opposed to lO lwice a day would have been markedly 
2 O greater and would have caused me more concern, 
2l. Q. But, beyond that, I would assume tliat you 
22 can1t answer my question? 
23 A. That's correct. 
24 Q. Okay. With respect to the titration, now 
2 5 that we have it cleared up that it was kept at twice 
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1 a day, describe for me what your criticism is with 
2 respect to the titration that Mr. Byrne advised 
3 Mrs. Schmechel to follow. 
4 MR. FOSTER: Object to the fom1. Go 
5 ahead. 
6 THE WITNESS: My objection to the way he 
7 did this, my concern abo11t the way he did this is 
8 that he increased the dose on a daily basis when the 
9 level of analgesia had not yet maximized. Now, when 
10 you keep increasing the dose, you are by definition 
11 seeking more pain relief and you are by definition 
12 inducing more risk of respiratory depression. 1t is, 
13 therefore, incumbent upon the clinician to not 
14 increase the dose until the maximal effect from 
15 the -- maximal analgesic effect from the dose has 
16 occurred. If you do that, if you increase the dose 
1 7 too rapidly, your rcspirat<,ry depression exceeds the 
18 target, gets you into risk when you have not yet 
19 reached the m_aximum analgesics dose. 
2 o· Therefore, it is incumbent upon him to 
21 increase the dose of methadone slowly. Had he 
22 increased the methadone every four days, for example, 
2 3 and had allowed her to use more of her short-acting 
24 hydrocodone for break-through pain to keep her 
2 5 comfo11able, that would have been far, far safer 
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1 because, as l mentioned earlier, the half-life of the 
2 hydrocodone is only two homs, 1.9 hours to be exact, 
3 and, therefore, it would be eliminated from the body 
4 rapidly. 
5 So it's a matter of~- and, again, we can 
6 show this graphically -- it's a matter of her serum 
7 level going up gradually. I'm sorry, of her 
8 analgesia going up gradually and her respirato1y 
9 depression going up more quickly. 
10 MR. HIPPLER: Before you go on, I was 
11 going to do this earlier, and l apologize for not 
12 having done that. Can I have a standing objection as 
13 to foundation with regard to the qualifications of 
14 the expert? I don't want to interrupt you every 
15 time. I'll just have a standing objection. 
16 Q. (BY MS, DUKE) Would itbe any different 
1 7 from the standpoint of the graphs you're talking 
18 about-- and have you prepared any of those graphs al 
19 this point? 
20 A. No. 
21 Q. Okay. Would it be any different with 
22 respect to the graphs that you're talking about 
2 3 potentially doing if you have a patient titrate up 
24 from 10 to 15 milligrams? You know, you've got them 
2 5 on 10 milligrams for the first couple of days, and 
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1 then, let's say, day three you bump them up to l 5 
2 milligrams. Would the graph be any different from 
3 that titration example versus just starting the 
4 patient on 15 milligrams, or would the levels be tbe 
s same? 
6 A. No. lfyou started the patient initiaJly 
. 7 on 15 milligrams twice a day and continued it for two 
8 or three days at 15 milligrams twice a day, yournet 
9 area under the curve, which is the geometric 
10 representation of how much drug is in the body, would 
11 be greater than if you started at l O and then went to 
12 15. The concern I have, however, is not just the 
13 area under the curve. It's the rapidity of the 
14 increase. Because it will take several days to reach 
15 the optimal analgesia from the twice daily dosing 
16 that this lady was receiving. Therefore, you don't 
1 7 really lmow what your target is. If you keep 
18 increasing the dose and your increases are occuning 
19 more quickly than the peak of the analgesia is 
2 O occuning, then you basically can go past your 
21 desired effect and get into the toxic range. That's 
22 the inherent risk of methadone. 
23 Q. How many increases do you believe 
24 Mr. Byrne advised Mrs. Schrnechel to undertake? 
25 A. My understanding is that he advised her 
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1 that she could increase the dose on a daily basis. 1 A. And as we've discussed earlier, everything 
2 So if she started her first dose on Friday evening, 2 is risldbenefit. There is an inherent risk in the 
3 as you have suggested, that she could then increase 3 use of every drug. It's our job to minimize the 
4 on Saturday, increase again on Sunday, increase again 4 risk, to optimize the benefit. And that wasn't done. 
5 on Monday. And he gave her a sliding scale of going 5 Q. Okay. So let me try to step back just a 
6 10 to 15. So if she started at 5 -- which is what he 6 little bit by that qualification that you just 
7 contended, although that's not what either his 7 provided. One increase in the dose would have been 
8 prescription label or his records documented -- ifhe B okay from the standpoint of Mrs. Schmechel's 
9 started her on 5 and then she went to l O the next day 9 treatment. It's the multiple increases withh, a 
10 and 15 the next day, that's a very rapid increase. 10 tight time frame that you're critical of? 
11 In pha,macokinetics we never deal with numbers. We 11 A. Exactly. One increase, obviously, would 
12 deal with percentages. The body and any 12 be more dangerous than no increase, but we're trying 
13 thermodynamic machine only relates to percent 13 to optimize analgesia, And we're accepting a certain 
14 increases. This is a JOO percent increase. This is 14 amount of inherent risk. 
15 the correct increase after you reach steady state 15 Q. And that would be something that·· you 
16 serum levels. This is a potentially fatal increase 16 know, an increase> that one increase would be 
17 before you reach steady state serum levels. Again, 1 7 something that you would feel -- we're walking a fine 
18 five half-lifes to reach steady state serum levels. 18 line here. It's still within the standard ofcare to 
19 Half-life of this drug, be conservative, say it's 40 19 do, but it's not within the standard of care to 
20 hours. Say it's 30 hours. That's 150 hours. So 20 increase multiple times over a six-day period? 
21 five, six, seven days, that's the right time to 21 A. l would agree with that. 
22 increase the dose. 22 Q. And with respect to that, when you talk 
23 Now, this is a lady who was -· did have 2 3 about the chart -- and I might need you to just draw 
24 some respiratory tolerance to the medication -- this 24 one out as a sample because when you're talking about :' 
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tolerance .. because she had be on the oxycodone and 1 referencing. So I'll give you a fancy piece of 
the hydrocodone previously. And, therefore, I would 2 yellow paper here. E 
be comfortable being a little bit more aggressive in 3 A. I'm sorry. I can't do it. It's not legal ·'' 
titrating her up. That's why I say every three or ·4 size. 
four days would be reasonable. Had she been opiate 5 Q, That's right. 
naive, no less than five, preferably seven days would 6 A, Okay. We're looking at the serum 
have been appropriate, 7 concentration, which is Cs here> and we're looking 
MR. HIPPLER: Can we take a break? 8 at -- let's see. She was dosed twice a day, so let's 
MS. DUKE: Sure. 9 put in 12-bour increments on the horizontal axis. 
(A short recess was taken.) 10 Q, So the horizontal axis is the time? 
MS. DUKE: Okay. Back on the record. 11 A. Exactly. 
!' Q. (BY MS. DUKE) l'm going to try to ask 12 Q. Okay, 
this in an artful way that hopefully makes sense. 13 A. So this is time 0, this is time J 2 hours, 
But with respect to this titTation issue that you've 14 24, 36, etc. So the first dose·· Now, let me start 
testified to, it's my understanding that your 15 by showing you something about methadone. The dose 
cdticism is that the first titration should not have 16 response curve on morphine or any other opioid is 
occurred until at least three or four days after the 17 going to look something like this, It's taken, it's 
initiation of the methadone with respect to 18 absorbed, it's distributed, it's eliminated. 
Mrs. Schmechel. ls that accurate? 19 Methadone, however, has a curve that looks like this. i 
A. Correct. 20 Q. And that would be the long half-life, 
Q. And in -- 21 correct? 
A. Or at least the second and third 22 A. The long what we call beta elimination 
titration. You might increase the dose once if she 23 half-life. 111is can go out to 72 hours. So the 
didn1t have any sufficient response. 24 curve on the methadone here is going to look like 
Q. Okay. 25 this. Now, you have to add up the area under the 
, .... ,. ..•, ............. 
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1 curve, if you remember your eighth grade geometry. 1 drugs for quite a while, been on the OxyContin for 
2 Q. I tried to forget it. 2 quite a while, The OxyContin that she took now, now 
3 A. And so lhe nel serum level is going up 3 we're 24 hours since her last dose of OxyContin. 
4 like this. 4 111al's really wearing off. So there's almost no 
5 Q. With the dotted lines? 5 residual effect left from lhat. And she probably 
6 A. Right. Now, because you're adding under 6 needs a little bit more analgesia. l would be much 
7 the curve of the overlapping areas, you're getting 7 happier giving her more hydrocodone, the short half-
8 multiple overlaps. So lhe next one is here, and 8 life drug, rather than increasing the methadone after 
9 you're getting contribution of three doses to this. 9 24 hours, but l'm not going to be stupidly obstinate 
10 Q. Okay. And so when you do this dotted 10 and say that, Oh, no, you can't increase it at all. 
11 line, is that the area that's contained -- 11 Scientifically, technically, I should say lhat. But, 
l.2 A. Exactly. 12 you know, clinicians you've got to cul some slack. 
13 Q. -- within the overlapping curves? 13 You've got to -- we're trying to deal with real 
14 A. Exactly. 14 people who are in real pain, which is the situation 
15 Q. All right. 15 here. So I'm not going to object to that, and I'm 
16 A. Now, the issue is that the -0 this will l. 6 trying to be very reasonable here, 
1 7 keep going up for a period as long as ten days. If 1 7 But, boy, when you do it a second time and 
18 the patient is increasing the analgesia in this time 18 a third time in that short time period, you're 
19 frame, our -- l.9 setting yourselfup for risk, particularly in a 
2 o Q. And "this time frame" being the 24 to -- 20 patient with a history of obstructive sleep apnea. 
21 A. To 36 hours to 48 hours -- 21 There's nothing uniquely toxic about methadone with 
22 Q. -- 36 to 48 hours. 2 2 her history ofobstructive sleep apnea. This is 
2 3 A. -- within the first three days, for 2 3 going to be true of any opioid that's increased 
24 example. If the patient starts increasing the dose 24 sooner than five half-lifes. But the beauty is that 
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effecl is still going up 0 - because when we've 1 well within a day. And with most of the other 
reached steady state, then it's going to be level. 2 commonly used opioids, with Dilaudid, with 
By definition the respiratory depression is also 3 hydromorphone, you've reached it within a day. You 
going up. Now, you cannot assume that at this point 4 haven't reached it "" you're probably four days out, 
that this -- ·5 five days out with methadone. And that's the uniqne 
Q. Being 48 hours? 6 lo xi city of methadone. Use methadone. It's a great 
A. Being 48 hours -- that this lady has 7 drug. But, damn it, know what you're doing before 
reached optimal analgesia because the net effect is 8 you use it. 
still going up. So if you increase the dose at that 9 Q. With respect to this chart, if you were 
time -- let's say 24 hours is when he did increase 10 tow~ let's not assume that there's a titration that 
the dose. If you increase the dose at 24 hours, it's 11 occurs in that first six days. Let's assume that 
terribly premature because you have not yet reached 12 you're started on l O milligrams and you stay on l 0 
the maximal analgesia for the two doses that have 13 milligrams that entire six days. 
been given in that 24-hour period. It just takes the 14 A. Twice a day. 
body longer to reach that point. 15 Q. Twice a day. 
Therefore, increasing the dose here will 16 A. Preferably three, but twice a day. 
obviously give you more analgesia. It will also give 17 Q. Do the serum levels change? 
you more risk of respiratory depression. But when 18 A. Yeah. The net serum level keeps going up. 
you've not yet reached the maximal analgesia from the 19 Q. But what's the difference in the change 
doses that you've already given, this is a very 20 between the serum levels if you were to titrate up, 
premature thing to do. 21 let's say, from 5 milligrams to l O milligrams or just 
Now, why did I qualify your statemenl a 22 have the patient start on l O milligrams? 
couple minutes ago? Why would l nol have objection 23 A. You're going to change the slope of the 
to his increasing the dose once in Lhat firsi couple 24 curve, the rapidity with which it goes up. 
of days? Look, this is a lady who's been on the 25 Q. Okay. Can you describe that for me? l 
... 
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l think that's what I'm not understanding. 
2 A. The issue is that if she remained on just 
3 IO milligrams -- here I'm showing -- I'm not showing 
4 any increase in dose, I'm showing the same dose 
5 being given. And because with each subsequent 
6 dose -- and I'm not drawing this exactly. Remember 
7 that the curve looks more like this. It's got a long 
8 asymptotic tail. So the next one comes like this. 
9 The next one comes like this. Well, as you can see, 
10 you're getting each dose adding to the net serum 
11 level with continued contribution from prior doses. 
12 So four doses ago still has a minor contribution. 
13 Four doses. Three doses ago has an even bigger 
14 eonttibution. Two doses ago has a big contribution. 
15 Current dose has a huge contribution. You give a 
16 fifth dose you've still got some contribution with a 
17 half-life of even 72 hours. That's a very 
18 conservative three-day half-life. It's longer than 
19 that. But even ifit were 72 hours, you'd have 
2 O contribution of six doses on a twice daily schedule. 
21 And this is straightforward pha1macokinetics. This 
22 is not questioned. TI1e science of this is -- this is 
23 black and white. 
24 What's not .black and white is whether 
2 5 she'll respond better to methadone than oxycodorie or 
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l what is incumbent upon -- what should have been 
2 incumbent upon Byrne was to say, Hey, I can1t 
3 increase the dose this quickly. Yeah, f have might 
4 have done it before and gotten away with it, 
5 particularly in somebody who has complete respiratory 
6 competence. But if I do this, I'm really increasing 
7 the risk of getting ahead of where l want to be, 
8 which means too much respiratory depression. So I'm 
9 going to control her with more of the short acting. 
l O When you give her a boat load of 
11 hydrocodone, that's just fine because that's going to 
12 clear quickly. It's going to get out of the body. 
13 It won't accumulate. She could take hydroeodone 
14 literally every four hours. Could take six doses a 
15 day of her hydrocodone. She wouldn't accumulate it 
16 because she'd be peeing it out as quickly as she'd be 
1 7 taking it in if she took six doses a day. But with 
18 methadone you've got it sticking around for 96 hours, 
19 100 hours, 120 hours. So you have all of these prior 
2 0 doses contributing to her serum level. 
21 Q. Is the respiratory effect greaterifyou 
2 2 were to start her on l 5 milligrams versus titrate her 
2 3 up to 15 milligrams? 
24 A. Well, by definition you'd have more total 
2 5 drug conttibuting to her effect. So if you started 
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1 vice versa because of her genetic variability, what 1 her at 15, you'd get up to a higher serum level 
2 we call genetic polymorphism. But what is clear is 2 sooner. So, yeah, there's a little bit more inherent 
3 she will be accumulating the amount because of the 3 respiratory tisk. The concern is not the starting 
4 long half-life and the contribution of multiple ptior · 4 dose. The concern is increasing the dose before you 
5 doses. So her serum level is creeping up. Her 5 know that the analgesia has optimized because every 
6 respiratory risk is creeping up. 6 time you increase the dose, you're going to increase 
7 Q. And that's what I'm trying to understand 7 the respiratory depression. Now, remember, the 
8 is with respect to the respiratory risk. Let's say 8 analgesia is going to take days to optimize, but the 
9 you start a patient on 5 milligrams. You titrate 9 respiratory depression happens immediately. TI1at's 
10 them up to IO over the first 24 or 48 hours. You 10 why people end up on day four, five, six on methadone J 
11 titrate them up to I 5 -- 11 waking up dead, which is a term of art in our field. 
12 A. So you're going here -- 12 Q. I understand. And all opioids have a risk 
13 Q. -~ versus -- 13 of respiratory depression 1 correct? 
14 A. -- here, here. You're changing the slope 14 A. Absolutely. But the key is you've got to 
15 of the curve. 15 be at steady state before you increase the dose. And 
16 Q. Okay -- versus just having them on 15 16 you can do that daily or even twice a day with most 
17 milligrams the whole time. The difference would be 17 other opiates. 
l.8 in the slope of the curve? 18 Q. Would you agree that respiratory 
19 A. Well, we're adjusting the patient's 19 depression rarely presents a clinical problem to 
2 o therapy [n response to how they respond to the 2 O patients receiving chronic opioid therapy due to 
21 therapy. If we adjust the dose of methadone because 21 tolerance for the respiratory depression? 
22 of less than desired analgesia, which is what clearly 22 A. ('Rarely 11 is a very non-quantitative word. 
2 3 was being done, this is being done out of unequivocal 2 3 Respiratory depression happens frequently to patients 
24 ignorance because leaving the dose the same would 24 taking opioids in the first week of opioid therapy 
25 still result in increasing analgesia. Therefore, 25 and it happens -- this is one ofour terms of art-- , 
'-,,,···=···•··=·""==~=~~~-=CC7C==··•••~··~•····~···~·=~~~=,-"""''"=====~··~·~o='"~"''~••··=•~•·• .. ·.=•~·•···=·····==c=\• 
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l not infrequently in patients who are changed from 
2 opioid A to opioid B, even though they have some 
3 respiratory tolerance to opioids from opioid A. 
4 As I said earlier, there is not complete 
5 cross-tolerance, tolerance reforring to the 
6 respiratory effect, not the analgesic effect. 
7 There's not complete cross-tolerance, very well 
8 documented in the literature, w),ich is why the norm 
9 today is to reduce by -· we woukl -- 50 percent 
lo reduction. As I said, you could find Kathy Foley's 
11 classic paper that says 20 percent reduction. So 
12 why? Because you do not have full protection. 
13 So when she was changed from OxyContin to 
14 methadone, she did not have the protection against 
15 respiratory depression that she would have had had 
16 she been continued on OxyContin. 
17 Q. Okay. 
18 A. The rule of thumb is start low, go slow. 
19 Critical with methadone. 
20 Q. Would you agree that after five to seven 
21 days of regular scheduled dosing, patients become 
22 tolerant to opioid-induced respiratory depression'? 
23 A. Yes. 
24 Q. With respect to what you were just talking 
2 s about on the opioid rotation, if you're taking a 
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1 patient off of the OxyContin, as I understood your 
2 testimony to be a while ago, that the equal analgesic 
3 tables, you know, they're a guide, but they're 
4 certainly not a this-is-what-you-have-to-do? 
5 A. They're population averages, J would not 
6 say they're a guide. They're specifically population 
7 averages. So if we take 500 patients, on average 
8 that would be the equivalent dose. But you or Steve 
9 or Byron or l may have very different responses from 
1 o the average. 
11 Q. And so what I was going to ask you is: 
12 What's the equal analgesic dose, you know, from 
13 OxyContin to methadone, in your opinion? 
14 A. Well, that's a very difficult question. 
15 Number one, we don 1t know the answer to that even 
16 with population averages. The literature is 
1 7 incredibly diverse. J usually use a -- well, you'll 
18 find literature ranging from a two-to-one to a four-
19 to-one ratio with morphine. And Oxycodone is 25 
20 percent more potent than morphine. So you're going 
21 to find a very variable listing. 
22 Furthennore, you'll find difference in the 
23 literature according to the initial dose the patients 
24 were on. I don't have any objection lo her being 
25 started on IO milligrams b.i.d. That was a 
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1 reasonable starting point. There's no magic number. 
2 We don't know the answer. But that's okay, 
3 Q. Okay. f'll let him write his note. Let 
4 me just --
5 A. You're asking that question in the context 
6 was that appropriate starting dose. Yeah, it was a 
7 reasonable stai1ing •• it was as reasonable as any 
8 other sta11ing dose. 
9 Q. What ifhe had done it three times a day 
1 o like you indicated should be done? 
11 A. Ten three times a day? 
12 Q. Yes. 
13 A. I would have preferred 5 three times a day 
14 because, you know, unfo1iunately, I see everybody 
15 else's mistakes. So [ have a bias toward the 
16 negative. I would have been more comfortable with 5 
l 7 three times a day. I wouldn't necessarily raise a 
18 huge red flag had she been started on l O three times 
19 a day if she'd been left on that for a week before 
2 O there was any increase. !t would have been safer, 
21 however, for her to be on 5 three times a day with 
2 2 more of the hydrocodone for break-through, 
23 Now, he did increase the hydrocodone in 
24 the number of milligrams, but he decreased it in the 
2 5 number of tablets, and that was not right. Because 
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1 the hydrocodone is going to give you a short blip. 
2 It's going to give you a short additional analgesia. 
3 She didn't need a greater amount of additional 
4 analgesia. She needed to have the ability to get 
5 that more frequently because that's on top of the 
6 methadone that's already on board. 
7 Again, that reflects lack of knowledge of 
8 pharmacokinetics. That's okay. Primary care P.A., I 
9 don't expect him to be a sophisticated pharmaco-
1 o kineticist. But I sure as hell expect him not to 
11 prescribe a medication for which he doesn't know the 
12 appropriate titration. 
13 You put Dille on the stand and ask him how 
14 rapidly he'd increase -- under oath ask him how 
15 rapidly he would increase methadone, and I would bet 
16 my house that he would not say every day. lt's not 
1 7 much of a house. 
1s Q. With respect to these titration increases, 
19 how many increases do you understand that Mr. Byrne 
20 advised Mrs. Schmechel to do? 
21 A. My understanding is that he advised her 
22 that she could increase the dose on a daily basis at 
2 3 least Saturday through Tuesday. 
2 4 Q. And what's the range that you understand 
25 he indicated that could be done? 
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1 A. Well, ifhe said you can go from 10 to 15, 
2 I would extrapolate that to being either a five-
3 milligram increase each time or a doubling each time. 
4 Either way it would scare me. 
5 Q. lfhe had started her on 5 and then 
6 indicated that she could increase up to JO on 
7 Monday-- so she's gone Friday evening, Saturday, 
B Sunday increased to l 0) as I understand it, thats 
9 not something you would --
10 A. On Monday or on Sunday? 
11 Q. On Monday. It's my understanding that 
12 whether it was Sunday or Monday, that initial 
l3 increase is not something that you have a criticism 
14 of? 
15 A. Well, you know, you bring this up again, 
16 and l have to qualify my statement again. I would 
17 not do that, I would not consider that to be optimal 
18 therapy. You're asking me, again, to make a judgment 
19 on a very gray issue as a black-and-white issue, and 
2 o r know why and I understand the law and I understand 
21 the issue of probability. Is it more probable than 
22 not that she would be at greater respiratory risk 
23 with a doubling from 5 to JO? You bet it is. ls it 
24 safer? Is it clearly much safer to have stayed at 5 
2 s until you reach steady state before going to l 0? 
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1 Absolutely, Would l, as a clinician, as somebody who 
2 teaches people how to do this, have a few hairs on my 
3 head go up on end if somebody had made one increase 
4 in the first 24 to 48 hours? Probably not. But I 
5 would have said, Hey, you know, that's it. You don't 
6 do another increase until at least five more days, 
7 You're pushing it right now, And make sure that this 
8 patient understands that there's a risk, there1s a 
9 real risk with this. 
10 Also, if this patient has a preexisting 
11 risk factor for respiratory depression, which by 
12 definition obstructive sleep apnea is even with CPAP, 
13 nobody can say that because she'd on CPAP, she's 
14 clear. That's absolutely untrue. She's much safer 
15 taking CPAP with CPAP than if she hadn't had CPAP, 
16 but she still has an increased risk, Our lady was 
1 7 overweight. That's an increased risk factor. Of 
18 course, that contributed to her obstructive sleep 
19 apnea. She had some cardiac dysfunction, That 
20 increases her risk. How much? I don't know. Let 
21 the cardiologists fight that one out. This is a lady 
22 who had risk factors. This is a not a lady in whom 
23 you're aggressive in titrating up methadone. 
24 Q. But with respect to an initial increase, 
2 5 that would not be something that would be below the 
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1 standard of care if you were to go up from 5 to I 0 
2 milligrams? 
3 A. One increase would not be below standard 
4 of care, Now, I'm having trouble differentiating 
5 standard of care from causation. 
6 Q. And let me ask you that since we're there. 
7 What do you understand 11standard of care 11 to mean as 
8 it applies in Twin Falls, Idaho in 2003? 
9 A. This is what is considered to be 
1 O appropriate and acceptable medical practice. 
11 Q. And how is tha.t determined, as you 
12 understand it? 
13 A. Very softly. ft's not a nice crisp black 
14 and white issue. It's -- J don't believe it's 
15 community standard. I don't believe that Idaho law 
16 now supports community standard. I think it's more 
1 7 national scientific standard, And l would defer here 
18 to the scientific literature, the Federation of State 
19 Medical Boards, the American Pain Society documents, 
2 o of which I'm an author of some, Federal Clinical 
21 Practice Guidelines, of which I'm an author of some, 
22 standard textbooks, of which I'm author of some, And 
2 3 they all consistently say with methadone you've got 
24 to titrate slowly. 
25 Q. With respect to it being whether a 
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1 national or community standard of care, you know, if 
2 we were to inform you that a community standard care 
3 is actually what's required in Idaho, how would you 
4 define what the appropriate and acceptable standard 
5 of care would be for Twin Falls in September and 
6 October of2003? 
7 A, Since the majority of physicians 
8 practicing in Idaho went to medical school in Utah 
9 and since the majority of anesthesiologists 
10 practicing in Idaho did their residencies in Utah, I 
11 would say it's what's being taught at the University 
i2 ofUtah. 
13 Q. Okay, And I understand that you have 
14 spoken to Dr. Vorse about the standard ofcare. ls 
l 5 that accurate? 
16 A. You know, I don't -- I remember talking to 
l 7 her about the patient. I don't know that we talked 
18 about standard of care. I know that we talked about 
19 standard of care with· the other Idaho 
20 anesthesiologist whose name I can't recall. 
21 MR. FOSTER: Flinders. 
22 THE WITNESS: Flinders. Thank you. 
23 Q. (BY MS. DUKE) Let me hand you Exhibit 4, 
24 if you could just read that. 
25 A. Okay. Then we did talk about it. 
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1 Q. So I've handed you your supplemental 
2 affidavit of Arthur G. Lipman, Pharm,D., and it 
3 indicates that you did speak with Dr. Vorse --
4 A, Yes. 
5 Q, -- with respect to the standard of care in 
6 Twin Falls in September of2003 regarding 
7 Mrs. Schmechel? 
8 A. Actually, we did, because we talked about 
9 whether or not the care that she received was within 
10 appropriate guidelines, which is the standard of 
11 care. So, yes, that is true, 
12 Q. Did Dr. Vorse provide any statements to 
13 you or make any statements as to whether she felt the 
14 care provided to Mrs. Schmechel by the Southern Idaho 
15 Pain Institute fell below the standard of care? 
16 A, I.don't recall. 
17 Q. Rather, it sounds like you and she just 
18 had a general discussion of, you know, l really think 
19 there's nothing different from what you do in Utah 
20 than what I do here in Sun Valley? 
21 A. Oh, sure, That was the case, and I've had 
22 that conversation with both her and with 
23 Dr. Flinders. And the other issue is that we were 
24 talking specifically about Mrs. Schmechel and about 
25 what was necessary in her care and about •• you know, 
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1 and Dr. Vorse, as I recall -- and as l say, this was 
2 how many months ago. l don't recall the exact 
3 details, July 2005. That's two years ago -- two 
4 years ago? ls ti1at right? The issue is that, you 
5 know, how rapidly can you titrate up methadone? You 
6 can't. You've got to go slow, And when you've got a 
7 patient who's already got respiratory disease, you've 
8 got to be even more conservative, It's better to err 
9 in the interest of being conservative and using a 
10 short-acting medication to cover her. That's most 
11 probably what we talked about. 
12 Q. Okay. Do you recall for certain what was 
D discussed? 
14 A. J know that we talked about what is 
15 reasonable care and the risks of methadone. I'm 
16 quite -- l do believe that we also discussed the 
1 7 wisdom of using a shatter acting as opposed to a 
18 longer acting. That would be my recollection, Let 
19 me clarify that, Using more of the shorter acting 
20 
21 
rather than increasing the dose of the methadone. 
Methadone is fine if used properly. 
22 Q. And did you understand where she 
2 3 practiced? 
24 A. In Ketchum. 
25 Q. And do you understand how far away that is 
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1 from Twin Falls? 
2 A. Yes. 
3 Q, You understand that's a different 
4 community? 
5 A. Yes. 
6 Q. Did she tell you how she felt she was 
7 knowledgeable with respect to the Twin Falls 
8 standard? 
9 A. Yeah. There's Idaho State Medical 
10 Society. There's Idaho anesthesia group, These 
11 people talk with each other. They meet periodically. 
12 In fact, they usually meet over in Sun Valley. 
13 Q, Those are things she told you? 
14 A, I know they meet in Sun Valley because 
15 I've spoken to the groups up there. But she told me, 
16 yes, that she talks with the other people in the 
17 state. 
18 Q. And that she believed she was familiar 
19 with the standard of care? 
20 A. Yes. 
21 Q. Then you talked to Dr. Flinders, as l 
22 understand it. 
23 A, Yes. 
24 Q. With respect to Dr. Flinders, what was 
25 your purpose in talking to him? 
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1 A, Well, it was Dr. Flinders, Dr. Lordon, and 
2 I were on the call to basically see ifwe agreed on 
· 3 the pharmacokinetic and scientific issues and whether 
4 the standard of practice was the same in Idaho and 
s Utah. Now, on that, of course, as far as the 
6 practice of pain medicine and anesthesiology, 
7 Dr, Lordon as a Utah practicing anesthesiologist and 
B Dr. Flinders as an Idaho practicing anesthesiologist 
9 were able to compare notes on that. And they 
10 certainly agreed and l concurred. But it was their 
11 agreement that the standard was me same. 
12 Q. Okay, And if you look at Exhibit 5, which 
13 is your second supplemental affidavit, it's my 
14 understanding -- well, stdke that, 
15 Does Exhibit 5 accurately reflect what 
16 you, Dr. Lordon, and Dr. Flinders discussed? I think 
1 7 it starts about paragraph 5. 
18 A. It does. Yes. Yes, One of lhe questions 
19 was what did they as practicing physicians think was 
2 o necessary in records to be obtained for the patient. 
21 And they both felt very strongly that they would not 
22 treat a patient such as Mrs. Schmechel without 
2 3 getting infom1ation from the previous treating --
24 prior treating physician, in this case Dr, Vorse. 
2 5 Q. f1m putting sheets away as we1re done so 






1 we can finish here. 
2 You indicated, when we were having you 
3 articulate your opinions in this case1 you were 
4 talking about the titration schedule, and you 
5 testified that there is a 50 percent reduction for 
6 methadone today. 
7 A. I'm sony? 
8 Q. There's a 50 percent reduction for 
9 methadone today when they rotate the doses. 
1 O A. Well, that's common practice among thought 
11 leaders in the field. 
12 Q. Does that mean if you're on the 60 
l3 milligrams of --
14 A. Let me clarify. That's not just 
15 methadone. That is when converting from opioid A to 
16 opioid B --
1 7 Q. B, okay. 
18 A. -- using the dose equivalency tables, that 
19 you would not convert at an equivalent dose. You 
2 o would convert at half the equivalent dose. 
21 Q. And that applies for all opioids? 
22 A. Yes. 
23 Q. Including methadone? 
24 A. Yes. 
25 Q. And so today if you're on 60 milligrams of 
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1 concern. It's part of the entire gestalt, again, but 
2 ies not the major concern. 
3 Q. And I know it's difficult per what you're 
4 saying to necessarily take those out piece by piece, 
5 but, obviously, I need to from my standpoint. When 
6 we do look at the issue of --
7 A. Had the titration been appropriate, the 
· 8 monitoring would not be an issue. 
9 Q. Okay. Explain that to me. 
10 A. Had the dose not been increased on a daily 
11 basis in those first few days, I would not have been 
12 concerned about the level of monitoring tliat was 
13 provided. If we're going to increase a drug like 
14 methadone that quickly, I'd want to have the patient 
15 in a closely monitored situation. We would not 
16 increase the dose that quickly. It's never necessary 
17 to increase the dose of methadone that quickly. We 
18 have alternative drugs to use ifwe have to increase 
19 it quickly. 
20 Q. Okay. Soifhehadstartedheron JO or 
21 15 milligrams twice a day, what monitoring would you 
22 have expected would have been required by the 
2 3 standard of care for him to do? 
24 A. We'd certainly want to know within two 
2 5 days how she was doing as far as her comfort level, 
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methadone, you'd be looking at 30 milligrams? 2 understanding is that he did do this, you know, that 
A. Well, no, because those are not a 3 there was some communication. We'd want to make sure/' 
one-to-one conversion. 4 the patient knows how to reach him, if necessary, 
Q. Okay. 5 should she have any difficulties. That's often a 
A. But I'd be looking at 50 percent of the 6 real issue over the weekend, but it sounds like he 
7 equivalent dose. The problem with methadone is we 7 may have been able to make himself available. 
8 
9 
don1t have a nice clean equivalent dose, We have one 8 Monitoring is not the issue, as 1 said. 
for morphine. We have one for hydromorphone, for 9 lfthe dose had stayed consistent at that starting 
10 oxymorphone, for hydrocodone. We don't have one for 10 point, then I think his communication with her was 
11 methadone. So when we don't have it, we have to err 11 perfectly adequate. He could not judge difficulty 
12 toward conservatism, which is -- and I have -- again, 12 she's going to be getting in very well over the 
13 IO milligrams twice a day was a very reasonable 13 telephone. He would have to see her. He would have 
14 starting dose. Was it the right dose? Nobody knows. 14 to check her respiratory function, check whether 
15 ls it a reasonable dose? Absolutely. But you've got 15 she's sedated, whether she's cognitively impaired, 
16 to give it five days at that dose before you know 16 issues like that, which is often difficult for the 
1 7 what the net analgesia and respiratory risk is going l. 7 patient to subjectively determine. 
18 to be before increasing it, 18 Q. So if it hadn't been for the titration, 
19 Q. With respect to your opinions in this 19 his monitoring was fine? 
20 case, are you in any way critical with respect to the 20 A. Yes, 
21 monitoring that Mr. Byrne provided to Mrs. Schmechel? 21 Q. And then with respect to the titration and 
22 A. I'm not really completely clear on the 22 monitoring, what monitoring should he have done given 
23 monitoring. That's not my vv because there appears 23 the initiation and titration of the therapy that he 
24 to be some disagreement as to whether or not certain 24 was providing for her? 
2 5 conversations took place, That's not my major 2 5 A. I don't think he could safely treat her 
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1 the way he treated her with the daily -- with the 
2 daily increases. That could not be done safely no 
3 matter what monitoring he did on an outpatient at-
4 home patient. That would have required inpatient 
5 hospitalization, totally cost ineffective, clinically 
6 inappropriate. 
7 Q, And so it would have required inpatient? 
8 A, Yeah, which is not going to be done. It's 
9 not going to be paid for by any insurance plan. So 
1 o he should have not increased the dose of the 
11 methadone and given her more of the short acting to 
12 cover her. 
13 Q. Okay. 
14 A. In case you 1ve noticed 1 rve been saying 
15 that consistently, 
16 Q, With respect to the dosing instructions 
1 7 that he did provide her, l know we've talked about 
18 those. 
19 (EXHlBff-10 WAS MARKED.) 
2 o Q, (BY MS. DUKE) You've been handed what's 
21 been marked as Exhibit Number l 0. Do you understand 
2 2 these to be the written dosing instroctions that 
2 3 Mr. Byrne provided to Mrs. Schmechel? 
2 4 A. Very interesting. This is different than 
25 what he wrote in his chart note. He wrote in his 
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1 chart note decreased the amitriptyline to 50 
2 mllligrams, and here he wrote decreased to 75, 
3 another indication of poor record keeping. 
4 "Methadone 1/2 - l pill every 12 hours, 
5 May increase to maximum 1-1/2 pills every 12 hours," 
6 May increase over what period of time? Can you go 
7 from one-ha If to 1- 1/2? That's a 300 percent 
8 increase, 200 percent increase. Hydrocodone, three 
9 to four a day is grossly inadequate. This is a 
1 O medication with a four-hour duration. When starting 
11 methadone, especially when starting it at an 
12 inadequate schedule of twice day, she should have had 
13 that available six times a day, not three to four 
14 times a day, He's putting her at major respiratory 
15 risk by giving her higher peaks of the hydrocodone 
16 less frequently rather than giving her lower peaks 
1 7 more frequently that would not approach the toxic 
18 threshold as much, 
19 So that would exacerbate her respiratmy 
2 O risk because, remember, he increased the dose of that 
21 by 25 percent. Dr. Vorse had her on 75 milligrams --
22 7.5 milligram, and Byrne changed it to 10 milligrams 
2 3 of hydrocodone per dose, 
24 Q. My question was: Are these the dosing 
25 instructions that you 1ve seen from him to 
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1 Mrs, Schmechel? 
2 A. On this piece of paper, yes, 
3 Q, Okay. So, obviously, you've seen these, 
4 Exhibit I 0. And then you've also seen what he wrote 
5 in Exhibit 9 with respect to dosing? 
6 A. Can l take a look at that? 
7 Q. Yeah. You have Exhibit 9. 
8 A, Thank you, And that's page number --
9 Q. Dille 16. 
1 o A. Thank you, Okay. "Will discontinue 
11 OxyContin and start her on methadone IO milligram 
12 q.12 titrated from 5 up to a maximum of l 5 over the 
13 next 72 hours, 11 No, he did not write over the next 
14 72 hours on the sheet that he gave her. 
15 Now, reading this, I could read this and 
16 say, Well, gee, if one-half didn't work and I can go 
1 7 up to one-and-a-half and I take one-halfon Friday 
18 evening, maybe I'll take one-and-a-half on Saturday 
19 morning, 1 don't know if that's what she did, but 
20 that would be consistent with what he wrote and gave 
21 her. That would be incredibly dangerous. But he did 
22 write over the next 72 hours, 
2 3 I've seen patients clearly who have had 
24 instructions to take their antibiotic one twice a 
2 5 day -- had a police lieutenant. His instructions for 
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1 a serious infection, take one tablet twice a day for 
2 a week, He took one at 8:00 in the morning and he 
3 took the next one at 10:00 in the morning when he had 
4 his next cup of coffee. He was following the label 
s on the prescription. He didn't understand that one 
6 twice a day meant once 12 hours apart, which is 
7 pharmaco- kinetically necessary for that antibiotic, 
8 It would not -- an intelligent person could actually 
9 misread this or could misunderstand this to think you 
1 o could just take a half. If that's not adequate, go 
11 right to one-and-a-half. If this is what he gave 
12 her, that1s dangerous. 
l3 Q. Okay, And so if you look at this, Exhibit 
14 l 0, 1 guess summarize what your criticisms would be 
15 with respect to what he's written there regarding 
16 methadone. 
1 7 A, He didn't specify a timeline, and it was a 
18 very rapid titration, And she could easily misread 
19 this from going from one-half tablet or one tablet, 
20 whichever she decided her first dose, and go right up 
21 on the next dose to one-and-a-half. 
22 Q. But you would agree that he provides a 
23 timeline from the standpoint of saying every 12 
2 4 hours, So that would be twice a day? 
2 5 A. Thal he did, but he didn't say when she 
. 
,. 





1 could increase and could she increase on the second 
2 dose 12 hours after the first dose. 
3 Q. Right. But this is different than your 
4 police lieutenant example that you just gave. 
5 A. Oh, yeah. I'm just pointing -- you 
6 understand the analogy that I was making. 
7 Q. I do, but l wanted to make sure it wasn't 
8 one you're applying to what he did here. 
9 A. Oh1 no, no, 
10 Q. S0--
11 A. I'm just pointing outthat reasonably 
12 intelligent thinking people can make very serious 
13 mistakes in dosing ifwe don't give them very clear 
14 instruction. 
15 Now, the other issue that concerns me is 
16 that the prescription bottle that she had said take 
17 one tablet twice a day or one -- I don't know. No. 
18 lt actually said 30 tablets. I haven't seen the 
19 label. Do we have that label available? I 
2 o understand it was being requested. Because --
21 Q. I don't have it with me. 
22 A. -- it was for 30 tablets and it said on 
23 the pharmacy printout 90 tablets to be taken in 30 
24 days. 
2 5 MR. FOSTER: One-and-a-half two times 
Page 
1 daily. That's what she told him. 
2 THE WITNESS: So the label said 
3 one-and-a-half two times daily. 
4 Q. (BY MS. DUKE) Okay. 
5 A. And the wlitten instructions say take from 
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6 one-half to one-and-a-half Now, does this mean that 
7 she actually -- if she followed the label on the 
8 presciiption bottle, which most studies of patient 
9 adherence -- we used to call it compliance -- so that 
10 the most telling instruction -- patients are 
11 notorious for not remembering what they were told in 
12 the doctor's office. And the most common thing that 
13 they follow is the prescription label. So she may 
14 well have started out at one-and-a-half right away. 
15 l don't know. 
16 Q. Okay, Any other criticisms with respect 
17 to the methadone --
18 A. I think that's enough. 
19 Q. -- on Exhibit l 0? 
20 A. No. 
21 Q. And then with respect to the 
22 amhTiptyline, I know that you testified earlier that 
23 you were critical of him decreasing it, and rather, 
24 he should have rotated her off of the amitriptyline 
25 and put her on something different? 
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1 A. Well, he has no rationale for decreasing 
2 it in his record. This is a lady who had spinal cord 
3 issues, and she clearly had neuropathic pain. 
4 Amitriptyline is not a drug of choice for neuropathic 
5 pain, It's in the literature. It has too many side 
6 effects. And there are preferred drugs, but that 
7 class of drug is a drug of choice. If you're going 
8 to use the drug, the optimal dose is 100 milligrams. 
9 There's no rationale for his decreasing it that he 
1 o documented. Ifhe pointed out that she had urinary 
11 retention or blurred vision or dizziness or sedation 
12 or constipation, which are side effects of that class 
13 of drug, then the correct thing would have been to 
14 change her from amitriptyline to desiprarnine that has 
15 one-quarter those effects, or the same efficacy. He 
16 simply decreased the dose. Now, Hare and others were 
17 not critical of that. 
18 Q. And that's what l was going to ask you. I 
19 mean, I understand that that might not have been the 
2 o approach that you would have taken, but you're not 
21 saying that's a breach of the standard of care, are 
22 you? 
23 A. lt would be pushing it to say that's a 
24 breach of die standard of care. Was it indicative of 



























Q. But you're not saying that's a breach of 
the standard of care, correct? 
A. l can't answer it in that context so Pm 
not going to say it's a breach of the standard of 
care. I'm going to say it's poor quality medicine. 
If poor quality medicine is a breach of the standard 
of care, I'll leave that to people more expert than I 
in defining what is the standard of care. 
Q. Well, and let me follow up on that. I 
mean, with respect to your opinions in this case, 
with respect to the standard of care that applied in 
Twin Falls, Idaho in September and October of 2003, 
with respect to the treatment to patients such as 
Mrs. Schmechel, based on your understanding of the 
standard of care, would that have been a departure of 
the standard of care to decrease the amitriptyline, 
or do you know? 
A. I don't know. J'll leave that one --
Q. Okay. 
A. -- as an unknown. Thank you. 
Q. And then on the hydrocodone, with respect 
lo increasing it to 10/500 -- I understand the 10 is 
the hydrocodone part of it. 
A. Correct. 
Q. The 500 is the acetaminophen -- three to 
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1 four times a day, you believe that's inadequate? 
2 A. Absolutely. 
3 Q. Because she could have had it up to six 
4 times a day? 
5 A. She would need it more frequently than 
6 three to four times a day. 
7 Q. But with respect to that, is that 
8 something tbat you foe] is a breach of the standard 
9 of care in Twin Falls, Idaho in September and October 
10 of2003? And if you don't know, then that's your 
11 answer. 
12 A. I have to say I don't know because that's 
13 a •• that's a legal call as opposed to a scientific 
14 call. If you ask me is that quality medicine 
15 consistent with the science, the answer is no. I 
16 need your help in defining whether that's a breach of 
1 7 the standard of care. 
18 Q. Now, you're aware that he followed up with 
19 Mrs. Schmechel, Mr. Byrne followed up with 
2 O Mrs. Schmechel on Monday and Tuesday, correct? 
21 A. Yes. 
22 Q. And that she was responding well to the 
23 therapy? 
24 A. I saw that noted that he telephoned her 
2 5 and she said she was doing better. 
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1 Q. I mean, you certainly have no reason to 
2 not believe that Mrs. Schmechel reported that she 
3 felt that she was doing well on the medications, 
4 correct? 
5 A. Let me go back to our graphic. If, 
6 indeed, she had stayed at the same dose, let alone 
7 increasing it, and if she were here and those doses 
8 would have brought the analgesia up to here, she 
9 would have said, Yes, I'm doing better. But she's 
10 still not at the maximum toxicity. So the toxicity, 
11 even without any medication at all, and she was 
12 taking additional medication, the toxicity would have 
13 continued to increase. 
14 Q, I understand, but my question is: You're 
15 certainly not saying that there1s any reason to not 
16 believe or trust what's contained in the medical 
17 records when it's reported thal1 you know, 
18 Mrs. Schmechel --
19 A. Said she was doing better. 
20 Q -- said she was doing better? 
21 A. However, there was a-~ there was 
22 something from her family that they felt that she 
23 was .. she had some problems that she was not being 
24 forthright with them. Now, whether that related to 
25 her lower limb edema or her general outcomes, l'm not 
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1 clear. 
2 Q. Okay. 
3 A. Patients frequently will tell us they're 
4 doing better than they are for a variety of reasons, 
s including hopefulness on their part. I honestly 
6 don't know what occurred here. 
. 7 Q. Okay. But I guess what I'm getting to is 
8 you have no reason to discount that, you know, she 
9 reported that she was doing well to Mr. Byrne? 
1 o A. That she was doing better, that she was 
11 getting some analgesia. I don't discount that. 
12 Q. Correct. Okay. And, in this case, you're 
13 not in any way alleging that she was drug seeking, 
14. correct? 
15 A. No, I'm not. 
16 Q. And you ce1tainly have no reason to 
1 7 believe that she was dishonest with Mr. Byrne --
18 A. No. 
19 Q. .. correct? 
2 o A. Correct. 
21 Q. I didn't ask that very well. And you 
22 agree that she was ready for a change in her pain 
23 management regimen? 
24 A. I believe she was requesting a change in 
2 5 her pain management medicine -- regimen, 
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1 Q. And that was because what she was on was 
2 not working for her? 
3 A. By her report. Now, Dr. Vorse's note 
4 indicated that Mrs. Schmechel had been titrated to 
5 what Dr. Vorse at that point-- this was months 
6 earlier .. but at that point Dr. Vorse considered to 
7 be -· provide a reasonable risk/benefit ratio, I 
8 didn't know Mrs. Schmechel. I never interviewed her. 
9 I can't make a judgment as to whether she was at a 
10 reasonable treatment level. One ofmy serious 
11 criticisms of Mr. Byrne is that he didn't discuss 
12 this with Dr. Vorse before making tbe change, and he 
13 di<ln'I know. ).)r. Vorse might have told him some 
14 things that would have markedly influenced his 
15 decision. 
16 Q, And do you know any of those things that 
17 could have markedly influenced the decision, or is 
18 that just speculation? 
19 A. That's speculation. But it's a reflection 
20 on the clinical necessity of his having contacted her 
21 before changing the regimen. 
22 Q. But going back to my question two 
23 questions ago, you do agree that she was ready for a 
24 change in her pain management regimen? 
25 A. She thought she was, yes. 
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1 Q, And she certainly had a right to be 
2 treated and to have someone try to get her out of 
3 pain? 
4 A. Certainly. 
5 Q, She was not opioid naive? 
6 A, Correct. 
7 Q. She had been receiving chronic opioid 
8 therapy for several years? 
9 A. But now I have to apply a little more 
1 o sophisticated phamrncology than I would expect 
11 Mr. Byrne to necessarily be on lop of. She was not 
12 opioid naive, but she was methadone naive. 
13 Q. I understand. 
14 A. That's an impo11ant difference. 
15 Q. But she had been receiving chronic opioid 
16 therapy for several years 1 conect? 
1 7 A. Certainly. 
18 Q. She had been on OxyContin for several 
19 years? 
20 A. Yes. 
21 Q. And hydrocodone for several years? 
2 2 A, Correct. 
2 3 Q. Did she have pulmonary dysfunction? 
2 4 A. She had respiratory impainnent. I'm not 
2 5 in a position to comment whether she had pulmonary 
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1 dysfunction. 
2 Q. Okay. Would you agree that in 2003 there 
3 was no infonnation generally available to pain 
4 management providers that there was any special 
5 concern or problem with methadone in patients who had 
6 obstructive sleep apnea versus any other opioids? 
7 A. Correct. I qualify that by saying that 
8 all opioids have the concern. Methadone is not a 
9 different drug. 
1 o Q. Right. Okay. So OxyContin would have the 
11 same concern? 
12 A. Correct. 
13 Q. Would you agree that ii was reasonable for 
14 Mr. Byrne to believe that Mrs. Schmechel was 
15 following his advice? 
16 MR. FOSTER: Object to the fonn, 
1 7 THE WITNESS: I cannot agree or disagree 
18 with that because he had just met her. He did not 
19 have an established relationship with her. 
2 O Therapeutic relationships take time to build. This 
2 l is another reason why it was important for him to 
2 2 talk to Dr. Vorse to get her sense of whether 
23 Mrs, Sehmechel was adherent with her physician's 
24 inslructions. 
2 s Q. (BY MS. DUKE) Okay. But you would agree 
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1 as a medical provider that's a patient responsibility 
2 to follow the advice of their practitioner? 
3 A. Well, I think it's a dual responsibility 
4 between the provider and the patient, and there has 
5 to be an agreement. There1s an implicit contract. 
6 And in many cases there1s an explicit medication 
7 management agreement ¥~ attorneys advise us not to 
s call it a contract·· which, in fact, Dr. Dille did 
9 speak to in his testimony. It has to be two way, It 
1 o can't be just one way. It is absolutely the 
11 provider's responsibility to assess the probability 
12 of the patient's adherence and to adjust therapy 
13 accordingly. 
14 Q. Right. But it's also the patient's 
15 responsibility to follow their practitioner's advice? 
16 A. As I said, it's a two-way obligation, yes. 
1 7 Q. Okay. And certainly a responsibility the 
1 B patient has is lo call or to contact the provider if 
19 they have any questions or problems? 
20 A. It is the obligation of the provider to 
21 explicitly tell the patient to call if you have any 
2 2 questions, and then it is ce,iainly the patient's 
2 3 responsibility to do so. 
2 4 Q. And it's also the responsibility of the 
2 5 patient to report how they are doing in an honest 
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l fashion so that the medical provider can accurately 
2 understand what1s going on? 
3 A. Certainly, And, again, it's the 
4 provider's responsibility to assess the probability 
5 of the patient reporting that in an honest fashion 
6 and adjust therapy accordingly. 
7 Q. Would yon, based upon your review of the 
8 records that you reviewed from Mrs. Schmechel, 
9 believe that she was a patient who was compliant? 
10 A. I believe so. 
11 Q. With respect to the cause of death, I know 
12 that you testified earlier that the cause of death is 
13 uncertain, but that you believe some potential causes 
14 are more certain than others. 





Q. Okay. I can just ask that. 
A. Okay. Reas'k that. 
Q. I was trying to .. 
20 MR. FOSTER: I want to object to 
2l something. 
22 Q. (BY MS. DUKE) Yeah, exactly. I was 
2 3 trying to cut to the chase, and l'll just ask you it 
24 rather than do that, What's your opinion with 
2 5 respect to Mrs. Schmechel's cause of death? Is that 
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i something you're rendering an opinion on? 
2 A. Yes. 
3 MR. HIPPLER: And I will object to that 
4 one on foundation. 
5 THE WITNESS: We've got everybody awake 
6 now. 
7 Yes. I can only do this on the 
8 probabilities, on the pha,macological probabilities. 
9 Ruling out other lethal morbidity which is 
l O inconsistent with the medical examiner1s report and 
11 the records that r read, I conclude that the most 
12 probable cause, more probable than not, is the 
13 accumulation toxicity of methadone causing 
14 respiratory depression. Unquestionably her 
15 comorbidities contributed to this. Unequivocally, it 
16 is the provider's responsibility to consider 
1 7 cornorbidities whenever prescribing a medication. 
18 And, therefore, I conclude that the major causation 
19 is methadone associated. 
2 o Q. (BY MS. DUKE) And so rather than just 
21 adopting the pathologist's opinion, you have your own 
22 independent opinion? 
2 3 A, Oh, absolutely. Pathologist didn't refer 
2 4 to pharmacokinetics, to risk of accumulation 
25 toxicity. This is an area that I'm well aware, that 
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1 I published in. 
2 Q. With respect to methadone levels, is it 
3 your understanding that when a patient expires and 
4 they've been taking methadone, that the level of 
5 methadone in their blood will actually increase? 
6 A. Depends on which blood. You have central 
7 blood and you have peripheral blood. 
8 Q, Con-ect. 
9 A. So there would be a central pooling 
10 effect. 
11 Q. And what does "central pooling effect" 
12 mean? 
13 A. Well, the drug is going to be in a higher 
14 level in the central, in the heart blood. But you've 
15 got to realize again that the scrum levels in a 
16 living patient or posunorlem do not directly 
17 correlate with clinical outcomes. Again) they're 
18 highly variable, huge inlerpatient variability. So 
19 the numbers that you have in -- what's his name? 
20 Standard textbooks. The numbers that you pull out 
21 there are, again) based on population averages that 
22 may or may not apply to an individual. It's the 
23 clinical course and the temporal relationships that 
24 matter. And that's the basis ofmy judgment. 
25 Certainly, they're supported by the findings on post. 
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1 Q. Okay. But I guess what I'm trying to 
3 
2 understand, and maybe you just said this, but it's my 
understanding that when you take blood out of someone 
4 who's deceased and analyze it with respect to 
5 methadone, you're actually going to see an increase. 
6 A. Heart blood, not peripheral blood, f 
7 don't recall --
8 Q. Peripheral meaning femoral or --
A. Yeah. 9 
10 Q. With respect to the blood here -- okay. 
11 So what you're saying is you're not going to have the 
12 increase in methadone in a deceased person's blood if 
13 you're taking it out of the femoral versus if you're 
14 taking it from the heart? 
15 A. Yeah. You won'! see as much ofa shift. 




A. I work with patients, not cadavers. 
19 Q. Okay, Your patients are probably happy 
2 o about that. 
21 A. They prefer to be patients than cadavers, 
22 yeah. 
23 Q. All right. 
24 toxicologist--
So you would defer to a 
25 A. Yes. 
Page 
1 Q. ~- or someone else on that issue? 
2 A. But of note, the postmortem data -- report 
3 that I read is certainly consistent with what l would 
4 have expected and what I concluded pharmaco-
5 kinetically, It is not the basis ofmy 
6 determination. 
7 Q. And why do you say the postmortem data is 
B supportive of your opinion? I think that that's 
9 under here somewhere. 
10 A. Well, ifwe had very low methadone levels, 
11 for example, that would have been inconsistent. 
12 Q, Well, what were her methadone levels? 
13 A. I'd have lo look in the report. 
14 Q. I think that's right here. 
15 A, Or is it this one? 
16 Q, I knew it was under there. I just don't 
17 know which one. 
18 A. Yeah. It was femoral blood that he looked 
19 at. And the conclusion which Dr. Grobin, the 
20 forensic pathologist, reached was that it was 
21 combined hydrocodone and methadone. That's 
22 completely consistent with what I said earlier. I 
23 didn't recall that, frankly. I read this a long time 
24 ago. This was nol my determination. My 
25 detennination was based on the science and what I 
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1 read. But you recall that I talked about going to a 
2 I 0-milligram versus a seven-and-a-half-milligram 
3 hydrocodone dose getting a higher peak, which would 
4 increase the risk. And as I look here at his 
5 hydrocodone levels, they were significant. And he 
6 sees it as a combined combination. He knows that the 
7 methadone concentration is within the lower range of 
8 no lethal concentrations. He did look a peripheral, 
9 not heart blood, so central pooling would not be in 
1 O effect here. Jf anything, you'd lose some in the 
11 peripheral because when it centrally pools, you lose 
12 it from the periphery to the heart blood. So, again, 
13 the Twin Falls County coroncrreport and the forensic 
14 pathologist's report are consistent with what I 
15 concluded based on the pharmacokinetics. 
16 Q. Okay. But the question is: What did you 
1 7 understand the level of methadone to have been in her 
18 blood at the time of death? 
19 A. He had a number there which I have to look 
2 o in the standard text to see if that's consistent. 
21 Q. Okay. 
22 A. My understanding is consistent with a 
23 lower level of lethality. 
24 Q. But as you sit here today, you don't know? 
2 5 A. I did look that up at the time, and my 
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1 recollection is that's correct. 
2 Q. And when you say it's a lower level of 
3 lethality, what does that mean? 
4 A. Well, when we look at methadone deaths 
5 reported in the literature, and there's a large 
6 literature on this, we see a broad range of what had 
7 been reported as levels found on postmortem 
a examination. A level of .3 nanograms that we had 
9 here was certainly consistent with other reports of 
1 o lethal methadone doses, levels. That doesn't mean 
11 that you or I could not have that level and be alive 
12 and breathing, and that somebody else may have a 
13 lower level and still die from it. It's not 
14 definitive. That level does not by itself say --
15 Q. Okay. 
16 A. ·- that the patient died of methadone. 
1 7 But add to that the level ofhydrocodone, add to that 
18 the temporal relationship, the rapidity of the 
19 titration, and you put it all together and you have 
20 to -- I'm dealing with science and probabilities 
21 here. And it says to me that the leading probable 
22 cause, and certainly more probable than not, was 
23 opioid toxicity, largely methadone) some contribution 
24 by the hydrocodone. 
25 Q. But you agree the methadone level in her 
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1 blood in and of itself does not lead you to tl1at 
2 conclusion) correct? 
3 A. It doesn't lead me to the conclusion 
4 because l'm not a forensic toxicologist. It may well 
5 lead a forensic toxicologist to that conclusion. 
6 From a viewpoint of pharmacotherapy pharmacokinetics, ' 
7 I've already concluded that. This supports my 
8 contention. 
9 Q. Right. But from your position, that 
10 figure in and of itself is not enough to bring you to 
11 your conclusion? 
12 A. I did not base my conclusion on that 
13 figure unto itself. I am not a forensic 
14 toxicologist. 
15 Q. And the hydrocodone level, is that the 
16 same with that? 
17 A. Same. 
18 Q. Okay. And so when we read in these i 
19 repo1is that it says, you know, a lethal amount, that 
2 o doesn't mean that that in and of itself was the cause 
21 of death. I mean, you could have a person, you know, 
2 2 taken 15 milligrams twice a day and be hit by a car 
23 and be killed because of that. 
24 A. Sure. 
2 5 Q. But have lethal levels of methadone and 
Page 173 
· 1 hydrocodone in their blood but not have that be the 
2 reason for their death? 
3 MR. FOSTER: Object to the form. 
4 THE WITNESS: The best way that l can 
5 answer that is by saying that did not-· I cannot and 
6 do not conclude on the basis of that report alone 
7 that methadone was the cause of death. I have read 
8 autopsy reports that said that an opioid was the 
9 cause of death when J agreed with that because the 
1 o clinical course and the phannacokinetics of the 
11 opioid dosing was inconsistent with that being 
1.2 causative. 
13 ln this case this is strongly supportive 
14 of what I concluded based on my knowledge of the 
15 properties of this drug and the way it was dosed. 
16 Q. (BY MS. DUKE) And so what are, I guess, 
1 7 the factors that you considered in concluding that 
18 you believe that she died as a result of methadnne or 
19 hydrocodone or both? 
2 o A. Both, primarily methadone. Straight-
21 forward accumulation toxicity based on the 
22 pharmacokinetics of the drug, that she was moving 
23 rapidly toward both analgesia and respiratory 
24 toxicity. Dose increases exceeded the safe time 
25 interval resulting in increasing toxicity. She was 





1 probably pretty eomfo1table when she stopped 
2 breathing. 
3 Q. As l understand it in this case, you1re 
4 not saying that Mr. Byrne was not appropriately 
5 trained or experienced as a physician assistant; is 
6 that cotTect? 
7 A. I don't know the answer to that. 1 don't 
8 know-- I don't recall where he went to P.A. 
9 training. As I recal11 it was some private program 
10 back East. I've been involved in P.A. training from 
11 the beginning. I'm aware of the incredible 
12 variability of n·aining programs and particularly in 
13 what the P.A. students learn in phannacology. I 
14 conclude that he did not know enough about methadone 
15 to use it safely. 
16 Q. That l understand. Bui from an overall 
17 global standpoint --
18 A. I can't comment. 
19 Q. Okay. You would agree that he was trying 
20 to help her? 
21 A. Absolutely. 
22 Q. And that he certainly did not want this 
23 outcome to occur? 
24 A. Absolutely. And l would not support any 
25 c1iminal action against him on the basis of what 
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1 OCCUl1'ed. 
2 Q. Do you believe he was trying to do what he 
3 believed was appropriate based on his clinical 
4 judgment? 
5 MR. FOSTER: Object to the form. 
6 THE WITNESS: Yes. 
7 Q. (BY MS. DUKE) And·· 
8 A. So was Ted Bundy. 
9 MR. HIPPLER: Move to strike. 
10 MS. DUKE: Join. 
11 THE WITNESS: Can I join that? 
12 Q. (BY MS. DUKE) Taking the infom,ation and 
13 knowledge that one may have had back in 2003 with 
14 respect to methadone, you would agree that clinical 
15 research in pain management is proceeding at an 
16 unprecedented rate? 
1 7 MR. FOSTER: Object to the fonn. 
18 Q. (BY MS. DUKE) And important information 
19 is continually coming to light with respect to pain 
2 o management? 
21 MR. FOSTER: Same objection. 
22 THE WITNESS: No. It's been moving at a 
23 pretty good rate for about the past 20 years. 171e 
24 problem is that the vast majority of clinicians in 
25 practice today either were trained longer than 20 
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1 years ago or, more commonly, the people who teach 
2 them their pharmacology were trained so much earlier 
3 and. are not up-to-date. So we still have a lot of 
4 people being taught out-of-date concepts. But the 
5 real growth in the science of pain pathophysiology ' 6 and pharmacotherapy has been going on since the 
7 1970s. 
8 Q. (BY MS. DUKE) Do you believe that today 
9 you !mow more about methadone than back in 2003 with : 
10 respect to its use? 
11 MR. FOSTER: Object to the form. 
12 THE WITNESS: I have more data to supporr 
' 13 what I believed then. 1 don't believe that my ideas 
14 about methadone have changed at all between the late 
15 nineties and now. The science was there in the late 
16 nineties. We now have much more clinical 
17 documentation of what the science supported at that 
18 time. 
19 Q. (BY MS. DUKE) And a lot of that clinical 
20 documentation, you 1ve mentioned some ofit today) the 
21 2007 FDA--
22 A. Yes. 
23 Q. -- issue with respect to methadone. 
24 A. 2005 CDC. 
25 Q. 2005 CDC. 
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·1 A. But a lot of this occurred before 2003. 
2 Q. But the publications related to 
3 summarizing information you would agree were coming 
4 out in the 2005, 2006, 2007? 
5 A. No. I don't agree we that. There's been 
6 more subsequent to 2003, but there certainly was 
7 enough information out there prior to 2003 tha( we 
8 knew what to do. Even the package labeling for 
9 methadone cautions about slow titration and did in 
10 2003. 
11 Q. And, 1 guess, what do you define to be 
12 slow titration in 2003 with methadone? 
13 A. Well, by definition the time to steady 
14 state serum levels. This is a pharmacokinetics l O l 
15 concept. I mean1 there1s a lot of sophisticated 
16 phannacokinetics that gets into very extensive 
1 7 mathematical modeling. We don't expect clinicians to 
18 know that. We absolutely expect clinicians to know 
19 the basic 101 principles. This is one of the very 
20 early 101 principles. 
21 Q. Okay. So how do you define it again? l 
22 didn't get it all written down, slow titration. 
23 -· A. You don't increase the dose until you1re 
24 at steady state serum level, five half-lifes, five 
2 5 elimination half-lifes. 
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1 Q. And would that definition of slow 1 Q. Okay. In providing your opinions, do you 
2 titration with respect lo n1ethadone be the same in 2 believe that Mr. Byrne's actions rose lo the level of 
3 2003 as it is today? 3 reckless conduct? 
4 A. Yes. 4 A. I don't know the definition of "reckless 
s Q, Okay. s conduct. 11 
6 A. H's more visible today because of more 6 Q, That's what l was going to ask you is, 
7 reports of death, but it w,is in the literature, it 7 obviously, if you said yes, what do you understand 
8 was i11 the labeling, and it was in normative practice 8 reckless to mean, So is it fair to assume that you 
9 in 2003, 9 are not taking the position one way or the other as 
10 Q. What was in the labeling was just slow 10 to whether this was negligent conduct or reckless 
11 titration) correct? 11 conduct? 
12 A. Correct. 12 A. l can't take a position until the terms 
13 Q. Not a definition ofwhal that meant? 13 are defined. I don't !mow what they mean. 
14 A. It's important to recognize that the 14 Q. So at this point today you have not 
15 label, labeling, which, by federal law, is the 15 rendered an opinion in that regard? 
16 package insert from the FDC Act, that that is not 16 A. That's correct. 
17 intended for the layman. Thal is intended for the 17 Q. Okay. The final opinion that l noted and 
1s trained health professional. Again, I'm referring 18 you've alluded to, l think, throughout your testimony 
1. 9 now to the federal law, code federal regulations. 19 today is that Dr. Dille failed to supervise and 
2 D And it explicitly says that this is to be interpreted 2 D should have corrected what Mr. Byrne did. rs that an 
21 by a trained health professional who has the 21 opinion you hold? 
22 scientific understanding to know what it means. 22 A. Yes. 
2 3 Therefore, any trained, licensed health professional, 2 3 Q. Okay. And if you could just explain that 
24 including a P.A., would, by law and by standard of 24 opinion. 
25 practice, be obligated to understand the principles 25 A. I found it interesting that this , 
1--"------'---"-------------'-------'----+--------------"-----;__;-----l' 
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1 before using the medication. 
2 Q. Okay. Other than the label or, you know, 
3 the package insert, what other literature, to your 
4 knowledge, was out there with respect to this concept 
5 of slow titration with respect to methadone? 
6 A. Standard medical textbooks, and f've given 
7 you examples of several previously. 
8 Q. If you could just give some examples. 
9 A. Bonica, B~oMn-i-c-a; Warfield1 
10 W-a-r-f-i-e-1-d; Tollison, T-o-l-l-i-s-o-n. l wrote 
11 the chapters on opioids in the latter two. I'm 
12 editor for the whole pharmacology section of the new 
13 Bonica. And the one other big one is Mel~ack, 
14 M-e-l-z-a-c-k, and Wall, W-a-1-1. Those are the four 
15 leading pain management textbooks. 
16 Q. All prior to 2003? 
17 A. Yes. 
18 Q. Any other literature or documents that you 
19 believe would suppo,t that position regarding slow 
2 0 titration of methadone? 
21 A. Everything that l've referred to earlier 
22 in the testimony today. 
23 Q. You mean of literature you've written 
2q and --
25 A. Yes. 
1 relatively complex patient, due to her comorbidities 
2 and her long history of chronic pain that was not 
3 well controlled, was not seen by Dr. Dille. Now, I 
4 do know the law as ii pertains to physician assistant 
5 practice. l do know that it's a collaborative 
6 practice; that Dr. Dille has the responsibility to be 
7 the supervisor, that he has a responsibility to 
8 review the patient case with the P.A., which he did; 
9 that he is responsible for countersigning the 
lo records, which he did. I just found it surprising 
11 that he was not more actively involved. 
12 l found it totally unacceptable and 
13 contradictory in his own testimony for him to state 
14 that Mr. Byrne provided excellent care to 
15 Mrs. Schmechel, and then he went on to criticize the 
16 care in a few places. He was relatively soft in his 
l 7 qualification, and l understand why. But he did 
18 comment about the use of the methadone. l don't 
19 remember all the details. l just remember the 
2 o contradiction between his use of the word 11excellenf1 
21 care and his further discussion. 
2 2 I understand busy practice. I understand 
23 what happens when P.A.s are physically remote from 
24. the supervising physician. But I also understand the 
25 law and the obligation of the supervising physician 
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1 to be just that. And, unfortunately, I don't think 1 Q. Okay. Any other areas where you feel that 
2 that really occurred to the necessary level in this 2 Dr. Dille did not support --
3 case. 3 A. I think that was the one that jumped out 
4 Q, And based on those statements youtve made, 4 atme. 
5 do you believe that Dr. Dille failed to meet the 5 Q, If we look at your notes which are Exhibit 
6 standard of care in Twin Falls for a physician 6 6, as I understand it, there1s two versions of these. 
7 practicing in 2003? 7 One looks like it was a prior, and then you keep 
8 MR, HIPPLER: Object to the form. 8 adding to it. 
9 Foundation, 9 A. Exactly. 
10 THE WITNESS: I don't know that I can 10 Q. Okay. 
11 speak to that. lam speaking specifically to his 1J. A So could I suggest that we simply destroy 
12 supervision of Mr. Byrne's use of methadone. And I 12 the earlier version? 
13 feel it is highly probable, had there been discussion 13 Q, I just marked Exhibit 6 as --
14 of the methadone dosing piior to the way that it was 14 A Okay, With your pennission I'm going to 
15 implemented, that there may have been some additional 1.5 destroy my earlier version of this because I -- !his 
16 consideration as to whether that was the appropriate 16 I printed earlier and the computer note is 
17 regimen. 17 up-to-date, This is as of yesterday, 
18 Q. (BY MS, DUKE) You indicated that you felt 18 MR. HIPPLER: I prefer that that be 
19 that there were items that Dr. Dille was not 19 marked. 
20 necessarily suppoJ1ive of Mr. Byrne on? 20 MS. DUKE: Yeah, You want it marked? 
21 A, That's my recollection, 21 MR. HIPPLER: Well, yeah, If there are 
22 Q, Okay, What do you recall those being? 22 earlier versions, I prefer we see the earlier 
23 A. 1 can't recall the exact statements, It 23 versions as well. 
24 ., 24 was in his testimony, I may have that in my notes, THE WITNESS: Yeah, Everylhing that's in 
25 Q, Okay, While you're looking for that, I'll 25 the earlier version is in the later version. /- -----~---------------;----------------------~!: 1; 
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1 look through my notes here real quick. 
2 A, I have it here, 
3 Q, Oh, you're referring to Exhibit-· 
4 A No, I'm sorry. I don't. 
5 Q, -- 6? 
6 A, Yes, He admitted that an increase to 30 
7 milligrams by Saturday would be too rapid an 
B increase, which contradicts what T,J, Byrne said, 
9 This is on page 29 of Dr, Dille's testimony, And 
1 o that's exactly what I concluded, 
11 Q. Let's see, This is on page 3, Okay. [ 
12 see what you 1re talking about there. 
13 A, Yeah, I mean, that jumped out at me in 
14 the statement. It was after he had sald) quote, 11he 
15 handled the care in an excellent fashion," You know, 
16 I -- I'll soften my prior statement that says that 
17 reflects either unacceptable ignorance or dishonesty. 
18 l was shocked by that statement. l think it reflects 
19 denial. This was a tragic outcome and nobody is 
2 o minimizing the tragickness of the outcome, It just 
21 is not -- it's just too dam bad that Dr, Dille was 
22 not more actively involved because I -- from what he 
2 3 said in his testimony and from what is clear to me 
24 scientifically, that had there been a slower 
2 5 increase, the risk would have been markedly lower. 
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1 MR, HIPPLER: I understand, It gives me a 
2 time perspective of your thought process, 
3 MS. DUKE: I'm going to go ahead and have 
4 it marked 1 then. · 
5 THE WITNESS: Yeah. Nothing changed here, 
6 Jt's just more of it. 
7 MR. HIPPLER: That's fine, 
a (EXHIB!T-11 WAS MARKED,) 
9 (A short recess was taken,) 
10 MS, DUKE: Back on the record, 
11 Q, (BY MS, DUKE) I understand during the 
12 break you had an opportunity to talk to Mr. Foster 
13 with respect to the reckless conduct question, Go 
14 ahead and let me know what you want to say, 
15 A As I said in my earlier testimony, I did 
16 not recall the definition of"reckless," which is why 
l 7 I couldn't answer it. Mr. Foster reminded me that 
18 the definition apparently under Idaho law is that 
19 Mr. Byrne should have-· either knew or should have 
2 o known that his action in this case, his prescribing 
21 of methadone the way he did, could have caused 
22 serious hann, I don't question that he didn't know 
2 3 it. I state clearly that he should have known it. 
24 That he was practicing outside of standard and 
25 unlawfully by prescribing the drug without knowing 
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1 it, unlawfully because he's outside of the P.A. 
2 Practice Act. And, therefore, that is consistent 
3 with the definition of reckless as I understand it. 
4 Q. And so, based on that definition, you 
5 believe his conduct was reckless? 
6 A. On that definition -- based on the 
7 definition of something he should have known, yes. 
8 That was defined for me earlier and l did put that in 
9 one of my earlier statements. Still don't know what 
1 o 11negligent'1 means. 
11 Q. We've talked in great length as to your 
12 opinions in this case. Have we adequately covered 
13 the opinions that you hold in this case here today? 
14 A. Yes. 
15 Q. Do you intend to do any other work with 
16 respect to the evaluation of this case prior to 
1 7 trial? 
18 A. Not unless asked to do so. 
19 Q. And so with respect to any opinions that 
2 o you would intend to testify to at trial, they would 
21 have been covered by us in this deposition today, 
22 correct? 
23 A. Ibelieveso. 
24 MR. FOSTER: I'm going to belatedly object 
2 5 to the form. . 
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1 MR. HIPPLER: What was wrong with the form 
2 just so we can correct it'? 
3 MR. FOSTER: Well, it's depending upon the 
4 examiner. I'm not casting aspersions. rm just --
5 Q. (BY MS. DUKE) What do you believe is the 
6 course of treatment that Mr. Byrne should have taken 
7 on that Friday with respect to Mrs. Schmechel? 
s A. Optimal care or acceptable care? 
9 Q. Acceptable care. What you believe would 
10 meet the standard of care, recognizing that there's 
11 other items that would meet the standard of care too. 
12 A. Start the methadone at the dose that he 
13 did, don't increase the dose for at least four and 
14 preferably five days, give Mrs. Schmechel an adequate 
15 amount of hydrocodone to be taken every four hours as 
16 necessary. I would have preferred to have -- rather 
17 than go up from seven and a half to 10 milligrams, 
18 change from seven and a half to five-milligram 
19 tablets and allow her to take one to two. ll would 
2 D be entirely appropriate to titrate the short-acting 
21 medication to response because you1ll get a rapid 
2 2 response and a rapid offset. But to absolutely not 
23 allow any titration, that is patient determination of 
24 the dose of methadone, in this case one-half to 
2 5 one-and-a-half tablets being as ordered, which is 
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1 grossly inappropriate based on the pharmacokinetics 
2 and slow onset response. 
3 And I would also have strongly recommended 
4 converting her from amitriptyline to desipramine as 
5 the drug of choice, nortriptyline as an alternative 
6 because the fonner would have a 25 percent, the 
7 latter 50 percent side effect profile of U1e 
8 amitriptyline, not reduce the dose of the 
9 amit1·iptyline. He was entirely appropriate to keep 
1 o her on her anti-inflammatory. She was taking Bextra 
11 at the time. Other than that, I think his care was 
12 okay. 
13 Q. And other than what you've just testified 
14 to, would you have done anything differently? 
15 A. Well, more careful documentation, as we 
16 discussed previously. But no. I think that's 
1 7 reasonable. 
18 Q. And with that addition, anything else? 
19 A. Well, l would have preferred not to change 
2 o the dose on a Friday, but he saw her on Friday and 
21 she was asking for help. So it's not unreasonable 
22 for him to want to do something right away. 
23 Q. Other than that, anything else? 
24 A. I think that should do it. 
2 5 Q. Okay. Well, I appreciate your time. I 
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1 might have a couple follow-ups after Mr. Hippler 
2 finishes his examination> but I appreciate your time 
3 today, Doctor. 
4 A. Thank you. 
5 EXAMINATION 
6 BY MR. HIPPLER: 
7 Q. Doctor, as you know by now from our 
s conversations off the record, I represent Dr. Dille 
9 and the Southern Idaho Pain and Rehabilitation 
1 o Jnstiiute in Twin Falls, Idaho. 
11 Have you ever been to Twin Falls, Idaho? 
12 A. Yes. 
13 Q. For what occasion? 
14 A. l gave Grand Rounds at the local hospital 
15 on one or two occasions in the past. 
16 Q. Does BYU have a physician's assistant 
17 school? 
18 A. I don't believe so, no. l believe 
19 University of Utah is the only one in the state. 
20 Q. We took a break after you said you didn't 
21 know whether or not the conduct of Mr. Byrne in this 
22 case was reckless, and then you came back in, and 
23 Mr. Foster had apparently given you a definition of 
2 4 "reckless." And based upon that, you indicated you 
2 5 thought the care was reckless, correct? 






1 A. Con·ect. 
2 Q. And the definition was that he knew or 
3 should have known that he shouldn't have prescribed 
4 as he did, correct? 
5 A. That's my understanding. 
6 Q. Okay. If the definition of reckless were 
7 that he consciously disregarded knowledge that he 
8 had, would you still feel the same with respect to 
9 recklessness? 
10 MR. FOSTER: Object to the form. That's 
11 not the definition of "reckless." But go ahead. 
12 THE WITNESS: No. l don't believe that he 
13 did consciously ignore infonnation that he had. l 
14 think he lacked the necessary information to function 
15 within the law. 
16 Q. (BY MS. DUKE) Do you believe that he knew 
1 7 that he lacked the necessary information? 
18 A. I don't know. I believe that was 
19 Dr. Dille's responsibility as his supervisor to know 
2 o that. This is a specialized practice. This not a 
21 primary care general practice. 
22 Q. So I take it you don't believe that 
2 3 Mr. Byme consciously disregarded the health or 
24 safety of Mrs. Schmechel? 
2 s A. No, not at all. 
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1 Q. Do you believe that Dr. Dille consciously 
2 disregarded the health or safety of Mrs. Schmechel? 
3 A. Not at all. 
4 Q. Now, the more you answer yes, the faster 
s we are. 
6 A. Not at all. 
7 (A discussion was held off the record.) 
8 Q. (BY MR. HIPPLER) Do you understand that 
9 physician's assistants in Idaho have, or did in 2003, 
1.0 have the authority to see patients on initial 
11 evaluation and to prescribe a course of treatment, 
12 including Schedule JI narcotics? 
13 A. Yes. 
14 Q. Without a physician first approving that 
15 course of conduct? 
16 A. Yes. As a point of law, there is no such 
l 7 thing as a Schedule ll narcotic. lt's a Schedule rr 
18 controlled substance. 
19 Q. Pardon me. You're correct. 
2 o A. Seven years oflaw school on my part. No. 
21 l'mjustjoking. But yes. I'm well aware of that. 
22 Q. Okay. 
23 A. And I was actually instrumental in the 
24 American Academy of Physician Assistants developing 
2 5 the protocol that they took to the state medical 
""'"'"'"•• .,· .. --, '•·, .. 
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1 boards to get that approved. 
2 Q. And you understand that Mr. Byrne spoke to 
3 Dr, Dille about the patient that he saw on a Friday 
4 the next business day, which would have been Monday 
5 after he initiated care, correct? 
6 A. I believe that's correct. I recall seeing 
'7 a note that was countersigned by Dr. Dille subsequent 
8 to the medication being prescribed and the titration 
9 regimen being initiated. 
10 Q. Do you recall from the deposition of both 
11 Mr. Byrne and Dr. Dille that that conversation took 
12 place on the Monday following the Friday? 
13 A. I don't recall the exact date. 
J.4 Q. Okay. 
15 A. J certainly accept that if that's what 
16 you're telling me. 
17 Q. And in terms of supervision .in a community 
18 pain management practice where there are just a 
19 couple providers, as in this case, do you believe 
2 o that's a reasonable approach? 
21 A. For this patient, no, for the reasons I 
22 stated. This is a complex patient who had 
2 3 significant comorbidities. And I do not place blame 
24 on either party. I think it was a tragic 
2 5 circumstance, but avoidable, had there been a 
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l protocol in place defining complex patients, the 
2 necessity for consultation before initiating 
3 phannacotherapy, especially an opioid in a patient 
4 with pre-existing respiratory impainnent. I think 
· 5 it's unfortunate that that had not been anticipated 
6 and set up in written policies and procedures within 
7 that clinic, which I don't believe existed. 
s Q. Do you understand such written policies 
9 and procedures to exist in the majority of community 
1 o centers such as that in small towns? 
11 A. I don't know the answer to that. I do 
12 know that they exist in many clinics with which I've 
13 interacted. I don't know if it's the majority or the 
14 minority. 
15 Q. Okay. Do you kuow whether standard of 
16 care in Twin Falls, ldaho required such screening 
1 7 protocols? 
18 A. I don't know. 
19 Q. And at'e you aware that Dr. Dille and 
2 o Mr. Byrne worked together for over two and a half 
2.1 years prior to Mr. Byrne seeing Mrs. Schmechel? 
2 2 A. I knew there was a longstanding 
23 relationship. J don't recall the exact length. 
24 Q. Do you have any reason to disagree with me 
2 s tliat Dr. Dille, through his work with Mr. Byrne, had 
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1 grown to trust Mr. Byrne's clinical judgment? 
2 A. No. No reason to disagree. 
3 Q. Okay. Now, I want to go back to what you 
4 talked about in the very first part of your 
5 deposition where you talked about how you work 
6 collaboratively with the collaborative team of 
7 specialists that come together to treat patients at 
8 the University of Utah Pain Management Clinic. Okay? 
9 But as I understand it, that typically includes at 
1 o least a pain management physician? 
ll A. Correct. 
12 Q. Yourselfor another phannacologist? 
13 A. Co-therapist. 
14 Q. Phann.D.? 
15 A. Right. 
16 Q. A psychologist? 
1 7 A. Correct. 
18 Q. And a physical therapist? 
19 A. Con·ect. 
2 o Q. Okay. lt might include other people 
21 depending on the patient? 
2 2 A. It usually does. There are medical 
2 3 students, residents, other people who come in on an 
2 4 as-needed basis. 
25 Q. And you understand that in a community 
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1 clinic such as the Southern Idaho Pain lnstitute in 
2 Twin Falls, those types of resources in practice 
3 don't exist? 
4 A. Of course. We're a tertiary care referral 
5 center. In fact, we get the referrals from places 
6 like your facility. 
7 Q. What is it about Mrs. Schmechel's 
B obstructive sleep apnea that Mr. Byrne needed to know 
9 before prescribing the pain medicine methadone 
10 instead ofOxyContin? 
11 A. Not methadone versus OxyContin. Before 
12 changing opioid, because of the increased risk of 
13 rnspiratory depression due to incomplete cross-
14 tolerance, it would be impo1iant for him to know that 
15 she was compliant with her CPAP, that she was using 
16 it at the proper pressures, and that she was getting 
1 7 good control of her obstructive sleep apnea. As you 
18 probably know, with sleep apnea patients will 
19 actually stop breathing during the night. And 
20 respiratory drive is markedly decreased by opioid. 
21 This risk is by far greater in the first five days to 
2 2 seven days of initial or changed opioid therapy than 
23 it is after that first week, as I was asked in 
24 earlier testimony. 
25 Q. And obstructive sleep apnea is an actual 
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1 physical obstruction in the airway, correct? 
2 A. Correct. 
3 Q. As opposed to central sleep apnea, which 
4 is a depressed respiratory state generally, correct? 
5 A. That's correct. But this all adds up to 
6 impaired respiratory drive. 
7 Q. Right. Alid CP AP keeps open the 
B respiratory tract to help prevent such occlusion, 
9 right? 
1 o A. If it's being used at the proper pressure, 
11 if the mask fits properly, and if the patient is 
12 compliant. 
13 Q. And you understand from Mr. Byrne's note 
14 that Mrs. Schmechel had indicated that she was using 
15 CPAP and that she was stable on the CPAP? 
16 A. That's a very difficult determination for 
17 a patient to make. This is my concern. We not 
18 infrequently have patients referred to our clinic who 
19 are on CPAP. We will invariably consult with the 
2 o primary care physician or the pulmonologist or the 
21 other physician who initiated the CP AP therapy to get 
22 a determination on the efficacy of the CPAP. A very 
2 3 large percentage, maybe even half of the patients who 
24 are receiving CPAP or BIPAP therapy are not getting 
2 5 an optimal effect from it. H requires periodic 
Page 197 
l follow-up and assurance that there's a good fit and 
2 the patients understand how to use it. 
3 I don't have any documentation to that 
4 effect. 1 do have some documentation in Dr. Vorse's 
5 notes that there was a problem at one time, but 
6 things are doing better later on. But this is not 
7 something for which we have a continuity of care 
8 record because Mrs. Schmechel left Dr. Verse's care 
9 when she converted over to the Twin Falls facility. 
10 Q. So you don't have any information to 
11 suggest that Mrs. Schmechel, at the time that she was 
12 treated by Mr. Byrne, was not getting adequate relief 
13 or treatment with her CPAP? 
14 A. No, nor do I have infonnation that she 
15 was. 
16 Q. Okay. What Mr. Byrne had was infonnation 
1 7 from Mrs. Schmechel that she was doing well with her 
18 CPAP? 
19 A. As I stated a moment ago, patients are 
2 o typically unaware of how well they're doing with it. 
21 Patients with obstructive sleep apnea, as you may 
22 well know, often awaken at night and have no memory 
23 of awakening in the morning. We often get reports 
2 4 from sleep partners that are completely different 
2 5 from what the patient reports. So any knowledgeable 
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clinician would not accept a patients subject report 
of how well the CPAP is working. We want more 
objective infonnation, 
Q. And do you consider Dr. Hare a 
knowledgeable and competent practitioner? 
A. Yes. 
Q. I take it you respect him as a clinician? 
A. I've worked with Brad for 28 years. 
Q. Do you have knowledge regarding the local 
standard of care in the community of Twin Falls, 
Idaho in 2003 of whether or nol a pain management 
physician, before changing opioids, had to obtain 
sleep study records or more specific secondary source 
information regarding the patient's efficacy with 
CP AP treatment? 
A. That's a very complex question. The only 
intelligent response l can give is that [ think it 
would be foolhardy of any clinician to undertake 
aggressive opioid therapy in a patient with multiple 
morbidities, including obstructive sleep apnea, if a . 
CPAP was being used without obtaining at least an 
outline of how well the patient has used and 
responded to the CPAP from the initial prescribing 
physician. 
Q, So if Dr. Hare indicates that il was 
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appropdate and within the standard of care to 
receive assurances from a patient that was utiJizing 
a CPAP and doing well, that that complied with 
standard of care, you would just disagree with that? 
A. l don't know what records Dr. Hare 
reviewed. I know I've worked with him for a long 
time. I suspect that he had limited information 
available to him at the time he made that 
determination. That's a judgment call on my part. 
!'m not sure that l would disagree with him. r 1hink 
that we're probably coming from a different knowledge 
of the case. 
Q, Okay. Well, let's assume thal he's read 
Dr. Vorse's records and read the sleep medicine 
records from the studies and assume that he1s read 
the depositions and assume that he's read the medical 
records of Mr. Byrne and the Southern Idaho Pain 
Institute. 
A. Well, that's a hypothetical that I don't 
think applies, 
Q. Because you don 1t think he1s read that 
stuff? 
A. That's correct. 
Q. Have you talked to him aboul that? 
A. No. I just know Dr. Hare very well. 
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Q. What do you mean by that? You don't 
believe he would review that or you don't believe he 
would have that opinion? 
A. I don't believe, ifhe had read all those 
records, that he would have that opinion. 
Q. Okay. And ifhe had and he does, tllen you 
would just disagree with him? 
A. Disagree, correct. 
Q. Sometimes clinicians can have reasonable 
differences of opinions? 
A. Absolutely. 
Q, Now, you weren't there, obviously1 when 
Mr. Byrne talked to Mrs. Schmcchel, conect? 
A. Correct, 
Q. And you don't know precisely what he told 
her, correct? 
A. Correct. 
Q. And, obviously, Mrs. Scl,mechel is not here 
to ask that question of what she was told, correct? 
A. Conect. 
Q. So the only one that is here to tell us 
that is Mr. Byrne, correct? 
A. Correct. 
Q. Do you recall that Mr. Byrne testified in 
his deposirion that he gave strict instructions to 
Page 201 
Mrs. Schmechel that she was not to increase her 
methadone beyond what he had prescribed without 
talking to him first? 
MR, FOSTER: Object to the form. 
THE WITNESS: l recall his having said 
that. l also share with you the dictum of clinical 
medicine: !fit isn't documented, it isn't done. 
And I looked explicitly for such documentation in the 
record and found none. 
Q. (BY MR. HIPPLER) Well, the truth of the 
matter is that a lot of physicians in their own 
clinic records use a shorthand method of 
documentation, do they not? 
A. l accept shorthand. I don't accept total 
omission. 
Q. Well, by "shorthand" I'm not talking about 
a fonnal shorthand. I'm talking about use of 
language that they know what it means. 
A. There is nothing in there to suggest that 
there was any such counseling given. If tllere had 
been a simple notation such as standard counseling or 
cautioned patient1 I would have accepted that as a 
shorthand. I don't recall having seen that. 
Q. Take a look at Exhibit -- what exhibit are 
the medical records? 
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1 MS. DUKE: Nine. 
2 Q. (BY MR. HrPPLER) -- 9. Look at Dille 
3 page 16. 
4 A. Okay. 
5 Q. And look under Plan. 
6 A. Right. 
7 Q. Tell me if I'm reading this correctly. 
8 About a third of the way down under Plan it says: 
9 "Today we had a lengthy discussion in reference to 
1 O pain management and the benefits of long-acting 
11 medications as well as periodically changing pain 
12 medications to avoid excessive dosing and adverse 
13 effects from this." Do you see that? 
14 A. Yes. 
15 Q. Okay. 
16 A. I see nothing there to suggest there was 
1 7 any discussion of the risk of exceeding dose. 
18 Q. Okay. 
19 A. This reflects what was well disproven 
2 o medical care at that time, which is called preemptive 
2 J. opioid rotation. It's completely ruled out as being 
22 efficacious. There was some advocacy of that in the 
2 3 mid-l 990s, the thinking being that ifwe rotated the 
2 4 patient from drug A to drug B every six months or so, 
2 5 that this would prevent tl1e development of analgesic 
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J. tolerance. But that had been completely disproven, 
2 So this reflects some out-of-date thinking. But, 
3 that said, there were still some people who were 
4 doing that type of preemptive rotation certainly into 
5 the early 2000s. 
6 But there's nothing here. That's 
7 periodically changing pain medications to avoid 
8 excessive dosing. Now, we certainly change from drug 
9 A to drug B if the dose of drug A is already creeping 
10 up to the point that we're getting excessive side 
11 effects. But there's nothing here to suggest that 
12 there was any caution given to the patient about the 
13 danger of exceeding the prescribed dose, 
14 And, additionally, let me add that there 
15 was the slip of paper that Mr. Byrne gave to 
16 Mrs. Schmeche!, said one-half to one-and-a-half 
1 7 tablets. That's not acceptable. And it did not say 
18 that you can -- you know I you can increase the dose 
19 even daily or every other day. It just said take 
2 o one-half to one-and-a-half tablets. In his chart 
21 note he indicated over 72 hours, but he didn't 
22 indicate whether that could be done in the first 12 
23 or 24 of the 72 hours or whether it could only be 
24 done once every 72 hours. And it's clear from the 
2 5 testimony that he advised her that she could increase 
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1 the dose daily. So I don't see any shorthand or any 
2 suggestion in here that he gave the necessary 
3 counseling to the patient. 
4 Q. Okay . .If Mr. Byrne testifies that it was 
5 the standard within his practice and in the clinic to 
6 document that he had a lengthy discussion regarding 
7 pain meds and benefits, that that also includes 
8 discussion of risks, would you find that unusual? 
9 A. l'm sorry, I didn't understand, Ask it 
10 again. 
J.l Q. lfMr. Byrne testifies that it is typical 
12 for him to dictate in that practice that he had a 
13 long discussion with the patient or had a discussion 
14 with the patient regarding the benefits oflong-
15 acting opioids, that that included the risks as well 
16 and, in particular, as had been explained to him by 
1 7 Dr. Dille, to stress the 1isks of exceeding doses? 
18 MR. FOSTER: Object to the fonn. 
19 THE WITNESS: My recollection, and, again, 
2 o correct me because this is several months ago that I 
21 read this, was that he said that's his normal 
22 practice, He couldn't recall whether he had done 
23 that with this patient ornot. But if I'm in error, 
24 please correct me. 
25 Q, (BY MR. HIPPLER) We'll just go with what 
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1 you remember. That's fine. 
2 A. But that's the reason we write things in 
3 the chart, because we can't remember what we do with 
4 patients in the past. 
5 Q. Well, and so1netimes, as I was alluding to, 
6 sometimes clinicians have a shorthand way of 
7 reminding themselves that they did have a discussion 
8 with the patient. 
9 A. Correct. But, unfortunately, I don't see 
1 o that here, 
11 Q, And if Mr. Byrne testifies that this is 
12 his shorthand way to say that he talked about the 
13 benefits of the medication, that the discussion of 
14 benefits always includes a discussion of the risks, 
15 that's a way of documenting it. 
16 A. Well, ljust--
1 7 MR. FOSTER: Objccl to the form. 
18 Argumentative. 
J.9 THE WITNESS: l had a different reading of 
2 0 the testimony because, again) as I said, my 
21 recollection is that he could not state that he 
2 2 specifically discussed this with her. He could only 
23 talk in generalities. 
24 Q, (BY MR. HrPPLER) As I understand it, if 
2 5 we were to boil down the crux of your opinion, it1s 
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1 pnmarily Mr. Byrne having titrated upward her dose 
2 on a daily basis? 
3 A. Correct. 
4 MR. FOSTER: Object to the fonn. 
5 THE WITNESS: And this led to the now well 
6 described phenomenon of accumulation respiratory 
7 toxicity. 
B Q. (BY MR. HIPPLER) Okay. You talked 
9 earlier -- and you'll have to excuse me, I'm going 
1 O to jump around for more than Keely did because I'm 
11 just picking up as opposed to having a game plan and 
12 going start to finish. 
13 A. l understand. 
14 Q. We talked earlier about this certificate 
15 or license that you could get if you filled out the 
16 paperwork in order for you to write prescriptions. 
1 7 A. Correct, 
18 Q, Does that include Schedule II medications? 
19 A. Yes. There's ample precedent of people 
20 who have done this receiving their own DEA number. 
21 As soon as you get the prescriptive authority from 
22 your state board, then you apply to the DEA for a DEA 
23 registration. And then you have Schedule II through 
24 V prescriptive authority. · 
2 5 Q. Do you know whether Pharm.D.s in Idaho 
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1 have that authority? 
2 A. I don't know. I know that it's been done 
3 in Nebraska and some other jurisdictions, Maryland 
4 . and others, 
5 Q. And Utah apparently? 
6 A. We have the mechanism to do it. And one 
7 of my staff actually looked into that, and we do have 
8 the mechanism. Bui I made an administrative decision 
9 that it's more important that we teach others how to 
10 do it. 
11 Q, Do you know whether any Phann.D. in Utah 
12 is licensed to prescribe Schedule II medications? 
13 A. l don't know. 
14 Q. So you don't know of any that are, I take 
15 it. 
16 A. Cotrect. 
1 7 Q. Now, you talked earlier in your deposition 
18 about how sometimes in clinic you would see a patient 
19 and come up with a plan regarding the medications 
2 O they were going to take, or perhaps changing the 
21 dosing of medications they were taking, correct? 
2 2 A. CotTect. 
2 3 Q, And just so that I'm clear, in order for 
24 that to take effecti a physician, or at least a 
2 5 physician1s assistant or nurse practitioner, actually 
::-::-: .... , ...... -., .. -·· ... ·~ . .. 
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l has to sign off on that, cotTect? 
2 A, If it's a new prescription, new 
3 medication, then somebody who does have a license to 
4 prescribe, a DEA number for a controlled substance, 
5 would have to write the prescription, or would have 
6 lo at least sign the prescription. 
7 Q. And if it's just instructions on how to 
8 take a medication they already have and there's not a 
9 new prescription, then what would it be? 
1 o A. Then normally l would simply write in the 
11 chai1 what recommendation l gave to the patient, I 
12 would usually give the patient a written piece of 
13 paper explaining what to do or ask the patient to 
14 repeat back to me how he or she is going to take the 
15 medication. And that would take care of it. 
16 Q. And in those cases you don't review that 
1 7 with the physician? 
18 A. Well, we always review all of our patients 
19 with the interdisciplinary team, but I don't have to 
2 o review in advance. This hasn't happened since 
21 Tuesday of this week when I saw a patient that was 
22 taking both a long-acting and short-acting opioid and 
23 was not taking them on an optimal schedule. I went 
24 through and educated the patient, had the patient 
2 5 repeat back to me what was happening. The patient 
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1 walked out very satisfied. 
2 After the patient left, I advised the 
3 physician of what I told him. The physician said, 
4 Thank you very much. And then the front desk clerk 
5 came in to talk to me later saying that the patient 
6 had been on his cell phone with his wife and had just 
7 called to say that in two years at the clinic this 
8 was his most satisfying interaction because he now 
9 for the first time really understood his medications, 
l O It's an educational issue, and it1s 
11 critically important that patients understand how to 
12 take these potentially toxic medications properly. 
13 Q. And you also described on some occasions 
14 where you would actually fill out a prescription and 
15 then go have a physician sign it? 
16 A. At times I do that just for expedieucy. 
1 7 Q. And when you do that, do you go through 
18 all of the underlying comorbidities with the 
19 physician and other medications that the patient is 
2 o on, or do your colleat,rues have enough trust in 
21 understanding you to sign off/ 
22 A. Well, nonnally, we've seen the patient 
23 already. Ifwe1re making a change in a regimen) 
24 then, obviously, we are already have that documented, 
25 !fit's a new patient, the latter of what you reflect 
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1 occurs. Certainly, I would have reviewed the 
2 eomorbidities. !fl had a patient in whom I did not 
3 have a complete medical record, either from the 
4 referring physician or referring clinic that gave us 
5 that background on comorbidities that we needed, th.on 
6 [ would not recommend a change until we had done the 
7 necessary workup at our own clinic. 
B Q. Okay. But once you're satisfied and you 
9 take it to one of the physicians, does the physician 
10 typically have the same level of knowledge about the 
11 patient as you do at that point when be signs the 
12 prescription? 
13 A. Sometimes would have more, sometimes would 
14 have less. 
15 Q. Okay. I take it there has to be some 
16 trust with the physician of you in doing that"" 
17 A. Yes. 
18 Q. -" based on his understanding of your 
19 knowledge and working with you. 
20 A. Yes. 
21 Q, Okay. You talked about some labeling 
22 requirements by the federation of"" or by somebody 
23 with regard to the label on the prescription has to 
24 correctly identify the dosing the patient is actually 
25 going to take, correct? 
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1 A. This would nonnally come under the State 
2 Phannacy Practice Act, that the label on the 
3 prescription vial has to reflect what the prescriber 
4 has written. 
s Q. Okay. 
6 A. And that the standard of practice is that 
7 what the prescriber has prescribed must be recorded 
8 in the medical record. Now, that's -" the latter is 
9 Federation of State Medical Boards. And ifa 
1 o physician prescribes something and does not record 
l l that in the medical record, that is below the 
12 standard of practice. 
13 Q. Okay. So it would be appropriate, then, 
14 for a physician to"- let's say he wanted a patient 
15 to take 15 "- strike that. ['JI do this from a drug 
16 l actually know. 
1 7 Say he wanted a patient to take 20 
18 milligrams of Pravachol. The patient had cost 
19 concerns, so he writes a prescription for 40 
20 milligrams of Pravachol and tells the patient to 
21 break it in half and take it. 
22 A. Okay. 
2 3 Q. But the bottle might say take one a day in 
24 order for the insurance to pay for 30 days' worth of 
2 5 40 milligrams in order to get 60 days' supply. Are 
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1 you aware of thal practice? 
2 A, I am, and l also am aware that that is 
3 insurance fraud. 
4 Q. Okay. But you're aware that that happens? 
5 A. Yes. I've never seen that happen with an 
6 opioid. 
7 Q. !'m not suggesting they do that. 
s A. And we're dealing "" methadone is a very 
9 inexpensive medication, whereas the antHipemics are 
10 very expensive. Yes, [ know that goes on. 
11 (A discussion was held offtlie record.) 
12 Q, (BY MR. HIPPLER) Now, we already talked 
13 about this, that you weren't there when Mr. Byrne 
14 explained the dosing-" 
15 A. Of course. 
16 Q. -" parameters to Mrs. Schmechel, correct? 
17 A. Or course. 
18 Q. And you talked about one of the ways that 
19 you explain it to them is talk to the patient, have 
20 the patient repeat it back, make sure they have a 
21 good understanding of what it is you're telling them 
22 to do1 co1yect? 
23 A. Correct. 
24 Q. Okay, 
25 A. But I also mentioned that if I'm changing 
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l the regimen from what's already on the prescription 
2 bottle, that [ give the instructions to the patient 
3 in writing, clear and explicit, explaining what's 
4 happening. 
5 Q. And you don't know, for example, in this 
6 case whether Mr. Byrne explained in detail to 
7 Mrs. Schmechel on how to take the medication and then 
B gave her the handout as a shorthand version of what 
9 he was saying that they were going to do on a longer 
1 o term basis? 
1i A. Well, as I already testified, of course, I 
12 don't know that. But as J already testified, what I 
13 see here is different from what's in his dictated 
14 note. Both of those differ somewhat from his 
15 testimony. And what the patient has to go by, what 
16 the patient is most apt to rely upon, is1 number one, 
17 the prescription label; and, number two, w1ilten 
18 instructions, 
19 Now, the prescription label appears to 
20 have said one-and"a-halftablets twice a day from the 
21 infonnation that Mr, Foster received what was 
22 actually on the label, and that's in earlier 
23 testimony. This says: "1/2" l pill every 12 hours, 
24 may increase to maximum of 1-112 pills every !2 
25 hours." We have three different conflicting pieces 
.,, .... -'"• ... ,,,,, C;t.~ ; •••• • '" ........... ,.,._,,., "• 'C'"'" 





1 of infonnatlon; One, the verbal counseling; tvlo, 
2 what is written here; and three, what is written on 
3 the prescription vial. That's a recipe for disaster 
4 on patient misunderstanding. 
5 Q. Okay. The other thing that we have is our 
6 notes from the physician on the 29th reflecting what 
7 she was to start taking on that day, correct? 
8 A. Did you say from the physician or from ·-
9 Q, From the physician's assistant. 
10 A. Yes, yes. That's one of the three things 
11 l referred to, So there are three different sets of 
12 instructions. And I'm not sure -- I have, obviously, 
13 no idea what Mrs. Schmechel came away understanding. 
14 But my fear is that she was confused by getting 
15 different instructions verbally and in writing on 
16 this pad handwritten. And those both differ somewhat 
1 7 from what was in the medical record. So I don't 
18 know -- I don't know exactly what was said to her. 
19 Q. Okay. The only one who can tell us what 
20 was said to her is Mr. Byrne, correct? 
21 A. Well, it's Mr. Byrne who wrote this note, 
2 2 who wrote the note that's in the chart, and who wrote 
23 the prescription that was reflected on the label. So 
24 he generated three different sets of documentation 
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1 the variability, correct? 
2 A. Well, there are two factors. One is that 
3 the published tables -- and I'm the author of the one 
4 from the American Pain Society, for example -- are 
5 population averages. So with one given patient you 
6 don't know whether the patient is on the median, is 
7 tucked in one corner of the bell-shaped curve or 01e 
8 other corner. So they're just starting points, and 
9 you have to titrate from those, which is why we must 
10 staii conservatively. And, indeed, Mr. Byrne did 
11 that initially. 
12 The second issue is that methadone has 
13 incredibly inconsistent reports on its dose 
14 equivalents. Unlike all of the other opioids for 
15 which we have fairly consistent population average 
16 dose equivalents, we don't have that for methadone. 
1 7 It varies greatly, which makes methadone a tricky 
18 drug to use. 
19 Q. So, for example, I might pick up a 
20 textbook from 2003 that might tell me that metl,adone 
21 is in an equal analgesic chart equivalent -- 10 
2 2 milligrams of methadone is equivalent to 10 
2 3 milligrams of OxyContin, and I might pick up another 
2 4 book that tells me 20 milligrams of methadone is 
:: 
2 5 which is all different. 2 5 equal to l O milligrams of OxyContin. : 1-----------------------f--~-----=-------'-------~~-I 
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1 Q. But he can tel1 us what he told her and 
2 what she reported to him the following Monday on what 
3 she was doing? 
4 MR. FOSTER: Object to the fonn. 
5 THE WITNESS: r honestly don't know ifhe 
6 can. l don't know ifhe can recall what he told her. 
7 And my recollection is in his testimony he thought 
8 that he recalled what it was, but I'm not sure that 
9 he was sure, 
10 Q, (BY MR. HIPPLER) Okay. Well, certainly, 
11 if anybody can, it would be he because he's the only 
12 one here. 
13 MR. FOSTER: Object to the lorm as 
14 argumentative. 
15 THE WITNESS: ff anybody could do it who 
16 is sti1J with us, he's the only one who could. 
17 Q, (BY MR. HIPPLER) Okay. 
18 A. But I can only go by the inconsistency of 
19 what he documented. 
20 Q. Now, I think you indicated and talked a 
21 little bit about equal analgesic dosing charts. 
22 A. Correct. 
2 3 Q. And I think you indicated that it's 
24 difficult to say precisely what an equal analgesic 
2 5 dose is comparing OxyContin lo methadone because of 
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1 A. Or it would actually be the other way 
2 around. But your answer is correct. I mean, your 
3 statement is correct. And there is actually a 
4 two-to-one variance that appears in the literature. 
5 Jt typically is a half as much of methadone or a 
6 quarter as much of methadone equivalent to morphine. 
7 In other words, 5 to 10 milligrams of methadone being 
8 equivalent to 20 milligrams of morphine is what you 
ti 
9 typically find. \ 
10 Q, So you're not aware of any equal analgesic , 
11 charts published between, say, 2000 and 2004 that i 
12 indicate on an equal analgesic basis that IO i 




A. There may be. 
Q. Okay. 
17 A. You know, as you said, there are a whole 
18 bunch of charts that are out there, and they're quite 
19 variable on methadone. 
20 Q. Are you aware of any literature that was 
21 out there in 2000 to 2004 that suggested that if a 
22 patient was-~ when converting from one analgesic 
2 3 opioid to another, that the patient was not receiving 
24 adequate pain control on the previous analgesic, that 
2 5 you could consider increasing the equal analgesic of 












Lipman, Arthur * July 5, 2007 
Page 218 Page 220 
the other dose by 20 percent? l could not have used this medication 50 times 
A. What I've typically seen has been that 2 previously and patients did okay. But this is not 
rather than do the 20 percent decrease, if the 3 mystery stuff that's unknown, This is well-known 
patient is not getting accurate analgesia with drug 4 pharmacokinetics. And it was clearly the 
A, that you might convert at an equal analgesic 5 responsibility of Mr. Byme, in my opinion, to know 
conversion, which is the equivalent of a 20 percent 6 these pham1acokinetics before using the drug. Jfhe 
increase, assuming that there should be a 20 percent 7 did not know them, which he obviously didn't·· 
decrease lo begin with. And that was thinking that 8 because l don't believe he did this in any malicious 
9 was occuning back in the early 2000s. We've become 9 manner. I think he did it in a frighteningly 
l O more conservative now because of reports. And as I 1 O dangerous manner but out of ignorance, not out of 
11 mentioned, it used to be 20 percent. Now we talk 50 11 malice. And it was clearly, in my opinion, 
12 percent. So I think your statement is reasonable. 12 Dr. Byme's responsibility .. Dr. Dille's 
13 Q. Would you agree with me that out there in 13 responsibility, as a supervising physician, to 
14 the general world of primary carry physicians and 14 ascertain that Mr. Byrne knew enough to use the drug 
15 sort of outpost pain management clinics, that the 15 safely and assure that that was done. 
16 standard of practice has evolved with regard lo 16 Q. f take it you don't know what Mr. Byrne's 
17 methadone from the late nineties and early 2000s to 1 7 and Dr. Dille's experience with Mr. Byrne was with 
18 today? 18 respect to other patients who started on methadone 
19 MR. POSTER: Object to the form. 19 converted from OxyContin or other drugs? 
20 THE WITNESS: That was a compound question 2 o A. Conect. 
21 and it's two different questions. In primary care, 21 (A short recess was taken.) 
22 yes. In what you call outpost pain management 22 Q. (BY MR. HlPPLER) Would you agree that if 
23 programs, no. I would disagree with that. Dr. Dille 2 3 Dr. Dille had instructed Mr. Byrne prior to having 
24 is a boarded anesthesiologist who has taken 24 seen Mrs. Schmechel in the course of his working with 
25 additional medical education in pain and has a clear 25 him that whenever he puts a patient on methadone, 
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1 interest in it. He certainly was aware of this. 
2 And, indeed, his testimony where he indicated that he 
3 would not have titrated the methadone as quickly 
4 reflects that. 
5 You can't hang out a shingle and say 
6 you1re a pain management center and use methadone and 
7 not know the pharmacokinetics of it full stop. So l 
8 would not consider this facility a quote, "outpost," 
9 your word, pain management program. And their not 
1 O understanding the phanuacokinetics of a drug that 
11 they're using such as methadone I consider 
12 unacceptable. 
13 Q. (BY MR. HIPPLER) From your review of 
J. 4 Dr. Dille's deposition, l think what you're saying is 
15 it appears to you from his deposition that he did 
16 have an understanding of the phannacodynamics and 
17 pharmacokinetics of methadone. 
18 A. Yeah. I'm not talking about dynamics al 
19 all. Pharmacokinetics, yes, I believe he did and 
2 O does. I also believe that he provided inadequate 
21 assessment of Mr. Byrne's knowledge base and/or 
22 supervision~- and supervision of Mr, Byrne's use of 
23 this medication in light of Mr. Byrne's clear lack of 
2 4 knowledge of how lo use this medication safely. 
25 Now, this is not to say tlrnt Mr. Byrne 
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1 that he is to instruct the patient that taking more 
2 than what is prescribed can be very dangerous and, in 
3 fact, lethal would be an appropriate thing to tell 
4 your P.A.? 
5 A. Yes. 
6 Q. You testified earlier that it was your 
7 understanding that Mrs. Schmechel's renal function 
8 was normal. What was your basis for that opinion? 
9 A. No. I said reasonable. The medical 
1 o records, the history reflect that this was a 
11 reasonably healthy person other than the specific 
12 morbidities that were indicated. She did have some 
13 cardiac insufficiency. But you have to have many 
14 years of cardiac·· or several years of mild or a 
15 very severe cardiac insufficiency nom1ally before it 
16 would impact renal function. 
l 7 Q. When you're talking about cardiac 
18 insufficiency, are you talking about her 
19 hypertension? 
2 O A. Well, hypertension eventually takes a role 
21 in the heart. It causes some cardiomegaly. It 
2 2 causes some changes in the fluid dynamics and> 
2 3 obviously, can have an effect on the kidneys also. 
2 4 But this was a relatively young woman. Forty-one? 
25 Q. Sixty. 
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1 A. Sixty? I'm sorry. Well, to me that's 
2 relatively young, And every year it gets younger. 
3 MR. FOSTER: I was going to say don't say, 
4 Oh, God. She was on death's door. 
5 THE WITNESS; No, no. But she was a 
6 reasonably otherwise healthy person. The records do 
7 reflect that. I'm sorry I didn't recall her age. 
B But you've got to have some significantly 
9 impaired renal function before you're really going to 
1 O get a longer duration of methadone. You normally --
11 ifwe have somebody who has severely elevated serum 
12 creatinine, then we will actually frequently see 
13 12-hour duration with methadone and see an eight-hour 
14 duration with morphine. But I'll be 63 in a couple 
15 weeks, and I'm -- my renal function is perfectly 
16 normal and I have a -- I would require morphine every 
1 7 six hours to maintain analgesia. I would require 
18 methadone every eight hours to maintain analgesia. 
19 Q. (BY MR. HIPPLER) Is edema ln the lower 
20 extremities a telltale sign of methadone toxicity? 
21 A. No. 
22 Q. Even with discoloration? 
23 A. No, it is not, Certainly, would not be an 
24 expected effect of methadone. 
25 Q. And with any patient who is starting a new 
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1 opioid, in the first few days you might expect a 
2 little bit of nausea, correct? 
3 A. Correct. 
4 Q. And that's not necessarily a dangerous 
5 sign? 
6 A. No. In fact, we routinely give patients 
7 mild antiemetic to take for a few days when starting 
B an opioid. 
9 Q. I wanted to address something that you 
10 talked about earlier, and that is ff Mrs. Schmechcl 
11 had a sudden cardiac arrhythmia, that methadone would 
12 have been contraindicated, I think is what you had 
13 said. 
14 A. Well, methadone itself, typically in 
15 relatively high doses, can cause a rhythm 
16 disturbance. 
1 7 Q. Prolonged Q? 
18 A. Yes, PQ interval. Very good, You got 
19 halfofit. 
2 o Q. Thought it was QT, 
21 A. QT interval. Did T say CQ? 
22 Q. You said PQ. 
23 A. RSD. Bui the -- I'm sorry. The -- it's 
24 QT interval disturbance that can occur. It's been a 
25 long day. It's not common. We don'! know whatthe 
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1 actual prevalence of it is. It's been reported 
2 relatively recently much more so than previously. 
3 Q. And that's mostly been reported in 
4 patients in methadone treatment programs who are 
5 taking large doses 1 correct? 
6 A. Well, it's actually been reported in 
7 higher doses but for clinical purposes. And this is 
8 most common in patients taking high doses such as we 
9 use in cancer care. not the doses that we use 
1 o typically in chronic nonmalignant pain. If a patient 
11 had a preexisting cardiac arrhythmia, however, 
12 particularly QT interval disturbanctl or abnormality, 
13 then methadone would be relatively, not absolutely, 
14 but relatively contraindicated, 
15 Q. And !just wanted to make sure that l was 
16 clear about your statement about contraindication. 
17 There was nothing apparent about this patient that 
1 B would have been known in advance --
19 A. Absolutely, 
2 0 Q. -- suggesting she was contraindicated for 
21 methadone. 
22 A. Absolutely. As l stated, clearly 
2 3 methadone was a very reasonable drug to try in this 
24 patient. 
25 Q, And if you don't feel qualified to answer 
Page 225 ; 
1 this because you're not a physician and you're not a 
2 cardiologist, !hat's fine. You canjust tell me 
3 that. But is it not true that patients with occluded 
4 vessels to the heart as well as cardiomegaly can have 
5 sudden arrhythmias? 
6 A. That is true. 
7 MR. HIPPLER: Off the record. 
8 (A discussion was held off the record,) 
9 Q, (BY MR. HIPPLER) I apologize. I'm 
1 o getting close. I'm just kind of going through my 
11 notes here. 
12 You talked about the amitriptyline and 
13 Mr. Byrne's reduction of that. There were actually 
14 two reductions of that. You thought there was a 
15 contraindication, but when you look at the chart, is 
16 it not true that •• 
1 7 A. I didn't say a contraindication. I saw a 
18 contradiction. l thought I saw in one place a note 
19 reducing it from JOO to 50, another place a reduction 
20 from 100 to 75. lfhe took it down step-wise JOO to 
21 75 to 50, that's reasonable. 
22 Q. Okay, That was my understanding of the 
23 records, and l just wondered. 
24 A, I don1t think that1s a major issue. You 
2 5 just asked me to comment on care. 
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1 Q. ls amitriptyline a type of drug that you l Dr. Vorse said? 
2 can just stop cold without adverse side effects? 2 A. Nothing that I can recall right now, 
3 A, Not a good idea at all af\er being on it 3 Q, Okay, And! take it you noted that 
4 for a period of time. That Jowers the seizure 4 Mr. Byrne was aware that the patient, in addition to 
5 threshold, can cause some rebound cholinergic 5 having had two prior surgeries on her back and 
6 effects. 6 surgeries on her knees and pain in her knees w-
7 Q. So if you're going -- 7 A. Yes. 
8 A. Titration would be right. Titration down 8 Q. -- had a diagnosis of arachnoiditis? 
9 would be correct. 9 A. Yes. 
10 Q. And if that's what he had in mind, that 10 Q, And, in fact, he obtained imaging reports 
ll would be the appropriate thing to do? 11 to confirm that before sta11ing his therapy? 
12 A. Yeah. l just don't understand why he was 12 A. Yes. 
13 going to eliminate that class of medication because 13 Q. And I take it you would expect a 
14 that's a drug of choice for neuropathic pain, and 14 physician1s assistant working in a pain management 
15 this lady had a neuropathic pain, or neuropathic 15 clinic to understand that a patient with 
16 component of her pain. 16 arachnoiditis is going to have relatively severe 
17 Q. Do you recall him discussing that in his 17 chronic pain? 
lB deposiHon, why he did that? 18 A. Yes. 
19 A. I don't recall. 19 Q. And then understand that arachnoiditis is 
20 MR. HIPPLER: Okay. Off!he record. 20 not a curable disease state? 
21 (A discussion was held off the record,) 21 A. Con-ect. 
22 Q. (BY MR. HIPPLER) I just want to go back. 22 Q. And that the typical goal with therapy 
23 Do you know for certain that BYU did or did not have 23 would be patient comfort? 
24 a P.A. program in the mid-nineties? 24 A. Yes, as I stated earlier. 
25 
' 
1-25 A I don't believe they ever had a P.A. Q. And other than Mr, Byrne not expressly and 1------------"-----------+----'----------'-----'--'----I 
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l program. 
2 Q, Okay. 
3 A I'm quite sure they didn't have one, 
4 Q. Jf they did, you certainly weren't 
5 involved in teaching their --
6 A. No, 
7 Q, "" their students of pharmacology? 
8 A No, not at all. 
9 Q. Okay. 
10 A They did have a nurse practitioner 
11 program. Brent Willey was teaching phannacology dowr 
12 there at that lime, but not P.A. 
J.3 Q. Did you -- and Ms. Duke may have asked you 
14 this, and l apologize if she did, but, as you 
15 indicate, it's been a long day"" did you find any 
16 inaccuracies in Mr. Byrne's documentation in tenns of 
l 7 the history that he wrote out coupled with the 
18 dictation? In other words, if you look at all these 
19 documents as one chart together, the history that he 
2 o and the medical assistant wrote out of the vitals and 
21 etc., the history and physical that he dictated as 
2 2 well as the pain questionnaire that the patient 
2 3 filled out, did you find inconsistencies between 
2 4 those documents and Dr. Vorsi:1s records where the 
2 5 infonnalion was just incmTect based on what 
Page 229 , 
1 explicitly documenting that, you have no reason to 
2 believe that he wasn't aware of that? 
3 A. No. I think that's pretty implicit. What 
4 Pm concerned about in documentation is the 
5 information that he provided to the patient, 
6 Q. Okay. And do you believe the standard of 
7 care requires a physician's assistant working in a 
8 pain management clinic to document everything that he , 
9 tells a patient regarding how to take the 
1 o medications? 
11 A. "Everything" is a very broad word. I 
12 think it's -- the standard of practice does 
13 dictate -- and this is not my interpretation. This 
14 is the Federation of State Medical Boards, presuming 
15 that.most P.A. boards would use !hat document. I'm 
16 not sure in Idaho if P .A.s are under the medical 
17 board or if they have a separate board. 
18 But the definition of what interventions 
19 are initiated and what instructions are given to the 
2 0 patient, with a clear explanation of the potential 
21 benefits and potential risks of the interventions, is 
22 mandated in the federation model policy. 
23 Q. That that he given lo lhe patient or that 
24 !hat be documented in the chart'/ 
25 A. Documented in the chart, 
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Q. And would it be sufficient to document in 1 as what a reasonably pnident physician in the same or 
the chart that, for example, quote1 11 I gave a clear 2 similar community does or would do, and if a good 
indication to the patient the risks and benefits of 3 number of physicians don't dictate in their own 
initiating the treatment therapy identified below"? 4 office chart the specific risks discussed with 
A. Thinking back to what the Federation 5 respect to a medication stai1ed, but simply a 
standard is, policy is, that it said specifically say 6 shorthand indication that they had a discussion with ' what are the risks and benefits. I would not expect 7 the patient about the risks or about the medication 
a reasonable busy clinician to write out a lot of 8 and an understanding between them what that means, 
detail. I would expect an explicit statement that 9 that that could under that definition of standard ( 
discussed with the patient risks of or discussed with 10 care meet standard of care? 
the patient our standard protocol. What's done in 11 MR. FOSTER: Object to the form. 
many clinics for medical/legal protection is they 12 THE WITNESS: I understand what you're ;: r 
have a simple policy statement in a policy and 13 saying and we discussed this previously. I really .. 
procedure manual that says, This is what we will 14 can't agree with that being acceptable unless there's 1 
discuss with patients. And then all a clinician has 15 something documented, either in a policy and '!. f, 
to do is document in the record, I did our policy, 16 procedure manual, a simple statement that's in the :.r 
As defense attorneys, you're obviously 17 file at U1e place. And in this particular case, I ;? 
aware of that process and you1re also aware that, 18 saw absolutely no allusion in the chart to the risks }; 
unfortunately, that often doesn't happen. 19 being discussed with the patient. This is a serious 
Q. One of the other things that some 20 issue, This is a potentially lethal issue. It's 
clinicians might do, particularly in a small office 21 something that cannot be done in a haphazard manner. 
of a physician's assistant and a physician, is to 22 It1s got to be done in a routine consistent manner. 
have a clear understanding through dialog with one 23 Most clinics will have a written 
another and working with one another that we're 24 medication management agreement that they -- many !. 
starting a patient on methadone or converting to 25 clinics would have a written medication management 
Page 231 Page 233 
methadone. Here arc the things that you will discuss 1 agreement that explicitly spells out the risks to the 
with the patient. 2 patient. It's typically signed by both the clinician 
MR. FOSTER: Object to the form. 3 and the patient. The patient is given a copy to take 
THE WITNESS: Well, I understand what 4 home. And this is to help protect the patient and to 
you're saying. l don't believe that meets the 5 point out that this is a two-way relationship. I 
standard of practice, 6 don't see evidence of the necessary information being 
Q. (BY MR. HIPPLER) And that's based upon 7 provided in this case, 
the Federation1s guidelines, correct? 8 Q. (BY MR. HIPPLER) One of the things that 
A. Conect. 9 was provided in this case and that Mrs. Schmechel 
Q. lt's not based upon necessarily what 10 signed was a drug contract, correct? 
actually occurs jn pain management clinics and ll A. Conect. 
throughout communities such as Twin Falls? 12 Q. And one of the things the drug contract 
A. I don't practice in Twin Falls, but I've 13 provides is that Mrs. Schmechel agrees that she will 
visited and consulted with and presented Grand Rounds 14 not take more of the medication than is directed for 
at many small community hospitals, and those are 15 her to take -- we can disagree about what was 
often attended, almost always attended by the local 16 directed -- without first talking to the clinic, 
' pain management physicians. And these are questions 17 con·ect? 
that often come up and are always addressed in the 18 A. Conect. My problem is that the direction 
same way. 19 she had said one-half to one-and-a-half. 
You and I both know that there ai·e things 20 Q. That's the part I said we can disagree 
that are done that are below standard of practice and 21 about. And ifwe want to disagree about it, we'll be 
that oftentimes people get away with that. But, 22 here forever disagreeing about it. 
unfortunately, when people don't follow standards of 23 A. Well, we'll agree to disagree. But just 
practice1 there can be serious adverse outcomes. 24 the fact that they use a medication management 
Q. Well, if we define "standard of practice" 25 agreement or drug contract like that indicates that, 
59 (Pages 230 to 233) 
CitiCourt, LLC 
801.532.3441 
•l 1'1 f' ~· . 
.l_ t. · . .) \_,1 
Lipman, Arthur 
Page 234 
1 you know, this is not an outpost clinic, that they're 
2 doing some contemporary things. 
3 Q. And in this case the clinic did obtain 
4 from the patient an objective assessment of the 
5 patient's pain level, correct? 
6 A. As objective as you can be. 
7 Q. The one to ten standard is about as 
8 objective as you can be. 
9 A. Well, there are actually --
10 Q. I've seen the crying faces and smiling 
11 faces and --
12 A. Well, there are actually a lot better 
13 things to do, but that's done, The zero to ten, not 
14 one to ten, zero to ten scale is typically and 
15 commonly done. 
16 Q. Cenainly within the standard of care, 
1 7 standard of practice? 
18 A. Yes. 
19 Q. And you talked about the board ofphannacy 
20 Federation -- or not board ofphannacy, This 
21 Federation of Medical Boards requiring that there be 
22 some documentation of consultations obtained, 
23 correct? 
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place? 
A. I don't know definitively what did occur. 
I've seen Mr. Byrne's testimony that -- and, 
actually, I think he had some documentation that he 
had conversations. I saw Mrs. Schmechel's family's 
report, I don't know. I'm not prepared to comment 
on that. 
Q. And Mr. Byrne's documentation is with 
respect to conversations on Monday and Tuesday, 
correct? 
A. Correct. So over the weekend is when we 
get the"· her children spoke. Yeah. That's 
correct. 
Q. So I take it you're not taking a position 
with regard to the credibility of the varying 
factorial accounts? 
A. No, 
Q. Just so that I understand, is it your 
testimony that Mr, Byrne needed to speak with 
Dt. Vorse or review her records or both? 
A. One or the other, at least. 
Q. One or the other? 
A. Yes. I believe that he needed to get her 
clinical impression of what was going on. 
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25 Q, And that could have been through record or 
1 of records placed in the charts, evidence of 
2 consultations received from the imaging pmvider as 
:i well as the orthopedic surgeon that had seen the 
4 patient two weeks prior, -correct? 
s A. That's correct. 
6 Q. You would agree with me that it was 
7 appropriate and, in fact, good practice for Mr. Byrne 
8 to get the 011hopedic surgeon's consultation record 
9 to assure that there was no operative fix for 
1 o Mrs. Schmechel? 
11 A. Absolutely. 
12 Q. In your discussions with either Mr. Foster 
13 or anyone from his office or with anyone else, for 
14 that matter, or in documentation you received other 
15 than the depositions of Mrs. Schmechel's children, 
16 have you seen evidence of a phone call between 
1 7 Mrs. Schmeche\ and somebody from Southern ldaho Pair 
18 Institute on either the Saturday or Sunday after the 
19 Friday visit? 
2 O A. As you stated, this is -- or as you imply, 
21 this is listed in the depositions from the children. 
2 2 I'm totally unclear on that issue as to what 
2 3 occurred. 
24 Q. Okay. And do you have an opinion as to 
2 5 whether or not a phone conversation, in fact, took 
1 through conversation? 
2 A. Yes. 
3 Q. ls it your contention that Mr. Byrne or 
4 Dr. Dille violated any applicable statute or rule of 
5 law in the state ofldaho? 
6 A. No. 
7 MR FOSTER: I'm going to object to the 
8 fonn. 
9 Q. (BY MR. HIPPLER) One of the reasons that 
1 o methadone is sometimes used is because irts felt to 
11 be an efficacious medication to give for neuropathic 
12 pain, correct? 
13 A Yeah. There's not evidence to support 
14 that. There were a number of speculations on that, 
15 and I've actually published in this area also. It's 
16 a very -- one of the isomers of the molecule is a 
l'I weak NMDA antagonist. We know that NMDA antagonis ~ 
18 are useful in managing neuropathic pain. There1s :: 
19 absolutely no real evidence that methadone is any ' 
2 o better than any other opioid for that purpose. There 
21 was a speculation to that effect in the literature in 
22 the late 1990s which could have influenced people 
2 3 using it in 200}. Thinking thal it's a better drug 
24 than morphine or oxycodone or any other opioid is not 
2 5 valid. It's just as good as tbe other drugs, 





1 however1 so theres no reason not to use it. 
2 Q. Okay. 
3 A. And it's cheap. 
4 Q. ll certainly wouldn't have been 
5 inappropdate in 2003 for Mr. Byrne working in a pain 
6 management clinic to think that methadone might be a 
7 good drug of choice for neuropathic pain? 
8 A. There's no reason to think it's a drug of 
9 choice. [t1s certainly a reasonable alternative 
1 o opioid. l have no problem with the selection of 
11 methadone. I've been ve1y clear on that. I think it 
12 was a reasonable choice. 
13 Q. I take it you don't feel it was necessary 
l4 for him to first try to increase her OxyContin to see 
1 s if that worked better? 
16 A. She was already -- she was not taking a 
17 large dose. She was only taking 20 milligrams three 
18 times a day, But that's sti!I a reasonably expensive 
19 drug, and methadone is a lot cheaper. So for 
20 economic reasons it would certainly be reasonable to 
21 try her on methadone, 
22 Q, It's at least, at a minimum, a matter of 
2 3 judgment, professional judgment? 
24 A. Yeah. Neither I nor anyone else on either 
25 side of this case, to my knowledge, faults the use of 
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1 methadone or the selection of the methadone, It's 
2 the way that ii was used that I fault. 
3 Q. And that relates, again, to the once-a-day 
4 upward titration? 
s A. Correct. 
6 Q. Are you knowledgeable enough about the 
7 scoring of sleep apnea to kn.ow whether her scores 
8 qualified her for severe or moderate sleep apnea? 
9 A. No. 
10 Q. You said you had a discussion with 
11 Dr. Vorse. Did she indicate lo you a belief, not 
12 with respect to the dosing i10w, but just a belief 
13 that this patient should not have been on mctliadone? 
14 A. Not that I recall. 
15 Q. And when you talked with the physician in 
16 Lewiston whose name 1 can't remember ~-
1 7 MS. DUKE: Flinders. 
1 s MR. FOSTER: Flinders. 
19 Q. (BY MR. HIPPLER) -- Flinders, did you 
2 o talk with him generally about the standard of care in 
21 Idaho, or did you talk specifically about the 
22 standard of care in 2003? 
23 A. The majorily of the conversation on the 
24 standard of care was between Dr. Flinders and 
2 5 Dr. Lord on since they're both practicing 
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1 anesthesiologists, r certainly concurred with what 
2 they said. l don't remember much more detail about 
3 it. 
4 Q, So you don't remember whether it was a 
5 general discussion or spedfic discussion related to 
6 2003? 
7 A. l suspect it was both. 
s Q. Okay. And do you recall what Dr. Flinders 
9 indicated, if anything, about what his knowledge of 
lo the standard of care in Twin Falls, Idaho was in 
11 2003? 
12 A. I don't recall. 
13 Q. Or what his basis of -- or how much 
14 contact he had with providers in 2003 from the Twin 
15 Falls region? 
16 A. That may have been part of the 
1 7 conversation. Again, I don1t have a recollection. I 
18 do recall that he felt tliat there was fairly 
19 consistent standard across the state of Idaho, and 
2 0 thal it was consistent between Idaho and Utah. 
21 Q. Okay. Do you know whether he practiced in 
22 Utah? 
2 3 A. I think he trained here. 
24 Q. Okay. Do you know whef) that was? 
2 5 A. I don't recall. · 
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1 Q. Do you know when he started practicing in 
2 Idaho? 
3 A. No. 
4 Q. Do you know whether it was before 2003? 
5 A. I don't recall. 
6 Q. As you sit here, do you have an 
7 understanding of what the published therapeutic range 
8 of blood concentrations of methadone arc considered 
9 to be? 
1 o A. J have tables to answer that question in 
11 my office. l don't know them off the top of my head. 
12 It's impottant to note again that those are highly 
13 variable, and these are all based on population 
14 averages. There's a huge standard deviation. The 
15 serum level for morphine is published as 44 plus or 
16 minus 65 nanograms, for example. So a mathematically 
1 7 impossible range from what's actually been reported. 
1s Q. What do you mean "mathematically 
19 impossible ra11ge11? 
2 o A. Well, if 44 is your mean and it's plus or 
21 minus 65, that puts it into the negative range. But 
22 that1s because of the -- means versus mediums if you 
2 3 want to play statistics. 
24 Q. Sure. Do you know whether, according to 
25 published tables, the 300 nanogrnms to milliliter was 
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1 within the therapeutic range of published tables? 
2 A. It's actually in the overlap range between 
3 therapeutic -- high therapeutic, low toxic or low 
4 lethal. There have certainly been deaths associated 
5 with 300 nanogram levels. And there have been 
6 patients who have been therapeutic at more than 300 
7 milligrams -- nanograrns. So) again) that1s that 
8 patient variability, So what we look for on those 
9 type of data are whether it's consistent with, I 
1 o don't consider that to be at all pathognornonic or 
11 diagnostic of methadone-induced death. And as I 
12 stated earlier, l just found it consistent with and 
13 supportive of the conclusions I've reached on 
14 phannacokinetics. 
15 Q. Do you have any knowledge or understanding 
16 or belief that Mrs. Schmechel took more than 30 
1 7 milligrams of methadone a day? 
18 A. I don't. 
19 Q. Do you }mow what the blood level of 
2 o hydrocodone translates to given its half-life in 
21 terms of number of tablets? 
2 2 A. Those are very difficult calculations to 
23 do. Again, I have all the tables in my office on 
24 what the blood levels are, what we typically see in a 
25 therapeutic range, what we commonly see in the toxic 
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l range. But l don't know them off the top of my head. 
2 Q, Would you agree that it appears that she, 
3 within the four hours of her death, took at least 
4 more than one narco? 
s MR. FOSTER: Object to the form, 
6 THE WITNESS: I don't have a recollection 
7 right now of -- l did look at that at one time, and I 
8 don't recall. My attitude toward the hydrocodone, as 
9 l said earlier, is that was contributory as opposed 
1 o to causative; that the methadone, in my opinion, was 
11 the major problem. She could have taken significant 
12 doses ofhydrocodone by itself. They would have 
13 cleared. It would have been far better to take lower 
14 doses more often than higher doses less often because 
15 you want a lower peak serum level. But the m~jor 
16 causative agent, in my opinion 1 was the methadone 
17 with the hydrocodone being an additive contributor. 
18 Q. (BY MR. HIPPLER) For someone like 
19 Mrs, Schmechel who had been on hydrocodone for years, 
2 o l assume she would have had a pretty good tolerance 
21 to hydrocodone, 
2 2 A. To the respiratory depression of 
23 hydrocodone. I would make the same assumption, which 
24 is another reason why l say I think it's only 
25 additive, where she would not have had time to have 
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1 developed full tolerance to the respiratory 
2 depressive effects of methadone. 
3 MR. HIPPLER: I'm just about done. Do you 
4 have more? 
5 MS. DUKE: No. 
6 MR. HIPPLER: Let's go off the record 
7 while I go through the rest of my notes here, I 
8 think I'm almost done. 
9 (A short recess was taken,) 
10 Q. (BY MR. HIPPLER) You'd indicated at the 
11 beginning of the deposition that you know Dr. Fakata. 
12 In fact, she did her fellowship under you, correct? 
13 A. Yes. 
14 Q. And do you consider her to be a competent 
15 and obviously well-trained Phann.D.? 
16 A. Dr. Fakata did not successfully complete 
1 7 her fellowship. 
18 Q. And why is that? 
19 A. She did not finish or publish her 
20 research, which ii was a research fellowship. And in 
21 her last several months in the fellowship she did not 
22 perfonn -- the last quarter of the fellowship she did 
23 not perform successfully, so she was never granted 
24 her fellowship certificate. I'd rather not say 
25 anything else about it. But, unfortunately, Keri 
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1 turned out to be a huge disappointment. 
2 Q, You did, however, publish a number of 
3 articles and chapters with her, correct? 
4 A. We do that with all of our fellows. One 
5 of -- it's important for them to get publications 
6 because most of them seek academic or other research-
7 based positions. And she's gone to work as 
8 essentially a research assistant in a for-profit 
9 private clinic, 
10 Q. And with respect to Mr. Kotenstette, who I 
11 think you also indicated you knew •• 
12 A. Yes. 
13 Q. -- from what you lrnow of him and his 
14 reputation, is he considered to be a well-respected 
15 and competent physician's assistant in pain 
16 management? 
17 A. I believe so, yes. 
18 Q, TI1en just so that I understand because l 
19 may be perhaps a little dense, but I just want to 
2 O make sure l understand tl1is and what you were saying 
21 correctly, In terms ofrespiratory risk and 
22 accumulation of methadone, would the respiratory risk 
23 in a patient be the same, less, or equal in a patient 
24 started on 15 milligrams twice a day and kept on that 
2 5 until steady serum state was reached -- during that 
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interval we're talking about the respiratory risl<; -- 1 days, during that 10-day interval is their 
versus a patient started on l O milligrams twice a day 2 respiratory risk greater, equal, or less than the 
and increased to 15 milligrams twice a day in the 3 patient who starts at 10 milligrams every 12 hours 
first 72 hours? 4 and then within 72 hours increases to 15 milligrams 
A. It's actually a very complex question. 5 every 12 hours? 
When patients have inadequate analgesia, they will 6 A. The total area under the curve is the 
tend to frequently take extra tablets. If a patient 7 driving factor for respiratory risk. So ifwe 
receives adequate analgesia, the patient is more apt B calculate out the total amount of drug that the 
to be adherent with the prescribed schedule. l have 9 patient received over that period of time, from which 
no information as (o whether Mrs. Schmechel was 10 we subtract that that has been eliminated already by 
adherent to the way it was prescribed, whether she 11 the body, we get the net answer. So it could go 
understood how lo take it, or whether not. All 12 either way for the reasons that I suggested. 
things being equal, the more drug on board, the more 13 The problem is that the patient has a 
respiratory risk. So starting at l 5 milligrams and 14 continuing risk until you've reached tolerance to the 
maintaining that as opposed to titrating up to the 15 respiratory depression, which is going to take a 
same total amount of medication could actually cause 16 period of time, perhaps seven to ten days. H could 
more respiratory risk. 17 happen within a week. But we don't know where we are ' 
At the same time, if somebody sta11ing at 18 if the dose is continually increasing. 
a lower dose is not getting adequate analgesic and, 19 Q, Okay. I want to go back to my question \ 
therefore, starts taking extra doses, there can be 20 because --
greater respiratory risk, 21 A. But I can't answer that question because i 
The biggest issue with methadone, however, 22 it could go either way. 
is not so much whether it was a l 0- or l 5-miltigram 23 Q. Well, and I guess mathematically I'm } 
dose initially. It's the fact that the dose was 24 trying to understand that. Because ifwe start at 15 
taken every 12 hours and it would take n to a 25 mllligrams twice a day and because of the longer ' 
Page 247 Page 249 
hundred hours to clear. Therefore, with each 1 half-life those initial doses of l 5 milligrams twice 
subsequent dose there is going to be additive and 2 a day versus those initial doses at !O milligmms 
ever increasing respiratory depression potential. 3 twice a day and then increase to l 5 milligrams twice 
And the analgesia will actually lag behind that 4 a day, wouldn't it mean necessarily that there would 
respiratory depression potential. Therefore, 5 be more respiratory risk under the curve, as you say, ii 
patients who think that they're doing well and are 6 mathematically? \' 
feeling better can, indeed, shoot well beyond the 7 A, With which one? 
therapeutic target into the toxic, potentially lethal 8 Q, At 15 twlce a day, 
range, even without taking additional doses because 9 A. Starting at i 5 twice a day. 
,, 
of the residual effect of doses they've already 10 Q. Starting at 15 twice a day. ~ :, 
taken. And if the patient continues to take doses on 11 A. Well, that's what it would appear 
;a 
f 
an eveiy-12-hour regimen, this tisk is going to 12 empirically. The question 1 have is whether the l 
increase. And that's the reason that we don't want l.3 dose -- if the dose started at 5 twice a day, low-end 
to go beyond a conservative starting dose until we've 14 conservative estimate, which we don't think was the 
reached steady state serum levels. 15 case, but it's conceivable that that was taken that 
Q. Okay. 16 way, and then went up to 10 and then went up to 15, 
A. I understand what you're asking and why 17 then there's an escalating amount of drug going into 
you're asking it, but it's not an easy question. 18 the body. In the same patient there's going to be i 
Q. Well, let me try it again because you 19 more risk with the l 5, What we don't -- starting 
threw in some stuff that I didn't ask you. Okay? 20 with the 15. What we don't know, however, is what 
l want you to assume that the patient 21 was the right dose for this particular patient. And 
_l: 
takes the medication in the doses that! described 22 so we want to start conservatively and we want to 
and doesn't take extra. Okay? And l just want to 23 keep it there until we know what's actually 
lmow about respiratory risk. lf a patient takes 15 I 24 happening. If we're increasing the dose, we don't 
milligrams every 12 hours and does so for, say, I 0 I 2s ever really know what's a.ctually happening. 
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l Q. But from a mathematical perspective in 
2 terms of amount of medication that is building in the 
3 patient, there's actually more building starting at 
4 15 •• 
5 A. Yes, 
6 Q. -· and continuing on a steady state than 
7 these increases up to 15? 
B A. I understand your question. And the 
9 answer to that is mathematically geometrically area 
1 o under the curve, yes. 
n MR. HIPPLER: 11,ank you. That's all ! 
12 have. 













MR. FOSTER: We'll reserve our questions 
for the time and place set for trial. 
MR. HlPPLER: Well, let me go back. 1 do 
have one more question just to make sure, house~ 
clCaning question. 
Have you today, do you believe, fairly 
expressed all the opinions you have as of today in 
this case'( 
THE WITNESS: Yes, 
MR. HIPPLER: Thank you. 
(EXHIB!T-8 WAS MARKED.) 
(The deposition concluded at 4:55 p.m.) 
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